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Abstract
Protein Z (PZ) is a vitamin k-dependent plasma glycoprotein produced mainly in 
the liver, which circulates as a complex with PZ-dependent protease inhibitor. 
Human PZ has been reported as having both procoagulant and anticoagulant 
activity, but its anticoagulant role appears to be more physiologically relevant. 
PZ levels vary widely among healthy individuals (normal range of 0.6 to 5.7 
pg/mL) with the average being higher in men than women. The aim of this 
study was to investigate the mechanisms by which PZ expression is controlled 
at the level of transcription, including whether hormonal and/or inflammatory 
signals modify expression and, therefore, possibly account, at least in part, for 
the wide normal range.
Bioinformatic analysis enabled the identification of two age stable elements 
(ASEs) in the PZ gene promoter showing close homology to those found in two 
evolutionarily related proteins, human factor IX and protein C. These regions 
were found to be bound specifically by potentially the same or a similar protein; 
but the identity of the protein could not be confirmed as either PEA3 or Ets1, 
although transactivation data from HepG2 cells suggested PEA3 is important in 
controlling expression of endogenous PZ.
Two further regions, proximal and distal to the PZ transcription start site, were 
identified by bioinformatic analysis for binding of hepatocyte nuclear factor 4 
alpha (HNF4a), with the proximal site also reported by Sugawara and 
colleagues. Although both sites showed specific binding of protein only the 
protein binding the proximal site was confirmed as being HNF4a. The 
importance of HNF4a was further demonstrated by overexpression and siRNA 
knockdown producing a respective increase and decrease in PZ mRNA levels. 
Furthermore, the role of steroid hormones and inflammatory signals as potential 
modifiers of PZ transcription were also assessed in the HepG2 model system. 
This study has demonstrated, to varying degrees, the importance of tissue- 
specific factors (HNF4a), more ubiquitous factors (PEA3, Ets1), steroid 
hormones (oestrogen and glucocorticoid) and inflammatory pathways (bacterial 
LPS induction) on the regulation of PZ gene transcription.
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Chapter 1-Introduction
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1.0. Introduction
The haemostatic system is responsible for the prevention of bleeding from 
injured blood vessels. This system must be controlled to ensure normal blood 
flow by preventing blood coagulation within the vasculature (Smith 2009). 
Haemostasis can be considered as an elegant balance between procoagulant 
and anticoagulant activities, and any imbalance in one of these two forces may 
cause either bleeding or thrombosis, respectively (Aird 2003). Interactions of 
the three components of haemostasis, coagulation factors, platelets and blood 
vessels, are crucial in order to maintain the dynamic balance between the 
essential processes of clotting and bleeding (Riddel and Aouizerat 2006). 
Cross-talk between the coagulation system and the complement system, the 
innate immune system, is recognised as the first line of immune response 
against invaders and potentially injurious stimuli (Choi et al. 2006). Both 
systems are activated early after injury, and the corruption of their cross-talk 
may lead to haemorrhagic shock (Amara 2008). The two cascades share some 
serine protease activity, such as the activation of complement 1 subcomponent 
(C1q) by factor Xlla (FXIIa); C1q, in turn, leads to activation of the complement 
classical pathway. Furthermore, C1 esterase inhibitor inhibits the complement 
pathways as well as inhibiting kallikrein and factor Xlla (Davis 2004).
1.1. The Coagulation Process
Blood coagulation is a process to halt blood loss from a damaged vessel. 
Platelet adherence and aggregation at sites of vessel wall injury form the 
primary hemostatic plug . Plasma coagulation factors are then activated at the 
site of vessel injury and lead to the formation of a fibrin clot (Riddel et al. 2007). 
Upon healing, the fibrin deposits at the former site of injury are degraded and 
broken down by the serine protease plasmin.
The traditional coagulation cascade describes a sequence of steps involving the 
activation of coagulation factors. These clotting proteins circulate as inactive 
zymogens which are sequentially activated upon clotting initiation. The 
coagulation process consists of two pathways; the extrinsic, which involves the 
activation of factor X to factor Xa by a tissue factor: factor VII complex (TF:
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FVIIa complex); and the intrinsic, that results in the activation of factor X via the 
contact activation pathway (Figure 1.1). Factor Xa, with its cofactor factor Va,
Intrinsic pathway
K allik re in  ^  ™ W K^  co llagen
FXIIa |
P rek allik re in
AT III
I ™ I
F IX a
-► F V IIIa
PS/A PC
F =  F a c to r  
A T =  a n tith ro m b in  
T F P N  T is s u e  fa c to r p a th w a y  
inhibitor 
P Z =  p ro te in  Z  
Z P N  P ro te in  Z -d e p e n d e n t  
p ro te a se  in h ib ito r  
P S =  P ro te in  S  
A P C =  a c tiv a ted  p rote in  C
CfxIiT)
Extrinsic pathway
T  
da/
is s u e
a m a g e
PZ/ZPI
F X IIIa
CjD CED
Figure 1.1. The coagulation cascade model adopted from Riddel etal. 2007
Both the extrinsic and the intrinsic pathways culminate in the activation of factor X with 
subsequent activation of thrombin to form the stabilized fibrin clot. Red color shows the 
intrinsic pathway. Blue color shows the extrinsic pathway. Green colour shows the 
anticoagulant action of a number of proteins.
then converts prothrombin to thrombin which in turn converts fibrinogen to fibrin 
(Davie and Ratnoff 1964, Macfarlane 1964). Tissue factor is expressed in 
many cell types and its deficiency has never been identified in humans 
(Mackman, Tilley and Key 2007, Bugge et al. 1996). This, and the fact that 
tissue factor knockout mice die in utero, are consistent with the vital role of this 
factor in haemostasis (Bugge et al. 1996).
The coagulation cascade model has failed to answer many questions In vivo. 
The flaws in this traditional cascade led to the remodeling of the coagulation 
cascade by Maureane Hoffman and her group to produce the cell-based model 
of coagulation. This model requires the participation of two types of cells; tissue 
factor-bearing cells (TF-bearing), where the procoagulant reactions are initiated,
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and platelets for localization of the response. The coagulation process remains 
inactivated unless these two cells come into contact, after injury (Hoffman 
2003). Three overlapping steps have been suggested; initiation, amplification 
and propagation (Fig 1.2). In the initiation step, a small amount of factor X is 
activated by the factor Vlla/TF complex to form factor Xa which with its cofactor 
factor Va forms the prothrombinase complex on the TF-bearing cell. Factor Xa 
activity is essentially localised to the TF-bearing cell under the control of the 
anticoagulant factors, tissue factor pathway inhibitor (TFPI) and antithrombin III 
(AT III), since its dissociation from this cell would result in its inhibition in the 
fluid phase by these anticogulants (Hoffman 2003). Factor Xa which escapes 
from the membrane surface may also be inhibited by the ZPI-PZ complex, that 
activated by heparin or heparin-like glycosaminoglycans at the site of injury 
(Huang et al. 2011).
FXV FHfvhK , . V
R  Rlfe-h--
T iss u e  fac to r b e a rin g  cell
FX
Fll FVIIIa ♦ vW FFVIII/vW F
FVII; FX I
,F lla FX a
FV a FV
T iss u e  fa c to r b e a rin g  cell FV Hlla
TF FVa,
FIXa
FIX
Initiation Phase Am plification Phase
T iss u e  fa c to r b e a rin g  cell
FlliFX
llaAFIX
X la .
FIX
Propagation Phase
Fig 1.2. The cell-based model of haemostasis adopted from Hoffman 2003.
The initiation phase (a) where FXa is localized on the tissue factor-bearing cell and the 
prothrombinase complex is formed. The amplification phase (b) where platelets are 
activated exposing binding sites for activated factors, and cofactors V and VIII are activated 
on the platelets. Platelet aggregation is mediated by vWF at the site of vascular injury. The 
propagation phase(c) where the tenase and prothrombinase complexes are formed on the 
activated platelets.
The amplification phase takes place by the activation of the platelets which 
escape from the blood vessels and aggregate at the site of injury by thrombin
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which has been generated and diffused from the TF-bearing cell. This 
thrombin, which has been generated in the initiation phase, also causes 
activation of factor XI (FXI) and factor V  (FV) in addition to the activation of 
factor VIII which leads to its dissociation from von Willebrand factor (vWF). The 
dissociated vWF mediates more aggregation and adhesion of platelets while 
FVIII is further activated by thrombin (Smith 2009). The propagation phase 
occurs effectively only on an activated platelet surface. In this process factor 
IXa, activated in the initiation phase and from the action of factor Xla, binds to 
factor Villa to form the tenase complex, which then activates factor X. Factor 
Xa binds to factor Va to form the prothrombinase complex which leads to 
generation of sufficient thrombin for the conversion of fibrinogen to fibrin and 
covalent crosslinking by factor Xllla (also activated by thrombin) (Hoffman 
2003).
In order to maintain blood haemostasis, anticoagulant proteins such as 
antithrombin III (AT III), protein C (PC), protein S (PS) and tissue factor pathway 
inhibitor (TFPI) act to inhibit the coagulation process (Becker 2005).
AT III is a serpin, a serine protease inhibitor, essential in the inhibition of serine 
proteases with procoagulant activity in the intrinsic pathway of blood 
coagulation (Olson et al. 1992). This inhibitor is bound by heparin to increase 
its inhibition activity (Ersdal-Badju et al. 1997). In addition to the inactivation of 
thrombin, AT III inhibits other factors in the coagulation process, such as factors 
IXa, Xa, Xla, Xlla, plasmin and kallikrein (Fourrier et al. 1992). The protein C 
(PC) anticoagulant pathway involves thrombin bound to thrombomodulin which 
activates PC. Activated protein C (APC) is a vitamin K-dependent serine 
protease that cleaves factor Va and factor Villa to factor Vi and factor Villi, 
respectively (Esmon 2003). APC also promotes fibrinolysis by neutralisation of 
plasmin activator inhibitor-1 (PAI-1) and interfering with thrombin-activatable 
fibrinolysis inhibitor (TAFI) which inhibits the generation of plasmin 
(Ravindranath et al. 2007, Amara et al. 2008, Grailhe et al. 1993). The APC 
blocks the inhibition of the tissue plasminogen activator by forming a tight 
complex with PAI-1 (Esmon 2001). Moreover, FVa inactivation by APC leads to 
the restriction of thrombin formation and subsequently limiting TAFI activation 
(Bajzar, Nesheim and Tracy 1996). Protein S also plays an important 
anticoagulant role as it enhances the proteolytic inactivation of coagulation
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factors Va and Villa to FVi and FVIIIi by APC (Persson etal. 2006) (see fig.1.1). 
TFPI, which is produced in the endothelial cells and stored in platelets, is 
responsible for the inhibition of FXa which is essential for the activation of 
prothrombin to thrombin and FIXa by preventing the formation TF-FVIIa 
complex (Ravindranath etal. 2007, Broze 2003).
The study of the protein motifs of gamma-carboxylated glutamic acid-epidermal 
growth factor-like-EGF2- serine proteases (Gla-EGF1-EGF2-SP) in factors VII, 
IX, X and protein C (PC), as well as the A domain in factors V  and VIII, has 
revealed that blood coagulation components may have evolved from two main 
gene structures, a Gla-EGF1-EGF2-SP domain and an A1-A2-B-A3-C1-C2 
domain through a series of duplications and diversification (Davidson, 
Tuddenham and McVey 2003).
1.2. Protein Z
Protein Z (PZ) is a vitamin K-dependent (VKD) plasma glycoprotein which was 
identified in bovine plasma in 1977 and named as it was the last VKD protein 
eluted by anion exchange chromatography (Prowse and Esnouf 1977). This 
protein was isolated in humans in 1984 (Broze and Miletich 1984). PZ is a 62 
kilodalton (KDa) protein produced predominantly in liver cells and secreted into 
the plasma (Kemkes-Matthes and Matthes 1995). PZ circulates as a complex 
with protein Z-dependent protease inhibitor (Han, Fiehler and Broze 2000, 
Broze 2001) and is composed of 360 amino acids (Fujimaki et al. 1998). In 
normal pooled plasma all PZ was found to be bound to PZ-dependent protease 
inhibitor (Tabatabai, Fiehler and Broze 2001). Another minor site of PZ 
expression are endothelial cells (Vasse etal. 2006).
1.2.1. Function of Protein Z
The physiological function of protein Z is still not clear, although this protein was 
isolated in humans more than twenty years ago. On the one hand, Hogg and 
Stenflo (1991) observed that bovine thrombin, in the presence of bovine protein 
Z, binds to the phospholipid layer in order to stop bleeding and this process 
cannot be accomplished in the absence of protein Z. Therefore, a decline in 
protein Z should logically lead to a bleeding tendency (Hogg and Stenflo 1991).
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However, human PZ showed a lower efficiency in promoting thrombin binding to 
the phospholipid layer than bovine PZ; this is due to the lack of the region 366 
to 369 of the bovine orthologue which forms the thrombin binding region (Hogg 
and Stenflo 1991). This assumption was supported by work from Kemkes- 
Matthes and Matthes (1995) who demonstrated that the average level of protein 
Z and the bleeding time in 36 patients with bleeding tendency of unknown origin 
were significantly lower than in healthy persons (Kemkes-Matthes and Matthes 
1995). The hypothetical procoagulant role of PZ was strengthened by Kobelt 
and colleagues when they found higher PZ levels in patients with ischemic 
stroke compared with normal controls (Kobelt et al. 2001). However, a further 
study demonstrated that the PZ level in 15 patients diagnosed with bleeding 
problems of unknown origin lay within the normal range (Gamba et al. 1998). 
Ravi et al (1998) also showed that protein Z levels in 48 patients with suspected 
bleeding were within the normal range compared to 200 healthy persons. 
Nevertheless, male patients in this study had lower protein Z than healthy 
males and one female with severe bleeding tendency of unknown cause was 
found to have the lowest level of protein Z (Ravi et al. 1998). On balance, these 
observations seem to support the procoagulant action of PZ to varying degrees. 
On the other hand, protein Z was found to enhance the inhibition of active factor 
X by protein Z-dependent protease inhibitor (ZPI) 1000 fold. This process 
involves formation of the Xa-PZ-\ZPI tertiary complex, in the presence Ca++ , at 
the phospholipid membrane surface (Han, Fiehler and Broze 2000, Han, Fiehler 
and Broze 1998). The ZPI reaction with FXa was found to be enhanced by 
heparin in the presence of calcium and this enhancement has a similar effect on 
free ZPI and ZPI-PZ complex (Huang et al. 2011). The location of the PZ 
interactive site with ZPI is within the C-terminal domain (Hogg and Stenflo 1991, 
Rezaie et al. 2008). The anticoagulant effect of ZPI, regulated by PZ, was 
confirmed by the observed formation of a high affinity stoichiometric complex of 
PZ with ZPI in the absence of phospholipid and Ca++, and the finding that PZ 
enhances the inhibition of the activation of factor X by protein Z-protease 
inhibitor (ZPI) (Huang et al. 2008). Hence PZ acts as an anticoagulant and its 
deficiency would be expected to lead to a procoagulant state and hence cause 
thrombosis. The risk of thrombosis which is caused by protein Z deficiency has 
been shown in mice with the factor V Leiden mutation (FVL). Researchers
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have indicated that the homozygote FVL genotype can lead to death of mice 
from intrauterine and perinatal thrombosis if combined with a deficiency in 
protein Z (Yin et al. 2000, Corral et al. 2007). In agreement with the results 
reported in the mice, thromboembolism was found to be experienced earlier in 
PZ deficient patients who also carried the FVL mutation (Kemkes-Matthes et al. 
2002). The theory that protein Z deficiency will lead to a procoagulant state 
was also supported by Vasse and other researchers when they found that a 
deficiency in protein Z is associated with ischaemic stroke and thrombotic 
complications of atherosclerosis (Vasse et al. 2001) and also with deep vein 
thrombosis (Santacroce et al. 2006). A stronger association of ischemic stroke 
with low levels of PZ was also reported by Heeb and colleagues in males with 
other risk factors such as hypertension, diabetes, high cholesterol and smoking 
(Heeb et al. 2002). These data are consistent with the fact that the 
physiological function of PZ is not clear. However, the current weight of 
evidence in these recent studies suggests that the role of protein Z in the 
coagulation process seems to be anticoagulant rather than procoagulant.
1.2.2. Structure of Protein Z
The modular organisation of PZ comprises four domains, a gama- 
carboxyglutamic acid domain, two epidermal growth factor (EGF1 and EGF2)- 
like domains, and a serine protease (SP)-like domain. This domain structure 
has close similarity with other coagulation factors such as factor VII (FVII), 
factor IX (FIX), factorX (FX) and protein C (PC) (Ichinose etal. 1990, Sejima et 
al. 1990). The modular organisation of PZ and the evolutionarily related 
proteins is shown in figure 1.3. However, PZ differs from the above in that it 
lacks the serine and histidine residues of the catalytic triad and, therefore, lacks 
the proteolytic activity (Ichinose etal. 1990, Sejima etal. 1990, Chandrasekaran 
et al. 2008). The serine-195 and histidine-57 residues in the active site are 
substituted by threonine and alanine, respectively (Hojrup, Jensen and 
Petersen 1985). PZ also contains the highest content of Gla-residues (13) 
among the vitamin-K dependent proteins (Vasse 2008, Hojrup, Jensen and 
Petersen 1985). Compared with other VKD proteins, PZ displays slower 
membrane binding and dissociation kinetics which may correlate with the 
unique Gla residue placement at location 11 (McDonald etal. 1997).
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Fig 1.3. Modular organisation of evolutionarily conserved coagulation proteins.
Protein Z has 39 and 22% homology to FVII, 45 and 25% to FIX and 47 and 24% to FX at 
the N-terminus and C-terminus, respectively; and, in common with these proteins, it features 
signal peptide and propeptide regions, a Gla domain, followed by an a-helical region 
containing a cluster of aromatic residues, two epidermal growth factor (EGF)-like domains 
and a serine protease-like domain. Protein Z, however, lacks catalytic activity and functions 
as a cofactor, unlike factors VII, IX and X which are all zymogens of serine proteases. 
Figure adapted from Floffbrand etal. (Hoffbrand, Moss and Pettit 2006).
1.2.3. Organisation of the Protein Z gene
The gene encoding protein Z is located on chromosome 13 at band q34 
(Fujimaki et al. 1998) and its organization is similar to other coagulation proteins 
such as coagulation factors VII, IX, X and protein C, again suggesting that they 
may have evolved from the same ancestral gene (Ichinose et al. 1990, Sejima 
et al. 1990). The PZ gene is approximately 14 kb in length, comprising eight 
regular and one alternative exons (Fujimaki et al. 1998); Fig 1.4).
la (-88 bp) lb (66 bp)
.GAGCCCTCAG A1 (0  4 6 8  k b ) ................CCACTTCACT................CAGGAAAGCT A2 (0 .7 4 9  k b )
.cacc ag| iscaagt..
II (164 bp) III (25 bp)
TATTTCTCCC AGTAGTCACT n l n n ,^x GATG.. ..CGATATAAGG
-Ctgtagl.................................................................................................................................... Igtatgt.........................................claaag|
IV (114 bp) V  (132 bp)
C (1.7 kb) GCGGCTCCCC................................TGCGAGCTGG D (1.5 kb) CTAAAAATGA...  GTGCCCCACG
 ctgcagl............................................................................................... Igtgagg........'________ ..tttcagl ~|gtc
VI (68 bp) VII (118 bp)
E (0.4 kb) ACCAGTGTGC...............CCCGTGGCAG F (5.8 kb) GTAAAGTTAA   GTAAAAACAT G
agt.....................atgcagl Igtaaca....  tlaaag | Igtaagt..
VIII (788 bp)
, . , ATTTTAACAG...................(1.0 kb)i------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 1
..tttcag I_______________________________________________________________________________________________________________ I
Fig 1.4. Organisation of the human Protein Z gene. The nine exons of PZ gene are shown 
with wide horizontal bars and are numbered with roman numerals. Nucleotides in capitals 
show the boundaries of the exons while nucleotides in small letters form the boundaries of the 
introns. The size and location of Introns A1 -  G are shown.
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1.2.4. Protein Z levels
Plasma PZ levels vary widely in different individuals with a correspondingly 
wide normal range (0.6-5.7 pg/mL) (Miletich and Broze 1987). The levels of 
plasma PZ in 200 healthy adults were found to be significantly higher in males 
than in females with no correlation with age (Ravi et al. 1998). Kobelt et al. 
(2001) supported this significant correlation of PZ levels with sex in addition to 
weak correlation with age (Kobelt et al. 2001). Furthermore, an earlier study 
also determined that there was no link between plasma PZ levels and age, 
although the correlation with sex was reported (Miletich and Broze 1987). This 
observed variation in PZ levels among normal individuals and sex may be 
explained, at least in part, by regulatory mechanisms controlling the rate of 
transcription from the PZ locus.
1.3. The regulation of gene expression
Gene expression is regulated through many subsequent stages that exist 
between the DNA and the production of specific protein. These stages are the 
transcription of the DNA to RNA, modification of the RNA transcript by the 
addition of a 5’ cap, addition of adenosine residues at the 3 ’ end of the RNA, 
removal of introns by RNA splicing, and transportation of the messenger RNA 
(mRNA) from the nucleus to the cytoplasm where the protein is translated 
(Latchman 1992). Regulation of transcription is vital in tissue-specific gene 
expression, as well as controlling expression of genes regulated in response to 
specific stimuli. These effects are mediated through the binding of specific 
transcription factors (which are themselves expressed in a tissue specific 
manner or activated in response to signalling pathways, respectively) to specific 
DNA sequences in the promoter regions of genes (Latchman 1997). 
Understanding of a genes promoter structure, where transcription factors bind 
their cognate sites in order to activate or inhibit transcription of the gene, is very 
important in knowing how that gene is regulated (Jiang, Jarrett and Haskins 
2009). Once transcription is completed and mRNA is transcribed additional 
processes take place to determine the expression profiles of proteins. These 
processes control post-transcriptional regulation and include mRNA splicing, 
mRNA export, RNA stability and translation, adding more complexity to the
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regulation of gene expression (Keene and Lager 2005, Mata, Marguerat and 
Bahler 2005). RNA-binding proteins (RBPs) and other mechanisms such as 
microRNAs and small interference RNAs are responsible for the post- 
transcriptional regulation (Keene and Lager 2005). The stablility of mRNAs, 
which is controlled by the poly(A) tails, is targeted for degradation. The 
degradation is accomplished by the exonucleolytic pathway which is initiated by 
deadenylation and in some transcripts is followed by removal of the 5’-methyl 
guanosine cap (Mata, Marguerat and Bahler 2005). mRNA decay can also be 
achieved by the endonucleolytic pathway including the degradation of a target 
transcript by RNA interference (Tomari and Zamore 2005). Translation of 
mRNA is the final process in the regulation of gene expression and is 
responsible for the adaptation of protein levels. This process can be divided 
into three steps, including initiation, elongation and termination (Jansen et al. 
1995). During the initiation of this process mRNA is recruited to the ribosomal 
complex and the AUG initiation codon is selected. The recognition of the AUG- 
codon and initiation of protein synthesis are facilitated by binding of the initiator 
Met-tRNA to eukaryotic initiation factor (elF2) and Guanosine 5’-triphosphate 
(GTP) (Calkhoven, Muller and Leutz 2002). The mRNA is decoded and the 
peptide bond is formed in the elongation step which is terminated once a 
termination codon is reached the active ribosomal site (Jansen et al. 1995). 
The accurate regulation of gene expression is essential, since its failure may 
lead to a disease development in the affected individual (Latchman 1992).
1.3.1. Basal promoter element
Gene expression is predominantly controlled at the level of the rate of
transcription initiation. The transcription initiation complex is composed of RNA
polymerase II and other basal proteins (also called general transcription factors)
that assemble on the promoter region in order to initiate mRNA synthesis
(Fickett and Wasserman 2000). RNA polymerase II (pol II) transcribes genes in
eukaryotes that encode mRNAs and some small nuclear RNAs (Orphanides,
Lagrange and Reinberg 1996). The genes that are transcribed by Pol II have
basal promoter elements which can be identified by general transcription
initiation factors and DNA elements recognised by transcription proteins
(Roeder 1996). Pol II requires the presence of general transcription factors,
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including TATA binding protein, transcription factor (TF) IIB, TFIIE, TFIIF and 
TFIIH in order to initiate transcription (Hampsey and Reinberg 1999). The 
structure and function of those factors are conserved among all eukaryotes 
(Orphanides, Lagrange and Reinberg 1996). Initiation of polymerase II 
transcription starts from the recognition of core promoter elements by the 
TBP/TFIID complex which is then supplemented with the binding of TFIIB and 
TFIIA. The TFIIF-pol II complex is then gathered and the preinitiation complex 
is completed by binding of TFIIE and TFIIH. Subsequently, the promoter is 
melted to give an open initiation complex. This is followed by synthesis of the 
phosphodiester bond of the mRNA transcript, promoter clearance and finally the 
RNA transcript elongation. TFIIA can stabilise the complex of initiation at any 
time after the binding of TFIID (Orphanides, Lagrange and Reinberg 1996). 
Therefore, basal transcription of genes encoding proteins is a complicated 
process which needs the interaction of many components including general 
transcription factors and the RNA pol II complex to be accomplished accurately.
1.3.2. Transcription factors
In addition to these basal factors the diversity of expression profiles seen in 
protein coding genes is produced by the action of a comprehensive array of 
general, tissue-specific and inducible transcription factors. These transcription 
factors are regulatory proteins which can bind to specific DNA sequence motifs 
within an enhancer or promoter region of a gene in order to regulate its 
transcription (Latchman 2005). Transcription factors interact with the general 
transcription factors, the RNA polymerase or intermediate complexes to activate 
or repress the efficiency of transcription initiation (Warren 2002). There are two 
essential roles, in general, for transcription factors to be effective; i) the ability to 
bind the DNA and, ii) to affect the transcription rate either positively or 
negatively (Latchman 1997). Binding of transcription factors to their specific 
DNA sequences is not sufficient; they also need to interact with other factors or 
the RNA polymerase complex itself in order to affect the rate of transcription 
(Latchman 1990). The synthesis of many transcription factors is cell-type 
specific (Latchman 1990) and these regulatory proteins are generally expressed 
at low levels in cells compared to house keeping proteins (Jiang et al. 2009).
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Genes encoding transcription factors make up approximately 6% of all human 
genes (Venter etal. 2001).
1.3.2.1. Structure of transcription factors
Transcription factors have specific regions for DNA binding. These regions are 
called DNA-binding domains, which allow transcription factors to interact with 
their appropriate DNA sequence in a gene promoter in order to regulate the 
gene (Latchman 1997). The DNA binding activities of transcription factors are 
found in relatively small regions comprising approximately 60 to 100 amino 
acids (Mitchell and Tjian 1989). The characterisation of the different structures 
found in DNA binding domains has led to the classification of the transcription 
factors according to those domains (Latchman 1997). For instance, the helix- 
turn-helix binding domain in the homeobox-containing transcription factors, the 
two cysteine-two histidine zinc finger domain in the TFIID, the E26 (Ets) binding 
domain in polyomavirus enhancer activator 3 (PEA3), and other well-defined 
structures acting to efficiently and specifically bind to DNA (Latchman 2005).
The binding of transcription factors to DNA is significant; however, it is not 
sufficient for the activation of transcription. In order for transcription to be 
activated other regions in the transcription factor are required. These regions 
are called activation domains which enhance transcription by modulating the 
rate at which the RNA polymerase complex assembles on and transcribes the 
DNA template (Latchman 2005). There are three broad types of activation 
domain, an acidic activation domain with a high proportion of acidic amino acids 
(Ptashne 1988, Sigler 1988), a glutamine rich activation domain (Courey and 
Tjian 1988, Courey etal. 1989) and a proline rich activation domain (Mermod et 
al. 1989). Some transcription factors contain activation domains, but not a DNA 
binding domain. These factors instead form a complex with other binding 
proteins, without contacting the DNA, in order to modulate transcriptional 
activation. For example, the herpes simplex virus trans-activating protein VP16, 
which does not have a DNA binding domain, forms a complex with the cellular 
Octamer binding protein, Oct-1, to bind the viral promoter and transactivate it 
(Latchman 2005). Also, although the majority of transcription factors have 
activation domains some can have inhibitory domains instead. These domains
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reduce gene transcription when they interact, either directly or indirectly, with 
the basal transcription complex (Latchman 1997).
1.3.2.2. Function of transcription factors
Transcription factors bind to sequence specific regulatory cis elements more 
frequently, located within the promoter region of the gene whose transcriptional 
activity they regulate. Indeed, these regulatory elements may be located 
several thousands of base pairs from the RNA transcription initiation site 
(Mitchell and Tjian 1989). As mentioned earlier many transcription factors 
activate transcription and are called activators, whilst others repress 
transcription and are known as inhibitory factors. Latchman has stated that 
activation of a gene by transcription factors occurs via different routes, the 
presence of the necessary active transcriptional protein in the correct tissue, 
activation of the pre-existing factor by binding to its ligand, dissociation of 
inhibitory protein from the activated protein, and activation of the protein by 
means of modification, such as phosphorylation, in response to a specific signal 
(Latchman 1990). Stargell et al. have reported that activators can induce 
transcription either directly by the interaction of the activation domain with the 
general transcription initiation factors, or indirectly by relieving nucleosome- 
mediated repression (Stargell and Struhl 1996). Activators can also initiate 
transcription by enhancing the assembly of the basal transcription complex or 
stimulating the activity and/or stability of the complex by altering the 
conformation of an already bound factor (Latchman 2005).
Inhibitory factors can act in a number of different ways to reduce transcription 
levels. They may block the activating effect of other transcription factors by 
preventing them from binding to the DNA. This prevention can be achieved by 
binding of the inhibitory factor to the DNA binding domain of the positively 
acting factor forming a non-binding complex, or interaction of the negatively 
acting factor with the positive one to block its activation domain (Latchman 
1997).
The nature of the amino acids that make up the DNA binding domains of 
transcription factors are important for their functional activity. The stimulatory 
effect of a transcription factor can be drastically altered by just a single amino
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acid substitution in its binding domain. For instance, replacement of isoleucine 
in the binding domain of Brn-3b, from the POU (Pit-Oct-Unc) family, with valine 
was sufficient to switch the activity of this transcription factor from a repressor to 
an activator (Dawson, Morris and Latchman 1996). Other transcription factors 
can also activate transcription of some genes and repress others depending on 
the DNA binding sites. For instance, glucocorticoid receptor binds the 
glucocorticoid response element (GRE), as a dimer, following hormone 
treatment and activates gene transcription. However, when this receptor binds 
as a trimer to a different but related GRE sequence, called a negative GRE 
(nGRE), this leads to repression of transcription (Latchman 2001).
1.3.3. Tissue-specific regulation
The regulation of transcription is often a key step in defining the expression
pattern of a particular gene in a tissue-specific or developmental stage-specific
manner (Latchman 1997). The expression levels of tissue enriched genes is
higher in a particular tissue type, establishing the cell's specialized function, and
being much lower or negligible in other tissues (She et al. 2009). Based on
expressed sequence tag data analyses, the genomic length of tissue specific
genes was found to be less and their expression level lower compared to house
keeping genes (Zhu et al. 2008). Moreover, the majority of tissue specific
genes lack both CpG-islands and TATA-boxes (Zhu et al. 2008). Many genes
encoding tissue-specific proteins have been found to be regulated by tissue-
specific transcription factors. The liver-enriched hepatocyte nuclear factor 4
(HNF4a) has been found to be essential in the regulation of many blood
coagulation factors including PZ (Sugawara et al. 2007), Factor VII ( FVII),
factor VIII (FVIII), factor IX (FIX), factor X ( FX), factor XI (FXI) and PS (Stauffer
et al. 1998, Figueiredo and Brownlee 1995, Reijnen et al. 1992, Miao et al.
1992, Tarumi et al. 2002), which are normally produced in a tissue-restricted
fashion in the liver. Sugawara and colleagues in 2007 reported the first step
towards understanding the mechanism of PZ expression. They reported that
the regulation of protein Z expression is controlled by HNF4a using
electrophoretic mobility shift assays (EMSAs) and reporter gene assays
(Sugawara et al. 2007). Moreover, the liver enriched factor HNF1 was found to
activate the PS gene promoter (Hall, Peake and Winship 2006), and the liver
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enriched factor GATA-4 and nuclear transcription factor Y (NF-Y) activate 
transcription of the gene encoding factor X (Hung et al. 2001). PZ, which is 
also predominantly produced in the liver, may, therefore, also be regulated by 
these transcription factors.
1.3.4. Inducible regulation
Regulation of the activity of transcription factors is important in the regulation of 
gene transcription (Latchman 1992). Transcription of a gene is sometimes not 
activated except in the presence of a particular stimulus. This stimulus 
activates the ability of a particular transcription factor, by conformational 
changes or a disruption of inhibitory protein-protein interaction, to bind the DNA 
and permit transcription of the gene (Latchman 1990). Examples of pathways 
that rely on signalling molecules to produce appropriate effects on gene 
expression include hormone and inflammatory responses.
1.3.4.1. Steroid hormone receptors
Steroid hormone receptors are crucial in the regulation of gene expression by 
steroid hormones, through their interaction with their DNA hormone responsive 
elements (HRE) (Beato et al. 1989). The steroid hormone receptors are related 
to a large family known as nuclear receptors and are bound by steroid 
hormones. (Laudet et al. 1992). The major groups of steroid hormones, 
androgen, oestrogen, glucocorticoids, progestins and mineralocorticoids are 
extensively metabolised in the liver and regulate many physiological processes 
in cells that express their corresponding receptors (Beato and Klug 2000). The 
nuclear proteins are ubiquitous eukaryotic and structurally related transcription 
factors. These proteins bind to specific DNA cis-acting sequence and different 
coregulators, in response to their ligands, and regulate the transcription of many 
genes in a ligand-dependent manner (Raviscioni et al. 2006, Ishizuka et al.
2005). Many transcriptional cofactors, which are organized in multiprotein 
complexes, have been recognized to initiate chromatin remodeling and the 
modification of histones in order to enhance or repress the binding of the 
nuclear receptors and the RNA polymerase II with the basal factors to the target 
DNA (Ishizuka et al. 2005). Some of these cofactors can act as coactivators,
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such as the CBP/P300 (Chakravarti et al. 1996) and P300/CBP associated 
factor (PCAF) / general control of amino-acid synthesis 5-like 2 (GCN5) (Blanco 
et al. 1998) whilst others act as corepressors, such as the silencing mediator of 
retinoid and thyroid receptor (SMRT) (Chen and Evans 1995) and the nuclear 
receptor corepressor (N-CoR) (Horlein etal. 1995). Transcription activation by 
steroid hormone receptors can occur directly by protein-protein interaction or 
indirectly by their synergistic action with adjacent transcription factors (Schule et 
al. 1988, Strahle, Schmid and Schutz 1988). A palindromic sequence 
composed of two sites interrupted by three bases has been identified as a 
hormone response element for nuclear receptors such as oestrogen, androgen 
and glucocorticoid receptors (Aumais et al. 1996). The DNA was found to be 
bent in response to oestrogen nuclear receptor binding, suggesting a change in 
the DNA conformation upon binding of the receptor is common to the steroid 
hormone family (Nardulli and Shapiro 1992). The structure of the nuclear 
receptors is organised as an N-terminal domain with ligand-independent 
activation function (AF-1) (Tora et al. 1989, Metzger et al. 1995), a C-terminal 
ligand binding domain, and a DNA binding domain (DBD) located between the 
two termini (Fig 1.5). The C-terminus domain is known as a ligand binding 
domain, with a complex structure composed of a ligand dependent activation 
function (AF-2), an interface for dimerisation as well as the ligand binding 
pocket (Steinmetz, Renaud and Moras 2001). The DBD, which binds to 
hormone response elements for regulation of a proposed gene 
(Khorasanizadeh and Rastinejad 2001), is a highly conserved region among 
nuclear receptors. It is composed of about 71 residues (Fig 1.5) containing two 
(cys 4) zinc finger domains (Evans 1988, Freedman et al. 1988, Hard et al. 
1990). Increased levels of testosterone and estradiol were observed 
throughout pregnancy and of course lower levels of testosterone are normally 
found in women than in men. Furthermore, Low levels of androgen and/or 
oestrogen were reported in obese people. Therefore, higher levels of PZ during 
pregnancy (Quack Loetscher et al. 2005, Ramsay et al. 2005) as well as higher 
levels found in men compared to women (Ravi et al. 1998) and in obese 
pregnant women compared to lean pregnant women (Ramsay et al. 2005) 
suggest a role for steroid hormones in PZ gene regulation.
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Fig 1.5. Organisation of the nuclear receptor structure, (a) The conserved architecture 
of nuclear receptors shows the locations of the ligand-independent activation function (AF1), 
DNA-binding domain (DBD), ligand-binding domain and the ligand-dependent activation 
function, (b) The DNA-binding domain of the rat glucocorticoid receptor (GR). The boxed 
amino acids are crucial for the distinction between glucocorticoid and oestrogen respose 
elements. The circled amino acids represent the region that essential for protein-protein 
interactions in the DBD-GRE complex, (c) The crystal structure of the DBD. The green 
spheres represent the zinc ions (Khorasanizadeh and Rastinejad 2001, Hard etal. 1990).
1.3.4.2. Inflammatory response
Inflammation is defined as a response of the tissue to injury and a defence 
mechanism for the organism against infections (Willoughby 1978). It is also 
defined as a responsive mechanism needed for re-establishing haemostasis 
(Medzhitov 2008). The inflammatory response, a part of the innate immune 
response, is a crucial step in restoring tissue damage, however, excessive 
inflammation can increase the severity of damaged tissue, and to avoid this 
many initiators of the inflammatory response can concurrently initiate reduction 
of inflammation (Anderson 2010). Inflammation is initiated exogenously by 
microbial and non-microbial inducers and endogenously by stressed, damaged 
or dysfunctioning tissues (Medzhitov 2008). The responses to inflammation can 
be regulated by cell-specific mechanisms which involve the regulation of the 
recruitment and activation of different cell types, signal-specific mechanisms 
which involve signalling pathways, and gene-specific mechanisms which 
function at individual gene and gene subset level (Medzhitov and Horng 2009). 
Cytokines, chemokines and other mediators of the inflammatory response 
which are produced by macrophages, mast cells (Medzhitov 2008), vessel
endothelial cells and fibroblasts (Ruminy et al. 2001) which are driven from 
microbial products ( e.g. lipopolysaccharide (LPS)) and the proinflammatory 
cytokines including tumor necrosis factor a (TNFa), interleukinl (IL1), interleukin 
17 (IL17) and interleukin 18 (IL18), lead to gathering of leukocytes at the site of 
damaged tissues. These proinflammatory cytokines and LPS bind to cell 
surface receptors in order to regulate inflammatory response genes at 
transcriptional and post-transcriptional levels (Kracht and Saklatvala 2002). 
The aggregation of proinflammatory cytokines on the receptors leads to 
oligomerisation of tissue necrosis factor receptor-associated factor (TRAF) and 
results in activation of the IkB and other kinase pathways (Kracht and 
Saklatvala 2002). Inflammation can induce activation of pre-existing inactive 
transcription factors. In this process, the inactive factor is dissociated from the 
inhibitory protein by means of different mechanisms such as ligand binding, 
alterations in protein-protein interaction or phosphorylation which then facilitates 
translocation to the nucleus to bind the appropriate response element and 
transactivate transcription (Perkins 1997). The promoters of inflammatory 
genes contain essential cis-elements for transactivating factors commonly 
NFkB, AP1, C/EBP and Ets (Kracht and Saklatvala 2002). A key 
transactivating factor which is important in the expression of inflammatory 
genes is NFkB. This transactivator, following activation of a relevant signal 
transduction pathway by LPS or interleukins, is dissociated from the inhibitory 
protein IkB in the cytoplasm. The dissociation of this factor is accomplished by 
degradation of IkB by proteases triggered by its phosphorylation and 
ubiquitination, allowing NFkB to translocate to the nucleus (Fig 1.6) and bind to 
its respective binding elements (Perkins 1997). Mutation or deletion of NF-kB 
or AP1 binding sites in the promoter of interleukin8 were found to impair its 
expression in response to inflammatory stimuli, indicating the essential role for 
the transactivating factors and their binding sites in the transcription of 
inflammatory genes (Mukaida et al. 1994). FVIII and tissue factor, proteins 
within the coagulation process, were reported to be induced by bacterial 
lipopolysaccharide (LPS) (Begbie et al 2000, Hall et al 1999). The NF-kB and 
AP1 binding sites in the tissue factor gene promoter and NF-kB and C/EBP 
binding sites in the FVIII gene promoter were found to be the LPS-responsive 
elements which are important in the expression of these genes. Previous
studies suggested that the PZ gene may also be regulated by inflammatory 
signals. For instance, levels of plasma protein Z were found to decrease in 
response to increasing levels of the cytokine interleukin 6 (IL-6) (Undar et al 
1999). Interleukin-4 (IL-4) and tumour necrosis factor (TNF-a) were found to 
have a down-regulatory effect on PZ, again supporting the hypothesis that this 
protein may be a negative acute phase protein (Vasse et al 2002).
Activator
Cytoplasm
Kinase
Phoshorylation
Ubiquitination
Nucleus 'anslocation
mRNA
GGGACTTTCC
Fig 1.6. The pathway leading to the translocation of NF-kB.
After cellular stimulation the NF-kB-IkB complex is phosphorylated by relevant signal 
pathways leading to degradation of IkB and its dissociation from NF-kB. The free NF­
kB, then, translocates to the nucleus to bind its DNA binding sites.
1.3.5. Role of chromatin structure in controlling expression
The architecture of chromatin plays an essential role in modulating the binding 
of transcription factors to the DNA and hence in regulating transcription (Wolffe 
and Guschin 2000). Chromatin is composed of a series of nucleosome core 
particles consisting of a histone octamer with about 160 base pairs of DNA
wrapped around it which are separated by regions of nucleosome-free linker
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DNA (Schrem, Klempnauer and Borlak 2002). The structure of chromatin is 
shown in figure 1.7. The histones H2A, H2B, H3 and H4 are the units that 
make up the histone octamer of the nucleosome core particle. Each octamer 
comprises two copies of an H3-H4 dimer which form a tetramer, with an H2A- 
H2B dimer on either side of the tetramer to form the octamer (Schrem, 
Klempnauer and Borlak 2002, Spencer and Davie 1999). A fifth class of 
histones, the linker histone (H1) with lysine-rich N and C-terminal domains, was 
found to maintain the stability of the DNA around the core histones by looping 
the nucleosomes on top of each other in order to further compact the DNA. 
This promotes formation of the 30 nm fiber characteristic of nucleosomeal 
organization (Spencer and Davie 1999, Stein et al. 1999, Hamon and Cossart 
2008).
Fig 1.7. The basic structure of chromatin.
The black spheres represent the histone octamers which with the DNA wrapped 
around them form what is called a nucleosome core particle. The linker DNA regions 
connect the nucleosome core particles (Stein et al. 1999).
The chromatin structure with a solenoid-type arrangement of folded 
nucleosomes shortens the distance between regulatory elements of the 
promoter which can act to facilitate interactions and, therefore, response to 
signaling pathways, resulting in the transcriptional control of target genes (Stein 
et al. 1999). Since the chromatin structure works as a barrier that prevents 
transcription, this structure has to be opened up or remodeled to facilitate the
Histone octamers
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accession of transcription factors for the control of gene expression (Demeret, 
Vassetzky and Mechali 2001).
A chromatin environment that allows transcription factors to interact with their 
respective DNA cis-elements is crucial for efficient gene transcription (Schrem, 
Klempnauer and Borlak 2002). There are two main levels of mechanism 
responsible for the modification and regulation of chromatin; firstly the post- 
transcriptional modification of histone tails by processes such as 
phosphorylation, acetylation, and methylation; and secondly the ATP- 
dependent remodeling of chromatin (Falbo and Shen 2006). Chromatin 
kinetics, directed by chromatin remodeling and histone modification, are very 
important in the regulation of gene transcription (Schrem, Klempnauer and 
Borlak 2002, Spencer and Davie 1999, Stein et al. 1999, Hamon and Cossart 
2008). Transcription is regulated by histone modifications through a two step 
mechanism, firstly the disruption of the connection between nucleosomes and 
then the encouragement of nonhistone proteins such as transcription factors to 
bind the DNA (Kouzarides 2007). The N-terminal tail is the most common site 
for histone modifications such as phosphorylation, methylation, acetylation and 
ubiquitinylation, however, these modifications might also occur in the histone 
core (Hamon and Cossart 2008). The chromatin remodeling is achieved by 
chromatin remodeling complexes which can alter the structure of the 
nucleosomes and their positioning (Demeret, Vassetzky and Mechali 2001). 
This change in the structure of the nucleosome affects the coiling of the DNA 
around the histone octamer, leading the DNA template to be accessible to its 
corresponding transcription factors (Schrem, Klempnauer and Borlak 2002, 
Falbo and Shen 2006).
Therefore, the modulation of chromatin structure by histone modifications and 
chromatin remodeling are the key mechanisms required for the transcriptional 
regulation of a genes. One of the advantages of using cell lines in studying 
gene expression, such as in overexpression and knock down techniques, is 
investigating the proposed endogenous gene within its intact chromatin context 
rather than using a purified in vitro system such as EMSA.
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1.3.6. Post-transcriptional regulation via the RNAi pathway
RNA interference (RNAi) is a process by which gene expression may be 
regulated at a post-transcriptional level. The two key RNA molecules involved 
in RNA interference are microRNAs (miRNAs) and small interfering RNAs 
(siRNAs). siRNAs are produced from a double stranded RNA (dsRNA) which 
can be made from inverted-repeat transgenes, viral infection or abnormal 
transcription products (Ghildiyal and Zamore 2009). Among the first natural 
siRNAs reported in mammals were those specific to the long interspersed 
nuclear element retrotransposon and were detected in cultured human cells: 
HEK293 (human embryonic kidney) and Hela (human epithelial carcinoma) cell 
lines (Yang and Kazazian 2006). RNAi is an increasingly important mechanism 
for the regulation of gene expression which restricts the level of the transcript of 
a gene by post-transcriptional silencing through the degradation of a specific 
sequence of RNA or the blocking of translation (Agrawal et al. 2003). As stated 
earlier RNA silencing can be accomplished by two species of small RNAs, 
miRNAs and siRNAs. The biogenesis, molecular characteristic and effector 
functions of these two species are basically similar, whilst their molecular origin 
and target recognition mode are different (He and Hannon 2004). The miRNA, 
which is produced from its genome-encoded precursor, binds imperfectly to the 
target 3’ UTR in order to negatively regulate expression at the translational 
level. By contrast, siRNA is cleaved from an exogenously introduced or 
endogenously bi-directionally transcribed (Hannon 2002) large double stranded 
DNA (dsDNA) and binds perfectly to its target mRNA causing cleavage (He and 
Hannon 2004).
RNAi, as well as being an important in vivo mechanism of post-transcriptional 
gene regulation, can also be utilised as a beneficial technique to study the 
function of genes in many organisms (Agrawal et al. 2003). The silencing of 
genes using siRNA can be exploited and used experimentally to modulate 
mRNA levels in cells for the analysis of most vertebral genes (McManus and 
Sharp 2002). The pathway of RNA interference by small double stranded 
RNAs (dsRNAs) was initially observed by Fire and his group (1998) when it was 
found that a mixture of sense and antisense RNA sequences of unc-22 gene 
had more potential interference with the endogenous gene activity than either 
RNA sequence alone (Fire etal. 1998). The trigger strands are required to form
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double stranded RNA and must have homology with the target RNA in order to 
initiate the interference (Parrish et al. 2000). The double stranded RNAs which 
mediate RNAi, known as siRNAs, were found to have a specific structure of 5’ 
phosphate, 3’ hydroxyl, being 21-22 nucleotides in length and having two 
nucleotide overhangs at the 3’ end (Fig 1.7a) (Elbashir, Lendeckel and Tuschl 
2001). siRNA was later reported to interfere with endogenous and 
heterologous genes in some mammalian cell lines (Elbashir et al. 2001). Two 
steps are essential for the RNAi pathway (Fig 1.7b), the cleavage of the large 
dsRNA into siRNA of 21 to 25-nucleotide by the RNA nucleases and the 
degradation of the corresponding single stranded mRNA by RNA-induced 
silencing complex (RISC) (Agrawal et al. 2003). The cleavage of the dsRNA is 
carried out by Dicer, an endoribonuclease enzyme of the RNAse III family of 
nucleases which is conserved in neurospora, drosophila, caenorhabditis and 
mammalia (Bernstein et al. 2001). RISC, which leads to the degradation of the 
mRNA, contains a single-stranded antisense siRNA residue links the mRNA 
and at least one member of the argonaute protein family (Martinez et al. 2002).
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Fig 1.8. The siRNA structure and the RNAi pathway.
(a) siRNA shows its 23 nt with 2 nt overhanging at 3’ end. (b) The RNAi pathway shows the 
two steps lead to the degradation of mRNA. Dicer is a nuclease enzyme involved in the 
formation of the siRNA in the first step. In the second step, The antisense strand of the 
siRNA binds the homologous sequence in the mRNA and leads to its cleavage and 
subsequently degradation, nt = nucleotides. RISC= RNA-induced silencing complex.
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1.4. Aim of the study
The object of this study was to elucidate the mechanisms responsible for 
controlling the synthesis of Protein Z (PZ), a protein with reported pro and 
anticoagulant properties. PZ plasma levels vary widely in the normal 
population; despite this, lowered levels have been associated with a bleeding 
tendency in some individuals and thromboembolic complications in others. 
Hence, PZ level interacting with genetic and/or environmental background 
appears to determine pathological consequence.
The major aim of this work was, therefore, to investigate the proposed 
hypothesis that a significant degree of the observed variation in PZ level arises 
as a consequence of inter-individual differences in rate of transcription from the 
PZ gene locus. The mechanisms of transcriptional activation of the PZ gene 
were investigated toward possible regulatory processes in common with other 
evolutionarily related haemostatic factors and also those regulatory processes 
likely to account for the inter-individual variation. Firstly, it was investigated 
whether the PZ promoter contains the same liver-restricted and age-stable 
regulatory elements reported in other, related haemostatic factors, factor IX and 
protein C. Secondly, the wide inter-individual variation in PZ level suggests that 
it may be an acute phase reactant and, therefore, evidence of transcriptional 
elements associated with this physiological response in the PZ promoter were 
sought. Finally, the effect of steroid hormones, which themselves show inter­
individual variation in level according to age and medication, were analysed for 
their potential effects in modulating transcriptional activity of the PZ gene.
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2.1. DNA sequencing
In order to validate the sequence of the PZ gene promoter in HepG2 (ECACC, 
UK) the promoter was compared with the sequence of the wild type PZ gene 
promoter. The wild type PZ gene promoter (Homo sapiens protein Z, 
AF440358, National Centre for Biotechnology Information) was divided into 
three regions overlapping each other which together spanned nucleotides -1884 
to +106 relative to the translation initiation site at nucleotide +1. Region 1 
spanned nucleotides -1883 to -1284, region 2 spanned nucleotides -1352 to - 
608 and region 3 spanned nucleotides -716 to +217. Primers were designed for 
each region in order to allow amplification by polymerase chain reaction (PCR). 
The primers for each region were designed using the webprimer website 
(http://www.yeastgenome.org/cgi-bin/web-primer) and synthesised by Eurofins 
MWG \ Operon (Eurofins MWG Operon, UK). The sequences of the designed 
primers are shown in table 2.1. The PCR reactions were performed in the 
Primus 96 plus PCR machine (MWG-BIOTECH, UK) using genomic DNA 
prepared from HepG2 cells using the GenElute Mammalian Genomic DNA 
miniprep kit (Sigma-Aldrich, UK), and the designed primers.
Primers description
PZ promoter
Forward
PZ promoter
Reverse
PZ promoter
Forward
PZ promoter
Reverse
PZ promoter
Forward
PZ promoter
Reverse
region-1 - 
region-1- 
region-2- 
region-2- 
region-3- 
region-3-
Sequences
S’-CCTGTCTGCCTTTCCATTTT-S’ 
5’-GATTGGGAGGATGGCAGTG-3’ 
5’-CC AAACCT CGCTT CCCTCT -3’ 
5’-TTT C AG AT GTAG G C CCTGTGT-3’ 
5’-C AT GTG G AACT G G G AGT C AA-3’ 
5’-C AAAC AG CTTTTT C AG G G G A-3’
Table 2.1. Oligonucleotide primers used for PZ promoter sequencing.
The primers of the PZ gene (Homo sapiens protein Z, AF440358, National Centre for 
Biotechnology Information) promoter were designed using a webprimer website and 
synthesized by Eurofin MWG Operon. Region-1 primers amplify 600 bp fragment (-1883  
to -1284), region-2 primers amplify 746 bp fragment (-1352 to -608), and region-3 
primers amplify 934 bp fragment (-716 to +217).
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2.1.1. PCR of sequencing template
To amplify the three regions of the PZ gene promoter for sequencing, PCRs 
were accomplished using the primers of each region and the prepared DNA 
from Human Caucasian hepatocyte carcinoma-derived (HepG2 cells) (ECACC, 
UK). PCR is an in vitro technique by which a specific DNA segment can be 
amplified using two specific primers that hybridise to opposite DNA strands 
(Sharma, Singh and Sharma 2002). Large quantities of specific DNA can be 
generated, in a single enzymatic reaction, from a complex DNA template within 
a matter of hours. PCR is performed in three clearly defined steps, DNA 
denaturation, primer annealing and primer extension (Sharma, Singh and 
Sharma 2002). The PCR cycle conditions used to amplify the regions of the PZ 
promoter for the sequencing were as follow: Firstly, one step at 9 5 C  for 2 
minutes, to ensure complete denaturation of the DNA template, followed by 30 
cycles of 95 C for 1 minute for DNA denaturation, annealing temperature of the 
proposed primers for 1 minute, to anneal the primers to their complementary 
regions, and 72°C for 1 minute for the extension of the primers by the Taq 
polymerase in order to synthesis complementary strands. Finally, 5 minutes at 
72 C was performed to ensure all the single-stranded DNAs were extended and 
formed double stranded DNAs, followed by a holding step at 4°C for short-term 
storage. The annealing temperature for the primers as well as MgC^ 
concentration used to amplify each region in the PZ gene promoter are shown 
in Table 2.2.
Primers of different PZ 
promoter regions
MgCI2
concentration
Annealing
temperature
promoter region-1 primers 1 mM 53 C
promoter region-2 primers 1 mM 52 C
promoter region-3 primers 2 mM 63 C
Table 2.2 Annealing temperatures and MgCI2 concentration used to amplify different 
PZ promoter regions for sequencing. The fragment of PZ gene promoter region-1 (-1883 
to -1284) was amplified using the respective primers at annealing temperature of 53 °C and 
MgCI2 concentration of 1 mM. Region-2 (-1352 to -608) was amplified using the designed 
primers at annealing temperature 52 °C and MgCI2 concentration of 1 mM while region-3 (- 
716 to +217) amplified at annealing temperature 63 °C and MgCI2 concentration of 2 mM. 
These amplified regions were used in the sequencing of PZ gene promoter. The genomic 
DNA template used to amplify the different PZ gene promoter was prepared from the HepG2 
cells usina GenElute Mammalian Genomic DNA minioreo kit (Siqma-Aldrich. UK).
28
The amplified fragments were electrophoresed, to check their quality, on 1% 
w/v agarose gel running in 1X Tris-Borate EDTA (TBE) buffer (Sigma Aldrich, 
UK) using 10 volt./cm and detected using 400 ng/ml ethidium bromide (Sigma 
Aldrich, UK) which was visualized using a UVP Biolmaging system.
2.1.2. Preparation of the 1% agarose gel
The 1 % agarose gel was prepared by dissolving 0.5 g of agarose powder 
(Promega Corporation, UK) in 50 ml of 1X TBE, using a microwave. The 
solution was left to cool down to about 50 °C and 2 pi of ethidium bromide (10 
mg/ml) was added. The gel tray was prepared by sealing the ends with tape 
and a comb was placed about 1 inch from the end of the gel tray before pouring 
the agarose solution to the tray to a depth of about 5 mm. The gel was left to 
solidify for 30 minutes at room temperature. The comb was then removed 
before placing the gel tray in the electrophoresis chamber.
2.1.3. Purification of amplicons
Prior to employing the PCR amplified DNA products from the different PZ 
promoter regions in sequencing, it is necessary to purify the products, removing 
any dNTPs and primer remnants which might interfere with the sequencing 
procedure. The Exonuclease I / Shrimp Alkaline Phosphatase (ExoSAP-IT) 
method was used to clean up the PCR products and remove these 
contaminants. The ExoSAP-IT (USB Europe GmbH, Germany) method has 
many advantages such as ease of use and speed, consistent performance from 
sample to sample and no sample loss. 2pl of the ExoSAP-IT reagent was 
mixed with each 5pl of the PCR product and incubated for 15 minutes at 37 C, 
to degrade remaining nucleotides and primers, followed by 15 minutes 
incubation at 80 C to inactivate the reagent. The purified products were then 
sent to the Genetic Core Facility, Sheffield Medical School for sequencing. 
BigDye v.3.1 terminator sequencing chemistry (Applied Biosystems, UK) was 
used and the results were analysed on the ABI3730 capillary electrophoresis 
system (Applied Biosystems, UK).
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2.2. Protein-DNA binding studies
The study of Regulatory systems that control gene expression forms a major 
area of interest in modern biology. One of the essential steps in gene 
expression is the control of transcription (Nagaraj, O'Flanagan and Sengupta 
2008). Protein-DNA binding is an essential step in the transcriptional regulation 
process and therefore, accurate recognition of transcription factor binding sites 
is very important in understanding complex gene expression patterns (Morozov 
et al. 2005). In order to perform protein-DNA binding studies, nuclear extracts 
should be prepared and incubated with a labelled double stranded DNA probe 
spanning the binding site of the proposed transcription factor.
2.2.1. Nuclear extract preparation
Nuclear extracts were prepared using a rapid micropreparation technique 
(Andrews and Faller 1991). Hep G2 cells (approximately between 2.0 to 2.5 x 
107 cells) were scraped into phosphate buffered saline, pelleted and then 
resuspended in buffer A (10mM Hepes-KOH pH 7.9, 1.5mM MgCI2,10mM KCI, 
0.5 mM DTT, Protease inhibitor cocktail (Sigma-Aldrich, UK)). The Hep G2 
cells were swollen in the hypotonic solution, on ice for 10 minutes, and vortexed 
for 10 seconds to extract the nuclei. The nuclear pellet was recovered by 
centrifugation at 16.1 x103 g for 10 seconds and resuspended in ice-cold buffer 
C (20mM Hepes-KOH pH 7.9, 2.5% glycerol, 420mM NaCI,1.5mM MgCI2, 
0.2mM EDTA, 0.5mM DTT, 1% (v/v) protease inhibitor cocktail) and incubated 
for 20 minutes on ice for high salt extraction of nuclei. The suspension was 
centrifuged again at maximum speed (16.1 x103 g) at 4°C for two minutes and 
the supernatant (nuclear extract) was stored at -80°C. The protein 
concentration was determined by the Bradford assay.
2.2.2. Bradford Protein Assay
Quantification of protein is necessary before processing protein samples for 
electrophoretic analysis. There are many methods for protein quantification 
such as Lowry (Lowry et al. 1951), Bicinchoninic acid (Smith et al. 1985) and 
Bradford protein (Bradford 1976) assays. One of the easiest and fastest protein
assays with high performance is the Bradford protein assay. The Bradford
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protein assay is a biochemical assay used for the determination of protein in a 
solution. Protein concentration is measured by a colour change which can be 
quantified using colourimetric techniques. Protein binding to the coomassie dye 
in an acidic environment causes a shift in spectrum from maximum absorbance 
at 456 nm (reddish/brown form) to maximum absorbance at 610 nm (blue form) 
with the greatest difference between the two forms at 595 nm. Different 
concentrations of Protein standards were made from a 10 mg/ml stock solution 
of bovine serum albumin (Promega Corporation, UK). In a 96 well plate 
(Thermo Fisher Scientific, UK), 5pl of each standard and sample (undiluted, 1:2, 
1:5, and 1:10 dilutions) were pipetted in triplicate. 250pl of Bradford reagent 
(Sigma Aldrich), a brilliant Blue G in phosphoric acid and methanol, was added. 
The 96 well plate was left to incubate at room temperature for 30 minutes 
before absorbances were recorded at 595nm on a GENios Plus reader (Tecan 
Group Ltd.). The absorbances of the different albumin concentrations were 
measured to plot a standard curve (Figure 2.1), which was then used to 
determine the protein concentration of the sample.
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Fig 2.1. Standard curve for measuring the concentration of the HepG2 nuclear 
extract. Different concentrations of bovine albumin were prepared and the absorbance of 
each concentration was measured at 590 nm using GENios Plus reader. The 
absorbances were plotted against their respective albumin concentrations to generate a 
standard curve. The axis (x) represents different albumin concentrations while the axis (y) 
represents the absorbance of each concentration. The concentration of the the nuclear 
extract was measured from its absorbance using the equation derived from the standard 
curve, where x is the concentration and y is the absorbance of the unknown sample. The 
value of coefficient of determination (R2) was high (0.99), revealing the close of the data 
points to the trend line.
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2.2.3. Double stranded DNA Probe preparation (Fluorescent and biotin 
labelled)
Detection of protein-DNA binding using a probe encompassing the putative cis- 
element is one of the most important steps for the characterization of gene 
transcriptional regulation (Garner and Revzin 1981). The recommended probe 
length used in EMSA is between 20 to 40 base pairs and spans the putative 
protein binding site region (Kako etal. 1998).
The in silico prediction (ALGGEN-PROMO) of putative binding sites was used 
to determine the hypothetical binding sites for a number of transcription factors 
in the PZ gene promoter. The determined sequences for the hypothetical 
binding sites were then synthesised by Eurofin MWG \ Operon (Eurofins MWG 
Operon, UK), for the biotin and infra red 700 labelled probes, and by Sigma 
Aldrich (Sigma Aldrich, UK), for Cy5.5 labelled probes. Other unlabeled 
oligonucleotides used in competition reactions were synthesized by Eurofins 
MWG \ Operon, UK. The sequences of the probes with their labelling and the 
unlabeled oligonucleotides used in this study are shown in Table 2.3.
Probes
pPZ ASE-Biotin 
dPZ ASE-Biotin 
FIX-ASE 
hPC-ASE 
PZ-PEA3(1)-IRD 
PZ-PEA3(2)-IRD 
pPZHNF4a-cy5.5 
dPZHNF4a-IRD 
PEA3 consensus 
HNF4a Consensus 
CREB consensus 
HNF3B consensus 
AP1 consensus 
SP1 consensus
Table 2.3. Fluorescent labeled and unlabeled oligonucleotides used in EMSA.
The oligonucleotides were synthesized by Eurofins MWG Operon. The bold types indicate 
putative binding site for the proposed protein. Oligonucleotides without bold type represent the 
non-specific competitors used in the assay, (p) represents the proximal site relative to the 
translation start site while (d) represents the distal site.
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Sequences
5'-AAAC GTCAGGAGG G AAG C AC-3’ 
5'-TTTTAT A AG GAT CTG G CATT-3’
5'-TT C AGT CGAGGAAG G ATAG G GT-3’ 
5'-TCGGAGCAGGAAGACGCTTA-3’ 
5’-GACTGCAAACGTGCTTCCTGCTGCATGGCT-3’ 
5’-AT CAGCTTT CCCTTCCTG AAGCAT CCA-3’ 
5’-CCCAGCCTGGACTTTGGCTG-3’
5’-AAG CT G CAT GT G ACTTT GTCTG-3’ 
5-GAT CT C G AG CAGGAAGTT CG A-3’
5’-CT CAG CTT GT ACTTTGGTACAACT -3’ 
5'-AGAGATTGCCTGACGTCAGAGAGCTAG-3' 
5’-CAACTAAACCTCTTTTCTTAAATTA-3’ 
5’-CGCTTGATGACTCAGCCGGAA-3’ 
5’-ATTCGATCGGGGCGGGGCGAG-3’
Homology
to
consensus
6/7
5/7
6/7
7/7
7/7
7/7
9/11
7/11
2.2.4.1. Electrophoretic Mobility Shift Assay (EMSA)
The electrophoretic mobility shift assay has been used extensively in DNA- 
protein interactions studies (Fried and Crothers 1981, Revzin 1989). The 
principal of this technique relies on the fact that protein bound-DNA migrates 
more slowly than non-bound DNA in a native polyacrylamide gel. This assay is 
an easy, rapid, and very sensitive means of detecting protein-bound DNA. 
Proteins that bind to the probe fragment cause discrete bands of protein-DNA 
complexes (Buratowski and Chodosh 2001). Before starting the experiment, 
the forward and reverse oligonucleotides spanning the proposed binding site 
should be annealed. This was done by mixing 1pMol/pl of each oligonucleotide 
(forward and reverse) in 25 mM KCI and incubating at 95 C for 5 minutes in a 
heating block. The mixture was then left to cool slowly in the switched off 
heating block for the annealing of the oligonucleotides to form double-stranded 
DNA.
20pl binding reactions containing 10 fmole biotin labelled double stranded DNA 
or 100 fmole fluorescent labelled double stranded DNA flanking the putative 
binding site, approximately 4pg /12pg HepG2 nuclear extract (HepG2 NE), 1pg 
of non-specific competitor Poly dl-dC (Sigma Aldrich, UK) and binding buffer 
(10mM Tris-HCI, pH 7.5, 50mM NaCI, 1mM DTT, 1mM EDTA, 19%v/v glycerol, 
10pl protease inhibitor cocktail) were incubated at room temperature for 20-30 
minutes for protein-DNA binding. The samples were size-fractionated through a 
5% w/v, 19:1 acrylamide/bis-acrylamide (Sigma Aldrich, UK) mini (8 x 8 x 0.1 
cm) gel, using a voltage of ~ 12.5 V/cm, in 1x Tris-Borate EDTA (TBE) buffer 
(89 mM Tris-borate and 2 mM EDTA). The 5% polyacrylamide gel was 
prepared by mixing 2 ml of 5X TBE (Sigma Aldrich, UK) with 1.66 ml of the 
acrylamide/bis-acrylamide (30%), 100 pi of 10% w/v ammonium persulfate 
(Sigma Aldrich, UK) for polymerisation and 10 pi of Tetramethylethylenediamine 
(TEMED) (Sigma Aldrich, UK) to initiate the polymerisation in a total volume of 
10 ml. The probes were then transferred (for biotin-labeled probes) to nylon 
membrane (Fluka Biochemika, UK) using an electrophoretic transfer unit (Bio- 
Rad, UK) using a voltage of ~ 12.5 V/cm for approximately 40 minutes at 4°C in 
0.5X TBE. Detection of biotin-labelled DNA was carried out using a 
chemiluminescent EMSA kit (Perbio, UK) which depended on a streptavidin 
horseradish peroxidase conjugate (See EMSA optimisation chapter,Section
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3.3.4) and the signal was visualised by the UVP Biolmaging system (UVP, UK). 
Fluorescently labelled DNA-protein complexes were detected using the Li-Cor 
Odyssey Imaging System (Li-Cor Biotechnology, UK Ltd) (See EMSA 
optimisation chapter,Section 3.3.4). Competition reactions were carried out 
with the indicated fold molar excess of unlabelled competitor added 
concurrently with the labelled probe.
2.2A.2. EMSA confirming the identity of the bound protein
To identify the transcription protein bound to the probe, all the steps in the 
previous section were performed with a specific antibody against the potential 
protein added to the binding reaction. The proposed antibody (Santa Cruz, 
Germany) was added to the binding buffer and HepG2 NE and incubated for 10 
minutes at room temperature before adding the probe for a further incubation of 
30 minutes. The antibody-protein-DNA complex, which is bigger in size than 
without the antibody, should normally form a supershift band with lower mobility.
2.3. Gene expression studies
The effect of selected transcriptional modulators on the expression of 
endogenous PZ was determined in the whole cell context by quantitative real­
time PCR (qPCR), using appropriate transcription factor expression plasmids 
and small interfering RNAs (siRNAs).
2.3.1. RNA preparation from HepG2 cells
The preparation of RNA is one of the essential steps in gene expression studies 
using qPCR. RNA was extracted from HepG2 cells using a GenElute 
mammalian total RNA miniprep kit (Sigma-Aldrich, UK). The cells were lysed 
using the lysis buffer (500-250pl of lysis buffer and 5-2.5 pi p-mercaptoethanol 
depending on the number of the cells). The lysate was transferred to a 
GenElute filtration column and centrifuged at 13,300 rpm for 2 minutes to 
remove cellular debris and shear DNA. An equal volume of 70 % v/v ethanol 
was added to the filtered lysate for RNA precipitation before loading the sample 
on to a silica binding column. After binding the RNA to the column, the column
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was washed with proprietary wash solution 1 and wash solution 2 from the kit to 
remove any residual proteins and salts. Finally, RNA was eluted in 50pl of 
elution buffer solution to release the RNA from the silica. Extracted RNA was 
treated with DNasel, Amp-D1 kit, (Sigma-Aldrich, UK) to prevent contamination 
of the sample with genomic DNA. 50pl ( average ~ 50pg) of extracted RNA 
was treated with 5pl of 10X reaction buffer (200 mM Tris-HCI, pH 8.3, 20 mM 
MgCh) and 5pl (5 units) of amplification grade DNase 1. The sample was 
incubated at 37°C for 30 minutes and then DNase 1 was inactivated by 
incubation at 70°C for 10 minutes after adding 5pl of 50 mM EDTA stop solution 
to chelate the divalent cations required by DNase for activity. The RNA was 
then stored at -80°C.
2.3.2. Analysis of RNA by agarose gel electrophoresis
The preparation of good quality RNA is one of the important steps in studying 
gene expression using qPCR. Degraded or impure RNA will affect the qPCR 
efficiency and give an inaccurate indication of gene expression (Applied 
Biosystems literature). Extensively degraded RNA samples should be excluded 
from real time PCR analysis (Miller et al. 2004). Nevertheless, RNA with 
moderate degradation might be used in gene expression analysis (Schoor et al. 
2003) with the expression of genes in microarray analysis using a degraded 
RNA was found to be very constant when the cDNA synthesis primed properly 
(Xiang et al. 2003). Extracted RNA from HepG2 was checked for concentration 
and purity using the NanoDrop®ND-1000 spectrophotometer (NanoDrop 
Technologies, USA). The integrity of RNA samples was analysed by size 
fractionation on 1% w/v agarose gels (See section 2.1.2 for agarose gel 
preparation). The samples were electrophoresed (10 volt/cm) on the gel for 
approximately 40-50 minutes, the bands were detected using ethidium bromide 
(400ng/ml) and then visualized on the UVP Biolmaging system. A good quality 
total RNA sample shows two bands of the ribosomal RNA, 18S and 28S.
2.3.3. cDNA synthesis
A single-stranded cDNA was transcribed using the iScript cDNA synthesis kit 
(Bio-Rad, UK). In each 20pl cDNA synthesis reaction 500 ng RNA, 10-14pl
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ddhbO, 4pl of iScript buffer and 1pl of reverse transcriptase (1U) were mixed. 
Reaction tubes were incubated at 25°C for 5 minutes, for efficient annealing of 
the random primers and then heated to 42°C for 30 minutes, the optimum 
temperature for reverse transcriptase activity and finally heated to 85°C for 5 
minutes to stop the reaction. These steps were carried out in a thermocycler. 
All cDNA samples were stored at -20°C before being used for real-time PCR.
2.3.4. Real-time PCR
Real-time PCR is becoming the major technique used in the detection and 
quantification of gene expression profiles (Deepak etal. 2007).
The great advantages of real-time PCR have enabled this technique to be one 
of the most broadly used methods in the field of gene expression quantification 
(Wong and Medrano 2005). The kinetics of this technique comprise four major 
phases: the early ground phase, early exponential phase, log-linear growth 
(exponential) phase and plateau phase (Fig 2.2). The quantitative information 
for the expression of a gene of interest is presented relative to the expression of 
a reference gene (Tichopad et al. 2003). The use of the terms cycle threshold 
(Ct), at which fluorescence for a gene is detectable above background, or 
Crossing point (Cp), or take-off point (TOP) depends on the instrument being 
used, but all have the same meaning, which should be referred to as 
quantification cycle (Cq) according to the Real-time PCR Data Markup 
Language (RDML) (Lefever etal. 2009).
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Fig 2.2. Real time PCR amplification curve showing the four major phases.
The graph shows the accumulation of the emitted fluorescence at each PCR cycle. The Y-axis 
indicates the magnitude of signal produced during PCR and the X-axis represents number of
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2.3.4.1. Primer design and efficiency
The primers used to amplify the cDNA synthesized from the mRNA of the gene 
under investigation were all designed to span at least one intron-exon boundary 
in the genomic DNA locus encoding the gene of interest. This was to ensure 
amplification of the cDNA, not the genomic copy of the gene. Short amplicons 
are recommended as they are more likely to denature at 95°C, allowing the 
primers and probes to bind their complementary sequence and hence produce 
efficient amplification (Bustin 2000). All the primers used in the qPCR 
procedure were therefore designed to produce a product of 90 to 170 base 
pairs. The designed primers were synthesized by Eurofins MWG Operon 
(Eurofins MWG Operon, UK) for SYBR green PCR and by Applied Biosystems 
(Applied Biosystems, UK) for TaqMan PCR. The comparative Cq qPCR 
(qPCR) is not accurate unless the amplification efficiency of both target and 
reference genes is highly similar and close to 100% (Liu and Saint 2002). The 
primer efficiency was calculated by diluting the cDNA template with serial 
dilutions (undiluted, 1:10, 1:100, 1:1000). PCR reactions for the primer of 
interest were carried out in triplicate. The Cq values for each dilution were 
determined and plotted against the logarithm of the cDNA concentrations. The 
slope was derived from the standard curve and used in the equation:
Efficiency = -1 + 10(-1/Sl°pe)
The primers which were used in the current study are shown in Table 2.4.
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Gene Forward primer Reverse primer Accession
number
intron-exon
boundaries
Primer
efficiency
PZ 5-TGGTGGTGTT 
ATAATAC GGGA-3'
5'-GGTCTTGGCT
CGTTCTGTTAA-3'
NM_003891 1 86%
PZ(2) 5-'AGGAAAAGAC
TTCTGTGGTGG-3'
5-TGCACATGG
ACGTGCGTTAT-3'
NM_003891 1 98%
PEA3 5-TGAGAAACCT
CTGCGACCATT-3'
5-CTCTCGAAA
TGCACCGACC-3’
NMJD0198B 1 96%
AR 5-CAATGTCAAC
TCCAGGATGCT-3'
5'-TGATTTGGA
GCCATCCAAAC-3'
NM_001011645 1 88%
GR 5-TTGGAGGATC
ATGACTACGCT-3'
5-ATCTCCACC
CCAGAGCAAAT-3'
NM_001018077 1 99%
OR 5-CAAATGCTAC
GAAGTGGGAAT-3'
5'-AAGGTTGGC
AGCTCTCATGT-3'
NM_001122741 1 96%
UBC 5'-ATTTGGGTC
GCGGTTCTTG-3'
5'-TGCCTTGACA
TTCTCGATGGT-3'
M26880 1 95%
YWHAZ 5-CCGCCAGGA
CAAACCAGTAT-3'
S’-ACTTTTGGTACA
TTGTGGCTTCAA-3'
NM_003406 0 95%
GAPDH 5-GGCATGGACT 
GT GGT CATGAG-3'
5-TGCACCACC
AACTGCTTAGC-3'
NM_002046 1 96%
Beta
Actin
S'-AAGGGACTTCC 
TGTAACAATG CA-3'
5-CTGGAACGGT
GAAGGTGACA-3'
NMJ001101 0 94%
Table 2.4. Oligonucleotide primers used in reference gene validation and SYBR Green 
chemistry quantitative PCR. The primers were designed to produce amplicon crosses two 
exons using Web primer website and synthesized by Eurofin MWG Operon. The primers were 
designed using the accession numbers (National Centre of Biotechnology information) of each 
gene which indicated in the table. The primers of the house keeping genes were taken from 
Vandesompele et al. 2002. YWHAZ is tyrosine 3-monooxygenase/tryptophan 5- 
monooxygenase activation protein, zeta polypeptide. GAPDH is Glyceraldehyde-3-phosphate 
dehydrogenase while UBC is a ubiquitin C. PZ, AR, GR and OR are protein Z, androgen 
receptor, glucocorticoid receptor and oestrogen receptor, respectively. Number 0 indicates the 
primers spanning within the same exon while number 1 indicates the primers which span an 
interon-exon boundary. The efficiencies of the primers were calculated by the equation shown 
above after deriving the slope from standard curve plotted for the logarithm of different cDNA 
concentrations against the Ct value for each concentration.
2.3.4.2. Validation of reference gene
Reference genes are needed to perform gene expression studies using qPCR 
and those genes should be selected carefully as their expression level may vary 
between different tissues and under different conditions (Cicinnati et al. 2008). 
The house keeping gene used in qPCR should be referred to as the reference 
gene according to the Real-time PCR Data Markup Language (RDML) (Bustin 
et al. 2009). The reference gene was selected from a set of four house keeping 
genes ((3-actin, GADPH, UBC, and YWHAZ) with primer seqeunces taken from 
Vandesompele et al. (Vandesompele et al. 2002).
The initial assessment of stable reference gene expression was done by 
performing qPCR for the set of house keeping genes using transfected
samples. This allowed the identification of the gene with the most stable
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expression in the presence of an over-expression of the HNF4a transcription 
factor. This reference gene was also found to be stably expressed in response 
to other treatments by assessing the consistency of the raw Cq values. The 
location of the primers and the sequence of the house keeping genes and other 
genes used in qPCR are shown in Table 2.4.
2.3.4.3. Different chemistries in real time PCR
A selection of different fluorescent chemistries can be used to correlate PCR 
product concentration with fluorescent intensity (Higuchi et al. 1993). Two PCR 
chemistries were used in this project.
SYBR green I chemistry
SYBR green I, a DNA dye, is a fluorophore used in qPCR that is more cost- 
effective when compared with fluorescent probes. The SYBR green chemistry 
of qPCR is based on the fluorescent emission of SYBR green upon binding to 
double stranded DNA (Gibson 2006) which is proportional to the amount of 
PCR amplified product in every cycle (Fig 2.3) (Applied Biosystems). SYBR 
green dye interacts with the minor groove of the DNA and its high binding 
affinity to dsDNA is due to the two positive charges, from one of the aromatic 
systems of the cyanine, and the protonation of the amino group, that it 
possesses (Zipper et al. 2004). One advantage of SYBR green chemistry is not 
requiring a specific fluorescently labelled probe for each amplification target. 
However, the disadvantage is that all double stranded DNA products will 
contribute to the fluorescent signal, including non specific amplicons and primer 
dimers (Newby, Hadfield and Roberto 2003). However, although it is 
considered as a non-specific dye, SYBR green is ideal for use in real-time 
qPCR in the absence of interfering DNA such as primer-dimers which compete 
with the specific product and might lead to unreliable results (Kubista et al.
2006). In order to identify these potential non-specific products a melt curve 
analysis is carried out at the end of the amplification. The Melt curve is 
generated by monitoring the fluorescence from the reaction as a function of 
temperature. A signal from the desired amplicon would be seen as a single 
peak on a derivative plot of fluorescence against temperature (Ririe, 
Rasmussen and Wittwer 1997).
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DNA Denaturation
Primer annealing
Primer extension
PCR product
Fig 2.3. Real time quantitative PCR cycles using SYBR green I dye.
The schematic chart shows the different steps from denaturation of the dsDNA to amplification 
of the product. Free SYBR green dye is unfluorescent which starts fluorescing upon binding 
the DNA template. The more fluorescence emitted the much product amplified.
A relatively good melt curve, as an example, was shown in the current study for 
the reference gene UBC and the target PZ gene (Fig 2.4). This was achieved 
by increasing the temperature of the amplicon slowly above its melting 
temperature, which depends on the nucleotide composition. The amplification 
of artefacts normally melt at lower temperatures compared with the specific 
amplicon (Bustin 2000). The qPCR was performed by mixing 10pl of (2X) 
power SYBR green mix (Applied Biosystems, UK), 10 pMol (1pl) of each primer 
and 6pl of DNase free water. 2pl of the tested cDNA was added to the reaction 
mixture in the 48-well plate which was placed in the StepOne v2.1 PCR 
instrument (Applied Biosystems, UK) to measure the relative expression of PZ 
gene. The housekeeping gene UBC (See Table 2.4) was used as an 
endogenous reference to normalise data. The PCR cycles were as follows: 
95 C for 15 minutes to activate the SYBR green mix followed by 40 cycles of the 
following steps; 95°C for 15 seconds to denature the cDNA, 55 C for 15 
seconds to anneal the primers, and 72 C for 30 seconds to extend the primers 
by the Taq polymerase.
Melt curve: denaturation at 95 C for 15 seconds, annealing at 60 C for 1 minute 
increasing in 0.3 C increments.
4 0
Melt Curve
or
Fig 2.4. Melt curve of PZ and UBC with transfected and non transfected samples. Green 
and red lines represented the UBC melt curve with untransfected and transfected samples, 
respectively. Dark blue and light blue lines represented the PZ melt curve with untransfected 
and transfected samples, respectively. No contamination or primer dimers were detected 
which would be characterised by an additional shoulder in addition to the main peak.
TaqMan chemistry
In this chemistry an oligonucleotide (probe) labelled with fluorescent dye at the 
5’ end and a quencher dye at the 3’ end are used. During PCR (Fig 2.5) the 
Taq DNA polymerase cleaves the fluorescent dye from the quencher in the 
hybridized probe causing an increase in the fluorescence intensity (Livak et al. 
1995). The 5’ endonucleolytic activity of Taq DNA polymerase is exploited 
during real time PCR amplification in the cleavage of the TaqMan probe 
causing a sequence-specific detectable signal from the separation of 
fluorophore and the quencher (Gibson 2006). Each 20pl of qPCR reaction 
contained 10pl of (2X) TaqMan® fast universal PCR master mix (Applied 
Biosystems, UK), 10 picomole of the probe with the two primers of the proposed 
gene, 7pl of Dnase free water and 2pl of the cDNA was added later to the 
mixture in the 48-well plate. An endogenous reference gene was used to 
normalise data.
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Fig 2.5. Real time PCR steps using TaqMan chemistry.
R is reporter dye and Q is quencher dye. After the probe hybridization and the 
polymerisation the Taq polymerase activity cleaves the probe from the quencher. The 
intensity of the fluorescence increases as the free reporter dye is no longer quenched.
The PCR cycles were as follows:
95 C for 20 seconds as a holding stage followed by 40 cycles of the following 
steps; denaturation at 95 C for 1 second and annealing at 60°C for 20 seconds.
2.4. Cell culture, validation, transfection and stimulation
2.4.1. Culturing of HepG2 cells
The restriction of using normal somatic human cells in research studies and 
biotechnology applications, in part, is due to their finite proliferative potential 
before becoming senescent (Hayflick and Moorhead 1961). For this reason 
and the difficulty in acquiring human tissue samples, immortalised human cell 
lines have been commonly used in research assays, despite the fact that they 
are abnormal cells and might show certain abnormal aspects. There are many 
means by which immortalized cell lines can be created including tumor-derived
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cell lines, DNA tumour virus transduction (Katakura, Alam and Shirahata 1998) 
and induction of telomerase activity (Yeager and Reddel 1999). HepG2 cells 
(ECACC, UK), which have been used in this study, were grown in MEM 
medium with 10% v/v fetal calf serum, 2mM L-glutamine, 50 unit of penicillin 
and 50pg of streptomycin per ml and 1X non essential amino acids (Invitrogen 
limited, UK) and incubated in a humidity controlled environment at 37°C / 5% 
CO2 . The cells were passaged by rinsing first with 1X phosphate buffered 
saline (Invitrogen limited, UK) which contains monobasic potassium phosphate, 
sodium chloride and dibasic sodium phosphate. The cells were then detached 
using 5 ml of Trypsin/EDTA (0.5 g/l Trypsin and 0.2 g/l EDTA) by incubating at 
37°C and 5% CO2 for approximately 5 minutes. Cells were recovered by 
agitating the flask, transferring to a 50 ml centrifugation tube where an equal 
volume of complete medium was added to neutralize the trypsin, and 
centrifugation at 1000 rpm (400 g) for 5 min. The recovered cells were re­
plated at a density of approximately 1.2x105 cells/ml. The cells take 
approximately 7-9 days to form a confluent monolayer, until then the growth 
occurs in islands (Fig 2.6). Cells were passaged when 80 to 90 % confluent. 
HepG2 stocks were prepared by suspending 1-2 x106 cells in 1ml of fetal calf 
serum supplemented with 10% DMSO with subsequent storage in liquid 
nitrogen.
Fig 2.6. HepG2 cells after 5 days from passage.
The cells are growing in MEM medium supplemented with fetal calf serum, non essential 
amino acid, glutamine and pencillin streptomycin antibiotic. The cells are normally growing 
in islands before they become confluent.
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2.4.2. Determination of relevant protein expression levels in HepG2 cells
To validate HepG2 cells as a suitable model for studying the liver specific 
expression of the proteins under investigation in this study, they were first 
compared with normal liver tissue for the expression of these proteins. RNA 
prepared (See Section 2.3.1) from HepG2 cells using a GenElute mammalian 
total RNA miniprep kit (Sigma-Aldrich, UK) and RNA from normal adult (64 
years old male) liver tissue (AMS biotechnology Ltd, UK) were reverse 
transcribed (See Section 2.3.3) to cDNA using the iScript cDNA synthesis kit 
(Bio-Rad, UK). A qPCR was performed using the cDNA templates with 
designed primers for the candidate protein transcripts (section 2.3.4.3). The 
expression of candidate proteins in HepG2 was normalised to liver tissue and 
the expression of the UBC reference gene.
2.4.3. Preparation of transcription factor expression plasmids for 
transactivation studies
2.4.3.1. Transformation of E. coli competent cells
Competent cells were transformed using expression plasmids (Fig 2.7) 
encoding the appropriate transcription factors (OriGene Technologies Inc, 
USA). Expression plasmids for steroid hormone receptors were obtained as a 
gift from Dr. Peter Winshjp. 70pl competent cells (JM109, Promega, UK) were 
transferred to an ice chilled tube and 5 ng of the expression vector added. The 
tube was then returned immediately to ice for 10 minutes and then heat- 
shocked for 40 to 50 seconds at 42 C to internalise the plasmid. The mixture 
was then incubated on ice for a further 2 minutes to bring the temperature back 
down. 900 pi of L-broth medium was then added and the cells further incubated 
with shaking for 60 minutes at 37 C to allow the bacteria to recover and to 
express the antibiotic resistance marker encoded by the plasmid. The L-broth 
medium was prepared by dissolving 20 g of L-broth powder (Sigma Aldrich, UK) 
in one litre of distilled water, autoclaved and then stored at 4°C. 100pl of the 
transformation reaction was spread on a plate with L-broth agar medium 
containing 80 pg/ml ampicillin, to allow the growth of only the bacteria which are 
resistant to ampicillin, incubating at 37 C overnight. The L-broth agar plates 
with the 80 pg/ml ampicillin were prepared by suspending 35 g of the agar in
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one litre of distilled water and the ingredients were dissolved and sterilised by 
autoclaving. 80 mg ampicillin powder (Sigma Aldrich, UK) were dissolved in 1 
ml distilled water and sterilised by passing through a filter unit with a pore size 
of 0.22 pm. The prepared sterilised ampicillin was then added to one litre of the 
autoclaved agar after it had cooled down to about 50-55 C. The agar was then 
poured into the plates, left to cool and stored at 4°C to be used.
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Fig 2.7. Physical Maps for the expression plasmids used in HNF4a and PEA3 transfection.
The expression plasmid pCMV6-XL4 (~ 4.7 kb) with an inserted HNF4a DNA of 3.6 kb was used 
for HNF4a transfection of HepG2 cells while the expression plasmid pCMV-XL5 (~ 4.5 kb) with 
an inserted PEA3 DNA of 2.2 kb was used for PEA3 transfections. MCS, ColE1, F1 ori and CMV 
promoter are multiple cloning site, the bacterial origin of replication, the filamentous phage origin 
of replication and the cytomegalovirus promoter, respectively. The ampicillin resistant gene is 
used to confer the selection of the plasmid in E. coli.
2.4.3.2. Growing up and purification of expression plasmids
A single colony from the L-broth agar plate was inoculated in 100ml of L-broth 
medium containing 80pg/ml ampicillin (100 pi of the 80 mg/ml sterilised 
ampicillin were added to 100 ml of the medium) and incubated shaking at 37°C 
overnight. The bacterial cells were harvested by centrifugation at 6000 x g and 
then purified using a midi kit for plasmid DNA purification (Qiagen, UK). The 
principle of this kit is based on the anion-exchange resin binding of plasmid 
after alkaline lysis. The harvested bacteria were resuspended in buffer P1, 
containing RNase to digest the bacterial RNA, then buffer P2 was added, 
containing sodium hydroxide to denature the chromosomal DNA and SDS to 
disrupt the cell membrane. Buffer N3 was then added which returned the pH to
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neutral in the presence of guanidine hydrochloride, causing the precipitation of 
the denatured proteins, chromosomal DNA and the detergent. The lysate was 
then centrifuged at > 20,000xg for 30 minutes at 4°C to pellet the precipitated 
cell debris. The supernatant was applied to an equilibrated Qiagen-tip for DNA 
binding and the DNA then washed and finally eluted. The eluted DNA was 
precipitated with isopropanol and centrifugation at > 15,000x g for 30 minutes at 
4°C. The DNA pellet was washed using 70% v/v ethanol, air dried and 
redissolved in 50pl of DNase free water.
2.4.3.3. Digestion of plasmids by restriction enzymes
Plasmids used in transfections were verified using FastDigest™ restriction 
enzymes and 1X FastDigest™ buffer (Fermentas life science, UK). 1 unit of the 
FastDigest enzyme (FDU) was added to 2pl (up to 0.8pg) of the plasmid in 1X 
FastDigest buffer in a 20pl total reaction volume. FDU is the amount of the 
enzyme needed to digest 1pg of lambda DNA-Hindlll in 5 minutes at 37 C in 1X 
FastDigest buffer. The mixture was incubated at 37°C for 5 minutes and then 
the enzyme was inactivated by heating at 65°C for 5 minutes. To confirm the 
digestion 3 to 5 pi of the mixture were size-fractionated (10 volt/cm) on a 1% 
w/v agarose gel and bands detected by ethidium bromide staining (See Section 
2 .1.1).
To determine the restriction sites, the inserted cDNA clone of the candidate 
expression plasmid was characterised for recognition sequences using the 
webcutter tool (http://bio.lundberg.gu.se/cutter2). The appropriate enzyme, 
which has one or two cut position sites, was then used to digest the candidate 
plasmid and the resultant bands were size-fractionated to verify the identity of 
the expression plasmid.
2.4.4. Transfection of HepG2 cells by expression vectors
Transfections of HepG2 cells using expression vectors encoding certain 
transcription factors were performed to check the effect of the overexpression of 
those transcription proteins on PZ mRNA expression levels. Tfx™-20 reagent 
(Promega corporation, UK) was used for this purpose which is based on the 
formation of multilamellar vesicles, which associate with nucleic acids, in the
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transfer of the nucleic acids into cells by fusion with the cell membrane. This 
transfection reagent has been used extensively in the transfection of HepG2 
cells (Carrasquillo et al. 2010, Takagi etal. 2008, Wong etal. 2007, Hattori and 
Maitani 2005). 1.25 pg of the proposed expression plasmid was added to 37°C 
prewarmed cell growth medium and vortexed. Tfx-20, with a charge ratio 4:1 
(reagent: DNA) was then added to the medium with the plasmid and vortexed 
immediately. The volume of medium, plasmid and the Tfx reagent was 
calculated using the online Promega transfection calculator. The transfection 
mixture (total volume 1 ml) was incubated at room temperature for 15 minutes 
and added to 80% confluent cells in a 6-well plate after removal of the old 
medium and incubated for a further hour at 37°C and 5% CO2 . 2 ml of fresh 
complete medium were added to the transfection mixture in the wells and 
incubated for a further 48 hours.
For determination of the PZ response to steroid hormones, 2 ml of fresh 
complete D-MEM phenol free medium (Invitrogen limited, UK) containing 
charcoal stripped fetal calf serum (Invitrogen limited, UK) was added to the 
transfection mixture as well as the proposed hormone (1x 10'8 M 17-p 
Oestradiol, 2.5 x 10'8 M Dihydrotestosterone, 1x 10'6 Dexamethasone final 
concentration in the HepG2 culture wells transfected with oestrogen, androgen 
and glucocorticoid receptors, respectively) and further incubated for 48 hours. 
Charcoal stripped foetal calf serum was used to remove any endogenous 
bovine steroid hormones that may have skewed the results.
2.4.5. Transfection of HepG2 with siRNAs
Small interfering RNAs are double stranded RNAs approximately 21 or 22 
nucleotides in length with overhanging 3’ ends involved in the RNA interference 
pathway and causing posttranscriptional gene silencing (Elbashir, Lendeckel 
and Tuschl 2001). Knocking down of the candidate transcription factor was 
achieved using the Thermo Scientific DharmaFECT® General Transfection 
Protocol (Dharmacon RNAi Technologies, UK). The HepG2 cells were 
trypsinized and diluted in antibiotic-free complete medium. 5 x 104 of cells were 
plated in 24-well plates and incubated overnight at 37°C/ 5% CO2 . For each 
transfection, two tubes were used to mix the contents. In the first tube 25 pi of
2pM on-targetplus smart pool (siRNA) (Dharmacon RNAi Technologies, UK)
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was added to 25 |jl of serum-free growth medium while in the second tube 2 pi 
of the transfection reagent (DharmaEFCT 4) was added to 48 pi of the serum 
free medium. The contents of each tube were mixed gently before being 
combined together and mixed gently by careful pipetting up and down. The 
mixture was incubated for 20 minutes at room temperature. 400 pi of antibiotic- 
free complete medium was added to the mixture giving a total volume of 500 pi 
which was then added to the well after removing the culture medium. The cells 
with the transfection medium were incubated for 48 hours at 37°C in 5% CO2 . 
The same was done for the negative (ON-Targetplus Non-Targeting pool) and 
positive (ON-Targetplus GAPD control pool) control samples (Dharmacon RNAi 
Technologies, UK). The efficiencies of the knocking down of the candidate 
protein and its effect on PZ were measured using qPCR (See Section 2.3.4.3).
2.4.6. Stimulation of HepG2 with Lipopolysaccharide
Lipopolysaccharide (LPS) is an outer membrane endotoxin glycoprotein which 
upon its identification by the body causes initiation of a variety of defence 
mechanisms (Schumann et al. 1990). Some coagulation factors have been 
found to be acute phase proteins and induced in response to LPS, such as 
factor VIII (Begbie et al. 2000) and tissue factor (Hall, Vos and Bertina 1999). 
To examine whether PZ is an acute phase protein or not, HepG2 cells were 
stimulated with lipopolysaccharide (LPS) from Salmonella typhimurium (Sigma 
Aldrich, UK). The cells were grown in 6-well plates to approximately 80%  
confluency and 10 pg/mL LPS was added to the cells and left for a time course 
of 30 minutes, 1 hour, 2 hours, 4 hours and 24 hours. RNA was extracted from 
HepG2 cells with each time point using a GenElute mammalian total RNA 
miniprep kit (See Section 2.3.1). Each RNA was then reverse transcribed to 
cDNA using the iScript cDNA synthesis kit (See section 2.3.3). The 
synthesised cDNA from each RNA sample was used in qPCR (2.3.4.3) to 
determine the effect of LPS on PZ at different time points.
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Chapter 3-Optimisation 
Of Electrophoretic 
Mobility Shift Assay
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3.1. Introduction
Transcriptional regulation is a process involving a diverse set of protein-nucleic 
acid interactions at multiple levels in the hierarchical organisation of the 
genome. One of the primary stages at which gene expression is regulated is by 
the binding of trans-acting factors to cis-regulatory elements within the promoter 
regions of genes. The binding of transcriptional regulatory proteins to their 
specific DNA binding sites needs to be assessed as part of any study of 
transcriptional regulatory mechanisms. However, the use of in vitro protein- 
DNA binding studies does inevitably lead to a certain loss of context in that 
some synergistic interactions between binding factors may be lost and/or the 
influence of chromatin structure and nucleosome positioning will no longer 
influence binding. However, these in vitro assays do provide important 
information in terms of the ability of particular factors to bind to specific 
sequences; information that can be corroborated in the higher order context by 
further analyses.
Therefore, protein-DNA binding studies, which lead to an accurate recognition 
of transcription factor binding sites, are essential in the understanding of 
complex gene expression patterns (Morozov et al. 2005). The electrophoretic 
mobility shift assay (EMSA) is one such technique, which has been used 
extensively in DNA-protein interaction studies (Fried and Crothers 1981, Revzin 
1989). This assay, also referred to as the band shift, gel shift and gel 
retardation assay, provides information about the protein binding specificity and 
the structural consequences of the protein-DNA interaction by using small 
amounts of the candidate protein and very simple apparatus (Savery and Busby
1998). The EMSA analyses of the equilibrium binding of the protein to its 
specific binding sequence is based on physical separation of protein-double­
stranded DNA (dsDNA) complexes from free dsDNA probes (Sidorova, 
Muradymov and Rau 2005). The electrophoretic mobility of a dsDNA is higher 
compared to the mobility of the dsDNA bound by protein (Carey 1988, Heilman 
and Fried 2007). The electrophoretic mobility of the protein-dsDNA complex is 
influenced by many factors, such as, the molecular weight of the protein, the 
size of the dsDNA (Fried and Crothers 1983), the pH and ionic strength of the 
electrophoresis buffer (Carey 1988) and the temperature and the concentration 
of the gel matrix (Taylor, Ackroyd and Halford 1994). Therefore, the
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electrophoretic mobility shift assay should be optimized to observe protein-DNA 
binding.
3.2. Optimisation of EMSAs
EMSAs were first developed using radioactively labelled dsDNA probes and 
highly purified nuclear protein extracts (Fried and Crothers 1981, Garner and 
Revzin 1981). This procedure had the obvious advantage, with the use of high 
energy emitters, such as P32, of a high degree of sensitivity (Heilman and Fried
2007). However, the drawbacks of the handling of radioactive reagents, the 
limited half-life of the isotopes and the cost of purchase and disposal of such 
labelled products (Jing et al. 2003) led to the development of alternative 
labelling systems. Two of these alternative methods were utilised and 
optimised throughout the current study.
The first method used was the Lightshift chemiluminescent EMSA system from 
Pierce, which relies on the use of biotinylated dsDNA probes, transfer of size 
fractionated complexes to a membrane, binding of streptavidin linked 
horseradish peroxidase and a chemiluminescent reaction to detect labelled 
products. The composition of the binding buffer, the length of the binding 
reaction incubation and the temperature at which the incubation is carried out 
are all parameters which can be modified to optimise the binding of the protein 
within a relatively broad range that encompasses physiological conditions. This 
chemiluminescent detection system has comparable sensitivity to a similar 
radiolabelled method (Fig. 3.1).
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Fig 3.1. Comparison of the sensitivity of various EMSA Methods (Thermo Scientific, UK). 
Three different EMSAs were performed and detected according to the manufacturer’s 
instructions using different concentrations of the labelled probes and electrophoresed on a 6% 
polyacrylamide gel. Comparable sensitivity was achieved using the biotin-labelled 
(chemilumescent kit) and 32P-radiolabelled EMSAs. However, 32P-radiolabelled EMSAs needed 
a significantly longer exposure time to achieve the comparable sensitivity to the biotin-labelled 
EMSAs. The signal detected using digoxigenin-labelled probes (another alternative labelling 
method) was very weak compared to the biotin-labelled probes with the same exposure time.
The second method of EMSA visualisation used in this study was the use of 
infra-red dye labelled (IRDye) DNA probes (see example assay Fig. 3.2). This 
system has a number of advantages over the use of radiolabelled DNA probes: 
similar to those mentioned above when discussing the chemiluminescent 
system, the IRDye system does not require the use of reagents subject to strict 
regulatory control with high purchase and disposal costs; IRDyes are non- 
hazardous and are stable compared to the limited half-life of radioisotopes 
(Ying, Fourmy and Yoshizawa 2007). In addition, following size fractionation 
through gel electrophoresis the products may be imaged directly on an IR 
scanner without the need to take the gel from between the electrophoresis 
plates; besides the obvious advantages of the time saving this also allows the 
electrophoresis to be restarted should further separation be required. This 
method, therefore, has a number of advantages over the radioisotope method 
and the chemiluminescent detection method with equivalent sensitivity.
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Fig 3.2. IRDye® 700 EMSA. Assays were carried out using consensus oligos for three different 
transcription factor targets, with and without the presence unlabelled competitor sequences (LI- 
COR Biosciences, 2006). EGR is the early growth transcription factor. Pax5 is a member of the 
paired pox family of transcription factors. NF-E1 is the nuclear factor erythroid 1.
In protein-DNA binding assays the quality of the nuclear extract is crucial in 
achieving optimal results and a number of precautions can be taken in the 
preparation dependent on the proteins being investigated. For example, in all 
methods, working on ice or at 4°C will maintain the integrity of the proteins 
(Holden and Tacon 2010) by limiting protease activity, as will the use of 
protease inhibitors such phenyl methylsulfonyl fluoride, aprotinin and papain 
(Shi and Sarna 2005, Weng et al. 2004, Stasiolek et al. 2000); although it is 
more usual nowadays to include a commercial protease inhibitor cocktail with 
the same broad range of action against the various types of protease activity 
present within the cell (Thermo Scientific and Sigma Aldrich literature). Also, if 
the activation state of the regulatory protein is being investigated phosphatase 
inhibitors may be included; this could be important if phosphorylation acts to 
modulate the DNA-binding domain of the transcription factor or if 
phosphorylation modulates transactivation potential and this is to be monitored 
with phospho-specifc antibodies in supershift assays (Hall, Vos and Bertina
1999). The original nuclear extract preparation method of Dignam et a l (1983)
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provides protein specific to the nucleus and of very good quality, when 
executed appropriately. However, the method is fairly time consuming and 
quicker and more straight forward methods have been developed that work well 
with cell culture samples; although for tissue the original Dignam method 
(Dignam et al. 1983) cannot be surpassed. These more time effective methods 
(Andrews and Faller 1991) may not produce protein that is quite as nucleus- 
specific, but the final sample is certainly nucleus enriched and provides protein 
that will function very well in the relatively crude environment of the in vitro 
EMSA (Personal communication with Hall AJ 2008).
There are, therefore, considerable number of variables to consider in optimising 
EMSA, from the labelling system to the binding reaction buffers, time and 
temperature of the binding reactions to electrophoresis parameters and 
detection methods. This chapter discusses the optimisation performed within 
the project.
3.3. Materials and Methods
3.3.1. Nuclear extract Preparation
The nuclear extract preparation method (Mirmira 2006) was based on a small 
scale development from the original Dignam (1983) procedure. The proteins 
were prepared by removing the growth medium from cells grown in culture 
using aspiration and then washing the cells with phosphate buffered saline 
(PBS) (Invitrogen, UK) (137 mM NaCI, 2.7 mM KCI, 8 mM sodium phosphate 
dibasic, 2 mM potassium phosphate monobasic pH 7.4) to remove residual 
growth medium prior to addition of 0.5 ml of buffer A (10 mM HEPES (Sigma 
Aldrich, UK) to buffer the solution at a near physiological pH 7.9, 10 mM KCI to 
facilitate the retention of proteins' functional conformations, 0.1 mM EDTA to 
chelate divalent cations, particularly magnesium, as these cations are 
necessary co-factors for a number of enzymes that could impact the quality of 
the final extract, 1mM dithiothreitol (DTT) (Sigma Aldrich, UK), a low 
concentration reducing agent, 20 pi protease inhibitor cocktail (Sigma Aldrich, 
UK) containing inhibitors with a broad specificity for aminopeptidase and 
serine, cysteine and acid proteases, and 200 pi of 10% of IGEPAL (Sigma 
Aldrich, UK), a detergent, to enhance cell lysis). The cells were incubated with
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buffer A at room temperature for 10 minutes to allow the cells to swell in the 
hypotonic solution. The cells were then scraped from the surface of the flask 
and the lysate incubated on ice for 5 minutes in a microcentrifuge tube. The 
lysate was then centrifuged at 4°C to pellet the nuclei, placed on ice for 3-5 
minutes and the supernatant containing the predominantly cytoplasmic fraction 
and cell debris was removed. 150 pi of hypertonic buffer B (20 mM HEPES 
(Sigma Aldrich, UK), 0.4 M Nacl, 1mM EDTA, 10% glycerol, 4 pi of the protease 
inhibitor cocktail (Sigma Aldrich, UK) and 1mM of DTT) was then added to the 
recovered nuclei and shaken for 2 hours at 4°C in 400 mM NaCI to perform a 
high salt extraction of the nuclear proteins from the nuclei. The sample was 
then centrifuged at maximum speed of 16.1 x103 g in a benchtop 
microcentrifuge to pellet the nuclear debris and the supernatant (nuclear protein 
extract) aliquoted into prechilled microcentrifuge tubes and snap frozen in liquid 
nitrogen and stored at -80°C.
An alternative small scale nuclear extract preparation method developed from 
the original Dignam method by Andrews and Fallerwas also used extensively in 
the current study (Andrews and Faller 1991). Hep G2 cells (approximately 2.38 
x 107 cells) were scraped into PBS and resuspended in buffer A (10mM Hepes 
(Sigma Aldrich, UK)-KOH pH 7.9, 1.5mM MgCI2,10mM KCI, 0.5 mM DTT, 
Protease inhibitor cocktail). The Hep G2 cells were swollen in the hypotonic 
solution, on ice for 10 minutes, and vortexed for 10 seconds to cause cell lysis. 
The nuclei were then recovered by centrifugation at 16.1 x103 g for 10 seconds 
and resuspended in ice-cold buffer C (20mM Hepes-KOH pH 7.9, 2.5%  
glycerol, 420mM NaCI,1.5mM MgCI2, 0.2mM EDTA, 0.5mM DTT, 1% (v/v) 
protease inhibitor cocktail) and incubated for 20 minutes on ice for high salt 
extraction of the nuclear proteins. The suspension was centrifuged again at 
maximum speed (16.1 x103 g) at 4°C for two minutes and the supernatant 
(nuclear extract) was aliquoted, snap frozen and stored at -80°C. The protein 
concentration was subsequently determined by the Bradford assay (See 
Section 2.2.2). The effect of dialysis of the nuclear protein nuclear extract 
prepared by the Andrew and Faller 1991 method following the final extraction 
was also assessed. The dialysis was done by placing the HepG2 NE in semi- 
permeable cellulose dialysis tubing (Sigma Aldrich, UK) and dialysed against a 
dialysis buffer (20 mM Hepes pH 7.9, 0.1 M KCI, 0.2 mM EDTA, 0.5 mM DTT
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and protease inhibitor cocktail) to reduce the salt concentration within the 
HepG2 NE.
3.3.2. EMSA Probe Preparation
The double-stranded DNA probes were prepared by annealing forward and 
reverse oligonucleotides, synthesised by Eurofins MWG Operon, UK, that 
spanned the putative cis-elements of the trans-acting factors. The designed 
putative cis-elements for candidate proteins used in the current study were 
predicted by bioinformatic analysis (ALGGEN-PROMO) of the PZ gene 
promoter (Homo sapiens protein Z, AF440358, National Centre for 
Biotechnology Information). The probes designed for EMSA in the current 
study were 20 to 30 base pairs in length and flanked the proposed binding sites; 
the recommended length of probes is usually between 20 and 40 base pairs 
(Kako et a/. 1998). The forward and reverse oligonucleotides for a proposed 
protein binding site were annealed by mixing 1pMol/pl (final concentration) of 
each oligonucleotide (forward and reverse) in 25 mM KCI (to promote the 
annealing of the two negatively charged oligonucleotides) and incubating them 
at 95°C for 5 minutes in a hot block, to denature the oligos, prior to switching off 
the block and leaving them to cool slowly to room temperature to enable the 
formation of double-stranded binding sites. The same solution (25 mM KCI) 
was then used for preparing the working concentration of the probe.
3.3.3. EMSA Binding Reactions and Size Fractionation
Once the proposed binding site probe (See Section 2.2.3) and nuclear extract 
were prepared (SeeSection 3.4.1), binding conditions were modified for 
optimum protein-DNA binding. Five binding buffers with different buffering 
agents (HEPES and TRIS) and differing ionic strength were used to optimise 
the protein-DNA interactions. Buffer-1 (as per Fisher Scientific, UK): 10 mM 
Tris-Hcl (Sigma Aldrich, UK) pH 7.5, 50 mM Nacl, 1mM DTT, 1 mM EDTA, 19% 
glycerol and 10 pl/ml protease inhibitor cocktail (Sigma Aldrich, UK). Buffer-2 
(Groupp and Donovan-Peluso 1996): 23 mM HEPES (Sigma Aldrich, UK) pH
7.9, 113 mM Nacl, 9 mM Mgcl2 , 0.23 mM EDTA, 19% glycerol, 4.5 mM DTT, 10 
pl/ml protease inhibitor cocktail . Buffer-3 (Pierce, UK): 10 mM Tris, 50 mM
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KCI, 1 mM DTT; pH 7.5. Santa Cruz binding buffer (Santa Cruz biotechnology, 
Germany): 10 mM Tris, pH 7.5, 50 mM NaCI, 1 mM DTT, 1 mM EDTA and 5% 
glycerol. Sugawara binding buffer (Sugawara et al. 2007): 20 mM Tris-HCI, pH
7.9, 4 mM MgCI2, 1 mM EDTA, 0.1 mM DTT (Sigma Aldrich, UK), 10% glycerol 
(Sigma Aldrich, UK), 0.1% Nonidet P-40 (Sigma Aldrich, UK). Binding reactions 
also contained 1pg of the non-specific competitor Poly(dl-dC) (Sigma Aldrich, 
UK), which acts as a sink to bind the majority of the non-specific DNA-binding 
proteins (alternatives such as sonicated herring testes DNA could have also 
been used, however, polydl-dC is often chosen for its consistency).
The incubation time and temperature for the binding of the nuclear extract with 
the probes was also optimised, balancing optimal interaction conditions against 
the potential for protein degradation. Binding reactions were performed at 
37°C, room temperature, at 4°C and on ice. These changes were also 
performed to determine optimal interaction for the antibody-protein binding 
reactions. The main variables used in optimisation of EMSAs are summarised 
in table 3.1. A total binding reaction volume of 20 pi was used for both 
biotinylated and fluorescent EMSAs. However, different amounts of probe and 
nuclear extract were used in the EMSAs with the different labelling systems. 
Approximately 4pg and 12 pg of nuclear extract were used with 10 fmole of the 
biotinylated probe and 100 fmole of the fluorescent probe, respectively. 
Moreover, different incubation periods for each probe with nuclear extract were 
performed to optimise the binding reaction. Having carried out the binding 
reaction a proprietary loading buffer (Pierce, UK) was added to each reaction 
and EMSAs performed using the biotinylated probes. The samples were 
predominantly size-fractionated through a 5% w/v, 19:1 acrylamide/bis- 
acrylamide (Sigma Aldrich, UK) mini (8 x 8 x 0.1 cm) gel, using a voltage of ~ 
12.5 V/cm, in a Tris-Borate EDTA (TBE) buffer (Sigma Aldrich, UK) (89 mM 
Tris-borate and 2 mM EDTA). Although other buffer systems such as Tris- 
Glycine EDTA (Sigma Aldrich, UK) (50 mM Tris, pH 7.5, 0.38 M glycine and 2 
mM EDTA) were tested in order to optimise separation conditions. In EMSAs 
using IRDye probes loading buffer was not added to conserve the composition 
of the binding buffer and to avoid the interference between the fluorescent 
signal of the labelled probes and the dyes within the loading buffer. The
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samples were size-fractionated using the same parameters performed with the 
biotinylated probes.
Amount of 
probe
10 and 20 fmole of biotinylated probes and 100 fmole of 
IRDye probes.
Nuclear
extract
preparation
- Protocol adopted from Raghu Mirmira (Mirmira 2006).
- Protocol adopted from Andrews and Faller (Andrews and 
Faller 1991), with and without dialysis.
- 4 and 12 pg of the nuclear extract were used with 
biotintlated and IRDye probes, respectively.
Temperature 37°C, room temperature, 4°C and ice.
Incubation
time
- Probe incubation: 15, 20 and 30 minutes.
-Antibody incubation: 10, 20, 25, 30, 90, 120 minutes 
and overnight
Binding
buffers
- Binding buffer-1 (Fisher Scientific,UK).
- Binding buffer-2 (Groupp and Donovan-Peluso 1996).
- Binding buffer-3 (Pierce, UK).
- Santa Cruz binding buffer (Santa Cruz biotechnology, 
Germany).
- Sugawara binding buffer (Sugawara et al. 2007)
Table 3.1. Different variables used in optimisation of EMSA. Five different binding 
buffers and three different prepared nuclear extracts with different amounts were used to 
optimise EMSAs. Moreover, four different temperatures with different incubation time of the 
antibody and different amounts of the probe were also performed.
3.3.4. Chemiluminescent Detection Of Biotinylated Probes
Following electrophoresis and size fractionation the probe and probe-protein 
complexes were transferred to a positively charged nylon membrane (Fluka 
Biochemika, Sigma Aldrich, UK) by electrotransfer. This was done by soaking 
the membrane in 1X Tris-borate EDTA (TBE) for at least 10 minutes and 
sandwiching it with the gel. The membrane-gel sandwich was placed in an 
electrophoretic transfer unit (Bio-Rad, UK) and electrophoresed in pre-cooled 
1X TBE. Following transfer of the molecules they were cross-linked to the 
membrane using a uv transilluminator with a 312 nm wavelength bulb for 10-15
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minutes. The biotin labelled DNA was then detected using the Lightshift 
chemilumescent detection kit (Pierce, UK) according the manufacturer’s 
instructions. First the nylon membrane was blocked using 20 ml of a 
proprietary blocking buffer (Pierce, UK), to reduce the background signal 
resulting from the non-specific binding of the streptavidin complex to the 
membrane. This was followed by the addition of 20 ml of blocking 
buffer/stabilized streptavidin-horseradish peroxidise conjugate solution. In this 
step the streptavidin binds to the biotin-labelled probes with high affinity. The 
membrane was then washed three times with 20 ml of 1x washing buffer 
(Pierce, UK) with gentle shaking for 5 minutes at room temperature, again to 
reduce the non-specific background signal, before adding a substrate 
equilibration buffer to the membrane and further incubating for 5 minutes with 
gentle shaking. The membrane was then incubated according to the 
manufacturer’s instruction in a substrate working solution containing luminol 
enhancer solution and stable peroxide solution for 5 minutes. In this step the 
enzyme horseradish peroxidase reacts with the substrate in the presence of the 
peroxide solution and produces light. The membrane was then wrapped in 
cling film to protect the membrane and the signals detected using a UVP 
Biolmaging system (UVP, UK).
3.3.5. IRDye Detection
Following size fractionation the IRDye labelled probe and probe-protein 
complexes were detected using the Li-Cor Odyssey system (LI-COR  
Biosciences, UK). The electrophoresis gel, still between the glass plates, was 
placed on the Li-Cor Odyssey scanner which detects emission at both 700 nm 
and 800 nm from IRDye labelled probes. Detection of the IRDye labelled 
probes with the gel still within the plates has the advantage that, should it be 
required, the electrophoresis could be recommenced to separate the complexes 
further. The Li-Cor Odyssey system also allows for the quantification of the 
fluorescent signal.
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3.3.6. EMSA analysis
Protein-DNA complexes are larger compared to free DNA pobes. Therefore 
protein-DNA complexes in EMSA were defined by bands with a lower mobility 
(shifted) compared to the mobility of the bands of the free probes. In 
competitive EMSA the decrease or loss of complex bands by unlabelled non­
specific oligos (Oligos with different sequences) revealed non-specific binding 
of the protein to the DNA (protein-DNA complex). Maintenance of protein-DNA 
complex bands with the unlabelled non-specific oligos showed the specific 
binding of the protein to the DNA. Complexes which result from binding of 
antibody to protein-DNA complexes, are also larger than free DNA and than 
protein-DNA complexes. Therefore, bands with lower mobility in the presence 
of antibody compared to the bands in the absence of the antibody 
(supershifted) were considered as antibody binding to protein. The intensity of 
the bands in competitive EMSA and supershift assays was measured using the 
software of the Biolmaging system, for biotinylated probes, and using the 
software of the Li-Cor Odyssey system for the IRDye probes. This was done by 
drawing a rectangle around one band which then was copied an pasted to the 
other proposed bands in order to have the same area around each band. The 
intensity of the bands was quantified by the system. The intensity of competed 
band (in the presence of unlabelled oligo) or antibody complex band were 
divided by the intensity of the band from the binding reaction (in the absence of 
competitor and antibody) to show the fold increase or decrease of band 
intensities.
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3.4. Results
3.4.1. Biotinylated Probe EMSA
The detection system originally used in the EMSA analyses was the LightShift 
chemiluminescent assay, (SeeSection 3.3.4), with an incubation of probe with 
HepG2 nuclear extract (Mirmira 2006) for 20 minutes at room temperature. The 
EMSA using the original protocol from Pierce detected three high molecular 
weight bands (A-C) when HepG2 nuclear extract was present in the binding 
reaction. A fourth band (D) was observed using the pPZ ASE probe (lanes 2 
and 3, Fig 3.3) which was absent when using the dPZ ASE probe (lanes 4 and 
5, Fig 3.3).
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Fig 3.3. EMSA using pPZ and dPZ ASEs. Lane 1 (control) contains pPZ ASE probe 
without HepG2 nuclear extract (HepG2 NE). Lane 2 and 3 contain pPZ ASE probe with 
2 pi and 4 pi HepG2 NE, respectively. Lane 4 and 5 contain dPZ ASE probe with 4 pi 
and 2 pi HepG2 NE, respectively. Lane 6 (control) contains dPZ ASE probe without 
HepG2 NE.
Competitive EMSA was carried out to confirm the specificity of binding following 
the standard LightShift protocol using the pPZ ASE probe (Fig 3.4).
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Fig 3.4. Competitive EMSA using Bio-pPZ ASE probe. Lane 1 (control) contains the 
probe without HepG2 NE. Lane 2 contains the binding reaction (pPZ ASE probe with 
HepG2 NE). Lane 3 and 4 contain the binding reaction with 50-fold and 100-fold excess 
unlabelled AP2 consensus (non-specific competitor), respectively. Lane 5 and 6 contain 
the binding reaction with 50-fold and 100-fold excess unlabelled HNF3B consensus (non­
specific competitor), respectively.
All four previously observed bands (A-D) were observed in the binding reaction 
without competitors (lane 2, Fig 3.4). The addition of both unrelated competitor 
sequences (AP2 and HNF3B) produced a reduction in intensity of band D 
(lanes 3-6), with the AP2 competitor having a more marked effect (lanes 3-4). 
However, bands A-C were unaffected by either competitor.
3.4.1.1. Effect of nuclear extract, longer incubation and probe amount on 
protein-DNA binding
A further assay was carried out increasing the incubation period of the binding 
reaction from 20 minutes to 30 minutes at room temperature and, in addition, an 
alternative nuclear extract preparation procedure was employed (See Section 
2.2.1 and 3.2.1). Band D of the EMSA appears to be more intense following 
this longer incubation and the modified nuclear extract preparation method (Fig 
3.5).
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Fig 3.5. EMSA using different Biotin-labelled ASEs and PEA3 consensus probes.
Lanel (control) is the pPZ ASE probe without HepG2 NE. All other lanes contain Hep NE 
as well as probes as follows; pPZ ASE, dPZ ASE, human (h) FIX ASE, hPC ASE and 
PEA3 binding site consensus, respectively.
In order to reduce the proportion of free probe observed in the EMSA the 
amount of probe added to the binding reaction was reduced from 20 fmole to 10 
fmole (Fig 3.6).
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Fig 3.6. Competitive EMSA using Bio-dPZ ASE probe. Lane 1 (control) contains the 
probe without HepG2 NE. Lane 2 contains the binding reaction (probe with HepG2 NE). 
Lane 3, 4, 5 and 6 contain the binding reaction with 100-fold excess unlabelled AP2 
consensus, pPZ ASE, hFIX ASE, hPC ASE (competitors), respectively. No clear 
competition was seen with all competitors.
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Incubation was again carried out at room temperature for 30 minutes. The 
results showed less saturated signal of free probe. The binding complex D was 
relatively weak and showed negligible competition with 100-fold AP2 consensus 
and pPZ, hFIX, and hPC ASEs.
3.4.1.2. Effect of binding buffer on protein-DNA binding
Alternative binding buffers (See Section 3.3.3) were used in the following assay, 
again with 30 minutes incubation at room temperature (Fig 3.7). The EMSA 
using the pPZ ASE probe and 4pg of nuclear extract (Andrews and Faller 1991 
method) with the two new binding buffers (buffers-1 and 2) were found to give 
more intense signals for the complexes than the original buffer (Pierce, UK), 
with buffer-1 giving the clearest and most intense signal. Moreover, bands A, B 
and C were detected in the second control lane (lane 2) where the Hep G2 NE 
and the binding buffer were incubated without the probe.
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Fig 3.7. EMSA using Bio-pPZ ASE with different binding buffers. Lane 1 contains 
binding reaction (pPZ ASE probe and 4 pg HepG2 NE) with the original binding buffer 
(buffer-3). Lane 2 contains only a nuclear extract (new control). Lane 3 contains 
binding reaction with binding buffer-1. Lane 4 contains binding reaction with binding 
buffer-2.
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Competitive EMSA were repeated using optimised binding buffer-1, 10 fmol of 
probe and 2pl of nuclear extract (4pg protein) in a 20pl total volume incubated 
for 30 minutes at room temperature. Bands A-C (Fig 3.8) appear in all lanes 
with Hep G2 NE present, indicating that non-specific proteins are present within 
the NE rather than being specific protein-biotinylated probe complexes. Bands 
1 and 2 with the pPZ ASE (Fig 3.8) are, however, protein-biotinylated probe 
complexes. No competition was found with the AP2 or HNF3B competitors and 
only weak competition of 1.2-fold and 1.5-fold decrease was seen with the 
related sequence dPZ ASE in the intensity of complexes 1 and 2 respectively. 
However, with the PEA3 consensus a dramatic reduction in intensity of both 
complexes 1 and 2 was observed. A 4-fold decrease in the intensity of complex 
1 and the disappearance of complex 2 was seen, as measured by the UVP 
software.
Fig 3.8. Competitive EMSA using the putative PZ proximal ASE binding site.
Control-1 is the proximal ASE (pPZ ASE) probe (-120/-101) without HepG2 NE. 
Control-2 is the HepG2 NE without the probe and Binding reaction is the probe 
with the HepG2 NE. All other competition reactions contain the probe and the NE 
as well as unlabelled 200-fold excess dPZ ASE, 200-fold excess unlabelled AP2 
consensus, 200-fold excess unlabelled HNF3B consensus and 200-fold excess 
PE A3 binding site consensus, respectively. Bands indicated by arrows A, B, and 
C represent a non-specific protein detected in the nuclear extract. Bands indicated 
by 1 and 2 represent protein-DNA complexes. Bands indicated by arrow 3 show 
unbound probe. Weak competition is seen with the dPZ ASE compared to strong 
competition with PEA3 binding site consensus. No competition is seen with AP2 
and HNF3B consensus.
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Competitive EMSA were again repeated with 10 fmole of dPZ ASE probe using 
optimised binding buffer 1 and 2pl of HepG2 NE (4pg protein) in a 20pl total 
volume incubated for 30 minutes at room temperature (Fig 3.9). Bands A-C 
(biotinylated protein) again appear in all lanes with nuclear extract present. 
Bands 1 and 2 with the dPZ ASE (Fig 3.9) showed protein-biotinylated probe 
complexes. No competition was observed with the AP2 or FINF3B competitors, 
however, strong competition was seen in both complexes 1 and 2 with the 
related sequence pPZ ASE and the PEA3 consensus. The intensity of both 
protein-DNA complexes were decreased 7-fold with pPZ ASE while complex 1 
decreased 6-fold and complex 2 was abolished with the PEA3 consensus 
measured by the UVP software.
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Fig 3.9. Competitive EMSA using the putative PZ distal ASE binding site.
Control-1 is the distal ASE (dPZ ASE) probe (-822/-803) without HepG2 NE. Control-2 is 
the HepG2 NE without the probe. Binding reaction is the probe with the HepG2 NE. All 
other competition reactions contain the probe and the NE as well as unlabelled 200-fold 
excess pPZ ASE, 200-fold excess unlabelled AP2 consensus, 200-fold excess 
unlabelled HNF3B consensus and 200-fold excess PEA3 binding site consensus, 
respectively. Bands indicated by arrows A, B, and C represent a biotinylated protein 
detected in the nuclear extract. Bands indicated by 1 and 2 represent protein-DNA 
complexes. Bands indicated by arrow 3 show unbound probe. Strong competition is 
seen with the dPZ ASE and PEA3 binding site consensus. No competition is seen with 
AP2 and HNF3B consensus.
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3.4.1.3. Effect of temperature and incubation period on antibody-protein 
binding
Supershift assays were performed to identify the protein bound to the candidate 
probe. This was accomplished using the same binding reaction in the EMSA 
with the addition of a specific antibody against the putative binding protein. 
Antibodies against PEA3 and Ets1, candidate proteins bound to the pPZ and 
dPZ ASEs, were used and the reactions were optimised with those probes.
The supershift assay for the pPZ ASE binding site with the PEA3 antibody was 
firstly performed at room temperature (Fig 3.10). The antibody was incubated 
with the HepG2 NE and binding buffer-1 for approximately 10 minutes at room 
temperature followed by addition of the probe and a further incubation for 25-30 
minutes, again at room temperature. The presence of the antibody produced a 
weak reduction in the intensity of bands 1 and 2, but no clear supershift.
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Fig 3.10. Supershift assay using biotinylated pPZ ASE binding sites.
Control-1 is the candidate probe without HepG2 NE. Control-2 is the HepG2 NE without 
probe. Binding reaction is the probe with HepG2 NE. Anti-PEA3 is an antibody against 
PEA3 protein together with the binding reaction. The antibody incubated with the HepG2 
NE for 10 minutes and further incubated with the probe for 25 minutes at room 
temperature. No supershift was seen with the probe. A, B and C are control bands 
which come up whenever the HepG2 NE is added. 1 and 2 are the protein-DNA 
complexes.
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The pPZ ASE binding site supershift was then performed with a prolonged 
incubation of the PEA3 antibody with the HepG2 NE and binding buffer-1 
overnight (Fig 3.11.a) and for 90 minutes (Fig 3.11 .b) at 4°C. The probe was 
then added and the incubation carried out for a further 25-30 minutes at room 
temperature.
b
Fig 3.11. Supershift assay at4°C  using biotinylated pPZ ASE binding sites.
Control-1 is the pPZ ASE probe without HepG2 NE. Control-2 is the Hep NE without 
probe. Binding reaction is the probe with HepG2 NE. Anti-PEA3 is an antibody against 
PEA3 protein together with the binding reaction. (a)The antibody incubated with the 
HepG2 NE overnight at 4°C and further incubated with the probe for 25 minutes at room 
temperature. (b)The antibody incubated with the HepG2 NE 90 minutes at 4°C and 
further incubated with the probe for 25 minutes at room temperature. No supershift was 
seen with both conditions. A, B and C are control bands which come up whenever the 
HepG2 NE is added.
Both assays demonstrated the presence of the biotinylated proteins (bands A- 
C), but no protein-DNA complexes. To determine if the lack of protein-DNA 
complexes may be due to the degradation of the protein the supershift assay 
was repeated overnight at 4°C (Fig 3.12) with fresh protease inhibitor cocktail. 
Although protease inhibitor was added to prevent protein degradation, the 
binding reaction did not show protein-DNA complexes.
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Fig 3.12. Supershift assay at 4°C using biotinylated pPZ ASE binding sites.
Control-1 is the pPZ ASE probe without HepG2 NE. Control-2 is the HepG2 NE without 
probe. Binding reaction is the probe with HepG2 NE. Anti-PEA3 is an antibody against 
PEA3 protein together with the binding reaction. From left to right, the first three lanes 
were performed at room temperature (RT) while the other following three lanes were 
performed at 4°C. Control-2-4°C is the HepG2 NE incubated with the binding buffer 
overnight at 4°C. Binding reaction-4°C is the HepG2 NE incubated with the binding 
buffer overnight at 4°C followed by incubation with the probe for 30 minutes at room 
temperature. Anti-PEA3-4°C is the antibody incubated with the HepG2 NE overnight at 
4°C and further incubated with the probe for 30 minutes at room temperature. No 
supershift was seen. A, B and C are control bands which come up whenever the 
HepG2 NE is added. Bands 1 and 2 are the protein-DNA complexes. Protease inhibitor 
cocktail and the DTT were added to the binding buffer just before the assay.
Supershift assays using the pPZ ASE probe with the Ets1 antibody were carried 
out on ice and at room temperature (Fig 3.13). The antibody was incubated 
with the Hep G2 NE on ice or at room temperature for 10 minutes followed by 
an addition of the probe and further incubation for 30 minutes on ice and at 
room temperature, respectively. The results showed protein-DNA complexes 
(bands 1 and 2), but no antibody-protein-DNA complex with the pPZ ASE 
binding site at room temperature. On ice no complexes were observed in the 
presence or absence of the antibody.
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Fig 3.13. Supershift assay on ice using biotinylated pPZ ASE binding sites with Ets1.
Control-1 is the pPZ ASE probe without HepG2 NE. Control-2 is the HepG2 NE without 
probe. Binding reaction is the probe with HepG2 NE. Anti-Ets1 is an antibody against Ets1 
protein together with the binding reaction. From right to left, the first four lanes were 
performed at room temperature (RT) where the HepG2 NE incubated with the binding 
mixture for 10 minutes and followed by 25-30 minutes incubation with the probe. The 
following two lanes were performed on ice where the HepG2 NE incubated with the binding 
mixture for 10 minutes and followed by 25-30 minutes incubation with the probe. No 
supershift was seen at room temperature while on ice neither protein-DNA complex nor 
antibody-protein-DNA complex. A, B and C are control bands which come up whenever the 
HepG2 NE is added. Bands 1 and 2 are the protein-DNA complexes.
Supershift assays were also carried out using the dPZ ASE binding site probe 
with the PEA3 antibody (anti-PEA3) and the Ets1 antibody (anti-Ets1) at room 
temperature and 37°C. The results at room temperature were found to show a 
good protein-DNA binding complex (band 1) but no supershift band with either 
the Ets1 or the PEA3 antibodies (Fig 3.14b). However, the protein-DNA 
complex (band 1) in the presence of Ets1 antibody showed a very strong signal 
compared to the protein-DNA complex in the absence of the antibody. The 
intensity of band 1 in the presence of the Ets1 antibody was found to be
70
approximately four times more intense than in its absence, using the UVP 
system software (UVP, UK).
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Fig 3.14. Supershift assay at room temperature and 37°C using biotinylated dPZ 
ASE binding sites with PEA3 and Ets1. Control-1 is the dPZ ASE probe without HepG2 
NE. Control-2 is the HepG2 NE without probe. Binding reaction is the probe with HepG2 
NE. Anti-PEA3 is an antibody against PEA3 protein together with the binding reaction. 
Anti-Ets1 is an antibody against Ets1 protein together with the binding reaction, (a) The 
reactions were performed at 37°C where the Hep NE incubated with the binding mixture 
for 10 minutes and followed by 25-30 minutes incubation with the probe, (b) The reactions 
were performed at room temperature where the HepG2 NE incubated with the binding 
mixture for 10 minutes and followed by 25-30 minutes incubation with the probe. No 
supershift was seen at room temperature with both anti-PEA3 and Ets1 although the 
intensity of the band with Ets1 increased which might be an indication for the antibody 
binding. However, at 37°C neither protein-DNA complex in the binding reaction nor 
antibody-protein-DNA complex with the antibodies were seen. A, B and C are control 
bands which come up whenever the HepG2 NE is added. Band 1 is the protein-DNA
The binding reaction of the dPZ ASE binding site probe with the HepG2 NE did 
not show protein-DNA binding at 37°C, although a clear band was detected in 
addition to the biotinylated protein bands A-C, in the presence of the Ets1 
antibody (Fig 3.14a). Another EMSA for the dPZ ASE probe was done at 4°C 
to check the Ets1 supershift complexes. The binding mixture (binding buffer, 
HepG2 NE and Ets1 antibody) was incubated overnight at 4°C before the probe
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was added and further incubated for 30 minutes. The results at 4°C showed 
neither protein-DNA complex in the binding reaction nor an additional band in 
the presence of the Ets1 antibody (Fig 3.15).
Fig 3.15. Supershift assay at 4°C using biotinylated dPZ ASE binding sites with Ets1.
Control-1 is the dPZ ASE probe without HepG2 NE. Control-2 is the HepG2 NE without 
probe. Binding reaction is the probe with HepG2 NE incubated at 4°C overnight followed by 
incubation with the probe for 25-30 minutes. Anti-Ets1 is an antibody against Ets1 protein 
together with the binding reaction. The Ets1 reaction was performed by incubating the 
antibody with the HepG2 NE at 4°C overnight followed by incubation with the probe for 25- 
30 minutes. Neither protein-DNA complex in the binding reaction nor antibody-protein-DNA 
complex with the antibodiy was seen. A, B and C are the control bands.
3.4.1.4. Optimisation of supershift assay using PEA3 binding site 
consensus
A supershift assay was also performed using the PEA3 consensus binding site 
probe with the PEA3 antibody. The binding buffer was pre-incubated with the 
antibody at room temperature for 10 minutes before the addition of the probe 
and further incubation for 25-30 minutes. The results showed a clear protein- 
DNA complex but no supershifted band with the antibody (Fig 3.16). The same 
assay was repeated using a dialysed HepG2 NE (SeeSection 3.3.1). The 
results of the PEA3 binding site consensus probe with the PEA3 antibody using 
a dialysed FlepG2 NE, again did not show the supershifted band which would
be an indication of the antibody-protein-DNA complex (Fig 3.17).
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Fig 3.16. Supershift assay using biotinylated PEA3 binding sites consensus 
with PEA3 antibody. Control-1 is the PEA3 binding consensus probe without 
HepG2 NE. Control-2 is the HepG2 NE without probe. Binding reaction is the probe 
with HepG2 NE incubated at room temperature followed by incubation with the 
probe for 25-30 minutes. Anti-PEA3 reaction was performed by incubating the 
antibody with the HepG2 NE at room temperature followed by incubation with the 
probe for 25-30 minutes. No antibody-protein-DNA complex in the presence of the 
antibodiy was seen. A, B and C are control bands which come up whenever the 
HepG2 NE is added. 1 and 2 is the potential PEA3-DNA binding complex.
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Fig 3.17. Supershift assay using biotinylated PEA3 binding sites consensus with 
PEA3 antibody and dialysed nuclear extract. Control-1 is the PEA3 binding consensus 
probe without HepG2 NE. Control-2 is the dialysed HepG2 NE without probe. Binding 
reaction is the probe with the dialysed HepG2 NE incubated at room temperature followed 
by incubation with the probe for 25-30 minutes. Anti-PEA3 reaction was performed by 
incubating the antibody with the dialysed HepG2 NE at room temperature followed by 
incubation with the probe for 25-30 minutes. No antibody-protein-DNA complex was seen 
in the presence of the antibodiy. A, B and C are control bands while 1 and 2 are the 
ootential PEA3-DNA bindina complex.
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3.4.2. Use of IRDye labelled Probes
Supershift assays using 100 fmole pPZ ASE and dPZ ASE fluorescent probes 
were performed with 4pg of HepG2 NE and the Ets1 antibody. The antibody 
was pre-incubated with the HepG2 NE in binding buffer-1 for 10 minutes at 
room temperature prior to incubation with the probes for 30 minutes at room 
temperature. The results showed a protein-DNA complex band with the pPZ 
ASE probe but no supershifted band (Fig 3.18a). The dPZ ASE probe was not 
bound by protein (Fig 3.18b).
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Fig 3.18. Supershift assay at room temperature using fluorescent pPZ ASE and dPZ 
ASE probes with Ets1. Control is probe without HepG2 NE. Binding reaction is the probe 
with HepG2 NE. Anti-Ets1 is an antibody against Ets1 protein together with the binding 
reaction. The reactions were performed at room temperature where the HepG2 NE 
incubated with the binding mixture for 10 minutes and followed by 25-30 minutes 
incubation with the probe, (a) is the reactions with pPZ ASE probe while (b) with the dPZ 
ASE probe. No supershift was seen at room temperature with both probes. dPZ ASE 
showed neither protein-DNA complex in the binding reaction nor antibody-protein-DNA 
complex with the antibody. Band 1 is the protein-DNA complex while band 2 is the free 
probe.
3.4.2.1. Optimisation of antibody-protein binding using CREB binding site 
consensus
Supershift assays were also performed using a CREB antibody with the 
fluorescently labelled CREB consensus binding site probe to optimise the 
formation of the antibody-protein-DNA complex. The HepG2 NE was pre­
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incubated with the CREB antibody in a binding buffer lacking dithiothreitol (DTT) 
for 10 minutes and then further incubated with the probe for 25-30 minutes at 
room temperature. The results (Fig 3.19) showed a major protein-DNA 
complex (1), but did not show an antibody-protein-DNA complex.
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Fig 3.19. Supershift assay at room temperature using fluorescent CREB probe with 
CREB antibody. Binding reaction is the probe with HepG2 NE. Anti-CREB is an antibody 
against CREB protein together with the binding reaction. The reaction was performed at 
room temperature where the HepG2 NE incubated with the CREB antibody for 10 minutes 
and followed by 25-30 minutes incubation with the probe. The binding buffer was without 
DTT. No supershift was seen. Band 1 is the protein-DNA complex while band 2 is the free 
probe.
3.4.2.2. Effect of temperature and incubation period on antibody-protein 
binding using CREB binding consensus
Supershift analysis with the CREB-fluorescent consensus binding site was 
repeated by incubating the CREB antibody with the HepG2 NE for one hour at 
4°C, in one experiment (Fig 3.20), and for 20 minutes at 37°C in another 
experiment (Fig 3.21), followed by the addition of the probe and further 
incubation for approximately 30 minutes. The results at 4°C, again, did not 
show any indication of antibody binding whilst at 37°C not even protein-DNA 
complexes were observed.
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Fig 3.20. Supershift assay at 4°C using fluorescent CREB probe with CREB antibody.
Binding reaction is the probe with one hour pre-incubated HepG2 NE at 4°C. Anti-CREB is 
the antibody against CREB protein together with the binding reaction. The antibody reaction 
was performed at 4°C where the HepG2 NE incubated with the CREB antibody for one hour 
and followed by 25-30 minutes incubation at room temperature with the probe. No supershift 
was seen. Bands 1 and 2 are the potential protein-DNA complexes.
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Fig 3.21. Supershift assay at 37°C using fluorescent CREB probe with CREB antibody.
Binding reaction is the probe with 20 minutes pre-incubated HepG2 NE at 37°C. Anti-CREB 
is the antibody against CREB protein together with the binding reaction. The antibody 
reaction was performed at 37°C where the HepG2 NE incubated with the CREB antibody for 
20 minutes and followed by 25-30 minutes incubation at room temperature with the probe. 
Neither protein-DNA nor antibody-protein-DNA complexes were seen.
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3.4.2.3. Effect of new protocol with different buffers on CREB supershift
An alternative protocol (Santa Cruz biotechnology, Germany) was then used in 
an attempt to optimise the supershift assay. The binding reaction contained 10 
pg of the HepG2 NE, 1 pg of poly dl-dC and 100 fmole of the CREB-fluorescent 
consensus binding site probe in a 20 pi binding reaction. The binding reaction 
was incubated for 20 minutes at room temperature. 4 pg of the CREB antibody 
were incubated in the binding mixture (SeeSection 3.3.3), without the probe, for 
20 minutes at room temperature followed by addition of the CREB-fluorescent 
probe and further incubation for 30 minutes at room temperature. The binding 
reactions were size-fractionated through a 4% polyacrylamide gel containing 50 
mM Tris, pH 7.5, 0.38 M glycine and 2mM EDTA and visualised by the Odyssey 
system (Li-Cor). Separation of the labelled products using this procedure was 
suboptimal and, therefore, difficult to interpret (Fig 3.22).
czo
co CD£  LU
TD
Fig 3.22. Supershift assay of the fluorescent CREB probe with CREB antibody 
using a new protocol (Santa Cruz, UK) . Binding reaction is the probe with 20 
minutes pre-incubated HepG2 NE in the new binding buffer (See above) at room 
temperature. Anti-CREB is the antibody against CREB protein together with the binding 
reaction. The antibody reaction was performed at room temperature where the HepG2 
NE incubated with the CREB antibody for 20 minutes and followed by 30 minutes 
incubation at room temperature with the probe. Neither clear protein-DNA binding nor 
antibody-protein-DNA complex was seen.
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3.4.2.4. EMSA and supershift assays for HNF4a
Competitive EMSAs and supershift analysis were also performed for the 
potential proximal HNF4a binding site (pPZ HNF4a) in the PZ gene promoter. 
Competitive EMSA was accomplished by incubating approximately 12pg of 
HepG2 NE with 100-fold excess (compared to the probe) of competitor sites for 
10 minutes at room temperature, followed by addition of 100 fmole of the probe 
and further incubation for 30 minutes. The results showed a strong competition 
with 100-fold unlabelled self and the HNF4a binding site consensus sequence 
and negligible competition with 100-fold of non-specific competitors, FINF3B, 
AP1 and SP1 (Fig 3.23).
Fig 3.23. Competitive EMSA using the reported pPZHNF4a-fluorescent binding site.
The binding reaction lane is the reported HNF4a (pPZHNF4a) probe (-48/-38) with HepG2 
NE. Self compet. lane is the pPZHNF4a probe, the HepG2 NE and the unlabeled 
pPZHNF4a. HNF4a cons, lane is the pPZHNF4a probe, the HepG2 NE and unlabeled 
HNF4a binding consensus. HNF3B, AP1 and SP1 cons, lanes are the pPZHNF4a probe 
with the HepG2 NE and unlabeled HNF3B, AP1 and SP1 binding site consensuses 
added, respectively. The HepG2 NE was incubated with the competitor for 10 minutes at 
room temperature followed by 30 minutes incubation with the probe. Bands indicated by 
arrow A represent protein DNA complexes. Bands represented by arrow B show unbound 
fluorescent probe. Competition is seen with the self competitor and the HNF4a consensus 
sequence. Negligible competition is seen with the non-specific competitors HNF3B, AP1 
and SP1 binding sites.
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Supershift analyses were later performed for the pPZHNF4a together with a 
repetition of the competitive EMSA using the same parameters. In the 
supershift assay the antibody was incubated with the HepG2 NE for 10 minutes 
followed by incubation with the probe for 30 minutes. The results of the 
competitive EMSA again showed a dramatic reduction in the protein-DNA 
complex with the self competitor and loss of the complex with the HNF4a 
binding site consensus (Fig 3.24). Supershift analysis with the HNF4a antibody 
(Santa Cruz biotechnology, Germany) showed a loss of the protein-DNA 
complex and greater fluorescence intensity (approximately 3.7-fold) in the well 
with the antibody.
Fig 3.24. Supershift assay and competitive EMSA using the pPZHNF4a-fluorescent 
binding site. Control was the pHNF4a probe (-48/-38) without HepG2 NE. Binding 
reaction was the pPZHNF4a probe (-48/-38) with HepG2 nuclear extract (Hep NE). Self 
competitor was the pPZHNF4a probe, the HepG2 NE and the unlabeled pPZHNF4a. 
HNF4a consensus lane was the pPZHNF4a probe, the HepG2 NE and unlabeled HNF4a 
binding consensus. HNF4a antibody lane contained the pPZHNF4a probe, the HepG2 NE 
and the HNF4a antibody. Bands indicated by arrow 1 represent protein DNA complexes. 
Band 2 represents the potential antibody-protein-DNA complex. Competition is seen with 
100-fold molar excess of self-competitor and the HNF4a consensus sequences. The 
reactions were at room temperature.
The assay was again repeated using the HNF4a binding site consensus probe
with the same parameters as with the pPZHNF4a. The results showed a
dramatic reduction in the protein-DNA complex and 4-fold increase in
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fluorescent intensity, measured using the software of the Li-Cor system, in the 
well with the antibody compared to the well without the antibody (Fig 3.25).
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Fig 3.25. Supershift assay using the consensus HNF4a-fluorescent binding site. The
binding reaction was the HNF4a binding site consensus probe with HepG2 NE. HNF4a 
antibody lane contained the HNF4a binding site consensus probe, the HepG2 NE and the 
HNF4a antibody. Band indicated by arrow 1 represents protein DNA complex. Band 2 
represents the potential antibody-protein-DNA complex. The reactions were at room 
temperature.
3.4.2.5. Effect of temperature and incubation period on HNF4a supershift
Other supershift analyses were performed with different conditions to see
whether a resolvable supershifted band could be obtained. One assay was 
done by incubating the FlepG2 NE with the antibody on ice for two hours 
followed by further incubation with the probe for 30 minutes on ice (Fig 3.26a). 
A second assay was done by incubating the FlepG2 NE with the antibody on ice 
for two hours followed by incubation with the probe for 30 minutes at room 
temperature (Fig 3.26b). The third experiment was performed by incubating the 
FlepG2 NE with the antibody on ice for one hour followed by incubation with the 
probe for 30 minutes on ice, in one reaction, and at room temperature in 
another reaction (Fig 3.26c). The binding reaction showed two binding 
complexes. Flowever, the reaction of the antibody with these three experiments
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did not show supershift bands although changes in the strength of the protein- 
DNA complex bands were seen.
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Fig 3.26. Supershift assay using the consensus HNF4a-fluorescent binding site at 
different conditions. The binding reaction was the HNF4a binding site consensus probe with 
HepG2 NE on ice. HNF4a antibody lane contained the HNF4a binding site consensus probe, 
the HepG2 NE and the HNF4a antibody, (a) The reactions were two hour incubation with the 
antibody on ice followed by 30 minutes incubation with the probe on ice. (b) The reactions 
were two hour incubation of the antibody on ice followed by 30 minutes incubation with the 
probe at room temperature, (c) The reactions were two hour incubation of the antibody on ice 
followed by 30 minutes incubation with the probe on ice and at room temperature. Bands 
indicated by arrow 1 and 2 represented potential protein-DNA complexes.
Other supershift experiments were done at 4°C. In the first experiment the 
FlepG2 NE was incubated with the antibody at 4°C for 25 minutes and followed 
by further incubation with the probe for 20 minutes at room temperature (Fig
3.27). The second experiment was done by incubating the HepG2 NE with the 
antibody for one hour at 4°C followed by incubation of the probe for 20 minutes 
at room temperature (Fig 3.28). The first experiment (Fig 3.27) did not show 
any differences between the binding reaction and the supershift reaction while 
the second experiment with a longer incubation time of the FlepG2 NE at 4°C 
did not show a clear discrete protein-DNA complex band (Fig 3.28). Three 
bands representing the protein-DNA complex were detected. Multiple bands 
instead of a single band may be due to protein degradation whilst maintaining 
DNA-binding capacity.
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Fig 3.27. Supershift assay using the consensus HNF4a-fluorescent binding site at 
4°C. The binding reaction was the HNF4a binding site consensus probe with HepG2 NE. 
HNF4a antibody lane contained the HepG2 NE, the HNF4a antibody and the HNF4a 
binding site consensus probe. The antibody was incubated with the HepG2 NE at 4°C 
followed by incubation with the probe at room temperature. The bands indicated by arrow 
1 represent protein DNA complex.
Fig 3.28. Supershift assay using the consensus HNF4a-fluorescent binding site at 4°C. 
The binding reaction was the FINF4a binding site consensus probe with HepG2 NE. HNF4a 
antibody lane contained the FlepG2 NE, the FINF4a antibody and the HNF4a binding site 
consensus probe. The antibody was incubated with the HepG2 NE at 4°C for 1 hour followed 
by incubation with the probe at room temperature. Three bands (1,2 and 3) were shown which 
may be due to protein degradation. However, the bands were not clear in the binding reaction 
lane.
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3.4.2.6. Effect of new binding buffer on EMSA using HNF4a binding site 
consensus
EMSA was also performed using the protocol published by Sugawara 
(Sugawara et al. 2007) for the HNF4a protein binding to the PZ gene promoter. 
The HepG2 NE was pre-incubated for 10 minutes at room temperature in a 
binding buffer (See Section 3.3.3) before addition of the probe and further 
incubation for 15 minutes. The results (Fig 3.29) did show protein-DNA binding, 
although the bands were not discrete.
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Fig 3.29. EMSA assay using the consensus HNF4a-fluorescent binding site.
Control lane contained the HNF4a probe without the HepG2 NE. The binding reaction was 
the HNF4a binding site consensus probe with HepG2 NE. The probe was added, after 10 
minutes of the HepG2 NE incubation, and further incubated for 15 minutes at room 
temperature. Smear (1) instead of binding band was seen in the binding reaction lane.
To confirm that binding with the HNF4a binding site consensus sequence and 
the potential pPZHNF4a were optimum and consistent when performed at room 
temperature, the experiments (Fig 3.24 and Fig 3.25) were repeated (Fig 3.30 
and Fig 3.31). The results of the repeated experiments again showed an 
abolition of the protein-DNA complex in the presence of the HNF4a antibody as 
well as a greater fluorescent intensity in the well compared to the binding 
reaction well without the antibody. The intensity was found to be approximately 
3.2-fold and 4.0-fold greater in the presence of the antibody with the HNF4a
oO
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binding site consensus and pPZHNF4a probe, respectively, compared to the 
well without the antibody using the Li-Cor software.
Fig 3.30. Supershift assay using the consensus HNF4a-fluorescent binding site.
The binding reaction was the HNF4a binding site consensus probe with HepG2 NE. HNF4a 
antibody lane contained the HNF4a binding site consensus probe, the HepG2 NE and the 
HNF4a antibody. Bands indicated by arrows 1 and 2 represent potential protein DNA 
complexes. Band 3 represents the potential antibody-protein-DNA complex. The protein- 
DNA complex (1) was competed with the addition of the antibody. The reactions were 
performed by the addition of the probe to 10 minutes pre-incubated binding mixture at room 
temperature followed bv further 30 minute incubation at room temoerature.
o
Fig 3.31. Supershift assay using the pPZHNF4a-fluorescent binding site.
The binding reaction was the pPZHNF4a binding site probe with HepG2 NE. HNF4a 
antibody lane contained the pPZHNF4a binding site probe, the HepG2 NE and the FINF4a 
antibody. Band indicated by arrow 1 represents the protein DNA complex. Band 2 
represents the potential antibody-protein-DNA complex. The protein-DNA complex (1) 
was competed with the addition of the antibody. The reactions were performed by the 
addition of the probe to 10 minutes pre-incubated binding mixture at room temperature 
followed by further 30 minute incubation at room temperature.
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3.5. Discussion
Binding of transacting proteins to their cis-regulatory elements within the 
promoter and/or enhancer is an essential stage in the transcriptional regulation 
of gene expression. Therefore, the accurate recognition of transcription factor 
binding sites and identification of the bound proteins is a crucial step in the 
characterisation of transcriptional gene regulation (Morozov et al. 2005). One 
of the techniques which has been used extensively in studying the interaction of 
proteins to their binding sites is the electrophoretic mobility shift assay (EMSA) 
(Fried and Crothers 1981, Revzin 1989). EMSAs were used in the study of the 
protein-DNA interactions in the current project. Since the electrophoretic 
mobility of the protein-DNA complex is affected by many factors, mentioned 
above, EMSA were optimised in this study to achieve optimum protein-DNA 
binding. Although the use of the radio-labelled probes is common in EMSA due 
to their sensitivity, alternative labelled probes were used in this study to avoid 
the many disadvantages encountered with the use of radioactive materials. All 
the probes used in this study (See Table 2.3) were composed of between 20 to 
30 base pairs. There is no lower limit for the size of the probe as long as all the 
sequence required for binding of the proposed protein is included (Savery and 
Busby 1998). Short probes with approximately 25 base pairs are usually used 
in EMSA (Adams and Fried 2007). The disadvantage of using a very long 
probe is that its binding by a protein will cause only a small shift in the mobility 
compared to the free probe unless very large protein molecules bind (Taylor, 
Ackroyd and Halford 1994). Moreover, large size probes usually have many 
target sites which can cause difficulty in characterising the binding of a single 
component, in addition to their slow migration which may require prolonged 
electrophoretic time (Adams and Fried 2007).
The first alternative labelling system used in the current study was biotinylation 
of the probe. The EMSA using biotinylated probes was optimised for the 
amount of the probe, incubation time, temperature, nuclear extract and the 
binding buffer. EMSA was first optimised using the LightShift chemiluminescent 
kit according to the manufacturer’s instruction (Pierce, UK). 20 fmole of the 
pPZ ASE and dPZ ASE probes were each incubated with 4 pg of nuclear 
extract in binding buffer-3 (SeeSection 3.3.3) for 20 minutes at room 
temperature. Three clear bands (A-C) with both probes and one faint band (D)
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with only pPZ ASE were observed indicating protein-DNA binding (Fig 3.3). 
The experiment was repeated with the same parameters using non-specific 
competitors to confirm the specificity of the bound protein (Fig 3.4). Bands A-C 
were not affected in the presence of the non-specific competitors whilst band D 
was competed by both competitors. The low signal of the bands could have 
been due to numerous experimental parameters, such as poor transfer from the 
gel to the nylon membrane (Fig 5, band 4), insufficient time of incubation of the 
binding reaction (20 minutes) or the quality of the nuclear extract. To further 
optimise the binding reaction, the incubation time of the probes with the nuclear 
extract was increased from 20 to 30 minutes (Cheng et a/. 2002) and a new 
nuclear extract (See Section 3.2.1) prepared with an alternative procedure 
(Andrews and Faller 1991). EMSA were performed with 20 fmole of different 
ASEs and the PEA3 consensus probes. EMSA with these parameters showed 
clear and more intense protein-DNA complex bands (A-D). However, the signal 
detected from the free probes was too strong, indicating that the probe was in 
significant excess (Fig 3.5). Therefore, the amount of the probe used was 
further optimized since using too much probe may exceed the dissociation 
constant of the protein affecting the equilibrium of the DNA-protein binding 
giving a false positive result (Rippe 1997).
Competitive EMSA using the 10 fmole of dPZ ASE probe with the new nuclear 
extract (Andrews and Faller 1991) and 100-fold excess of different competitors 
was performed at room temperature with 30 minutes incubation time (Fig 3.6). 
The competitive EMSA showed a relatively good binding reaction with very 
weak competition with the competitors. In order to further optimise the protein- 
DNA interaction alternative binding buffers (SeeSection 3.3.3) were used with 
the same parameters (Fig 3.7). Moreover, a new control containing the binding 
buffer with 4 pg of the HepG2 NE, but without the probe was included. The 
results showed better binding reactions using both new binding buffers 
(SeeSection 3.3.3) with buffer-1 giving the clearest and most intense signal. 
Moreover, this EMSA has revealed that the three bands A, B and C were not 
protein-DNA complexes, since these bands appeared whenever HepG2 NE 
was used, even without the probe present (Fig 3.7 lane 2). A similar artefact 
(band) was reported previously in chemiluminescent EMSA with HepG2 NE in 
the absence of probe and referred to as a non-specific band (Liang, Hassett
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and Omiecinski 2005). Although these bands (A, B and C) were not due to the 
specific interaction of protein with the biotinylated probe, they were likely still 
due to a specific interaction of the streptavidin and therefore referred to as non­
specific protein. Biotin has been identified to bind histones, such as H4, in 
human and other eukaryotes and plays a role in gene expression (Hassan and 
Zempleni 2008). Therefore, a control containing nuclear extract without probe 
was used to indicate the presence of non-specific proteins within the nuclear 
extract in subsequent assays. An advantage of these non-specific proteins is 
that they can be used as a good control for the transfer of the probes and the 
binding of streptavidin.
Competitive EMSA of the pPZ ASE was performed with the optimised 
parameters, binding buffer-1, 10 fmole of the probe and 4pg of the HepG2 NE 
with an incubation time of 30 minutes at room temperature (Moeenrezakhanlou, 
Nandan and Reiner 2008). The competitors were pre-incubated (Jing et al. 
2004) for 10 minutes with the HepG2 NE in binding buffer-1 to improve the 
competition. The results showed the three bands (A, B and C) representing the 
biotinylated protein and clear strong intense bands (1 and 2), representing the 
protein-DNA complexes (Fig 3.8). The protein-DNA complexes were not 
competed with a 200-fold excess of non-specific competitors AP2 and HNF3B 
while weak competition with dPZ ASE and strong competition with PEA3 
consensus were observed. Another competitive EMSA was again performed 
for the dPZ ASE probe with the same parameters to ensure that they were 
optimised for the protein-DNA interaction (Fig 3.9). The results again showed 
optimum protein-DNA complex bands with no competition with the 200-fold 
excess of AP2 and FINF3B non-specific competitors and strong competition 
with the pPZ ASE and PEA3 binding consensus. The results from the last two 
experiments (Fig 3.8 and 3.9) indicate that optimum protein-DNA binding can 
be accomplished using 10 fmole of the probe and 4 pg of HepG2 NE incubated 
in a 20 pi total volume with binding buffer-1 for 30 minutes at room temperature. 
To identify the protein bound to the pPZ ASE and dPZ ASE, supershift assays 
were carried out using antibodies against the putative proteins bound to those 
sites. Bioinformatic analysis had revealed that the protein bound to the pPZ 
ASE and dPZ ASE could be either PEA3 or Ets1. The potential binding of 
these two proteins was confirmed to some extent by competitive EMSA using
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the unlabelled PEA3 binding site consensus. No Ets1 binding site consensus 
was mentioned in competitive EMSA since it has the same sequences with the 
PEA3 binding site sequence (Santa Cruz literature). Supershift assays were 
performed for the pPZ ASE binding site biotinylated probe with the PEA3 
antibody using the same parameters mentioned above for the optimum protein- 
DNA binding reaction. Moreover, the antibody was pre-incubated with the 
HepG2 NE for 10 minutes at room temperature (Han et al. 2002) in binding 
buffer-1 before adding the probe for a further 30 minutes at room temperature. 
The results showed only a weak reduction in the intensity of the protein-DNA 
complex bands 1 and 2, but no supershift band (Fig 3.10). The same 
parameters were used in other supershift assays again for the pPZ ASE with a 
prolonged incubation (overnight and for 90 minutes) of the PEA3 antibody with 
the HepG2 NE at 4°C (Poch et al. 2005, Boucher, Piechocki and Hines 1995, 
Zhang et al. 2001). The use of lower temperatures can avoid the potential 
degradation of the bound protein from the prolonged incubation. The results 
(Fig 3.11) with both conditions showed only the bands representing the 
biotinylated proteins (bands A-C). The absence of both supershift and protein- 
DNA complexes was considered to be due to protein degradation. To 
determine if the lack of protein-DNA complexes may be due to the degradation 
of the protein the supershift assay was repeated overnight at 4°C (Fig 3.12) with 
fresh protease inhibitor cocktail. Protease inhibitor was added to prevent 
protein degradation, suggesting that the problem was likely not due to protein 
degradation from protease activity.
Supershift assays were further performed for the pPZ ASE using Ets1 antibody 
on ice (Woo et al. 2002, Penner et al. 2002) and at room temperature. A 
protein-DNA complex was seen at room temperature, but no supershift band 
was observed. However, on ice the protein was not able to bind to the DNA 
(Fig 3.13). Further supershift assays were performed for the other proposed 
binding site, dPZ ASE, using the PEA3 and the Ets1 antibodies at room 
temperature and at 37°C (Fig 3.14). The antibody was pre-incubated with the 
HepG2 NE for 10 minutes and further incubated with the probe for 30 minutes 
at room temperature. A short incubation time at 37°C is to avoid potential 
degradation of proteins. Clear Protein-DNA complex bands were observed at 
room temperature, but again no supershift bands were seen in the presence of
the antibodies. However, although there was no supershift band, a much 
stronger complex band was seen in the presence of the Ets1 antibody (four 
times greater) compared to the complex in the absence of the antibody (Fig 
3.14b). The assay at 37°C did not show protein-DNA complexes, however, a 
complex was seen in the presence of the Ets1 antibody (Fig 3.14a). The results 
from the supershift assays of the dPZ ASE at room temperature and 37°C has 
given some indication to a potential binding of the Ets1 protein. Further 
supershift assays were performed with an incubation of the HepG2 NE with the 
Ets1 antibody overnight at 4°C prior to the addition of the dPZ ASE probe 
followed by a further incubation for 30 minutes at room temperature. The 
results showed no protein-DNA complexes (Fig 3.15).
To determine if the antibody-protein binding reaction was optimised and PEA3 
was not the protein which bound the ASE regions, a supershift assay was 
performed using the PEA3 binding site consensus with the PEA3 antibody at 
room temperature. In optimum reaction conditions this assay should show a 
supershift band. The assay again did not show a supershift band (Fig 3.16). 
The assay was repeated using dialysed (Kim and Nelson 1998) HepG2 NE to 
reduce the salt concentration which might affect the antibody-protein binding. 
The results again showed protein-DNA binding but no supershift band (Fig 
3.17).
EMSA using biotinylated probes although they are sensitive (Fig 3.1), they are 
time consuming. In addition, the DNA needs to be transferred to the nylon 
membrane (Section 3.2.4) before the detection which sometimes may cause 
loss during this process (Fig 3.5). Therefore, infrared fluorescently-labelled 
probes, which can be detected directly with the Li-cor Odyssey system 
(SeeSection 3.3.5) without the transfer process, were used in EMSA in the 
current study. EMSA and supershift assays were performed using both pPZ 
ASE and dPZ ASE probes with the Ets1 antibody. The antibody was pre- 
incubated with 12 pg of HepG2 NE for 10 minutes at room temperature and 
further incubated with 100 fmole of the probe. Protein-DNA complexes were 
observed with the pPZ ASE probe, but no supershifted band showing the 
antibody-protein-DNA complex (Fig 3.18a). However, the dPZ ASE probe did 
not show even protein binding (Fig 3.18b).
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Further bioinformatic analysis revealed a potential binding site for the CREB 
protein to the pPZ ASE. Therefore, supershift assays were firstly performed 
using the CREB antibody with a CREB binding site consensus probe to 
optimize the formation of the antibody-protein complex before starting to use 
the antibody with the pPZ ASE probe. The same parameters were used as in 
the previous experiment, 10 minutes pre-incubation of HepG2 NE with the 
antibody and 30 minutes incubation with 100 fmole CREB binding site 
consensus probe. Binding buffer-1 was used without dithiothreitol (DTT). The 
assay was done in the binding buffer without DTT since this reducing agent 
disrupts disulfide bonds of proteins (Chen et al. 2003) and therefore may affect 
the activity of the antibody. The assay, again, showed a protein-DNA complex 
band, but no shifted band due to the antibody binding (Fig 3.19). The same 
results were seen when the antibody pre-incubated with the HepG2 NE for one 
hour at 4°C before their incubation with probe for 30 minutes at room 
temperature (Fig 3.20). The experiment was performed at 4°C to avoid 
potential degradation of the protein from prolonged incubation. The same 
supershift assay was performed with a 20 minute pre-incubation time of the 
antibody with the HepG2 NE at 37°C. The results showed neither protein-DNA 
complex band formation nor a complex in the presence of the antibody (Fig 
3.21). As the supershift assay could not be optimised with different incubation 
periods and different temperatures, the optimisation of the antibody binding to 
the protein was carried out again using a new protocol modified from Santa 
Cruz biotechnology (SeeSection 3.4.2). The results with this protocol did not 
show any distinct bands (Fig 3.22).
Competitive EMSAs and supershift assays were also performed for the putative 
proximal HNF4a (pPZNHF4a) binding site. Competitive EMSA were first 
optimised using 100 fmole of the pPZHNF4a added to 10 minutes pre- 
incubated 12pg HepG2 NE with the 100-fold of the competitor in binding buffer- 
1 at room temperature and further incubated for 30 minutes at room 
temperature. The assay showed a typical protein-DNA complex with abolition 
of the complex with 100-fold excess of specific competitors (self and HNF4a 
binding site consensus) and negligible with the 100-fold excess of non-specific 
competitors (Fig 3.23). A supershift assay was then performed with the same 
parameters with a repetition of the competition with the specific competitors.
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The HNF4a antibody was pre-incubated with the HepG2 NE for 10 minutes at 
room temperature and the pPZHNF4a probe was added for further 30 minute 
incubation at room temperature. Strong competition again was seen with the 
specific competitors in addition to abolition of the protein-DNA complex band in 
the presence of the HNF4a antibody (Fig 3.24). The loss of the protein-DNA 
complex rather than a complex of increased size that would have a lower 
mobility upon electrophoresis could be due to either the antibody binding to or 
sterically hindering the DNA binding domain of the protein or to the size of the 
complex being too large to efficiently migrate into the gel matrix. To confirm the 
latter hypothesis the intensity of the fluorescent band, indicated by arrow 2 (Fig 
3.24), in the well with the antibody was compared to the fluorescent intensity in 
the well without the antibody. The fluorescence in the antibody well showed 
approximately 3.7-fold greater intensity compared with the other wells without 
antibody. The loss of the protein-DNA complex with the greater intensity of the 
fluorescence in the well in the presence of the antibody confirmed, to some 
extent, the binding of the antibody to the protein and the hindrance of migration 
rather than the antibody recognising the DNA binding domain of the protein and 
preventing its binding to the DNA (Carey and Smale 2001), resulting in a loss of 
the protein-DNA complex.
To confirm the previous result the supershift assay was performed using the 
HNF4a binding site consensus probe with HNF4a antibody. The results 
showed a similar picture to that with the pPZHNF4a (Fig 3.25). The protein- 
DNA complex was dramatically reduced in the presence of the antibody and the 
well showed fluorescent intensity of approximately 4-fold more than the intensity 
in the well without the antibody.
To determine whether a better supershifted complex could be obtained, more 
supershift assays were performed on ice (Ye, Zhang and Dong 1996) and at 
4°C (Heltemes, Tuggle and Lamont 1999) with different incubation times with 
the antibody followed by further incubation with the probe at room temperature. 
However, although there were some changes in the intensity of the protein-DNA 
complexes in the presence of the antibody, those assays did not show any clear 
indications for antibody-protein-DNA complexes (Fig 3.26, Fig 3.27 and Fig
3.28). Sugawara and colleagues reported the binding of the HNF4a protein to 
the PZ gene promoter which was confirmed using the HNF4a antibody in a
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supershift assay (Sugawara et al. 2007). The same binding buffer (See Section 
3.4.2) used by the Sugawara group 2007 was used in performing EMSA in the 
current study. Nevertheless, results from EMSA using this binding buffer did 
not show distinct protein-DNA complexes (Fig 3.29); so this buffer was not used 
in subsequent supershift assays. The reason that no clear protein-DNA 
complex was seen may be due to optimisation of this buffer only for radio­
labelled probes. The supershift assays with the parameters showing the best 
results (Fig 3.24 and Fig 3.25) were repeated to confirm their quality and 
consistency. The repeated assays again showed the best results (Fig 3.30 and 
Fig 3.31) compared to the assays performed with other different parameters 
throughout the optimisation. The fluorescence intensity in the antibody well with 
pPZHNF4a probe (Fig 3.31) was greater than the antibody well with the HNF4a 
binding consensus probe (Fig 3.30). This might be due to some of the protein 
bound to the HNF4a binding consensus probe was not bound by the antibody, 
which was indicated by the faint band of protein-DNA complex in the antibody 
well.
It can be concluded that optimum EMSA and supershift assays can be 
accomplished using 10 fmole or 100 fmole of the biotin-labelled or fluorescent- 
labelled probes, respectively, with 4 pg of HepG2 NE for the biotinylated probes 
and 12 pg for the fluorescent probes. The assays should be incubated at room 
temperature and use binding buffer-1 for optimal complex formation. These 
parameters were used to perform all EMSAs and supershift assays throughout 
the current study. Although EMSA is an easy and sensitive method in studying 
protein-DNA interactions, many limitations encountered in this assay were 
reported. For instance, transcription factors that require another protein for its 
binding to DNA may not be optimised by in vitro conditions (Wells and Farnham 
2002), in addition different results may be obtained for the same DNA-protein 
system using different electrophoresis conditions (Sidorova, Muradymov and 
Rau 2005). Moreover, DNA secondary structure, such as looping out of 
intervening sequences which is required for bringing together of two distal 
protein binding sites into close proximity in vivo, cannot be created in vitro 
(Wells and Farnham 2002). The information of the DNA region location 
required for the protein binding can not be obtained directly by EMSA (Heilman
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and Fried 2007) and needs to be determined indirectly by bioinformatic analysis 
or directly by footprinting (Brenowitz et al. 1986).
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Chapter 4-Liver specific 
transcriptional 
regulation of Protein Z
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4.1. Introduction
The regulation of gene product synthesis is essential for the expression pattern 
of a particular gene in a tissue-specific or developmental stage-specific way 
(Latchman 1997). Whilst the majority of genes differ in their expression from 
one tissue to another, the expression levels of tissue enriched genes is higher 
in a particular tissue type, controlling its specialised function, and much lower or 
negligible in other tissues (She et al. 2009). The genomic length of tissue 
specific genes was found to be shorter (less base pairs) and their expression 
was lower compared to house keeping genes according to the expressed 
sequence tag data analysis (Zhu et al. 2008). House keeping genes are 
expressed in all tissues and are needed to preserve basic cellular functions. 
Most house keeping genes have regulatory sequences termed CpG islands 
associated with them, but lack TATA-boxes in their proximal promoters whilst 
the majority of tissue specific genes lack both CpG-islands and TATA-boxes 
(Zhu etal. 2008).
4.1.1. Liver specificity
The liver is the organ responsible for many important functions such as 
synthesis and detoxification of plasma proteins, carbohydrates and fats, protein 
metabolism and many other processes. Moreover, this organ is considered as 
unique in its production of protein components required in coagulation, 
anticoagulation, fibrinolysis and the complement system. There have been 
6,788 proteins identified in the human liver protaome database. Approximately 
67% of the proteins taking part in the coagulation, anticoagulation and 
fibrinolysis systems were distinctly recognized and are significantly enriched in 
the liver (Jiang etal. 2009). Liver-specific expression is controlled by a network 
of liver-enriched transcription factors. The idea that these hepatic transcription 
factors set up a complex cross-regulatory network to ensure their abundance in 
liver cells might be attributed to the presence of binding regions for members of 
the hepatic transcription factors within their own promoters leading to a 
feedback loop (Kyrmizi et al. 2006). Kyrmizi et al. also suggest that the stability 
of expression of individual hepatic transcription factors is determined by the 
multiple regulatory interactions within the liver network (Kyrmizi etal. 2006). Six
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families of liver-enriched transcription factors, the homeodomain containing 
hepatocyte nuclear factor 1 (HNF1) family, the leucine zipper domain family 
including CCAAT-enhancer-binding proteins (C/EBP), the winged helix domain 
family including hepatocyte nuclear factor 3 (HNF3), the zinc finger domain 
nuclear receptor family including hepatocyte nuclear factor 4 (FINF4), the 
onecut family (new class of homeodomain) including hepatocyte nuclear factor 
6 (HNF6) and PAR of the leucine zipper domain family including D site-binding 
protein have been characterised and shown to be involved in liver-confined 
gene expression in adult hepatocytes (Schrem, Klempnauer and Borlak 2002, 
Schrem, Klempnauer and Borlak 2004). Furthermore, HNF4 expression was 
shown to be specific for hepatocyte-lineage cells in the heterogeneous cultured 
mouse embryonic stem cells (Kheolamai and Dickson 2009).
4.1.2. Hepatocyte nuclear factor 4
HNF4 expression is established at the very earliest stages of embryonic 
development. HNF4 messenger RNA (mRNA) can be detected in the 
endoderm of the blastocyst at embryonic day 4.5. The expression of HNF4 
continues throughout embryonic development in the endoderm of the 
extraembryonic visceral cells of the yolk sac (Watt, Garrison and Duncan 2003). 
At embryonic day 8.5 of the developing mouse foetus the liver diverticulum and 
hindgut starts to express HNF4 mRNA followed by expression in the pancreas, 
stomach, intestine and kidney (Duncan et al. 1994). Saldek et al. found the 
expression of this factor is limited to the liver, kidney and intestine and not 
expressed in spleen, brain, lung and heart of rat (Sladek et al. 1990). The 
amino acid sequence of HNF4 revealed that this protein is a member of the 
nuclear receptor superfamily which includes steroid and thyroid hormone 
receptors and non steroid ligand-dependent transcription factors (Sladek et al. 
1990). This transcription factor is different from many other group members as 
it localizes to the nucleus and its transcriptional activity occurs via homodimer 
formation. Other members of this group which show the ability to dimerize with 
themselves are present in the cytoplasm while others that show an ability to 
heterodimerize are found in the nucleus (Jiang et al. 1995). The proteins 
belonging to this superfamily contains small DNA-binding peptide motifs known 
as zinc fingers (Schrem, Klempnauer and Borlak 2002). These small motifs can
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be used as modular building blocks to achieve the recognition of specific 
sequence of DNA (Klug 1999). The region of the two potential zinc fingers 
between amino acids 50 and 116 in the HNF4a protein was found to show 40- 
63% homology to the zinc finger domain found in other members of the nuclear 
receptor superfamily (Sladek et al. 1990). However, HNF4a was not identified 
to bind any ligand and, therefore, initially classified as an orphan nuclear 
receptor. The transactivation of HNF4a is seen in many cell types suggesting 
that its ligand is present in all cells or is not needed for its activation (Cereghini 
1996). Hertz et al. went on to show that recombinant rat HNF4a is 
transcriptionally regulated by the naturally occurring ligands, fatty acyl-CoA 
thioesters (Hertz et al. 1998). This has been confirmed when the rat 
recombinant HNF4 ligand-binding domain was shown to be bound by fatty acyl- 
CoA by direct molecular interaction (Petrescu et al. 2002). Therefore, HNF4 
should be considered as a nuclear receptor ligand-dependent transcription 
factor and not as an orphan nuclear receptor.
4.1.3. HNF4a binding to the PZ gene promoter
The HNF4a transcription factor was found to play a major role in the expression 
of a number of blood coagulation factors that are normally produced in the liver 
and will be discussed below. HNF4a has been found to play an important role 
in the transcription of PZ with the PZ gene promoter bound by HNF4a between 
nucleotides -70 and -30, relative to the translation start site (Sugawara et al. 
2007). Bioinformatic analysis (ALGGEN-PROMO) identified proximal 
sequences within the PZ gene promoter that show homology to the HNF4a 
binding site consensus sequence spanning, nucleotides -48 to-38 (5’- 
CTGGACTTTGG-3) and distal sequences from -310 to -300 (5’-
TGTGACTTTGT-3’) relative to the translation start site (Fig 4.1).
Other coagulation factors, which are believed to share a common evolutionary 
origin with PZ, and are suggested to have evolved from the same ancestral 
gene (Ichinose et al. 1990, Fujimaki et al. 1998), which include Prothrombin, 
Factor (F) VII, FIX and FX, have all been reported to be regulated by liver- 
enriched transcription factors, as would be predicted from their expression 
profile. FVII, FVIII, FIX, FX and FXI are activated by the binding of HNF4a to its
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binding sites within their promoters (Stauffer et al. 1998, Figueiredo and 
Brownlee 1995, Reijnen etal. 1992, Miao et al. 1992, Tarumi et al. 2002).
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Figure 4.1. The previously reported (pPZHNF4a) and hypothetical (dPZHNF4a) 
HNF4a binding sites in the PZ gene promoter. Highlighted numbers show the 
degree of homology with the 11 bp HNF4a consensus. Numbering is relative to the 
translation start site at +1.
A number of patients with haemophilia B, FIX deficiency, and patients with 
severe deficiency of FVII have been found to have mutations in critical FINF4a 
binding sites within their respective gene promoters (Reijnen et al. 1992, Arbini 
et al. 1997). Flowever, the levels of FVII, FVIII and FX in HNF4a-null mice show 
no significant variation, suggesting evolutionary diversity and possible functional 
redundancy in regulatory sequences between mouse and human systems 
(Inoue et al. 2006). By contrast, FIX levels are reduced in HNF4a-null mice. 
Similarly, HNF4a-null mice do show an abolition of expression of FXII and 
FXIIIB expression in the adult liver and promoter activity has been found to be 
totally dependent on the binding of HNF4a to its binding sites (Inoue et al. 
2006). Therefore, mutation in HNF4a binding site of factors XII and XIIIB might 
cause potential deficiency in these coagulation factors.
Protein S, which is a cofactor for activated protein C in the inactivation of FVa 
and FVIIIa and is expressed in a number of tissues including hepatocytes, 
vascular endothelial cells and megakaryocytes (Malm et al. 1994), has been 
reported to be activated by the liver-enriched factor FINF4a (Hall, Peake and 
Winship 2006). The characterised binding of HNF4a to the promoter of the 
protein S gene (nucleotides -415 to -375) in HepG2 cells may contribute to its
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liver specific transcription (Hall, Peake and Winship 2006). As HNF4a has been 
demonstrated to regulate the transcription of many coagulation factors, it was 
hypothesised that, given its close ancestral origin to these factors, the 
transcription of PZ may be similarly regulated by HNF4.
4.2. Aims
To characterise the role of HNF4a in the regulation of PZ transcription by gene 
expression analysis of the endogenous PZ gene in the human liver-derived cell 
line HepG2 and to define such regulatory protein-DNA interactions.
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4.3. Methods
4.3.1. Protein-DNA binding analysis
4.3.1.1. Electrophoretic Mobility Shift Assay (EMSA)
EMSAs were performed for the two potential binding sites of HNF4a identified 
using bioinformatic analysis (ALGGEN-PROMO) in the PZ gene promoter, the 
proximal site (pPZHNF4a) spanning nucleotides -48 to -38 and the distal site 
(dPZHNF4a) spanning nucleotides -310 to -300 relative to the translation start 
site, in order to demonstrate protein-DNA binding. 100 fmole of the candidate 
probe (See Table 2.3), 1 pg of poly dl-dC, 12 pg of HepG2 nuclear extract 
(HepG2 NE) (See Section 2.2.1) in 20 pi binding buffer (See Section 2.2.4.1) 
were used. The binding mixture was incubated for 30 minutes at room 
temperature and size-fractionated through 5% w/v, 19:1 acrylamide/bis- 
acrylamide (See Section 2.2.4.1) mini (8 x 8 x 0.1 cm) gel, using a voltage of ~ 
12.5 V/cm, in 1x Tris-Borate EDTA (TBE) buffer. The protein-DNA complex 
was visualised (SeeSection 3.3.5) using the Odyssey Licor Imaging System 
(Applied Biosystems, UK) and identified by slower migration through the gel 
compared with the free probe. In competitive EMSAs, the indicated fold molar 
excess of unlabelled competitors was incubated for 10 minutes with the Hep NE 
at room temperature prior to addition of the labelled probe and further 
incubation.
4.3.1.2. Supershift assays
Specific binding of the protein to the probe, based on competitive EMSA, was 
further analysed using supershift assays for specific identification. 2pg of 
HNF4a antibody (H-171, Santa Cruz, Germany) was pre-incubated with the 12 
pg HepG2 NE for 10 minutes at room temperature before the addition of 100 
fmole of the probe and a further 30 minute incubation. The binding mixture was 
size fractionated through a 5% polyacrylamide gel (See Section 2.2.4.1). A 
typical antibody-protein-DNA complex is usually characterised by a shift in the 
protein-DNA complex due to its increased size.
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4.3.2. Gene expression studies of the endogenous PZ gene in HepG2 cells
4.3.2.1. Comparison of PZ gene promoter sequences in HepG2 cells with 
the wild type promoter.
To sequence the PZ gene promoter present in HepG2 cells, the nucleotide 
sequence of the human wild type PZ gene promoter (Homo sapiens protein Z, 
AF440358, National Centre for Biotechnology Information) spanning -18845 to 
+106 relative to the translation site was divided into three overlapping regions 
(See Section 2.1). Primers for each region (See Table 2.1) were designed (See 
Section 2.1) to allow amplification by the polymerase chain reaction (PCR). 
PCR (See Section 2.1.1) were optimised to amplify each region using genomic 
DNA template prepared by the GenElute Mammalian Genomic DNA miniprep 
kit (Sigma-Aldrich, UK), from cultured HepG2 cells, and the respective primers. 
Each amplified fragment was size-fractionated on a 1% w/v agarose gel (See 
Sections 2.1.1 and 2.1.2), and visualised using a UVP Biolmaging system. The 
fragments amplified for each region were then purified (See Section 2.1.3) and 
sent to the Genetic Core Facility of Sheffield Medical School for sequencing. 
The sequencing was performed using the Applied Biosystems BigDye v.3.1 ®  
Terminator sequencing chemistry and analysed by the ABI3730 capillary 
electrophoresis system (Applied Biosystems, UK). The sequence of the PZ 
gene promoter in HepG2 cells was compared with the sequence of the wild type 
promoter.
4.3.2.2. Expression plasmid verification
The identity of the expression vector pCMV6-XL4 (OriGene Technologies, 
USA), ~4.7 kb, with the HNF4a cDNA (3.6 kb), which was used in transfection 
of HepG2 cells, was confirmed by digestion with restriction enzymes (See 
Section 2.4.3.3). Sufficient quantities of plasmid were prepared for transfection 
(See Section 2.4.3). The webcutter 2.0 programme was used to determine the 
appropriate restriction enzyme for the HNF4a insert and the resultant fragments 
produced after digestion. The restriction enzyme Sac1 (Fermentas life science, 
UK) cuts the insert at nucleotides 721 and 3024 and was used to digest the 
plasmid encoding HNF4a for verification purposes. The resultant fragments 
were analysed using a1% v/w agarose gel.
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4.3.2.3. Extraction of RNA
RNA was extracted using the GenElute mammalian total RNA miniprep kit (See 
Section 2.3.1) from untransfected HepG2 and HepG2 cells transfected with the 
HNF4a expression plasmid. The quality of the extracted RNA was determined 
by size fractionation through a 1% v/w agarose gel and assessment of the 
ribosomal 18S and 28S bands. Purity and concentration were measured using 
the NanoDrop®ND-1000 spectrophotometer (NanoDrop Technologies, USA). 
The RNA was treated with DNase 1 (Sigma-Aldrich, UK) to remove any 
contaminating genomic DNA. The RNA was then used to synthesise cDNA 
(See Section 2.3.3) using the iScript cDNA synthesis kit (Bio-Rad, UK) for use 
in the qPCR assays.
4.3.2.4. Primer efficiency
To calculate the efficiency of the primer pairs for qPCR, template cDNA was 
serially diluted (undiluted, 1:10, 1:100 and 1:1000) and each PCR reaction was 
carried out in triplicate. The Cq values obtained from each dilution were plotted 
against the logarithm of the cDNA concentrations and the slope of the line of 
best fit determined (See Section 2.3.4.1). The efficiency was then calculated by 
the equation: Efficiency = -1 + I0 ('1/Slope)
A slope o f-3.32 indicates a primer efficiency of 100%.
4.3.2.5. Reference gene Validation
The reference gene for normalising qPCR quantification was selected by 
performing qPCR (See Section 2.3.4.3) on a set of housekeeping genes, (3- 
actin, GADPH, UBC, and YWHAZ (See Table 2.4), taken from Vandesompele 
et al. (Vandesompele et al. 2002), using cDNA from untransfected and HNF4a 
transfected HepG2 cells. The most stable housekeeping gene, which showed 
the least variation in its relative expression between the untransfected and 
HNF4a transfected HepG2 cells, was then used as a reference gene to study 
the effect of HNF4a overexpression and knockdown on PZ gene expression in 
the HepG2 cell model.
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4.3.2.6. The effect of HNF4a overexpression in HepG2 cells on 
endogenous PZ transcript levels
Tfx™-20 reagent (Promega corporation, UK) was used for the transfection (See 
Section 2.4.4) of HepG2 cells with HNF4a encoding plasmid (Fig 2.7) according 
to the manufacturer’s instructions. The effect of HNF4a overexpression in 
HepG2 cells on the endogenous PZ gene was measured by qPCR using SYBR 
green chemistry (See Section 2.3.4.3).
The relative expression ratio of the PZ gene was normalised to the reference 
gene, UBC, and calculated using Pfaffl equation (Pfaffl 2001).
Target)&Cq tar3et (Control-Sam ple)
Ratio= ___________________________________________
R eference ) ^ Cq reference (Control-Sam ple)
E Target is the amplification efficiency of the primer pair specific for the gene of 
interest. E Reference is the amplification efficiency of the primer pair specific 
for the reference gene. ACq target is the difference between the quantification 
cycle (Cq) of the gene of interest in the control cells and the sample cells. ACq 
reference is the difference between the quantification cycle (Cq) of the 
reference gene in the control cells and the sample cells.
The data was analysed using the Pfaffl equation since the efficiency (86%) of 
the gene of interest (PZ) and the efficiency (95%) of the reference gene (UBC) 
primers showed some discrepancy. Melt curve analysis (See Section 2.3.4.3) 
was carried out to detect non-specific products and primer dimers.
4.3.2.7. The effect of HNF4a Knock down on the levels of endogenous PZ 
expression
HNF4a expression in HepG2 cells was knocked down using a smart pool 
siRNA (Dharmacon RNAi Technologies, UK) according to the protocol provided. 
2pM of the siRNA and 2 pi of the transfection reagent in a total volume of 500 pi 
of medium were added to the cells and incubated for 24 hours (See Section 
2.4.5). A positive control (ON-Targetplus GAPDH control pool) was used to 
optimise the protocol for transfection of the HepG2 cells and a negative control 
(ON-Targetplus Non-Targeting pool) was used to make sure the observed
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effects were specific to the sequence being targeted by the particular siRNA 
being used in the experiment. The efficiencies of the knock down of the 
candidate gene expression and its effect on PZ were measured using qPCR 
(See Section 2.3.4.3).
4.3.2.8. Comparison of the relative HNF4a mRNA expression in HepG2 to 
normal liver tissue.
To compare the relative expression of HNF4a mRNA in HepG2 cells to normal 
liver tissue, RNA was prepared from the HepG2 cells (See Section 2.3.1) and a 
commercial preparation of total RNA from normal adult human liver was 
purchased (AMS biotechnology Ltd, UK) The two RNA samples were reverse 
transcribed to cDNA (See Section 2.3.3) and subjected to qPCR (See Section 
2.3.4.3). The relative expression of HNF4a mRNA in HepG2 cells and normal 
liver was normalised to the UBC reference gene. For more details see section
2.4.2.
4.3.2.9. Data analysis
EMSA analysis: To determine protein-DNA binding specificity unrelated
dsDNA competitors were used. Specific protein-DNA complexes show no 
diminution in the presence of a fold-excess of unrelated competitors. 
Competition was determined by measuring the intensity of the binding complex 
in the presence of a competitor and compared with the intensity of the complex 
in the absence of the competitor. The intensity of the protein-DNA complexes 
was measured using the Li-Cor instrument and quantitative software (Li-Cor, 
UK).
Real time PCR analysis: The fold increase of the target gene (PZ) after 
HNF4a overexpression was normalised by UBC and determined by Pfaffl 
equation (See Section 4.3.2.6), since the primer efficiency of the reference 
gene and the target gene were not close to each other. Basal gene expression 
was first expressed as the change in the quantification cycle (ACq) for the gene 
of interest and for the reference gene, where the quantification cycle (Cq) was 
the detectable fluorescence above the background for the candidate genes.
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The fold decrease of PZ and HNF4a after HNF4a siRNA knockdown was 
determined using the formula 2'ACq, where 2 was the presumed amplification 
efficiency for the target and reference genes and the ACq was the Cq of target 
gene - the Cq of reference gene. To compare the relative expression of HNF4a 
and PZ mRNA in HepG2 to normal liver tissue, the formula 2'AACq was used, 
where the relative expression in HepG2 was calculated after normalisation with 
the UBC reference gene and the liver tissue. These two formulas were used 
since the primers of both the target genes and the reference gene were 100%  
(Applied Biosystems, UK).
The significant difference between samples and controls was determined using 
REST 2009 software, developed by M. Pfaffl and Qiagen, taking into account 
the primers efficiencies and normalisation of reference gene. Randomization 
techniques are employed to determine whether any differences in expression 
are significant.
105
4.3. Results
4.3.1. Protein binding to putative HNF4a sites in the PZ promoter
EMSA reactions using fluorescently labelled dsDNA probes spanning the PZ 
HNF4a sites, pPZHNF4a (-48/-38) and dPZHNF4a (-310/-300), were shown to 
be bound by protein present within the nuclear extract from FlepG2 cells 
(HepG2NE) (Fig 4.2 & 4.3).
a
Fig 4.2. EMSA using the reported pPZHNF4a-fluorescent (cy5.5) binding site.
(a) Nucleotide sequences of the probes and competitors are shown in Table 2.2 (Section
2.2.3). The binding reaction lane is the reported HNF4a (pPZHNF4a) probe (-48/-38) with 
HepG2 NE. Self compet lane is the pPZHNF4a probe, the HepG2 NE and the unlabeled 
pPZHNF4a. HNF4a cons lane is the pPZHNF4a probe, the HepG2 NE and unlabeled 
HNF4a binding consensus. HNF3B, AP1 and SP1 cons lanes are the pPZHNF4a probe 
with the HepG2 NE and unlabeled HNF3B, AP1 and SP1 binding site consensuses 
added, respectively. Bands indicated by arrow A represent protein DNA complexes. 
Bands represented by arrow B represent unbound fluorescent probe. Competition is seen 
with the self competitor and the HNF4a consensus sequence. Negligible competition is 
seen with the non-specific competitors HNF3B, AP1 and SP1 binding sites, (b) The red 
circle shows the proximal HNF4a site in the PZ gene promoter while the numbers indicate 
the hypothetical spanning region.
The binding reaction with the pPZPZHNF4a probe showed one bound complex 
(Fig 4.2, band A) while dPZHNF4a showed two bound complexes (Fig 4.3, 
bands A and B). Competition reactions using the pPZHNF4a probe with both a
106
100-fold excess of unlabelled self and HNF4a binding site consensus sequence 
competitor showed significant competition of 60% and 100%, respectively. 
Competition with a 100-fold excess of non-specific competitor, HNF3B, AP1 
and SP1, did not show any significant competition (reductions of bound 
complex of 9%, 17% and 21%, respectively).
Competition reactions using the dPZFiNF4a probe demonstrated that the bound 
complex A (Fig 4.3) showed specificity to the probe sequence, with no 
observable competition with 50, 100 and 200-fold excess of FINF4a consensus 
binding site and non-specific competitors. The bound complex B, however, was 
demonstrated to be non-specific to the sequence, with 50, 100 and 200-fold 
excess of the HNF4a consensus and non-specific AP1 binding site consensus 
competitors showing a similar effect on bound complex levels (Fig 4.3).
Fig 4.3. EMSA using the putative PZ distal HNF4a-fluorescent (IRD-700) binding site.
(a) Nucleotide sequences of the probes and competitors are shown in table 2.2 (section
2.2.3). Binding reaction lane is the distal HNF4a (dPZHNF4a) probe (-310/-300) with 
HepG2 NE. HNF4a lanes are (dPZHNF4a) probe with HepG2 NE and 50, 100 and 200- 
fold molar excess unlabeled HNF4a consensus added, respectively. Lanes 5, 6 and 7 are 
(dPZHNF4a) probe with HepG2 NE and 50, 100 and 200-fold excess unlabeled AP1 
added, respectively. Bands indicated by arrows A &B represent protein DNA complexes. 
Bands represented by arrow C represent unbound fluorescent probe. No competition of 
complex A is seen with increasing fold excess of the unlabeled HNF4a consensus and the 
unlabeled non-specific competitor AP1 binding site consensus. Competition of complex B 
is seen with both unlabeled FINF4a consensus and the unlabeled AP1. (b) The red circle 
shows the distal HNF4a site in the PZ gene promoter while the numbers indicate the 
hypothetical spanning regions.
a b
A
B
C
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4.3.2. Confirmation of the identity of the protein bound to the proximal 
HNF4a site
The assay described here used the HNF4a antibody to specifically identify the 
protein bound to the pPZHNF4a sequence as HNF4a (Fig 4.4). Again, arrow A 
indicates a protein-DNA complex and arrow B indicated the free probe. 
Competition with self competitor and the HNF4a competition both led to a 
dramatic reduction in the amount of bound probe present. The final reaction 
with the HNF4a antibody present also showed a loss of the protein DNA- 
complex and increased levels of non-migrating complex in the well (3.7-fold 
higher fluorescence intensity (Fig 4.4, band C)) compared with the other wells.
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Fig 4.4. Supershift assay using the pPZHNF4a-fluorescent (cy5.5) binding site. Control 
is the pHNF4a probe (-48/-38) without HepG2 NE. Binding reaction was the pPZHNF4a probe 
(-48/-38) with HepG2 NE. Self competitor is the pPZHNF4a probe, the HepG2 NE and the 
unlabeled pPZHNF4a. HNF4a consensus lane is the pPZHNF4a probe, the HepG2 NE and 
unlabeled HNF4a binding consensus. HNF4a antibody lane contained the pPZHNF4a probe, 
the Hep NE and the HNF4a antibody. Bands indicated by arrow A represent protein DNA 
complexes. Bands indicated by arrow B represent unbound fluorescent probe. Band C 
represent the potential antibody-protein-DNA complex. Competition is seen with 100-fold 
molar excess of self-competitor and the HNF4a consensus sequences.
A supershift assay with the HNF4a antibody using the HNF4a binding site 
consensus sequence probe (Fig 4.5) showed very similar results, with a loss of 
protein-DNA complex (Fig 4.5, band A) and a greater fluorescence intensity
(approximately 4-fold) in the well containing the antibody (Fig 4.5, band C), 
compared to the well of the binding reaction without the antibody.
Free
probe
Fig 4.5. Supershift assay using the consensus HNF4a-fluorescent binding site.
The binding reaction is the HNF4a binding site consensus probe with HepG2 NE.
HNF4a antibody lane contains the HNF4a binding site consensus probe, the HepG2 NE 
and the HNF4a antibody. Bands indicated by arrow A and B represent protein DNA 
complexes. Band C represent the potential antibody-protein-DNA complex.
4.3.3. Gene expression studies of the endogenous PZ gene in HepG2 cells
4.3.3.1. Sequencing of PZ gene promoter
The results (See Appendix) of the PZ gene promoter sequencing indicated that 
the nucleotide sequence of the promoter region (residues -1884 to +106) of the 
endogenous PZ gene in HepG2 cells was identical to that reported as the 
reference sequence for human PZ (Homo sapiens protein Z, AF440358, 
National Centre for Biotechnology Information). The genotypes of the PZ 
promoter sequence single nucleotide polymorphisms (SNPs) in HepG2 cells 
were found to be GG at -13, CC at -336, GG at -861, GG at -984, CC at -1185, 
AA at -1252, TT at -1338, GG at -1498 and TT at -1621.
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4.3.3.2. Expression plasmid verification
Restriction enzyme digestion of the expression plasmid encoding HNF4a 
(OriGene Technologies, UK) using the Sacl restriction enzyme (Fermentas life 
science) showed three bands of 5.27 kb, 2.3 kb and 0.72 kb (Fig 4.6, lane 3) on 
1% w/v agaros gel.
10 k b
3 k b  
2  k b
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Fig 4.6. HNF4a encoded plasmid digested with restriction enzymes.
Lane 1 was a 1 Kb ladder, lane 2 the HNF4a plasmid and lane 3 the HNF4a plasmid 
digested with S a d . The size of the HNF4a encoded plasmid before digestion was found 
to be approximately 8.3 kb (lane 2). Three bands of 5.72 kb, 2.3kb and 0.72 kb were 
detected as a result of the digested plasmid (lane 3).
4.3.3.3. RNA analyses
The purity of the RNA prepared from FlepG2 cells before and after transfection
with the expression plasmid encoding HNF4a was measured by the ratio of
absorbance at 260 and 280 and found to be pure (>1.8). Moreover, no
observable degradation was shown in the ribosomal bands 18S and 28S (Fig
4.7) upon assessment by gel electrophoresis.
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Fig 4.7. Ribosomal RNA 28S and 18S bands on 1% w/v agaros gel.
Lane 1 represented the 28S and 18S RNA bands from untransfected HepG2 cells. Lane 2 
showed the RNA bands from the HNF4a transfected HepG2 cells. Both RNAs was shown 
to be with good quality.
4.3.3.4. Efficiency of primers
The Cq values were plotted against the log of template cDNA concentration and 
the slope of the line of best fit for both the reference gene (UBC) and the gene 
of interest (PZ) primer pairs were determined, both showinga high coefficient of 
determination (R2>0.98), indicating the data points fitted very closely to the 
trend line (Fig 4.8). Primer efficiencies calculated were found to be 95% for 
UBC and 86% for PZ.
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Fig 4.8. Determination of real time PCR efficiencies. The efficiencies of the reference gene 
(UBC) and the target gene (PZ) primers were measured by plotting Cq versus log cDNA for 
the serial dilutions. The slope was determined and used to calculate the efficiency of the 
primers. The efficiency of UBC was found to be 95% while PZ 86%.
4.3.3.5. Reference gene Validation
The UBC gene was found to be expressed at a constant level in untransfected 
and HNF4a transfected HepG2 cells with only a negligible change (2% 
decrease). However, the relative expression of GAPDH, Yahwaz and Bactin 
was found to be decreased in the transfected HepG2, 50%, 56% and 42%, 
respectively, compared to the untransfected HepG2 cells (Fig 4.9).
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Fig 4.9. Comparision of relative expression of some housekeeping genes for the 
stability. Relative expression of housekeeping genes in HNF4a transfected HepG2 cells 
normalised to their expression in untransfected cells (100%). UBC gene relative expression 
was found to be the most stable in untransfected and HNF4a transfected cells. The relative 
expression of GAPDH, Yahwaz and Bactin was found to decrease 50%, 56% and 42%, 
respectively, in the transfected HepG2. The results shown are from four independent 
experiments.
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4.3.3.6. Relative PZ mRNA expression in HNF4a overexpressed HepG2 
cells.
T h e  a m p lif ic a tio n  p lo t (F ig  4 .1 0 ) and  M e lt cu rve  (F ig  2 .4 ) s h o w e d  n e ith e r th e  
fo rm a tio n  o f n o n -s p e c if ic  p ro d u c ts  n o r p r im e r d im e rs , re s p e c tive ly .
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Fig 4.10. Amplification plot of PZ and UBC with transfected and non transfected cells.
Green lines represent the UBC amplification with untransfected HepG2 cells while the red 
line with the transfected HepG2 cells. Dark blue colour represents the PZ amplification with 
the transfected sample while the light blue with the untransfected sample. The Cq values 
with PZ in the transfected samples (dark blue lines) decreased compared with non 
transfected (light blue lines). No amplification in no template wells indicates no non specific 
transcript or primer dimers. ARn, the magnitude of the signal generated, is the baseline 
signal from the initial stages of PCR subtracted from the real time data.
T h e  le ve l o f e n d o g e n o u s  P Z  m R N A  w a s  fo u n d  to  be in c re a s e d  2 .5  fo ld  a fte r  
tra n s fe c tin g  H e p G 2  ce lls  w ith  th e  e x p re s s io n  v e c to r  e n c o d in g  F IN F4a  (F ig  4 .1 1 ) . 
S ta tis t ic a l a n a ly s is  o f  th e  d a ta  us ing  th e  R E S T  2 0 0 9  s o ftw a re  s h o w e d  th a t th e  
in c re a s e  w a s  s ig n if ic a n t (p<  0 .0 5 , n = 6 ). T h e  re la tive  e x p re s s io n  o f P Z  m R N A  
a fte r  m o c k  tra n s fe c tio n  o f  F !epG 2 c e lls  (u s in g  an e q u iv a le n t a m o u n t o f  th e  
p la sm id  pCATOO) co m p a re d  to  u n tra n s fe c te d  c e lls  (w ith o u t tra n s fe c tio n  re a g e n t 
o r p la sm id  D N A ), in the  p re s e n c e  o f th e  re fe re n c e  g e n e  (U B C ), w a s  fo u n d  to  be  
u n a ffe c te d  (n e g lig ib le  in c re a s e  0.01 fo ld ) (F ig  4 .1 2 ).
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Untransfected cells Transfected cells
Fig 4.11. The effect of HNF4a overexpression on PZ mRNA relative expression.
The HNF4a transfected cells showed 2.5 fold higher level of PZ mRNA expression 
(P value < 0.05. REST2009, n=6) compared with the untransfected (control) sample 
and normalised to UBC reference gene.
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Fig 4.12. The effect of mock transfection on PZ mRNA relative expression.
The relative expression of PZ in mock transfected (pCATOO) HepG2 cells showed 
negligible increase (0.01 fold change) compared to untransfected cells and normalised by 
UBC reference gene. The results were from four experiments.
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4.3.3.7. Knockdown of HNF4a using small interfering RNAs
The positive control (ON-Targetplus GAPDH control pool) for GAPDH silencing 
resulted in an approximately 80% reduction (5-fold decrease) of GAPDH mRNA 
relative expression (Fig 4.13) compared to the negative control (ON-Targetplus 
Non-Targeting pool). The decrease in the GAPDH mRNA relative expression 
was found to be statistically significant (P<0.05, REST 2009, n=3)
o
e  s'NonTarg si GAPDH
Fig 4.13. GAPDH knockdown in HepG2 cells using siRNAs.
The ON-Targetplus GAPDH control pool (siRNA) showed reduction of GAPDH mRNA to 
approximately 20% (5-fold decrease) compared with ON-Targetplus Non-Targeting pool 
(negative control) using qPCR. The reduction was statistically significant (P<0.05, 
REST 2009, n=3).
The HNF4a knockdown in HepG2 cells using an On-targetplus smart pool 
siRNA showed a 60% average reduction (2.5-fold decrease) of HNF4a mRNA 
relative expression compared to the ON-Targetplus Non-Targeting pool 
negative control (Fig 4.14). This reduction was found to be statistically 
significant using the REST 2009 software (P< 0.05, n=5).
115
a- siNonTargettransfected cells siHNF4a transfected cells
Fig 4.14. HNF4a knockdown in HepG2 cells using siRNAs.
HepG2 cells transfected with the On-targetplus smart pool siRNA for HNF4a (siHNF4a) 
showed a reduction in HNF4a mRNA expression to approximately 40% (~ 2.5 fold 
decrease) compared to the non targeting siRNA (siNonTarget) negative control (P<0.05, 
REST 2009, n=5) and normalised to UBC reference gene.
QPCR experiments using HNF4a mRNA knocked down HepG2 cells showed a 
significant effect on the level of PZ mRNA. Knockdown of HNF4a to 40% 
significantly reduced the relative expression of PZ mRNA (Fig 4.15) to 
approximately 36% (~ 2.8 fold decrease) (p value < 0.05, REST2009, n=6).
siNonTarget transfected cells siHNF4a transfected cells
Fig 4.15. The effect of HNF4a Knockdown on PZ mRNA expression.
Knockdown of HNF4a in HepG2 cells decreased the PZ mRNA expression. 60% 
knockdown of HNF4a showed a decrease in the PZ mRNA expression to approximately 
36% (P value< 0.05, REST 2009, n=6).
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4.3.3.8. Expression of PZ and HNF4a in HepG2 compared to normal 
human liver
The relative expression of HNF4a mRNA in HepG2 was found to be 
approximately 2.3-fold more than in normal human liver tissue. The relative 
expression of PZ mRNA was found to be relatively expressed at very low levels 
in HepG2 cells, approximately 0.03-fold (~ 33-fold less) than that of the normal 
human liver tissue (Fig 4.16). The variation in the relative expression of PZ and 
FINF4a mRNA between FlepG2 and normal human liver tissue were found to be 
statistically significant using the REST 2009 software (P<0.05, n=3).
Fig 4.16. The relative expression of HNF4a and PZ mRNA in HepG2 and normal 
liver tissue. The figure showed a logarithmic scale for the relative expression of PZ 
and HNF4a in HepG2 cells compared to liver cells and normalised to UBC reference 
gene. The relative expression of HNF4a mRNA in HepG2 was found to approximately 
2.3-fold more than in liver tissue. PZ mRNA expression was shown to be 
approximately 33-fold less in HepG2 than that of liver tissue. The horizontal thick line 
represented the levels of mRNA expression in liver tissue. The housekeeping gene 
UBC was used as a reference gene.
4.4. Discussion
The electrophoretic mobility shift assay is a gel electrophoresis technique which 
can be used to determine the ability of a protein to bind a linear double stranded 
DNA molecule, typically 20-25 base pairs and containing the binding site of 
interest (Jiang, Jarrett and Haskins 2009). This assay (EMSA) has been used 
extensively in DNA-protein interaction studies (Fried and Crothers 1981, Revzin 
1989). Short sequence motifs which are found in the promoter and enhancer 
regions of genes and the transcription factors bound to those motifs are 
essential for the regulation of gene transcription. The in silico prediction of 
putative binding sites is of great importance to restrict the experiments and save 
the time used in protein-DNA interactions for characterisation of new genes 
(Messeguer etal. 2002).
As mentioned above two potential sequences for HNF4a binding (proximal -48 
to -38 and distal -310 to -300) were identified using ALGGEN-PROMO. Probes 
were prepared that spanned the putative binding sites and also included 
flanking sequences (Section 2.2.3, Table 2.2). The EMSA probe spanning 
residues -54 to -35 of the PZ promoter, containing the potential binding site (-48 
to -38) for HNF4a, was found to be bound by a protein. This protein showed 
binding specificity as it was dramatically competed with itself (60%) and the 
HNF4a binding site consensus sequence (100%), but showed negligible 
competition with non specific competitors such as the HNF3B consensus (7%), 
the AP1 consensus (19%) and the SP1 consensus (21%) sequences (Fig 3.2). 
The intensify of the protein-DNA complexes were quantified using the software 
associated with the Li-Cor odyssey imaging system (Li-Cor, UK). The 
specificity of the competition gave an indication that the protein bound to this 
site was indeed HNF4a.
To confirm HNF4a binding, a supershift binding assay was done using an 
antibody against HNF4a. The antibody added to the binding reaction caused a 
loss of the protein-DNA complex rather than a complex of increased size that 
would have a lower mobility upon electrophoresis. This could be due to the size 
of the complex being too large to efficiently migrate into the gel matrix (indicated 
by arrow C) where the well with the antibody showed the greatest fluorescence 
intensity (3.7-fold higher) compared with the other wells (Fig 4.4). To confirm 
this result and the electrophoretic properties of the HNF4a antibody-protein-
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DNA complex, another EMSA reaction was done using the HNF4a antibody 
added to a binding reaction with the HNF4a binding site consensus sequence 
as a probe. The result showed that the DNA-protein-antibody complex using 
the HNF4a binding site consensus sequence was approximately the same as 
when the putative pPZHNF4a was used, with a 4-fold greater intensity in well 
with the antibody compared to the well with the binding reaction without 
antibody (Fig 4.5).
The binding of HNF4a to the PZ gene promoter was reported by Sugawara and 
colleagues (Sugawara et al. 2007) and, therefore, is consistent with the results 
in the current study. Moreover, evolutionarily related proteins with similar 
expression profiles, such as FVII, FIX and FX (Ichinose et al. 1990, Sejima et 
al. 1990) have also been found to be regulated by HNF4a (Stauffer et al. 1998, 
Reijnen etal. 1992, Miao etal. 1992).
The other potential HNF4a region identified (-310 to -300) by bioinformatic 
analysis was found to be bound by nuclear protein. This protein binding was 
found to be specific, since addition of various molar excesses of the non­
specific competitor AP1 did not compete the bound protein. However, 
competition reactions with different molar excesses of the HNF4a binding site 
consensus also did not compete the bound protein, indicating that the protein 
bound to this region was not HNF4a (Fig 4.3, bands A).
Transient transfection is an important technique that can be used in the study of 
gene function (Miura and Yuan 2000) and has been used with hepatoma cell 
lines to analyse the promoters and enhancers of numerous genes in order to 
study their transcriptional regulation (Cereghini 1996). Therefore, to further 
analyse the role of HNF4a in PZ transcription, this transcription factor was 
overexpressed in HepG2 cells. Prior to the transfection, the HNF4a expression 
plasmid (pCMV6-XL4-HNF4a) was prepared (see section 2.4.3) and its identity 
was verified by digestion with Sacl restriction enzyme and size-fractionated on 
a 1% w/v agarose gel (Section 2.4.3.3). Digestion of the expression plasmid 
with Sacl showed the predicted fragments (Fig 3.6) of 5.27 kb, 2.3 kb and 0.72 
kb according to the webcutter website (webcutter 2.0 website). Having verified 
the HNF4a encoding expression plasmid it was transfected transiently into 
HepG2 cells (See Section 2.4.4) and the effect on endogenous PZ mRNA 
levels measured using qPCR (See Section 2.3.4.3). The advantage of carrying
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out experiments utilising the endogenous gene locus and qPCR rather than a 
reporter gene construct bearing a PZ promoter fragment is that the level of 
expression will be measured from the full endogenous gene promoter rather 
than a synthetic construct of a limited proportion of the promoter directing 
expression of the reporter gene. In addition, the DNA will be in the context of its 
normal chromatin structure wrapped around the histone octamers, rather than 
in a naked supercoiled plasmid. Also, synergistic interactions important for 
normal gene expression will occur within the intact nucleus when such 
interactions may be limited or absent in the reporter gene vector.
Preparation of good quality RNA is the first key step in the analysis of gene 
expression. Therefore, the RNA prepared from the HepG2 cells (See Section 
2.3.1) before and after transfection was size fractionated using 1% w/v agarose 
gel. The prepared RNA showed no observable degradation of the ribosomal 
RNA bands 18S and 28S (Fig 4.7) and, therefore, was considered of good 
quality. Nevertheless, Auer et al in 2003 reported that degraded RNA samples 
could be used in gene expression studies, in this instance microarray analysis, 
if their integrity is comparable (Auer et al. 2003). The RNAs were also 
quantified and their purity was measured by the ratio of absorbance at 260 and 
280 and found to be >1.8 using a NanoDrop®ND-1000. The RNAs from 
transfected and non-transfected HepG2 cells were then used to prepare cDNA, 
which used in qPCR.
A reference gene selected for gene expression studies should be expressed at 
a constant level and not be affected by experimental conditions. As it is difficult 
to find such a gene, the reference gene should be validated for expression and 
stability for every new transfection experiment (Schmittgen and Zakrajsek 
2000). QPCR was performed on HNF4a transfected samples using four 
housekeeping genes (p-actin, GADPH, UBC, and YWHAZ). The housekeeping 
genes were analysed for amplification and stability after the transfection.
UBC was found to be the most appropriate reference gene for use in the 
calculation of expression ratios after HNF4a transfection by the SYBR green 
qPCR, as it was the gene whose expression was least affected by HNF4 
overexpression (Fig 4.9).
Transfection of HepG2 cells by HNF4a was found to increase the relative 
expression of PZ mRNA (Fig 4.11). Although SYBR green I is normally used at
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low concentrations which can lead to unreliable melt curves due to a dye 
distribution phenomenon (Varga and James 2006), the melt curve detected in 
this experiment was consistent with published data and showed no non-specific 
amplification products or primer dimers (Fig 2.4). The increase in the relative 
expression of PZ mRNA was detected by a decrease in the Cq value of PZ 
mRNA expression with transfected samples compared to the untransfected 
samples (control) in the presence of the reference gene (UBC). Since the 
primer efficiencies of the reference and target gene were not the same (Fig
4.8), the data were analysed using the Pfaffl equation (See Section 4.3.2.6). 
The increase of the relative PZ mRNA expression in the HNF4a overexpressed 
HepG2 cells was determined to be approximately 2.5-fold which is statistically 
significant (p<0.05, n=6).
An off-target effect is a potential biological response that could be caused by 
the introduction of foreign DNA and should be considered in studying any gene 
of interest by cell transfection (Jacobsen, Calvin and Lobenhofer 2009). This 
off-target effect could be due to the transfection reagent which is used in the 
transfection process. Tfx-20 is a highly efficient transfection reagent which has 
been used successfully for the transfection of HepG2 cells in studying gene 
transcription (Dongol et al. 2007). However, it was checked in this study for its 
potential effects on the transcription of the gene of interest. The ratio of PZ 
mRNA levels after mock transfection of HepG2 cells (using an equivalent 
amount of the plasmid pCATOO) to untransfected cells (without transfection 
reagent or plasmid DNA) was determined in the presence of the reference gene 
(UBC). The relative expression was found to be unaffected (a negligible 
increase of 0.01-fold) by the mock transfection (Fig 4.12), indicating the 
transfection reagent had no effect on the expression of the gene of interest.
To confirm the role of the HNF4a transactivational response in the 
transcriptional regulation of the endogenous PZ gene in HepG2 cells, the 
expression of the endogenous HNF4a was knocked down using an on- 
targetplus smart pool small interfering RNA (siRNA) and the effects on the 
endogenous PZ mRNA quantified using TagMan qPCR. Since UBC was found 
to be the most stable house keeping gene with HNF4a overexpression, it was 
used as reference gene assuming its stability with decreasing HNF4a levels. 
Off-target silencing has been observed with genes containing a limited
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complement sequence with siRNAs (Jackson et al. 2003). Therefore, a positive 
control (ON-Targetplus GAPDH control pool) to optimise the protocol and 
transfection reagent with HepG2 cells and a negative control (ON-Targetplus 
Non-Targeting pool) to make sure the specific effects to the sequence targeting 
of the particular siRNA were used in the experiment. The smart pool 
technology was developed by Dharmacon Technologies for highly potent 
silencing and minimising off-target effects using reduced concentrations of four 
predesigned siRNA targeting one gene. On-targetplus smart pool siRNAs 
along with the positive GAPDH control pool and the negative Non-Targeting 
pool were used extensively in studying gene expression (Danes et al. 2008, 
Kwei et al. 2008, Hariparsad et al. 2009, Taniguchi et al. 2009, Rizzo et al. 
2010, Lahkim Bennani-Belhaj etal. 2010)
Knock down of GAPDH mRNA expression level was first performed (Fig 4.13) 
to optimise the protocol and found to be reduced 80% (P<0.05, n=3) by the 
GAPDH positive control pool siRNA compared with the negative control, 
indicating an optimum protocol. Prior to determining the effect of HNF4a 
silencing on PZ the knockdown was confirmed using HNF4a primers. The level 
of HNF4a mRNA relative expression was found to be reduced to 60% (P<0.05, 
n=5) in the HepG2 cells transfected with the siRNA smart pool for HNF4a 
compared to the negative control (Fig 4.14). The HNF4a knocked down HepG2 
cells were determined for their PZ relative expression compared to the negative 
control. The relative expression of PZ mRNA in HepG2 was found to be 
reduced to 36% (2.8-fold) in response to 60% HNF4a knock down compared to 
the negative control and normalised with the UBC reference gene (Fig 4.15). 
The decrease was statistically significant (P<0.05, n=6). These results were 
consistent with the HNF4a overexpression study and EMSA results in the 
current study in addition to the EMSA and reporter gene assays reported by 
Sugawara and colleagues (Sugawara et al. 2007). The current study, therefore, 
confirms the Sugawara data in that HNF4a has a significant role to play in 
expression of the PZ gene. However, the use of overexpression and 
knockdown of HNF4a, and analysis of the endogenous PZ locus adds a further 
level of characterisation to the promoter study, in that the importance of HNF4a  
activity is confirmed within the chromatin context of the intact nucleus.
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The HepG2 cell line is a common model system for analysis of liver-specific 
gene expression. It was used to study the effect of the HNF4a in the 
transcriptional regulation of many coagulation proteins, such as, FVII (Stauffer 
et al. 1998), FVIII (Figueiredo and Brownlee 1995), FIX (Reijnen et al. 1992), 
FX (Miao etal. 1992), FXI (Tarumi etal. 2002) and FXII (Farsetti etal. 1998). 
However, as HepG2 is a hepatoma cell line, its genome are inevitably different 
to normal primary liver cells and the transcriptome may exhibit differences to 
normal liver cells that could impact on such studies. Therefore, it is important to 
assess whether or not the HepG2 cell line expresses PZ and HNF4a, and if so 
at what levels. Expression of HNF4a mRNA and PZ mRNA in the HepG2 cell 
line were, therefore, compared to their expression in normal liver cells using 
qPCR. Total RNA prepared from HepG2 cells and RNA from normal human 
liver cells (AMS biotechnology Ltd, UK) were reverse transcribed to cDNA and 
used to determine the relative expression for PZ and HNF4a by qPCR. The 
relative expression level of HNF4a in HepG2 was found to be 2.3-fold more 
than in liver tissue while PZ mRNA relative expression was shown to be 
approximately 33-fold less in HepG2 than that of liver tissue (Fig 4.16). The 
difference in the relative expression in HNF4a and PZ between HepG2 and liver 
tissue was found statistically significant (P<0.05, n=3). The high level of HNF4a 
and significantly low level of PZ in HepG2 compared to liver tissue may indicate 
that these cells were not the best model to study PZ transcriptional regulation 
and may affect the accuracy of the results. However, the RNA from the liver 
tissue that used in the comparison to HepG2 was prepared from only one male, 
and therefore, these differences may be not reliable.
4.5. Conclusion
The present study has defined an up-regulatory role for HNF4a in the regulation 
of the endogenous PZ gene within HepG2 cells. This was initially indicated by 
its specific binding to the proposed binding site in the PZ promoter spanning 
nucleotides -48 to -38 which was confirmed by supershift assay. The 
importance of HNF4a was then confirmed by its effect on the relative 
expression of PZ mRNA within the chromatin context in the HepG2 cell model 
using overexpression and knockdown techniques and measured by qPCR. The
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effect was statistically significant (P< 0.05) in 6 independent experiments with 
each technique. These results were consistent with the study reported by 
Sugawara in 2007 (Sugawara et al. 2007). However, although these significant 
results were obtained within the chromatin context, they are still considered as 
in vitro and need to be confirmed in vivo.
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Chapter 5-The role of 
transcription factors 
PEA3, Ets 1 and CREB 
in regulating protein Z 
expression
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5.1. Introduction
The majority of blood coagulation proteins usually reach their adult levels by the 
age of six months (Andrew et al. 1987); with further increases in levels of a 
number of key factors and also their activation with subsequent increasing age 
(Hager et al. 1989); with analysis of centenarians showing increased levels of 
coagulation enzymes and activation peptides as well as enzyme-inhibitor 
complexes indicating activation of coagulation (Mari etal. 1995). Levels of the 
major procoagulants and anticoagulants, which were assessed by Mari et al, 
are shown in Table 5.1.
Measurments Young
controls
Old controls Centenarians
FVIIa (ng/mL) 3.18(2.76-3.64) 3.24 (2.86- 
3.67)
4.46 (3.91-5.06)
FIX activation peptide 
(pmol/L)
164 (144-185) 207 (187-229) 391 (351-435)
FX activation peptide 
(pmol/L)
86 (81-92) 99 (85-115) 248 (226-272)
Prothrombin fragment 
1+2 (nmol/L)
0.56 (0.49-0.64) 0.69 (0.61- 
0.78)
1.15(0.93-1.43)
Thrombin/antithrombin 
complex (ng/mL)
2.0 (1.6-2.4) 2.4 (2.0-2.8) 5.9 (4.6-7.6)
Fibrinopeptide A 
(nmol/L)
0.89 (0.74-1.06) 1.22 (1.0-1.50) 1.99 (1.72-2.31)
Fibrinogen (mg/dL) 263 (244-284) 312 (287-338) 347 (313-385)
F VIII (%) 97 (90-105) 134 (119-151) 165 (147-185)
Prothrombin (%) 104 (99-108) 98 (95-102) 88 (82-93)
F VII (%) 99 (93-105) 110(104-116) 111 (103-119)
F IX (%) 96 (93-100) 104 (95-113) 107 (98-117)
Antithrombin (%) 98 (95-101) 97 (91-104) 91 (85-98)
Protein C (%) 87 (82-92) 88 (83-93) 90 (83-98)
Tissue factor pathway 
inhibitor (%)
95 (89-102) 110(102-118) 109 (100-118)
Protein S (%) 106 (98-113) 115 (100-132) 109 (97-123)
Table 5.1. Haemostasis measurements for young, older and centenarians (Mari et al. 
1995). Younger controls are 18-50 year old healthy individuals. Older controls are 51-69 year 
old healthy individuals. Centenarians are 100-102 year old healthy individuals. All the groups 
were including both males and males.
The increase in blood coagulation activity as people age may be due, in part at 
least, to the greater increase in expression of procoagulants of the coagulation 
system compared to anticoagulants, which in turn could lead to increased risk 
of thrombosis (Lowe et al. 1997). However, the risk of thrombosis'does not
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necessarily increase in response to increased activity of coagulation enzymes 
(Mari, Coppola and Provenzano 2008). The age-related imbalance between 
procoagulants and anticoagulants and the potential contribution to increasing 
thrombosis cases was also discussed by Massimo Franchini (Franchini 2006). 
To understand why coagulation activity increases with age the genetic 
mechanisms responsible for age regulation of one of the key procoagulants, 
human factor IX (hFIX), was studied using transgenic mice (Kurachi etal. 1999, 
Kurachi et al. 2000, Kurachi and Kurachi 2000). The study of factor IX (FIX) 
using transgenic mice with a hFIX minigene vector provided evidence for two 
age-regulatory elements, AE5’ and AE3’. AE5’ is located in the FIX promoter 
region and was shown to be responsible for age-stable plasma levels, while 
AE3’ is located in the 3’ untranslated region (UTR) and is thought to be 
responsible for the increase in expression of FIX in the liver with increasing age 
(Kurachi et al. 1999). Both age-regulatory elements are important for the 
normal age-dependent regulation of FIX gene (Kurachi etal. 2000).
The minigene study using mice with a vector spanning the 5 ’ end (-802 to -770) 
of hFIX promoter where the AE5’ is located, showed age stable levels of 
plasma hFIX through the entire lifespan of the mice which correlated with 
stable levels of mRNA (Kurachi et al. 1999). These results defined the location 
of the sequence responsible for the age-stable expression of the hFIX gene, 
which was then supported by the presence of a DNA-protein complex detected 
within this region (-790/-784) using DNase I footprint analysis and 
electrophoretic mobility shift assays (EMSA) (Kurachi et al. 1999). The 
sequence spanning the AE5’ (-790/-784) was found to have homology with the 
binding site consensus sequence ((G/C)AGGA(A/T)G) of the Ets family protein, 
polyomavirus enhancer activator 3 (PEA3). The consensus binding site of 
PEA3 competed for the protein bound to the AE5’ region and gave an indication 
that the protein binding to the age-stable element was in fact PEA3 (Kurachi et 
al. 1999). Subsequent studies demonstrated an age-stable element with 
homology to the PEA3 motif within the human protein C (hPC) gene promoter. 
Minigene analysis of transgenic mice defined this element between -849 and - 
803 and determined that it was responsible for age-stable expression (Zhang, 
Kurachi and Kurachi 2002). The protein bound to the region spanning the age- 
stable element in the hPC gene had competition with the AE5’ sequence of the
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hFIX gene using EMSA, suggesting the same protein binds to both promoter 
sequences. However, Kurachi and his colleaques in 2009 reported that the age 
stable element (AE51 also referred as ASE) was bound by Ets1 and had an 
essential role in the spontaneous recovery of haemophilia B Leyden (Kurachi et 
al. 2009). Due to the close homology and suggested evolutionary relationship 
between PZ and PC and FIX (Ichinose et al. 1990), there is the possibility that 
this conservation extends to the regulatory mechanisms of expression including 
Ets family binding sites, such as those for Ets1 or PEA3. PEA3 and Ets1 are 
expressed in a number of different tissues, including the liver (Yanai etal. 2005) 
and may have a role in the constitutive expression of PZ.
5.1.1. E twenty six transformation-specific (Ets) family proteins
The E twenty six transformation-specific (Ets) gene was originally found to be
transduced by the E twenty six (E26) avian leukaemia virus. Cellular
sequences and transcripts in human and other organisms were subsequently
identified by their homology to the Ets region of the E26 retrovirus (Watson,
Ascione and Papas 1990), thus, defining the Ets family.
The proteins of the Ets family are transacting phosphoproteins which were
found to play essential roles in the epithelial, endothelial, haemopoietic,
neuronal and endocrine systems; particularly, in cell differentiation, proliferation,
migration and oncogenesis (Seth and Watson 2005, Sharrocks 2001, Wasylyk,
Hagman and Gutierrez-Hartmann 1998, Feldman, Sementchenko and Watson
2003, Gutierrez-Hartmann, Duval and Bradford 2007). The Ets family was
classified as a winged helix-turn-helix family of DNA-binding domains by the
analysis of the structure using nuclear magnetic resonance spectroscopy
(NMR) (Shore et al. 1995, Werner et al. 1995, Donaldson et al. 1996). The
distinctive characteristic of the Ets family is the presence of the Ets DNA-
binding domain which is composed of approximately eighty five amino acids
(Karim et al. 1990) and characterized by the presence of three conserved
tryptophans separated by eighteen residues (Shore et al. 1995). Apart from the
GA-binding protein (GABP)a, all Ets family proteins bind their DNA-binding site
in the promoter of the target gene as monomers (Gutierrez-Hartmann, Duval
and Bradford 2007, Graves and Petersen 1998). The core binding consensus
for Ets family members was recognized as GGAA/T, with the interaction of each
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protein in this family involving the bases flanking this core (Xin et al. 1992). 
Binding sites have been found in many genes such as those encoding 
transcription factors, regulators of apoptosis and cell cycle, protineases, 
transforming and tumor-associated products, ligands, receptors and tissue 
specific products (Sementchenko and Watson 2000). The bases adjacent to 
the core sequence may contain binding elements for other transcription factors 
which could interact synergistically with the Ets protein in order to activate or 
repress target genes (Li, Pei and Watson 2000). The Ets domain and the 
conserved arginine residues of the DNA recognition helix a3 have been shown 
to mediate the interaction with other transcriptional proteins, while the optimal 
contacts which result in a specific transcriptional response is set up by other 
specific domains (Verger and Duterque-Coquillaud 2002).
The GGA core is recognized by the a3 recognition helix which, mediated by two 
conserved arginine residues, embeds into the major groove (Fig 5.1), while the 
(33- (34 hairpin (wing) and a2 contacts the DNA phosphate backbone in the 
minor grooves (Mo etal. 2000, Mo etal. 1998).
Fig 5.1. Ribbon diagram shows the Ets family member Elk-1 binding to DNA
(Verger and Duterque-Coquillaud 2002). The DNA is white, the GGA core is green, the 
a-helices are pink and the (3-strands are yellow. The two arginines which mediate the a3 
recognition of the GGA core are greenish blue (R62 and R65).
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Many proteins of this family are posttranslationally modified by signal 
transduction cascades, causing changes in their binding to DNA, transcriptional 
activities and association with cellular partners (Sharrocks 2001).
The 27 genes in humans and the 26 in mice that compose the Ets family can be 
subdivided into 11 subfamilies based on the structure composition; PEA3, ETS, 
TEL, ERG, TCF, ERF, ELG, ELF, ESE, SPI, and PDEF (Oikawa and Yamada 
2003, Galang et al. 2004, Hollenhorst, Jones and Graves 2004). Although the 
majority of the Ets family members contain the Ets DNA-binding domain in their 
carboxyl-terminus many, such as the ternary complex factor (TCF) subfamily, 
were found to have their Ets domain in the amino-terminus. Furthermore, many 
members of the family have shown the presence of another evolutionarily- 
conserved domain in addition to the Ets DNA-binding domain. This domain is 
called the Pointed domain and has a role in protein-protein interactions by the 
presence of a helix-turn-helix structure (Kim etal. 2001). Some members of the 
Ets family, such as the Ets-related gene (ERG) subfamily, were discovered to 
have two activation domains, one in the amino-terminus and the other in the 
carboxyl terminus (Rao etal. 1993).
The DNA binding sequences which are bound by proteins of the Ets family are 
similar since the Ets binding domain of this family is highly conserved (Graves 
and Petersen 1998). Therefore, to ensure correct binding to the DNA site, 
many of the Ets family proteins contain auto-inhibitory domains providing 
increased specificity (Graves etal. 1998). The stressed conformation of the Ets 
domain, maintained by the interaction of the two inhibitory domains, is disrupted 
upon DNA binding. This disruption leads to changes in the N-terminal inhibitory 
region and a transient relaxed conformation of the Ets domain, stabilising the 
contact with the DNA (Jonsen etal. 1996). All proteins of the Ets family contain 
two inhibitory regions flanking the Ets domain responsible for their auto­
inhibition (Gutierrez-Hartmann, Duval and Bradford 2007). Although the 
majority of Ets family proteins have been shown as transcriptional activators, 
some proteins such as Ets2 repressor factor (ERF), Ets variant 6 gene (ETV6, 
also called TEL), NET (a member of ternary complex factor) and YAN (the 
invertebrate ortholog of TEL, which appears to be regulated by MAPKs) have 
revealed activity as repressors (Mavrothalassitis and Ghysdael 2000). Several 
proteins of this family were also suggested to be able to activate and repress
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transcription, depending on the cellular context, as they possess both activation 
and repression domains (Sharrocks 2001, Bojovic and Hassell 2001).
The PEA3 transcription factor is a member of the PEA3 group of the Ets family. 
The PEA3 group of transcription factors consists of PEA3 (also called ETV4 
and E1AF) (Xin et al. 1992, Higashino et al. 1993), Ets related 81(ER81, also 
called ETV1) (Brown and McKnight 1992) and Ets Related Molecule PEA3-like 
(ERM, also called ETV5) (Monte et al. 1994). Members of the group show a 
structural similarity with 95% homology in the Ets domain, 85% in the acidic 
domain and 50% in the carboxyl-terminal tail. Their expression has been 
detected in many normal as well as cancerous tissues (de Launoit et al. 1997). 
The Ets domain of the PEA3 transcription factor spans residues 334 to 417 with 
deletions in this domain showing abrogation in the transcriptional activity of the 
protein (Bojovic and Hassell 2001). The PEA3 protein contains a strong 
activation domain spanning residues 42 to 85 and two negative regulatory 
regions flanking the activation domain that are located between residues 1 and 
42 and residues 85 and 100, respectively, suggesting both negative and 
positive regulatory mechanisms (Bojovic and Hassell 2001). EMSA analysis 
has indicated that the DNA-binding consensus sequence for the PEA3 group 
members is GGAA/T (Xin et al. 1992, Brown and McKnight 1992, Monte et al. 
1994, Laget et al. 1996). The PEA3 transcription factor messenger RNA 
(mRNA) in mice was found to be expressed in brain, epididymis and mammary 
glands (Xin et al. 1992). The expression of PEA3 was found in many human 
cancer cells. Higashino etal. detected the PEA3 mRNA in Hela cells, a cell line 
derived from the cervical cancer (Higashino et al. 1993). This transcription 
factor was also detected in carcinoma cells and stromal cells, suggesting its 
role in the progression of the tumor in patients with ovarian carcinoma 
(Davidson et al. 2003). PEA3 overexpression was detected in breast cancer 
and most HER2/Neu-mediated mammary tumors (O'Hagan and Hassell 1998, 
Shepherd et al. 2001), although Xing et al. (2000) reported that the expression 
of PEA3 might lead to the inhibition of HER2/Neu-mediated oncogenesis, which 
is contradictory to this observation (Xing et al. 2000). However, Shepherd et al. 
(2001) found that PEA3 is involved in mammary oncogenesis and the abolition 
of this transcription factor could suppress the oncogenesis (Shepherd et al. 
2001). Other research demonstrated that there was no correlation between the
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expression of PEA3 and HER2/Neu in the tumour tissues of breast cancer (Xia 
et al. 2006). The oncogenic role of PEA3 was also shown by its upregulation of 
multiple matrix metalloproteinase genes and induction of invasive and 
metastatic activities (Shindoh, Higashino and Kohgo 2004).
Ets1 is another protein of the Ets family. This protein was found to be 
overexpressed in tissues with pathological conditions requiring new formation of 
blood vessels and reported to have an important role in embryonic 
development, viral transformation, haemopoietic cell differentiation and 
regulation of invasive action of many tumour and normal cells (Dittmer 2003). 
The Ets1 DNA-binding domain was found to span 80 amino acids of the Ets 
domain and binds DNA as a monomer (Nye etal. 1992). The Ets domain of the 
Ets1 spans from 331 to 415 residues (Dittmer 2003). The full length Ets1 (p51) 
was shown to have an autoinhibition counteraction increasing its binding activity 
to a palindromic Ets binding site in the stromelysin-1 promoter to form an Ets1- 
DNA-Ets1 ternary complex (Baillat et al. 2002). The Ets1 isoform p42 was not 
able to form the same complex, implying the importance of the exon VII region 
in the autoinhibition counteraction.
5.1.2. The role of Ets family in the coagulation process
There is some evidence to indicate a role for the Ets family of transcription 
factors in the regulation of expression of certain coagulation factors. For 
instance, as mentioned earlier, the binding of Ets1 to the promoters of hFIX and 
the potential binding of the same protein to the hPC promoter was indicated by 
minigene constructs and EMSA competition assays (Zhang, Kurachi and 
Kurachi 2002, Kurachi et al. 2009). Another protein from the Ets family, Fli1, a 
member of the ERG subfamily, may also have an indirect effect on the 
coagulation process since its malfunction might lead to abnormal platelet 
production (Spyropoulos et al. 2000). The promoter activity of von Willebrand 
factor (vWF), the carrier and activity stabilizer for the coagulation factor VIII 
(Ruggeri and Ware 1993), was reported to be increased by the overexpression 
of Ets1 and Erg in HeLa cells (Schwachtgen et al. 1997). In line with this, 
bioinformatic analysis of the human protein Z gene promoter revealed the 
presence of two regions (Fig 5.2) showing close homology to the age-stable
elements found in hFIX and hPC, two evolutionarily related proteins. The two
132
regions were termed proximal (spanning nucleotides -114 to -108 (CAGGAGG)) 
and distal (spanning nucleotides -816 to -810 (AAGGATC)). Two further 
sequences showing close homology to the PEA3 binding consensus were also 
identified by bioinformatic analysis. These upstream sites (Fig 4.2) span 
nucleotides -1190 to -1184 (CTTCCTG) and -1219 to -1213 (CTTCCTG).
5.1.3. The cAMP response element-binding protein (CREB)
The cAMP (cyclic adenosine-3’,5’-monophosphate) response element-binding 
protein (CREB) is a member of the basic leucine zipper family of transcription 
factors (Smolik, Rose and Goodman 1992, Shaywitz and Greenberg 1999, 
Hoeffler et al. 1988) which binds to the cAMP response element (TGACGTCA). 
The factor binds as a dimer in order to regulate specific gene expression 
(Carlezon, Duman and Nestler 2005). CREB and other related proteins, such 
as activating transcription factor 1 (ATF-1) and cAMP response modulator 
(CREM), which form a subgroup of this family, contain a group of residues 
forming a basic region important for DNA binding followed by a zipper region of 
seven leucine repeats for homo- and hetero-dimerisation with other family 
members (Meyer and Habener 1993, Montminy 1997). The expression of 
CREB and ATF-1 was shown to be ubiquitous while CREM was limited to 
neuroendocrine tissues (Meyer and Habener 1993). The structure of CREB 
shows a conserved arrangement with a glutamine-rich domain at the N- 
terminus, a domain containing phosphorylation consensus sites for kinases 
known as the kinase-inducible domain followed by a region rich with glutamine 
residues responsible the basal activity and finally the basic leucine zipper 
domain at the C-terminus (Sands and Palmer 2008). The initiation of gene 
transcription by cAMP was shown to be activated by protein kinase A (PKA) 
phosphorylation of CREB at Ser-133 (Gonzalez and Montminy 1989). This 
phosphorylation, in turn, activates the interaction of CREB with the CREB 
binding protein in order to induce the transcription of the target gene (Brindle, 
Nakajima and Montminy 1995). CREB was also reported to be phosphorylated 
in response to adenosine 5’-monophosphate-activated protein kinase (AMPK) 
in order to regulate expression of genes that possess cAMP response elements 
in their promoters (Li et al. 2003, Thomson et al. 2008). Bittinger et al (2004)
demonstrated a role for CREB coactivators, transducers of regulated CREB
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activity (TORC) which activate CREB independently of Ser 133 
phosphorylation, in the activation of CRE-mediated gene expression (Bittinger 
et al. 2004). They found that the nuclear translocation of these coactivators and 
PKA simultaneously is essential for the activation of CREB by cAMP. Shi et al. 
(2006) suggested a novel PKA-independent signal transduction pathway, with a 
cyclic AMP-dependent Epac-Rit signaling pathway being implicated in CREB 
activation (Shi, Rehmann and Andres 2006). CREB was also reported to be 
phosphorylated in response to other stimuli such as Ca2+/calmodulin- 
dependent kinase IV (Enslen et al. 1994) and mitogen/stress-activated kinases 
Mskland Msk2 (Wiggin et al. 2002). CREB was found to upregulate pro- 
apoptotic proteins such as Puma and Bak and reduce survival of keratinocytes 
after CREB phosphorylation and activation via the extracellular-signal regulated 
kinase (ERK) pathway (Versteeg et al. 2008).
Although CREB has been reported to regulate many proteins, its regulatory role 
has not been associated, so far, with the coagulation factors. However, a 
sequence showing a high degree of homology to the cAMP response element, 
and overlapping a proposed PEA3 or Ets1 element, has been identified in the 
PZ gene promoter between -120 and -113 (Fig 4.2) by bioinformatic analysis.
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Fig 5.2. The hypothetical PEA3 and CREB binding sites in the PZ gene promoter.
Sites are numbered relative to the translation start site and the numbers in boxes show 
the homology with the respective consensus sequence (Santa Cruz, Germany).
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5.2. Aims
The aim of the present study was to characterise the role of the hypothetical 
age-stable elements identified in the PZ gene promoter in silico in regulating the 
transcription of PZ in a cell model system (HepG2 cells). Initial experiments 
looked to elucidate, by EMSA, whether nuclear proteins from a human liver- 
derived cell line bind to the putative PZ ASEs. Protein-DNA binding studies 
were also be used to test the hypothesis that the bound proteins were the Ets 
family members PEA3 and/or Ets1, which have previously been shown to bind 
to the hfIX ASE and potentially the PC ASE.. Also, to support any in vitro 
data,the role of these proteins was analysed in cell, in the context of the intact 
chromatin; with gene expression analysis of the endogenous PZ gene in the 
human liver-derived cell line HepG2.
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5.3. Methods
5.3.1. Protein-DNA binding analysis
5.3.1.1. Electrophoretic Mobility Shift Assay (EMSA)
The DNA-protein binding reaction for EMSA was conducted in a 20 pi reaction 
volume (See Section 2.2.4.1), with the prepared (See Section 2.2.1) HepG2 
nuclear extract (HepG2 NE) with 10 fmole of the biotinylated probe flanking the 
hypothetical proximal (pP2!ASE -114/-108) or distal (dPZASE -816/-810) age- 
stable element (See Table 2.3, Section 2.2.3). The binding mixture was 
incubated for 30 minutes at room temperature, size-fractionated through 5% 
w/v, 19:1 acrylamide/bis-acrylamide (See Section 2.2.4.1) mini (8 x 8 x 0.1 cm) 
gel, using a voltage of ~ 12.5 V/cm, in 1x Tris-Borate EDTA (TBE) buffer and 
binding complexes were detected (SeeSection 3.3.4) using the UVP Biolmaging 
system (UVP, UK). Competitive EMSAs were performed by incubating the 
indicated fold molar excess of unlabelled competitors for 10 minutes with the 
Hep NE at room temperature prior to further incubation with the labelled probe 
for 30 minutes.
The same was done with IRDye probes using 100 fmole of the proposed probe 
and 12 pg of the HepG2 NE. The protein-DNA complexes were detected 
(SeeSection 3.3.5) using the Li-Cor Odyssey imaging system (LI-COR 
Biosciences, UK).
5.3.1.2. Supershift assays
Supershift assays were used to identify the protein binding specifically to the 
proposed probe. To perform the assay 2 pg of the candidate antibody (Santa 
Cruz, Germany) were pre-incubated with 4 pg of HepG2 NE for 10 minutes at 
room temperature followed by further incubation with 10 fmole of biotinylated 
probe for approximately 30 minutes. The binding mixture was size fractionated 
using a 5% polyacrylamide gel (See Section 2.2.4.1) and visualised by the UVP 
Biolmaging system (SeeSection 3.3.4). The assay using IRDye probes was 
performed using 12 pg of the HepG2 NE and 100 fmole of the candidate probe 
and visualised by the Li-Cor Odyssey imaging system (SeeSection 3.3.5). The
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incubation of the antibody with the HepG2 NE was performed on ice and at 
room temperature.
5.3.2. Gene expression studies of the endogenous PZ gene in HepG2 cells
5.3.2.1. Comparison of PZ gene promoter sequences in HepG2 cells with 
the wild type promoter.
The comparison of the wild type PZ gene promoter sequence to that present in 
the HepG2 cells has been described previously (See Section 2.1 and 4.3.2.1).
5.3.2.2. Expression plasmid verification
The expression vector encoding PEA3 was prepared (see Section 2.4.3) and 
verified using restriction enzyme mapping (Fermentas life science, UK). The 
appropriate restriction enzyme and its digestion sites in the PEA3 insert (2.2 kb) 
were determined using webcutter 2.0. The plasmid pCMV6-XL5-PEA3 
(OriGene Technologies, USA), 4.5 kb, was digested (See Section 2.4.3.3) with 
Sac1. The expected size of the bands was confirmed by electrophoresis on a 
1% w/v agarose gel for the verification of the expression plasmid to be used in 
the transactivation.
5.3.2.3. Extraction of RNA
RNA was extracted from untransfected and HepG2 cells transfected with the 
PEA3 expression vector using the GenElute mammalian total RNA miniprep kit 
(See Section 2.3.1). The quality of the extracted RNA was determined by a 1% 
w/v agarose gel and analysis of the ribosomal 18S and 28S bands. The purity 
and concentration of the RNA samples were measured using the 
NanoDrop®ND-1000 spectrophotometer (NanoDrop Technologies, USA). The 
RNA was treated with DNase 1 (Sigma-Aldrich, UK) to remove any genomic 
DNA. The RNA was then used to synthesise cDNA (See Section 2.3.3) using 
the iScript cDNA synthesis kit (Bio-Rad, UK) for subsequent use in qPCR.
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5.3.2.4. Primer efficiency
Primer efficiencies were determined, as described previously (See Sections
2.3.4.1 and 4.3.2.4), using the efficiency equation Efficiency = -1 + 1 o('1/slope). 
However, the efficiency of primers used in the TaqMan qPCR were considered 
as 100% according to the manufacturer (Applied Biosystems, UK).
5.3.2.5. The effect of overexpression of PEA3 on the transcription levels of 
the endogenous PZ gene in HepG2 cells
The Tfx™-20 transfection reagent (Promega corporation, UK) was used for the 
overexpression of PEA3 in HepG2 cells by transfection of a PEA3 expression 
plasmid (Fig 2.7) according to the manufacturer’s instructions (See Section 
2.4.4). The effect of PEA3 overexpression in HepG2 cells on the endogenous 
PZ gene was quantified by qPCR using SYBR green chemistry (See Section 
2.3.4.3).
The relative expression ratio of the PZ gene was normalised using the 
reference UBC gene and calculated using the Pfaffl equation (PfaffI 2001) (See 
Section 4.3.2.6). Melt curve (See Section 2.3.4.3) analysis was carried out to 
detect non-specific amplification products and primer dimers.
5.3.2.6. The effect of PEA3 knock down on the expression of the 
endogenous PZ gene in HepG2 cells
The target-specific smart pool siRNA (Dharmacon RNAi Technologies, UK) was 
used to knock down PEA3 according to the manufacturer's instructions (See 
Section 2.4.5 and 4.3.2.7). The effect of PEA3 knock down in HepG2 cells on 
PZ expression and the knock down efficiency were quantified by qPCR (See 
Section 2.3.4.3).
5.3.2.7. Comparison of the relative PEA3 mRNA expression in HepG2 to 
normal liver tissue.
To compare the relative expression of PEA3 mRNA in HepG2 to normal liver 
tissue, qPCR experiments were performed. Prior to the qPCR the RNA was 
prepared (See Section 2.3.1) from HepG2 cells. The HepG2 total RNA and the
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commercial human liver tissue total RNA (AMS biotechnology Ltd, UK) were 
reverse transcribed to cDNA (See Section 2.3.3) and used in qPCR 
quantification (See Section 2.3.4.3). The relative expression of PEA3 mRNA in 
HepG2 was normalised to the UBC reference gene. For more details see 
section 2.4.2.
5.3.2.8. Data analysis
EMSA analysis: The specificity of the protein-DNA binding was determined by 
non-specific competitors (See Section 4.3.2.9). The intensity of the protein- 
DNA complexes for the biotinylated probes was measured using the UVP 
Biolmaging software (UVP, UK), while for the IRDye probes measured by the 
Li-Cor software (Li-Cor, UK).
Real time PCR analysis: Basal gene expression was first expressed as ACq, 
the quantification cycle (Cq) at which fluorescence was detectable above 
background for the test gene minus the Cq of the reference gene (UBC). The 
ACq values were then standardised relative to the expression levels of the 
target in the HepG2 cells. The fold increase of the target gene (PZ) after PEA3 
overexpression was normalised against UBC and determined using the Pfaffl 
equation (See Section 4.3.2.6) since the primer efficiency of the reference gene 
and the target gene were significantly different. The fold decrease of PZ and 
PEA3 after PEA3 knock down was determined using the formula 2'ACq, where 2 
was the presumed amplification efficiency for the target and reference genes 
and the ACq was the Cq of target gene - the Cq of the reference gene. To 
compare the relative expression of PEA3 and CREB mRNA in HepG2 to normal 
liver tissue, the formula 2'AACq was used, where the relative expression in 
HepG2 was calculated after normalisation with the UBC gene and the liver 
tissue. These two formulas were used to analyse the results after TaqMan 
qPCR, since the primers of both the target genes and the reference gene were 
100% (Applied Biosystems, UK), and to analyse the PEA3 knock down 
experiments by SYBR green since the primer efficiencies of PEA3, PZ(2) and 
UBC highly similar (See Table 2.4). The significance of the difference between 
samples and controls was determined using REST 2009 software (See Section 
4.3.2.9).
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5.3. Results
5.3.1. Protein binding to the putative age-stable elements and other 
potential PEA3 binding sites in the PZ promoter
E M S A  re a c tio n s  us ing  b io tin  la b e lle d  p P Z  A S E  p ro b e , s p a n n in g  n u c le o tid e s  - 
12 0 /-1 01, fla n k in g  th e  p ro x im a l a g e -s ta b le - lik e  e le m e n t ( -1 1 4 /-1 0 8 ) sh o w e d  
p ro te in  b in d in g  us ing  n u c le a r e x tra c t fro m  H e p G 2  c e lls  (F ig  5 .3  b a n d s  1 and  2 ). 
T h is  d e te c tio n  sy s te m  a ls o  v is u a lis e d  a p o te n tia lly  b io tin y la te d  p ro te in  (n o n ­
s p e c if ic  p ro te in ) in th e  H e p G 2  N E  (b a n d s  A -C , F ig  5 .3 ) in a d d tio n  to  th e  
b io tin y la te d  D N A  p rob e .
HI o
Free
prope
Fig 5.3. EMSA using the putative biotinylated PZ proximal ASE (pPZ ASE) binding site.
(a) Nucleotide sequences of the probe and competitors are shown in Table 2.2 (Section
2.2.3). Control-1 is the biotinylated probe (pPZ ASE -120/-101) flanking the hypothetical 
proximal ASE (-114/-108) without HepG2 nuclear extract (HepG2 NE). Control-2 is the HepG2 
NE without the probe. Binding reaction is the probe with the HepG2 NE. All other competition 
reactions contain the probe and the NE as well as unlabelled 200-fold excess dPZ ASE, 200- 
fold excess unlabelled AP2 (non-specific competitor) consensus, 200-fold excess unlabelled 
HNF3B and 200-fold excess PEA3 binding site consensus, respectively. Bands indicated by 
arrows A, B, and C represent a non-specific protein detected in the nuclear extract. Bands 
indicated by 1 and 2 represent protein-DNA complexes. No competition was found with the 
AP2 or HNF3B competitors and only weak competition of 1.1-fold and 1.2-fold decrease was 
seen with the related sequence dPZ ASE in the intensity of complex 1 and 2 respectively. 
However, complex 1 with the PEA3 consensus was dramatically reduced, with 4-fold decrease 
in the intensity, both complexes 1 and 2. However, PEA3 consensus showed a strong 
competition to both complexes, with 4-fold decrease in the intensity of complex 1 and 
abolishment of complex 2. The intensity was measured by the UVP software, (b) Red colour 
circle shows the proximal ASE site in the PZ gene promoter while the numbers indicate the 
hypothetical spanning region. Unfilled circles represent other potential binding sites. 
Numbers in the boxes show the similarity with the binding sites consequences in terms of 
number of nucleotides.
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C o m p e tit io n  re a c tio n s  us ing  th e  p P Z  A S E  p ro b e  sh o w e d  no s ig n if ic a n t 
d e c re a s e  in th e  fo rm a tio n  o f  th e  p ro b e -p ro te in  c o m p le x  w ith  th e  a d d itio n  o f a 
2 0 0 -fo ld  e x c e s s  o f e ith e r u n la b e lle d  H N F 3 B  o r A P 2  b in d in g  s ite  c o n s e n s u s  
s e q u e n c e s , an d  n e g lig ib le  c o m p e tit io n  w ith  a 2 0 0  fo ld  e x c e s s  o f  th e  d P Z  A S E  in 
th e  in te n s ity  o f  th e  p ro te in -D N A  c o m p le x e s  1 and  2 (a 1 .1 -fo ld  an d  1 .2 -fo ld  
d e c re a s e , re s p e c tiv e ly ). A  2 0 0 -fo ld  e x c e s s  o f th e  P E A 3  b in d in g  s ite  c o n s e n s u s  
s h o w e d  a s ig n if ic a n t c o m p e tit io n  w ith  a 4 -fo ld  d e c re a s e  in th e  in te n s ity  o f 
c o m p le x  1 a nd  a b o lit io n  o f  c o m p le x  2 (F ig  5 .3 ). T h e  in te n s ity  o f  th e  c o m p le x e s  
w e re  d e te rm in e d  b y  th e  U V P  s o ftw a re  (U V P , U K).
U s ing  th e  flo u re c e n t la b e llin g  s y s te m  a s in g le  p ro te in -p ro b e  c o m p le x  w a s  
id e n tifie d , as o p p o se d  to  th e  tw o  c o m p le x e s  se e n  us ing  th e  c h e m ilu m in e s c e n t 
p ro c e d u re . T h e  in te n s ity  o f th is  p ro te in -D N A  c o m p le x  o f  th e  p P Z  A S E  w a s  
in s ig n if ic a n tly  c o m p e te d  (a p p ro x im a te ly  1 .3 -fo ld  d e c re a s e ) w ith  a 1 0 0 -fo ld  
e x c e s s  o f  C R E B  b in d in g  s ite  c o n s e n s u s  and  w ith  a 1 0 0 -fo ld  e x c e s s  o f  SP1 
b in d in g  s ite  c o n s e n s u s  (a p p ro x im a te ly  1 .1 -fo ld  d e c re a s e ) w h ils t  no c o m p e tit io n  
w ith  a 1 0 0 -fo ld  e x c e s s  o f  AP1 b in d in g  s ite  c o n s e n s u s  (F ig  5 .4 ).
Free
probe
Fig 5.4. IRDye pPZ ASE (-120/-101) competitive EMSA
(a) Nucleotide sequences of the probe and competitors are shown in Table 2.2 (Section 
2.2.3). Binding reaction is the probe spanning the region -120/-101 with HepG2 NE. Other 
reactions contained the probe, HepG2 NE, and a 100-fold excess of CREB, 100-fold excess 
AP1 or a 100-fold excess of SP1 consensus binding sitesrespectively. Bands indicated by 
arrow 1 represent DNA-protein complexes. The binding reaction showed the DNA-protein 
binding complex (1). With 100-fold CREB competitor a relatively weak competition of the 
bound protein with the 100-fold excess CREB binding site consensus is seen (1.3-fold). No 
competition is seen in the next reaction, with a 100-fold excess of the AP1 while a 100-fold 
excess of the SP1 binding sites consensus sequences negligibly competed the complex (1.1- 
fold). (b) The blue circle shows the potential CREB binding site in the PZ gene promoter while 
the numbers indicate the hypothetical spanning region. Unfilled circles represent other 
potential binding sites. Numbers in the boxes show the similarity with the binding sites 
conseauences.
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C o m p e tit iv e  E M S A  o f th e  p ro b e  (d P Z  A S E  -8 2 2 /-8 0 3 ) f la n k in g  th e  d is ta l a g e - 
s ta b le  like  e le m e n t (-8 1 6 /-8 1 0 ) s h o w e d  s tro n g  re d u c tio n  o f  th e  p ro te in -D N A  
c o m p le x e s  w ith  th e  a d d itio n  o f  a 2 0 0 -fo ld  e x c e s s  o f  th e  u n la b e lle d  p P Z  A S E , 
w ith  a 7 -fo ld  d e c re a s e  in th e  in te n s ity  o f b o th  b in d in g  c o m p le x e s  1 a n d  2. 
A d d itio n  o f 2 0 0 -fo ld  e x c e s s  o f u n la b e lle d  H N F 3 B  o r A P 2  b in d in g  s ite  c o n s e n s u s  
s e q u e n c e s  s h o w e d  no e ffe c t on e ith e r p ro te in -D N A  co m p le x . A  2 0 0 -fo ld  
e x c e s s  o f  th e  P E A 3  b in d in g  s ite  c o n s e n s u s  sh o w e d  a s ig n if ic a n t c o m p e tit io n  to  
bo th  b in d in g  c o m p le x e s  w ith  a 6 -fo ld  d e c re a s e  in th e  in te n s ity  o f c o m p le x  1 and  
a b o lit io n  o f  c o m p le x  2 (F ig  5 .5 ).
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Fig 5.5. EMSA using the putative biotinylated PZ distal ASE (dPZ ASE) binding site.
(a) Nucleotide sequences of the probe and competitors are shown in Table 2.2 (Section
2.2.3). Control-1 is the biotinylated probe (dPZ ASE -822/-803) flanking the hypothetical 
proximal ASE (-816/-810) without HepG2 NE. Control-2 is the HepG2 NE without the probe. 
Binding reaction is the probe with the HepG2 NE. All competition reactions contain the 
probe and the NE as well as unlabelled 200-fold excess of pPZ ASE, 200-fold excess of 
unlabelled AP2 (non-specific competitor) consensus, 200-fold excess of unlabelled HNF3B 
and 200-fold excess of PEA3 binding site consensus, respectively. Bands indicated by 
arrows A, B, and C represent biotinylated protein detected in the nuclear extract. Bands 
indicated by 1 and 2 represent protein-DNA complexes. No competition was observed with 
the AP2 or HNF3B competitors, however, strong competition was seen in both complexes 1 
and 2 with the related sequence pPZ ASE and the PEA3 consensus. The intensity of both 
protein-DNA complexes (1 and 2) were decreased 7-fold with the pPZ ASE. Protein-DNA 
complex 1 decreased 6-fold in intensity while complex 2 was abolished with the PEA3 
consensus. The intensity of the complexes was measured by the UVP software, (b) The red 
circle shows the distal ASE site in the PZ gene promoter while the numbers indicate the 
hypothetical spanning region. Unfilled circles represent other potential binding sites. 
Numbers in the boxes show the similarity with the binding sites consensus sequences in 
terms of number of nucleotides.
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The PZ-PEA3(1) probe (-1203/-1174) flanking a potential binding site for PEA3 
(-1190/-1184) showed a protein-DNA binding complexes (Fig 5.6, bands 1 and 
2) with the Hep NE. Competitive EMSA showed a reduction in the intensity of 
the protein-DNA complexes with increasing fold excess of either the PEA3 
binding site consensus or the AP1 binding site consensus. The protein-DNA 
complex showed a reduction of 1.5-fold, 2.2-fold and 4-fold with a 50-fold, 100- 
fold and 200-fold excess of the PEA3 binding site consensus, respectively. The 
protein-DNA complex also showed a reduction of 1.5-fold, 1.7-fold and 3-fold 
with a 50-fold, 100-fold and 200-fold excess of the AP1 binding site consensus, 
respectively.
a
Fig 5.6. PZ-PEA3(1)-fluorescent (IRDye) competitive EMSA
(a) Nucleotide sequences of the probe and competitors are shown in Table 2.2 (Section
2.2.3). The binding reaction is the probe flanking the region -1190/-1184 with HepG2 NE 
and without competitor. Competition reactions contain the probe, HepG2 NE, and 50, 
100 and 200-fold excess of PEA3 consensus, and 50, 100 and 200-fold excesses of 
AP1 consensus, respectively. Bands indicated by arrows 1 and 2 represent DNA-protein 
complexes. Both DNA-protein binding complexes represented by 1 and 2 did not show 
specificity, since they competed with increasing fold excess of PEA3 and AP1 binding 
site Consensuses, (b) The red circle shows the hypothetical PZ-PEA3(1) site in the PZ 
gene promoter while the numbers indicate the spanning region. Unfilled circles 
represent other potential binding sites. Numbers in the boxes show the similarity with 
binding sites consensus sequences.
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The PZ-PEA3(2) probe (-1230 to -1204) flanking another potential PEA3 
binding site (-1219 to -1213) was also shown to be bound by a protein (Fig 5.7). 
Competition analyses showed a reduction of the bound protein of 2-fold, 2.5- 
fold and 3-fold with a 100-fold, 200-fold and 300-fold excess of the PEA3 
binding site consensus sequence, respectively, and a decrease of 1.8-fold, 2.8- 
fold and 3.5-fold with a 100-fold, 200-fold and 300-fold excess of the AP1 
binding site consensus sequence, respectively (Fig 5.7).
a
Fig 5.7. PZ-PEA3(2)-fluorescent (IRDye) competitive EMSA
(a) Nucleotide sequences of the probe and competitors are shown in Table 2.2 (Section
2.2.3). Binding reaction is the probe flanking the region -1219/-1213 with HepG2 NE and 
without competitor. Competition reactions contain the probe, HepG2 NE, and 100, 200 
and 300-fold excess of PEA3 consensus and 100, 200 and 300-fold excess of AP1 
consensus, respectively. Bands indicated by arrows A show an artifact from the running 
samples on the gel. B represents DNA-protein complexes. Protein bound to DNA which 
represented by arrow B is non-specific as it is competed with increasing fold excess of 
both PEA3 and AP1. (b) The red circle shows the hypothetical PZ-PEA3(2) site in the PZ 
gene promoter while the numbers indicate the spanning region. Unfilled circles represent 
other potential binding sites. Numbers in the boxes show the nucleotide similarity 
compared to binding sites consequences.
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5.3.2. Identification of the protein bound to the pPZ ASE and dPZ ASE
Polyclonal antibodies raised against a PEA3 or Ets1 polypeptide were pre­
incubated with the HepG2 NE for 10 minutes and further incubated with the pPZ 
ASE binding reaction at room temperature for approximately 30 minutes. No 
effect on the protein-DNA complex was observed with the addition of the Ets1 
antibody (Fig 5.9). However, weak competition was observed with the addition 
of a PEA3 antibody (Fig 5.8). The intensity of the protein-DNA complex was 
decreased a 1.5-fold with the addition of the antibody. The incubation of the 
Ets1 antibody with the HepG2 NE for 10 minutes on ice and further incubated 
with the probe for approximately 35 minutes again did not show any effect on 
the protein-DNA complex (Fig 5.9).
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Fig 5.8. Supershift assay using biotinylated pPZ ASE binding sites.
Control-1 is the pPZ ASE probe without HepG2 NE. Control-2 is the HepG2 NE 
without probe. Binding reaction is the probe with HepG2 NE. Anti-PEA3 is an 
antibody against the PEA3 protein together with the binding reaction. The antibody 
was incubated with the HepG2 NE for 10 minutes and then further incubated with 
the probe for 25 minutes at room temperature. No supershift was seen with the 
probe. However, the intensity of the protein-DNA complex was reduced 1,5 fold. A 
and B are control bands which come up whenever the NE is added. 1 and 2 are the 
protein-DNA complexes.
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Fig 5.9. Supershift assay on ice and room temperature using biotinylated pPZ ASE 
binding sites with Ets1. Control-1 is the pPZ ASE probe without HepG2 NE. Control-2 is 
the HepG2 NE without probe. Binding reaction is the probe with HepG2 NE. Anti-Ets1 is 
an antibody against Ets1 protein together with the binding reaction. From right to left, the 
first four lanes were performed at room temperature (RT) where the HepG2 NE incubated 
with the binding mixture for 10 minutes and followed by 25-30 minutes incubation with the 
probe. The following two lanes were performed on ice where the HepG2 NE incubated 
with the binding mixture for 10 minutes and followed by 25-30 minutes incubation with the 
probe. No supershift was seen at room temperature while on ice neither protein-DNA 
complex nor antibody-protein-DNA complex. A, B and C are biotinylated protein which 
come up whenever the NE is added. Bands 1 and 2 are the protein-DNA complexes.
A supershift assay of the IRDye-labelled pPZ ASE probe using a CREB 
antibody was also performed. The antibody was pre-incubated with the Hep NE 
for 10 minutes followed by a further incubation with the probe for 30 minutes. 
No effect on the protein-DNA complex was observed (Fig 5.10).
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Fig 5.10. Supershift assay at room temperature using fluorescent CREB probe 
with CREB antibody. Binding reaction is the probe with HepG2 NE. Anti-CREB is an 
antibody against the CREB protein together with the binding reaction. The reaction 
was performed at room temperature where the HepG2 NE was pre-incubated with the 
CREB antibody for 10 minutes and followed by 25-30 minutes incubation with the 
probe. No supershift is seen. Band 1 is the protein-DNA complex.
Supershift assays of the dPZ ASE performed by pre-incubation of the HepG2 
NE with either the PEA3 or Ets1 antibody at room temperature for 10 minutes 
followed by incubation with the probe for approximately 30 minutes also did not 
show a shift in the protein-DNA complex (Fig 5.11). However, in the presence 
of the Ets1 antibody the intensity of the protein-DNA complex increased four­
fold.
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Fig 5.11. Supershift assay at room temperature using biotinylated dPZ ASE binding 
sites with PEA3 and Ets1. Control-1 is the dPZ ASE probe without HepG2 NE. Control-2 
is the HepG2 NE without probe. Binding reaction is the probe with HepG2 NE. Anti-PEA3 
is an antibody against PEA3 protein together with the binding reaction. Anti-E tsi is an 
antibody against Ets1 protein together with the binding reaction. The reactions were 
performed at room temperature where the HepG2 NE incubated with the binding mixture 
for 10 minutes and followed by 25-30 minutes incubation with the probe. No supershift 
was seen with both anti-PEA3 and Ets1 although 4-fold increase in the intensity of the 
band in the presence of Ets1. A, B and C are control bands which come up whenever the 
NE is added. Band 1 is the protein-DNA complex.
5.3.3. Gene expression studies of the endogenous PZ gene in HepG2 cells
5.3.3.1. Sequencing of PZ gene promoter
The promoter sequence of the HepG2 endogenous PZ locus (See Appendix) 
was found to match the reported wild type PZ promoter sequence (Homo 
sapiens protein Z, AF440358, NCBI).
5.3.3.2. Verification of the PEA3 expression plasmid
The digestion of the PEA3 expression plasmid (pCMV6-XL5-PEA3) with Sac1 
showed the expected restriction fragments of 1.91 kb and 4.78 kb (Fig 5.12).
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Fig 5.12. PEA3-encoded plasmid digested with restriction enzymes.
Kb ladder (fermentas, UK). The PEA3 plasmid was digested with Sac1, 
showing the expected bands 4.8 kb and 1.9 kb.
5.3.3.3. RNA analysis
The purity of the RNA samples was determined by the ratio of absorbance at 
260 nm and 280 nm and found to be > 1.8 in all cases. The 18S and 28S rRNA 
bands from both transfected and untransfected HepG2 cells appeared without 
significant degradation upon analysis on a 1% agarose gel, indicating a good 
quality of RNA samples (Fig 5.13).
1 2
Fig 5.13. Analysis of total RNA from transfected and untransfected HepG2
The integrity of RNA was checked using a 1% w/v 1x TBE agarose gel. The 28S and 18S 
bands are the ribosomal RNA (rRNA). Lane 1 represents the rRNA bands from 
untransfected sample. Lane 2 shows the rRNA bands from the PEA3 transfected samples 
(500ng of total RNA was loaded). Bands from both samples show good quality RNA.
5.3.3.4. Reference gene validation
The UBC housekeeping gene in untransfected and PEA3 expression plasmid 
transfected HepG2 cells showed no change in its relative expression 
determined by SYBR green qPCR (2Adelta Cq = 0.99, n=5).
5.3.3.5. Efficiency of primers
The primer efficiencies of the reference gene (UBC) and the gene of interest 
(PZ) were determined (See Section 2.3.4.1) before calculating relative gene 
expression: primer pair efficiencies were found to be 95% and 86% for UBC 
and PZ, respectively (Fig 4.8).
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5.3.3.6. Transactivation of PZ gene by PEAS overexpression in HepG2 
ceils
The relative expression ratio was determined on the basis of primer efficiencies 
and Cq values from the control (untransfected) and sample (PEA3 transfected) 
cells for the investigated transcripts using the Pfaffl equation (See Section 
5.3.2.8 and Section 4.3.2.6). The level of endogenous PZ mRNA was found to 
be increased by an average of 1.9 fold in response to overexpression of PEA3 
in HepG2 cells (Fig 5.14). This increase in PZ expression was found to be 
statistically significant (p < 0.05, n=6) using the REST 2009 software. No 
primer dimers or non-specific amplification was detected by melt curve analysis 
(See Fig 2.4).
o
Untransfected HepG2 Transfected HepG2
Fig 5.14. The effect of PEA3 overexpression on PZ mRNA relative expression.
The PEA3 transfected cells show a relative expression of 1.9-fold more PZ mRNA 
compared with the untransfected (control) sample. The increase in the relative expression 
was found statistically significant using the REST 2009 software (P<0.05, n=6).
5.3.3.7. The effect of PEA3 knockdown on PZ mRNA expression
The efficiencies of UBC, PEA3 and PZ(2) primers used in PEA3 knockdown 
experiments were found to be 95%, 96% and 98%, respectively (Fig 5.15). 
Knockdown of PEA3 in HepG2 cells using an On-targetplus smart pool siRNA 
led to an 80% average reduction of PEA3 mRNA compared to the negative 
control (ON-Targetplus Non-Targeting pool).
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Fig 5.15. Determination of primers efficiencies used in PEA3 Knockdown analyses
The efficiency of the reference gene (UBC) and the target genes, PEA3 and PZ(2) 
primers were measured by plotting Cq cycles versus cDNA serial dilution to calculate 
the slope which used in the efficiency equation. Investigated transcripts showed high 
primers efficiencies of 95%, 96% and 98% for UBC, PEA3 and PZ(2), respectively, with 
high linearity.
However, this reduction (Fig 5.16) was not found to be statistically significant 
using the REST 2009 analysis package (P=0.1, n=5).
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Fig 5.16. PEA3 knockdown in HepG2 cells using siRNAs.
The On-targetplus smart pool siRNA for PEA3 shows an 80% reduction in relative 
PEA3 mRNA levels compared to the non targeting negative control. However, the 
decrease was found statistically not significant (P=0.1, REST 2009, n=5).
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The knockdown of the relative PEA3 mRNA expression increased the levels of 
relative expression of PZ mRNA to 1.9 fold (Fig 5.17). The REST 2009 
software, however, showed that the increase in the PZ mRNA relative 
expression was not statistically significant (P=0.5, n=6).
siNonTargeting siPEAS
Fig 5.17. The effect of PEA3 Knockdown on PZ mRNA relative expression.
Knockdown of PEA3 in HepG2 cells increased the PZ mRNA levels. 80% reduction of 
PEA3 mRNA relative expression increased the relative expression of PZ mRNA by 
approximately 1.9 fold. The increase of the PZ mRNA relative expression was found 
statistically not significant using the REST 2009 software (P=0.5, n=6).
5.3.3.8. The effect of CREB knockdown on PZ mRNA expression
The relative expression of CREB mRNA in HepG2 cells was knocked down 
using the respective siRNA and found to be reduced by 75% (Fig 5.18). The 
reduction was found to be statistically significant using the REST 2009 software 
(P< 0.05, n=7).
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siNonTargeting
Fig 5.18. CREB knockdown in HepG2 cells using siRNAs.
The transfection of the siRNA for CREB showed 75% reduction in relative 
expression of CREB mRNA compared to the non targeting negative control. The 
Knockdown was found statistically significant using the REST 2009 software 
(P<0.05 t-test, n=7).
The 75% reduction of CREB mRNA in HepG2 cells increased the relative 
expression of PZ mRNA by 1.4 fold (Fig 5.19). This increase, however, was not 
found to be statistically significant using the REST 2009 software (P= 0.2, n=7).
siNonTargeting siCREB
Fig 5.19. The effect of CREB Knockdown on PZ mRNA relative expression.
Knockdown of CREB in HepG2 cells increased the PZ mRNA levels. 75% reduction 
of CREB mRNA relative expression increased the relative expression of PZ mRNA 
to approximately 1.4 fold (P= 0.2, REST 2009, n=7).
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5.3.3.9. Expression of PEA3 and CREB in HepG2 compared to normal 
human liver
The relative gene expression of PEA3 and CREB was found to be higher in 
HepG2 cells compared to normal liver tissue (Fig 5.20). PEA3 mRNA relative 
expression was found to be considerably higher in HepG2 cells with 
approximately a 1767-fold higher level than normal liver tissue. The relative 
expression of CREB mRNA was found to be 2-fold higher in HepG2 compared 
to the normal liver tissue. These differences of relative expression of PEA3 and 
CREB mRNAs between HepG2 and the normal liver tissue were found 
statistically significant using the REST 2009 software (P<0.05, n=3).
10000
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Fig 5.20. The realtive expression of CREB and PE A3 mRNA in HepG2 and 
normal liver cells. The figure shows a logarithmic scale for the relative expression of 
PEA3 and CREB in HepG2 cells compared to liver tissue and normalised to UBC 
reference gene. The relative expression of PEA3 mRNA in HepG2 was found to be 
approximately 1767-fold more than in liver tissue. CREB mRNA expression was 
shown to be approximately 2-fold more in HepG2 than that of liver tissue. The results 
were found statistically significant (P<0.05, REST 2009, n=3). The horizontal thick line 
represents the relative expression of mRNA expression in liver tissue. The 
housekeeping gene UBC was used as a reference gene.
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5.4. Discussion
The accurate identification of transcription binding sites, which can be 
accomplished by protein-DNA interaction studies, is essential for understanding 
complex gene expression patterns (Morozov et al. 2005). EMSA has been one 
of the most common techniques extensively used in such DNA-protein 
interaction studies (Fried and Crothers 1981, Revzin 1989) and in the current 
study. The protein-DNA binding results from the EMSAs showed interaction 
between regions of the PZ gene promoter and nuclear proteins prepared from 
HepG2 cells. Two age-stable like elements, identified in the PZ gene promoter 
by bioinformatic analysis, show a close homology to those reported in hFIX and 
hPC (Kurachi et al. 1999, Zhang, Kurachi and Kurachi 2002). The age-stable 
like elements in hFIX and hPC, genes that are evolutionarily related to hPZ 
(Ichinose et al. 1990), have been proposed as PEA3 binding sites (Kurachi et 
al. 1999, Zhang, Kurachi and Kurachi 2002). However, a more recent study 
from Kurachi and colleagues in 2009 using minigenes and transgenic mice 
constructs, as well as EMSA, indicated that the protein bound to the age-stable 
element (ASE) in the hFIX promoter was in fact Ets1 (Kurachi et al. 2009). The 
two age-stable like elements identified in PZ, the proximal (pPZ ASE) and distal 
(dPZ ASE) sites, showed binding with protein in the nuclear extract of HepG2 
cells using EMSA (Fig 5.3 and 5.5).
During chemiluminescent detection bands on the EMSA, which were not due to 
the interaction of the streptavidin with the biotinylated probes, were detected 
whenever HepG2 NE used. These protein bands were likely due to the 
interaction of the streptavidin with nuclear protein and referred to as non­
specific protein (Bands A, B and C, Fig 5.3 and 5.4). A similar artefact was 
detected previously in chemiluminescet EMSA using Hep NE and referred to as 
a non-specific band (Liang, Hassett and Omiecinski 2005).
Competitive EMSAs showed no competition of the protein bound pPZ ASE with 
unlabelled 200-fold AP1 and 200-fold HNF3B excess binding consensus 
sequences, suggesting specificity of the bound protein (Fig 5.3). The bound 
protein was strongly competed by the PEA3 binding site consensus sequence, 
with a 4-fold decrease in the intensity of binding complex 1 and a loss of 
complex 2. Competitive EMSA of the dPZ ASE showed similar results, with no 
effect from the 200-fold AP1 or HNF3B, but a significant reduction of binding
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complexes by 200-fold PEA3, with a 6-fold decrease in the intensity of binding 
complex 1 and loss of binding complex 2 (Fig 5.5). The strong competition of 
the bound protein to the pPZ ASE and the dPZ ASE by the PEA3 binding site 
consensus suggested that the bound protein was PEA3. However, there 
remained the possibility that the bound protein may also be Ets1, since the 
PEA3 binding site consensus used in the competitive EMSAs (Table 2.2) was 
the same binding site consensus as Ets1 (Santa Cruz literature). The 
interaction of different Ets family members to DNA is based on the bases 
flanking the core binding site consensus GGAA/T (Xin et al. 1992). However, 
different bases flanking the core binding site were reported for the binding 
specificity of PEA3 and Ets 1. PEA3 was found to bind the sequence 
CAGGAAG in the polyomavirus enhancer (Martin et al. 1988) and suggested to 
bind A/CGGAAGT in a study of the DNA binding specificity of PEA3 using 
nuclear extract from mouse FM3A cells and bacterial extract (Xin et al. 1992). 
Moreover, a PEA3 oligonucleotide flanking the AGGAAA core sequence was 
used to demonstrate the expression of PEA3 in HepG2 cells (Guo and Inagami 
1994). The Ets 1 protein was also found to bind the AGCGGAAGCG sequence 
in the promoter of murine sarcoma virus long terminal repeat (MSV LTR) 
(Gunther et al. 1990), AGAGGATGTG in T-cell receptor a gene enhancer (Ho 
et al. 1990), GCA/CGGAAGT in the stromelysin promoter (Wasylyk et al. 1991) 
and GAGGAAG in the hFIX promoter (Kurachi et al. 2009). Therefore, 
competitive EMSAs could not provide a definitive answer as to the identity of 
the bound protein.
The region (-120/-101) flanking the pPZ ASE was also found to contain another 
hypothetical binding site (ALGGEN-PROMO), that of CREB (-120/-113) sharing 
two base pairs with the overlapping pPZ ASE (-114/-108); suggesting that the 
protein bound to the region (-120/-101) flanking the pPZ ASE could be CREB. 
Competition reactions of the IRDye labelled pPZ ASE showed some 
competition of the bound protein with 100-fold excess of the CREB and SP1 
binding site consensus sequences but no competition with 100-fold excess of 
AP1 binding site (Fig 5.4). The intensity of the protein-DNA complex was 
reduced to 1.3-fold and 1.1-fold with the CREB and SP1 binding site 
consensuses, respectively. However, another study found that the probe 
flanking this region was competed by a mutated CREB binding site consensus
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(Sugawara etal. 2007). Therefore, the role of CREB in regulating expression of 
PZ remains unclear.
Bioinformatic analysis showed two other potential binding sites for PEA3 in the 
PZ promoter, PZ-PEA3(1) spanning the region -1190 to -1184 (CTTCCTG) and 
PZ-PEA3(2) from -1219 to -1213 (CTTCCTG). EMSA reactions using the probe 
flanking the PZ-PEA3(1) binding site and the probe flanking the PZ-PEA3(2) 
binding site indicated non-specific protein binding to both sites (Fig 5.6 and 5.7). 
The bound protein at both sites, using competitive EMSA, was competed with 
an increasing fold excess of either the PEA3 binding site consensus or the AP1 
binding site consensus. These results suggest that the protein which is bound 
to both regions was not specific, despite the slightly better affinity of the PZ- 
PEA3(1) bound protein to the PEA3 binding site consensus compared to the 
non specific competitor AP1 (Fig 5.6).
The initial EMSAs suggested that the protein bound specifically to the pPZ ASE 
could in fact be PEA3, Ets 1 or, possibly, CREB, while the protein bound to the 
dPZ ASE could be PEA3 or Ets 1. These hypotheses were based on the strong 
competition of the bound protein at pPZ ASE with the PEA3 binding site 
consensus, which is also considered as an Ets 1 binding site consensus, and 
also some competition with the CREB binding site consensus (Fig 5.3 and 5.4); 
in addition to the strong competition of the protein bound to dPZ ASE with the 
PEA3 binding site consensus (Fig 5.5).
To identify the specific protein bound to the pPZ ASE and dPZ ASE supershift 
assays were performed. Supershift assay of the pPZ ASE using a polyclonal 
antibody raised against a PEA3 polypeptide in the binding reaction did not show 
a shift of the protein-DNA complex band (Fig 5.8). Nevertheless, the protein- 
DNA complexes were weakly competed in the presence of the antibody, with a 
decrease of 1.5-fold in the intensity of the complexes. The protein-antibody 
interaction in EMSA may cause a reduction of the protein-DNA complex, a 
complete supershift of the protein-DNA complex or a supershifted complex 
along with the protein-DNA complex (Carey and Smale 2001). Ets 1 and CREB 
antibodies were also used in supershift assays of the pPZ ASE and showed no 
effect on the protein-DNA complexes (Fig 5.9 and 5.10). CREB and PEA3 
antibodies, however, did not show interactions with the protein bound to CREB 
and PEA3 consensus sequences, respectively.
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Further supershift assays were also performed with the dPZ ASE using PEA3 
and Ets 1 antibodies. The results showed no interaction of the PEA3 antibody, 
again, with the bound protein. However, the presence of the Ets 1 antibody 
caused a 4-fold increase in the intensity of the protein-DNA complex, which 
could potentially be due to a antibody-protein-DNA complex (Fig 5.11). Ets 1 
antibody was found to increase the intensity of the binding complex in the 
supershift assay used to identify the protein bound ASE in hFIX promoter 
(Kurachi et al. 2009) and therefore, support the result of the Ets 1 antibody with 
the dPZ ASE in the current study.
Although EMSA is an easy and sensitive technique that has been used 
extensively in studying protein-DNA interactions in vitro, many disadvantages of 
this assay have been reported. In vivo conditions required to optimise 
transcription factor binding, such as the need for other proteins for their binding 
to the DNA may not be obtained in vitro (Wells and Farnham 2002). Moreover, 
the in vivo conformation of the DNA secondary structure, such as looping, 
which is needed to bring distal protein binding sites into close proximity can not 
be created in vitro. Different results from different electrophoresis condition 
may also be obtained for the same DNA-protein system (Sidorova, Muradymov 
and Rau 2005). Therefore, transcriptional analyses of the endogenous PZ 
gene within its chromatin environment were performed.
To further analyse the role of PEA3 in PZ transcription, this transcription factor 
was overexpressed in HepG2 cells. Prior to the transfection, the PEA3 
encoded expression plasmid (pCMV6-XL5-PEA3) was prepared (see section 
2.4.3) and its identity was verified by digestion with the Sacl restriction enzyme 
and size-fractionated on a 1% w/v agarose gel (Section 2.4.3.3). Digestion of 
the expression plasmid with Sacl showed the expected bands 1.91 kb and 4.78 
kb (Fig 5.12) according to the webcutter website (webcutter 2.0 website). The 
sequence as well as SNPs of the PZ gene promoter in HepG2 was validated 
(See Sections 5.3.3.1, 4.3.2.1 and 2.1) and found to be identical to the reported 
wild type PZ promoter (Homo sapiens protein Z, AF440358, NCBI). Having 
verified the PEA3 expression plasmid it was transfected transiently into HepG2 
cells (See Section 2.4.4) and the effect on the endogenous PZ mRNA relative 
expression measured using qPCR (See Section 2.3.4.3). Overexpression of 
PEA3 in HepG2 was found to increase the relative expression of PZ mRNA 1.9
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fold (Fig 5.14). The increase of the PZ mRNA relative expression was found to 
be statistically significant (P<0.05, REST 2009, n=6). PEA3 has previously 
been reported to up-regulate the expression of many genes, such as, the 
vimentin gene in the mammary epithelial and tumour cells (Chen et al. 1996) 
and increase the human transmembrane mucin (MUC4) mRNA in pancreatic 
cancer cells (Fauquette et al. 2005). However, it was also reported to have 
down-regulatory effect on other genes, such as, HER-2/neu (Xing et al. 2000, 
Hung and Wang 1999).
The transfection reagent, Tfx-20, which has been used successfully in the 
transfection of HepG2 cell to study gene transcription (Dongol et al. 2007) and 
in the current study, was tested for the off-target effect which may be caused by 
the introduction of foreign DNA (Jacobsen, Calvin and Lobenhofer 2009) and 
found to have no effect on the expression of the gene of interest (Fig 4.12). 
This confirmed that the increase in the relative expression of PZ mRNA was 
due to the overexpression of PEA3. The moderate increase of the relative 
expression of PZ mRNA (1.9-fold) in response to PEA3 overexpression might 
be due to the high level of PEA3 relative expression in HepG2 (1767-fold more 
than normal liver tissue), which may be close to the effect threshold of PEA3 on 
PZ expression.
To confirm the role of PEA3 transactivation in the transcriptional regulation of 
the endogenous PZ gene in HepG2, the expression of endogenous PEA3 was 
knocked down using small interfering RNAs (siRNA) (see Section 2.4.5) and the 
effect on the endogenous PZ mRNA determined using qPCR. UBC was used 
as a reference gene assuming its stability with PEA3 overexpression would be 
the same as with PEA3 knock down. A new primer pair PZ(2) (Table 2.3) was 
also used which is different to that used in the PEA3 and HNF4a 
overexpression qPCR experiments. The reason for designing additional 
primers for the PZ transcript was to obtain a level of efficiency closer to that of 
the reference gene primers. Smart pool siRNAs, which have been used 
extensively in gene expression studies (Danes et al. 2008, Kwei et al. 2008, 
Hariparsad et al. 2009, Taniguchi et al. 2009, Rizzo et al. 2010, Lahkim 
Bennani-Belhaj et al. 2010), were used to knock down PEA3 in HepG2 cells. 
Smart pool siRNAs were developed and used to minimise the off-target 
silencing which has been observed with genes containing a limited
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complementary sequence with siRNAs (Jackson etal. 2003), since they contain 
four predesigned siRNAs targeting one gene (Dharmacon Technologies 
Literature).
The observed PEA3 knockdown and the small increase of the relative 
expression of PZ mRNA in response to the PEA3 knockdown were both found 
not to be statistically significant (P=0.1, n=5 and P=0.5, n=6, respectively). The 
significant increase in PZ mRNA relative expression due to the overexpression 
of PEA3, along with the non significant results of the PEA3 knockdown 
(presumably because of the very high endogenous level of PEA3 expression in 
HepG2) may indicate, overall, that PEA3 may be a transcriptional activator of 
PZ, either directly or indirectly.
Study of the knockdown of CREB in HepG2 cells showed an increase in PZ 
mRNA. The 75% reduction of CREB relative expression (Fig 5.18), which was 
statistically significant (P<0.05, n=7), was found to increase the relative 
expression of PZ mRNA 1.4 fold (Fig 5.19). However, this increase in PZ 
expression was not found to be statistically significant (P=0.2, n=7). Although 
CREB protein is expressed in normal liver tissue and HepG2 cells (Fig 5.20), 
the knockdown results along with the competition of the protein-DNA complex in 
the potential CREB binding site by the mutated CREB binding site consensus 
(Sugawara et al. 2007) suggest that CREB has no regulatory effect on the PZ 
gene.
The expression of the endogenous PZ gene in the HepG2 cell model, is an in 
cell system with the gene in the context of the intact chromatin structure of the 
DNA rather than naked dsDNA. However such an in cell system is still 
considered an in vitro situation and such data derived from this model should be 
confirmed in vivo.
5.5. Conclusion
It can be concluded that PZ gene expression may be regulated by PEA3 
transcription factors. Competitive EMSAs for the protein bound to the ASE-like 
regions (potential binding sites for PEA3 or Ets 1) suggest the potential role for 
PE A3 and/or Ets 1 in the regulation of the PZ gene (Fig 5.3 and 5.5). Ets 1 
binding to the dPZ ASE was confirmed using the Ets 1 antibody in the
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supershift assay (Fig 5.11). However, the regulation of this transcription factor 
to the endogenous PZ gene needs to be confirmed. The up-regulatory role of 
PEA3 on the endogenous PZ gene (Fig 5.14) was confirmed by over 
expressing PEA3 in the HepG2 cell model (P<0.05, n=6). However, this 
technique still considered as an in vitro, and therefore, in vivo studies should be 
further performed for confirmation.
Although CREB was initially suggested in the current study to bind the PZ gene 
promoter by competition of the protein-DNA complex by the CREB binding site 
consensus, a mutated CREB binding site consensus has shown the same 
competition in other studies, indicating that the bound protein was not CREB. 
This was investigated by the gene expression study of the endogenous PZ 
using the knockdown technique by siRNAs in HepG2 cells. Knockdown of 
CREB mRNA (75 %) showed a 1.4-fold increase in the relative expression of 
PZ mRNA; however this was not found to be statistically significant (P=0.2, 
n=7). Therefore, it can be concluded that CREB has no role in the regulation of 
the PZ gene.
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Chapter 6-Optimisation 
Of Footprinting and 
Chromatin 
Immunoprecipitation 
Assays
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6.0. Introduction
The binding of transcriptional regulatory proteins to their specific DNA binding 
sites which was studied by EMSA, as discussed in chapter three, can also be 
studied by DNase I footprinting. Although EMSA is more sensitive compared to 
footprinting and the protein-DNA complex can be detected with a lower 
concentration of the protein in the nuclear extract (Carey and Smale 2001, 
Heilman and Fried 2007), the footprinting assay can provide information which 
cannot be obtained by EMSA. This information is, for instance, the location of 
protein binding as well as multiple protein binding sites within a DNA fragment. 
In addition, detection of proteins requiring binding of factors to adjacent 
recognition sequences on the probe can also be visualized (Carey and Smale 
2001). Examples of such interactions include the synergistic binding of a 
multiprotein Polycomb core complex (PCC) and Pleiohomeotic (PHO) to the 
Polycomb response elements (PREs), an epigenetic DNA element in 
Drosophilia (Mohd-Sarip et al. 2005), and the synergistic binding of the Vibno 
fischeri Luminescence gene activator (LuxR) and the RNA polymerase (RNAP) 
in the promoter of the luminescence gene coding for autoinducer synthase 
(Luxl) (Stevens, Dolan and Greenberg 1994).
The footprinting assay which is used for studying a wide variety of sequence- 
specific protein-DNA interactions and which can potentially allow 
characterisation of transcriptional regulatory mechanisms of a gene, was 
developed by Galas and Schmitz in 1978 (Galas and Schmitz 1978). The 
technique is based on the protection of the protein bound DNA regions from 
digestion by a cleavage agent. The undigested region of DNA, which is 
protected by the bound protein, shows a gap in the resulting ladder of DNA 
fragments on denaturing polyacrylamide gel electrophoresis (Hampshire et al. 
2007). Alternatively, the bound protein may cause severe distortions to the 
DNA structure, resulting in an increase in the intensity of the bands rather than 
their decrease (Guille and Kneale 1997). The footprinting assay is summarised 
in figure 6.1. Footprints, where the DNA is protected by the bound protein are 
normally localised using G+A and/or C+T sequencing ladders (Maxam and 
Gilbert 1980) which are run alongside the protected and naked DNA ladders 
(Leblanc and Moss 2009). Cleavage agents such as hydroxyl radicals which 
are produced from the Fenton reaction between Fe2+ and H2O2 can be used in
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the footprinting assay. Although the accuracy in the estimation of protein 
binding sites is high, hydroxyl radical footprinting has disadvantages such as 
being time consuming and it is sensitive to solvents that scavenge free radicals 
(Hampshire et al. 2007).
Protein4
agent
DNA
Cleavage
treatment
Single-hit 
kinetics by 
the cleavage 
agent
Denaturing polyacrylamide 
gel electrophoresis
Fig 6.1. Schematic representation of the footprinting assay. The DNA fragment is 
labelled (star) at one end of one strand. The DNA is digested using a cleavage agent, 
such as, DNase I, The digested DNA is size fractionated using denaturing 
polyacrylamide and visualised. The DNA region bound by protein shows a gap 
(footprint) due to the protein protection of this region from digestion.
The cleavage agent DNase I is prone to steric hindrance when attacking DNA, 
because of its large size and, therefore, it has been the most popular choice in 
footprinting, producing clear interference patterns (Leblanc and Moss 2009). 
However, a disadvantage of its large size is that it prevents it from cutting the 
DNA immediately after the protein-DNA complex and, therefore, does not show 
the exact boundaries of the footprint (Guille and Kneale 1997). DNase I is a 
double-stranded DNA endonuclease which binds the minor groove of the DNA
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and interacts with the backbone, cleaving the 0 3 ’-P of both strands 
independently (Hampshire etal. 2007, Suck, Lahm and Oefner 1988).
A development of this technology is, instead of using nuclear extracts which 
may not accurately represent the in vivo situation, to look at binding site 
occupancy ‘in vivo’. The in vivo techniques in protein-DNA analyses have many 
advantages over the in vitro assays. Such advantages include transcription 
factors, in vivo, interacting with the DNA in its chromatin context which can work 
as a barrier to the accession of proteins (Demeret, Vassetzky and Mechali 
2001), rather than naked DNA in vitro, which may not represent the real 
situation in the body. Moreover, sequences which are similar or identical to 
those bound by tissue specific factors could be bound by ubiquitous factors in 
vitro, complicating analyses (Ikuta and Kan 1991).
The 'in vivo' footprinting technique, although not strictly in vivo, has been 
commonly used to detect protein-DNA binding sites within intact cells (Hornstra 
and Yang 1993). Dimethyl sulphate (DMS) is a common agent used in ‘in vivo’ 
footprinting. This agent preferentially reacts with guanine bases causing their 
methylation (Sclavi 2008) and the degree of reactivity between the DNA bound 
by protein and the same sequence of the naked DNA is compared. Although ‘in 
vivo’ footprinting using DMS was the most common technique, because of its 
membrane permeability, the use of DNase I has been found to provide better 
information about the protein-DNA interaction. This is due to the better 
delineation of footprinting boundaries, since DNase I cleaves the DNA 
surrounding protein-DNA complexes and detection of complexes without 
guanine contacts is observed (Hornstra and Yang 1993). The permeability of 
the cells to be subjected to ‘in vivo’ DNase I footprinting has been achieved 
using ethanol, described for use with Escherichia coli (Cassler et al. 1999), and 
lysolecithin in the footprinting of primary cultures of vascular umbilical smooth 
muscle cells and peripheral blood lymphocytes (Angers et al. 2005). Ligation- 
mediated PCR exponentially amplifies the genomic sequence ladder, following 
denaturation of the chemically or enzymatically cleaved genomic DNA, and has 
been used in ‘in vivo’ footprinting to eliminate experimental signal-to-noise ratio 
and the use of large numbers of cells (Mueller and Wold 1989). The PCR- 
mediated ligation is performed using two primers complementary to the ends of 
the DNA fragments. One end of the DNA fragments is fixed by a primer or
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restriction cut whilst the other end is unique as it is determined by chemical 
cleavage or chain termination (Mueller and Wold 1989).
Having localised the binding sites for a protein by EMSA using bioinformatic 
analysis or practically by footprinting the identity of the bound protein has to be 
determined. EMSA (supershift assay) is one of the assays which can be used 
for the identification of the potential protein using a protein-specific antibody. 
However, using a synthetic probe spanning the detected binding site in the 
EMSA analysis does not represent the normal situation of the regulatory DNA 
sequence within its complex chromatin environment. Therefore, the 
identification of the bound protein by the chromatin immunoprecipitation 
technique may be utilised since the protein is identified within that chromatin 
context, as mentioned above, in the discussion of 'in vivo' footprinting. Although 
this assay has been used for several years to confirm the identity of the protein 
which was predetermined to bind a specific binding sequence (Narayanan et al. 
2004, Collas 2009, Hill et al. 2011), the development of this technique has been 
able to identify target binding sites for specific transcriptional regulators 
throughout the genome (Collas 2009).
In the technique of ChIP (Fig 6.2), the protein and DNA are cross-linked in live 
cells with formaldehyde and then the sheared chromatin immunoprecipitated 
with an antibody against the putative protein to enrich the chromatin for regions 
to which the proposed protein binds. This is followed by chromatin reverse 
cross-linking and comparison of the immunoprecipitated enriched DNA with 
negative control DNA using PCR (Aparicio, Geisberg and Struhl 2004).
The development of the ChIP assay has led to its combination with microarrays 
in a technique known as ChlP-on-Chip to provide greater knowledge by 
mapping transcription factor binding throughout the genome. The ChlP-on-Chip 
experiment (Fig 6.2) was first reported by the group of Ren et al (2000) for their 
mapping of the binding sites of Gal4 and Ste12 transcription factors in the entire 
yeast genome (Ren et al. 2000). In this technique blunt ends are generated in 
the sheared reverse cross-linked DNA using DNA polymerase, ligated with 
common linkers and amplified with primers complementary to the linkers using 
PCR. This is followed by hybridisation of the recovered DNA fragments to a 
microarray containing probes for the transcription factor binding regions of 
interest on a genome-wide scale (Sikder and Kodadek 2005). However, bias
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from the extensive amplification required for the large amounts of DNA 
necessary for the hybridisation, the hindrance to interpretation posed by 
repetitive sequence, the detection of allelic variants due to cross-hybridisation,
Living cell
Protein-DNA cross linking, cell 
lysis and chromatin isolation
• -Q
DNA sharing and addition 
of antibody of interest
- - Q
Precipitation of antibody-bound 
protein-DNA complex
Reverse cross-linking, protein 
degradation and DNA purification
Standard ChIP
PCR analysis of 
immunoprecipitated DNA.
Hybridisation of the fragments to 
probes of the binding site of interest 
in a microarray (ChIP on chip).
Genome-wide ChIP
Mapping of the binding sequence of 
interest by single molecule-based 
sequencing (ChlP-seq).
Fig 6.2. Schematic representation of various techniques of chromatin 
immunoprecipitation. Protein is cross-linked in living cells and the ceils are breaked 
open and the chromatin is sheared. The antibody of interest is added and the antibody- 
protein complex is precipitated. The immunoprecipitated chromatin is reverse cross- 
linked, the protein is degraded and the DNA is purified. The immunoprecipitated DNA is 
analysed for the protein of interest in the proposed region by PCR analysis (Standard 
ChIP) or in genome-wide ChIP using hybridisation in a microarray (ChIP on ChIP) or 
mapping of the sequence of interest (ChlP-seq).
and cost are all considered practical limitations of the ChlP-on-Chip technique 
in analysing the mammalian genome in such a way (Mikkelsen et al. 2007). 
Another approach recently reported to characterise the immunoprecipitated 
DNA is high-throughput sequencing (ChlP-seq). This single molecule-based 
sequencing technology was reported by Robertson's group in Hela S3 cells to
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map the binding sequences for the STAT1 protein (Robertson et al. 2007). In 
this technique (Fig 6.2) the molecules of DNA are arrayed across a surface and 
locally amplified, followed by single-base extension and determination of the 
added bases. Although the ‘read length’ is short (25 to 50 bases), simultaneous 
reads of millions of DNA fragments give sequence data across the full fragment 
lengths (Mikkelsen etal. 2007).
The time involved with the ChIP protocol (3-4 days) and the multi-millions of 
cells required for immunoprecipitation (Collas 2009), in addition to the 
involvement of extensive handling which may lead to material loss, technical 
error and contamination are all limitations of what is a powerful technique. 
However, to minimise these limitations, modifications to the ChIP protocol have 
been made to make it simpler, shorter and valid for small cell numbers. For 
instance, Nelson and his group in 2006 modified the ChIP protocol to take less 
time. They used the chelating resin Chelex-100 to reduce the time for the 
preparation of PCR-ready templates after immunoprecipitatin, to one hour 
instead of one day. Moreover, they incubated the antibody with pre-incubated 
sheared chromatin in an ultrasonic bath to increase the rate of antibody-protein 
binding, shortening the time of immunoprecipitation from several hours to only 
15 minutes (Nelson etal. 2006).
Therefore, numerous techniques exist to map protein-DNA interactions all with 
their respective benefits and disadvantages. From a holistic regulatory 
perspective those techniques that allow increased characterisation of such 
interactions in the context of the three-dimensional organisation of the nuclear 
DNA, although technically more demanding, are preferable.
The Aims
The aims of this work are to confirm the binding sites which have been 
identified in the current study by bioinformatic analysis, and to identify additional 
binding sites in a longer DNA fragment using the footprinting technique. 
Moreover, to confirm the identity of the proteins, which have been characterised 
by in vitro EMSA in the current study, in their chromatin environment using an 
‘in vivo’ chromatin immunoprecipitation technique.
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6.1. Methods
6.1.1. Footprinting assay
T h e  P Z  g e n e  p ro m o te r (N C B I, A F 4 4 0 3 5 8 ) w a s  d iv id e d  in to  fo u r  o v e r la p p in g  
re g io n s  s p a n n in g  n u c le o tid e s  -1 0 9 9  to  +86 , re la tive  to  th e  tra n s la tio n  s ta r t s ite  
a t n u c le o tid e  +1 ; p r im e rs  w e re  d e s ig n e d  fo r  e a ch  re g io n  (F ig  6 .3 ) in o rd e r to  
a llo w  a m p lif ic a tio n  b y  th e  p o ly m e ra s e  ch a in  re a c tio n  (P C R ).
-1099
+1
-804 -785 494 455 -213 -166 +86 * 3 ’
FP4
FP1
Fig 6.3. Location of the PZ gene promoter regions amplified by the designed primers 
in footprinting assay. Different colours show the different regions for footprinting assay. 
Arrows with different colours show the location of primers used to amplify the respective 
region. The sequences of the primers are shown in table 1. The translation start site is 
represented by +1. FP is an abbreviation for footprinting region.
T h e  p rim e rs  fo r  e a ch  re g io n  w e re  d e s ig n e d  u s ing  th e  w e b p r im e r w e b s ite  
(h ttp :/ /w w w .y e a s tg e n o m e .o rg /c g i-b in /w e b -p r im e r) and  s y n th e s is e d  b y  E u ro fin  
M W G /O p e ro n  (E u ro fin s  M W G  O p e ro n , U K ). T h e  P C R  re a c tio n s  w e re  
p e rfo rm e d  b y  th e  P rim u s  96  p lu s  P C R  m a c h in e  (M W G -B IO T E C F I, U K ) u s ing  
c o m m e rc ia l h u m a n  g e n o m ic  D N A  (5 0 n g /p l)  p re p a re d  fro m  p la c e n ta  (S ig m a - 
A ld r ic h , U K ), and  th e  d e s ig n e d  p r im e r p a irs  (T a b le  6 .1 ). T h e  P C R  c y c le  
c o n d it io n s  used  to  a m p lify  th e  fo o tp r in t in g  re g io n s  in th e  P Z  p ro m o te r  w e re  as 
fo llo w : f irs tly , o n e  s te p  a t 95  C fo r  2 m in u te s , to  e n s u re  c o m p le te  d e n a tu ra t io n  o f  
th e  D N A  te m p la te , fo llo w e d  by  3 0  c y c le s  o f  95  C fo r  1 m in u te  fo r  D N A  
d e n a tu ra tio n , a n n e a lin g  te m p e ra tu re  o f  th e  p ro p o s e d  p r im e rs  (T a b le  2 .2 ) fo r  1 
m in u te , to  a n n e a l th e  p r im e rs  to  th e ir  c o m p le m e n ta ry  re g io n s , a n d  7 2  C fo r  1 
m in u te  fo r  th e  e x te n s io n  o f th e  p r im e rs  b y  T a q  p o ly m e ra s e  in o rd e r  to  
s y n th e s is e  c o m p le m e n ta ry  s tra n d s . F in a lly , 5 m in u te s  a t 7 2  C w a s  p e rfo rm e d  
to  e n s u re  a ll th e  s in g le -s tra n d e d  D N A s  w e re  e x te n d e d  a n d  fo rm e d  d o u b le  
s tra n d e d  D N A s, fo llo w e d  b y  a h o ld in g  s te p  a t 4°C  fo r  s h o r t- te rm  s to ra g e .
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Primers description
Footprinting
(Fp1) -Forward
Footprinting
(Fpl)-Reverse
Footprinting
(Fp2)-Forward
Footprinting
(Fp2)-Reverse
Footprinting
(Fp3)-Forward
Footprinting
(Fp3)-Reverse
Footprinting
(Fp4)-Forward
Footprinting
(Fp4)-Reverse
region-1
region-1
region-2
region-2
region-3
region-3
region-4
region-4
Sequences
5’-TGCTGCCTTTACCTTCTGTTC-3’ 
5-TAAG CC AG ATG CCTACCTG A-3’ 
5’-AATGGTGCTGAGCTGTAGTGA-3’ 
5’-ACCCTGGGAGATATTTAGGGA-3’ 
5’-TTTCCCCT G CTT CAGT CATT-3’ 
5’-AAGGGCCAAATAGTGTCTGTC-3’ 
5-AGCCCAGTGATCCCTTCAGA-3’ 
5’-AATGACTGAAGCAGGGGAAA-3’
Amplicon
size
300 bp
329 bp
350 bp
315 bp
Table 6.1. Oligonucleotide primers used to amplify different PZ promoter regions for 
footprinting. The primers were designed using webprimer (http://www.yeastgenome.org/cgi- 
bin/web-primer) and synthesized by Eurofin MWG Operon. The forward primers for each 
region were biotin-labelled for their detection by the UVP Biolmaging system (UVP, UK). In 
the modified footprinting assay forward primers were labeled by IRDye-700 while reverse 
primers were labeled by IRDye-800 for their detection in the Licor 4200L electrophoresis 
system (Li-cor, UK). The annealing temperatures for Fp1, Fp2, Fp3 and Fp4 are 60, 58, 57 
and 62.5 °C, respectively.
T h e  P C R  c o c k ta il and  d iffe re n t p a ra m e te rs  used  in th e  a m p lif ic a tio n s  a re  s h o w n  
b e lo w  in ta b le  6 .2 .
G e n o m ic  D N A  (10 0  n g /p l) 1 pi
P C R  b u ffe r  (1 OX) 2 .5  pi
d N T P s  (2 m M ) 1 .25  pi
M gcl2 (25  m M ) 1-4  pi
B io tin -fo rw a rd  p r im e r (5 p m / p i) 1 pi
R e v e rs e  p r im e r (5 p m / p i) 1 pi
N u c le a s e - fre e  w a te r U p to  2 5  to ta l v o lu m e .
T a q  D N A  p o ly m e ra s e  (5 u n its / p i) 0 .5  pi
Table 6.2. PCR template and cocktail used in amplifying different promoter regions.
the various promoter regions were amplified with the same amounts and concentrations of 
the cocktail. MgCI2 was optimised for the amplification of different regions.
P rio r to  th e  fo o tp r in tin g  b in d in g  re a c tio n  th e  a m p lif ie d  P C R  p ro d u c ts  w e re  
p u rifie d  by  a d d in g  th e  sa m e  v o lu m e  o f p h e n o l-c h lo ro fo rm  an d  v o r te x in g , 
fo llo w e d  by m ic ro c e n tr ifu g a tio n  (1 6 .1 x 1 0 3 g). T h e  u p p e r a q u e o u s  la y e r w a s
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transferred to a clean microcentrifuge tube followed by addition of 1/10:and 3X 
volumes of 3 M sodium acetate and absolute ethanol, respectively. The 
presence of the salt and alcohol disrupts the interaction between the water 
molecules and the nucleic acid causing precipitation. The solution was chilled 
for 15 minutes at -70°C and centrifuged at 16.1x103 g for 15 minutes at 4°C. 
The pellets were rinsed with 500 pi 70% ethanol and centrifuged at 16.1x103 g 
for 15 minutes at 4°C. The pellets were dried at room temperature and 
resuspended in 10 pi of water to be used in the footprinting binding reaction.
6.1.1.1. Binding reaction using biotin-labelled primers
DNase I footprinting was performed according to the protocol reported in 2001 
by Sambrook and Russell (Sambrook and Russell 2001). The experiment was 
carried out in 5 different tubes; each 25 pi reaction contained binding buffer-1 
(Andrews and Faller 1991) (a final concentration of 16 mM Hepes-KOH pH 7.9, 
20 % glycerol, 336 mM NaCI, 1.2 mM MgCI2, 0.16 mM EDTA, 0.32 mM DTT, 
1% (v/v) protease inhibitor cocktail (Sigma Aldrich, UK)), 1 pg of poly (dl-dC) 
and 1.0 pi of the 10 pi total volume of the proposed purified biotin labelled DNA 
fragment (PZ promoter region +86 to -213). HepG2 nuclear extract (HepG2 
NE), 10, 20 and 40 pg was added to tubes 2, 3 and 4, respectively, while no 
nuclear extract was added to tube 1 and 5 (controls). The reaction mixture was 
centrifuged for 5 seconds at 4°C and incubated for 20 minutes on ice. 50 pi of 
MgCI2-CaCI2 (10 mM MgCI2 + 5 mM CaCI2) solution, for DNase I activity, was 
added to the mixture and mixed gently and incubated for 1 minute at room 
temperature. Digestion with 0.01 units of DNase I (Sigma Aldrich, UK) was left 
for exactly 1 minute at room temperature and the enzyme was inactivated using 
75 pi of stop mix solution (20 mM EDTA, 1% w/v SDS, 0.2 M NaCI2 , and 125 
pg/ml yeast tRNA). The DNA was extracted using phenol:chloroform and 
centrifuged at 4°C for 10 minutes at 16.1 x103 g after incubation at -20°C  
overnight in 2.5 volumes of absolute ethanol to precipitate the DNA. The added 
tRNA acted as a carrier to assist in the precipitation of the small amounts of 
labelled DNA. The pellets were rinsed with 500 pi of 70% ethanol and dried at 
room temperature. The pellets were solubilised in 5 pi of formamide dye mix 
(10 pi dionised formamide+ 10 pi bromophenol blue-xylene cyanol), which was
used as a loading buffer and to maintain the strands of DNA in their denatured
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state, by vigorous vortexing and the DNA solution was denatured by boiling for 
3 minutes. The denatured DNA was placed on ice for 5 minutes. 5 pi of each 
sample were electrophoresed on a denaturing (7M urea) 5%, 19:1 
polyacrylamide gel. The gel was separated into two pieces (upper and lower), 
in order to fit in the electrotransfer unit (Bio-Rad, UK) and to reduce the amount 
of reagents used in the detection during optimisation, and the DNA was 
transferred to nylon membrane and detected using the chemiluminesent EMSA 
kit (SeeSection 3.3.4).
6.1.1.2. Binding reaction using fluorescence-labelled primers
The procedure described using biotin-labelled primers was repeated using 
fluorescent labelled primers. In order to improve sensitivity, a new modified 
protocol using infra-red (IRDye) labelled primers was developed in this study. 
The new protocol was performed as follows; the region of interest of the PZ 
gene promoter (See table 6.1) was amplified using unlabelled amplification 
primers. The amplification product was purified and then used in the binding 
reactions. The binding reaction with the unlabelled amplified region was 
performed (with and without nuclear extract) with the same parameters as with 
the biotin-labelled amplified region (See Section 6.1.1.1). Nevertheless, 
different concentrations of the unlabelled amplified region, different binding 
buffers and different incubation conditions were used for optimisation. The 
different binding buffers used in the optimization were as follows: binding buffer- 
1 (described in section 6.1.1.1), binding buffer-2 (Cordingley and Hager 1988) 
(final concentration of 12 mM HEPES (pH 7.9), 0.12 mM EDTA, 60 mM KCI, 
12% glycerol and 0.5 mM DTT) and binding buffer-3 (Batista et al. 2007) (final 
concentration of 50 mM Tris-HCI, pH 8.0, 100 mM KCI, 12.5 mM MgCI, 1 mM 
EDTA, 1 mM DTT and 20% glycerol). Having carried out the binding reaction 
the DNA fragment was digested with DNasel (0.01 units) for 1 minute at room 
temperature, extracted by phenol:chloroform, precipitated with alcohol and air 
dried at room temperature (See Section 6.1.1). The DNA was then re­
suspended in 10 pi of DNase free water.
In order to increase assay sensitivity the digested DNA was then amplified in a 
linear fashion using single primers (an IRDye 700-labelled forward primer and
an IRDye 800-labelled reverse primer). The use of a forward primer in one
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PCR reaction and a reverse primer in a second PCR reaction allowed the 
mapping of binding sites along both DNA strands. Moreover, as the primers 
had different fluorescent labels the ultimate aim was to develop a multiplex 
fluorescent footprinting technique where the amplifications and analysis could 
be carried out in combination.
The amplifications were carried out using the same parameters shown in table 
6.2 with the exception that 5 pi (from the 10 pi purified total volume) of 
amplified DNA used in the binding reaction were used instead of the genomic 
DNA and only one primer (700 or 800 IRD) was used. Having PCR amplified 
the DNA fragment it was again precipitated using sodium acetate and alcohol 
(See Section 6.1.1) and air dried at room temperature. The pellets were re­
suspended in 4 pi microSTOP loading buffer (Li-Cor, UK), vortexed and 
denatured by boiling at 100 °C for 3 minutes. 2 pi of each sample were 
electrophoresed on a denaturing (7 M urea) 5%, 19:1 polyacrylamide gel (40 x 
20 x 0.2 cm) and detected using a Li-Cor 4200 sequencing system (Li-Cor, UK). 
A 20 base pair ladder (Li-Cor, UK) was run alongside to serve as a size marker.
6.1.2. Chromatin immunoprecipitation (CHIP) assay
The chromatin immunoprecipitation assay was performed according the 
manufacturer’s instructions (Active Motif, Belgium). 20 ml of 1% formaldehyde 
were added to each of three 75 cm2 flasks with 70-80% confluency for 10 
minutes to cross-link nuclear protein to genomic DNA and prevent their 
dissociation in subsequent steps. This was followed by washing with 1X PBS. 
The cross-linking was stopped by adding a glycine stop-fix solution for 5 
minutes and then washing w ithlX PBS. The cells were scraped from the 
surface of the flasks into cell scraping solution and pooled together in a 15 ml 
conical tube. The cells were pelleted at 747 x g resuspended in lysis buffer and 
incubated on ice for 30 minutes. The nuclei were released by the aid of dounce 
homogenisation and then pelleted at 2988 x g for 10 minutes at 4°C. The pellet 
was re-suspended in 1 ml of pre-warmed digestion buffer and 50 pi of 
enzymatic shearing cocktail (200U/ml) was added and incubated at 37°C for 15 
minutes (optimal time was determined for shearing). The reaction was stopped 
by addition of 1 pi EDTA (0.5 M) and incubated on ice for 10 minutes. The
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sheared DNA (chromatin) was centrifuged, aliquoted and stored at -80°C if not 
used immediately.
The sheared chromatin was pre-cleared of immunoglobulins by adding protein 
G beads, to reduce non-specific background, and rotated at 4°C for 2 hours. 
The protein G beads were then removed by centrifugation. 10 pi of pre-cleared 
chromatin were stored at -20°C to be used in PCR analysis. 3 pg of the 
antibody of interest were added to 170 pi of the pre-cleared chromatin in a 0.65 
ml tube. Positive and negative antibodies (Active Motif, Belgium) were also 
used in separate control tubes. The reactions were incubated overnight on a 
rotator at 4°C to allow maximal antibody binding. The antibody-bound protein- 
DNA complexes were collected using protein G beads followed by incubation 
on a rotator for 1.5 hours at 4°C. The beads were pelleted by centrifugation at 
1912 x g for 2 minutes and allowed to settle completely by leaving them to 
stand for 30 seconds. The beads were washed, using the proprietary wash 
buffers provided, by vortexing for 10 seconds on a low setting, incubating on the 
rotator for 3 minutes, centrifugation and removal of the supernatant without 
disturbing the beads. The immunoprecipitated DNA was eluted from the 
washed protein G beads using elution buffer containing 50 mM NaHCC>2 and 
1% SDS. The washed protein G beads were briefly vortexed for 10 seconds 
with the elution buffer and incubated for 15 minutes at room temperature. The 
eluted DNA (supernatant) was collected by centrifuging the mixture for 2 
minutes at 1912 x g and leaving the beads to settle completely.
The chromatin immunoprecipitated (eluted DNA) along with the input DNA were 
reverse cross-linked and RNA was removed using 5 M NaCI and RNase 
incubating at 65°C overnight. The proteins were digested using 0.5 M EDTA, 1 
M Tris-CI pH 6.5 and proteinase K solution with incubation at 42°Cfor 2 hours. 
The eluted DNA was finally purified using the provided DNA purification mini­
columns (Active Motif, Belgium). This was done by adding 500 pi of the 
supplied binding buffer to the eluted DNA and centrifugation of the mini-column 
for 30 seconds at 26890 x g. The flow-through was discarded and the mini­
column was replaced in the tube to be washed using the provided DNA wash 
buffer. The DNA was washed on the mini-column by adding the wash buffer 
and centrifuging for 30 seconds at 26890 x g. The flow-through was, again, 
discarded and the DNA was washed a second time for 2 minutes at 26890 x g.
175
The purified DNA was finally eluted by adding 50 pi DEPC-treated water and 
centrifuging for 1 minute at 26890 x g. The purified DNA was stored at -20°C to 
be used in subsequent PCR analysis.
PCR was used to analyse the DNA fragments obtained by ChIP. The same 
amount of each PCR product was size fractionated on a 5%, 19:1 
polyacrylamide gel. The signal of the products was detected and the signal 
intensity was measured using the UVP Biolmaging system (UVP, UK).
Primers used in PCR analysis were complementary to the GAPDH template 
(Forward primer: 5’- TACTAGCGGTTTTACGGGCG-3’, Reverse: 5’-
TCGAACAGGAGGAGCAGAGAGCGA-3’: which produces a fragment of 166 
bp spanning nucleotides -222 to -55, and flanking the transcription start site at - 
102 (relative to the translation initiation site), as a positive control (Active Motif, 
Belgium) and the protein Z template (PZ -13/-163) primers (Forward primer: 5’- 
TCTGAGCCTTCACCGTTCATT-3’, Reverse primer: 5-
TGCTGGGACAGGGCTACAAA-3’) designed using webprimer 
(http://www.yeastgenome.org/cgi-bin/web-primer) and synthesised by Eurofin 
MWG \ Operon.
6.1.3. Analysis
In the footprinting assay the samples electrophoresed on the denaturing 
polyacrylamide gel were visualised using the UVP Bioimaging system (UVP, 
UK), for the biotin-labelled probes, and the Li-Cor 4200 sequencing system (Li- 
Cor, UK), for the IRDye-labelled probes. A 20 base pair ladder (Li-Cor, UK) 
was run alongside the IRDye-labelled fragments to serve as a size marker and 
determine the location of protein-DNA binding. Moreover, a DNase I digested 
naked DNA (without the addition of nuclear extract) was also run along side to 
serve as a negative control.
In the ChIP assay the PCR products from the immunoprecipitated and input 
chromatins were visualised and their intensity were determined using the UVP 
bioimaging system. The intensity of the PCR product from the 
immunoprecipitated chromatin was compared with the input chromatin to 
determine the enrichment of the candidate region with the proposed antibody.
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6.2. Results
6.2.1. Footprinting with biotinylated primers
T h e  d iffe re n t re g io n s  o f th e  P Z  p ro m o te r w e re  a m p lif ie d  by  th e  re s p e c tiv e  
b io tin y la te d  p r im e rs  an d  P C R  re a g e n ts  (S e e  S e c tio n  6 .1 .1 ) u s ing  th e  P r im u s  96 
p lu s  P C R  m a c h in e  (M W G -B IO T E C H , U K ). P C R  o f th e  F P 1 , F P 2  a n d  FP 3  
re g io n s  sh o w e d  o p tim u m  a m p lif ie d  p ro d u c t us ing  1 m M  M g C I2 w h ile  2  m M  fo r  
th e  F P 4  (F ig  6 .4 ). T h e  a n n e a lin g  te m p e ra tu re s  w e re  6 0 °C , 5 8 °C , 5 7  and  
6 2 .5 °C  fo r  F P 1 , FP 2 , F P 3  an d  FP 4 , re s p e c tiv e ly .
1 2  1 2  1 2  3
Fig 6.4. PCR of different regions of PZ gene promoter used for footprinting analysis.
Number 1 in all images represents the 100bp ladder (Promega, UK). Number 2 in the 
images A, B, C and D represents the amplified fragments fp1 (+86 to -213), fp2 (-166 to - 
494), fp3 (-455 to -804), fp4 (-785 to -1099), respectively. The optimal concentration of 
MgCI2 in the PCR reactions for fp1, fp2 and fp3 was 1mM. Although both 1mM and 2mM 
MgCI2 showed good product with fp4, the 2mM was better than 1mM. Numbers 2 and 3 in 
the image D shows the PCR fragments of fp4 with 1mM and 2mM, respectively.
F o o tp r in tin g  us ing  th e  re g io n  + 8 6  to  -2 1 3  w ith  d iffe re n t a m o u n ts  o f  n u c le a r 
e x tra c t s h o w e d  a u n ifo rm  la d d e r o f  th e  D N A  a s  w e ll as  a la ck  o f  a c c u m u la te d  
D N A  in th e  u p p e r o r lo w e r ge l, in d ica tin g  th e  a p p ro p r ia te  a m o u n t o f  D N a s e  I 
a nd  tim e  o f d ig e s tio n  had  be en  used  . H o w e ve r, no p ro te in  b in d in g  w a s  
o b se rv e d  (F ig  6 .5 .A  and  B). A  fre s h ly  p re p a re d  n u c le a r e x tra c t w a s  u se d  in 
a n o th e r fo o tp r in t in g  a ssa y , b u t a g a in  no  p ro te in  b in d in g  to  th e  D N A  w a s  
o b se rv e d  (F ig  6 .5  C and  D).
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N. Extract No 10 2o 40 No No 10 20 40 No
(Mg)
Purified 1jjI 1pl 1jjI 1|jI 1|jI 1|jI 1|jI 1|jl 1|j| 1(jI 
DNA
1 2 3 4 5  1 2 3  4 5
N.
Purified
DNA
1 2 3 4 5  1 2 3 4 5
Fig 6.5. Footprinting of the Protein Z promoter region +86 to -213. Lanes 1 and 5 
contain the DNA fragment without nuclear extract (control). Lanes 2, 3 and 4 contain the 
DNA fragment with 1Opg, 20pg and 40 pg of HepG2 NE and 15 pi, 10 pi and no binding 
buffer, repectively (25 pi totai volume). [A] is an upper region of the gel. [B] is the bottom 
region of the gel. No protein was found to bind the DNA fragment. [C] and [D] is an 
upper and lower region of the gel from another experiment for the same promoter region 
with the same parameters but with freshly prepared HepG2 NE.
C D
Extract No 10 20 40 No No 10 20 40 No
(M9)
1pl 1pl 1pl 1pl 1pl 1pl 1pl 1pl 1 pi 1pl
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Protein binding to DNA should be seen as a gap (footprint) in the DNA ladder, 
due to the protection of the region bound by the protein from the DNase I 
digestion. Another footprinting experiment was performed using a 20 minute 
binding incubation time at room temperature instead of on ice. Moreover, the 
amount of DNA template used was 0.5 pi instead of 1.0 pl. The results showed 
uniform DNA bands due to DNasel digestion, but again did not show any 
protein binding to the DNA fragment as no footprinting was detected (Fig 6.6).
N .  E x t r a c t  
(M9 )
P u r i f i e d  
D N A
1 2  3  4
Fig 6.6. Footprinting of the PZ region +86 to -213 with incubation at room 
temperature. Lane 1 contains the DNA fragment without HepG2 NE (control). Lanes 2,
3 and 4 contain the DNA fragment with 10jjg, 20|jg and 40 pg HepG2 NE. The binding 
reaction mixture was incubated for 20 minutes at room temperature instead of ice. 
Approximately 0.5 pl of the purified DNA fragment was used.
6.2.2. Footprinting with IRD primers
The first footprinting experiment with the IRD primers was performed using the 
previous protocol (See Section 6.1.1.1). Ten fmole of the 700 and 800 IRD- 
labelled amplified fragments were incubated for 20 minutes on ice with different 
amounts (10, 20 and 40 pg) of dialysed HepG2 NE (SeeSection 3.3.1). The 
results showed that no visible fragments were detected at either 800 nm or 700 
nm apart from the molecular weight ladder (Fig 6.7).
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1RD l a b e l l e d  D N A  
f r a g m e n t  ( f m o le )
N u c l e a r  e x t r a c t  
(pg) R ^
Fig 6.7. Footprinting assay of the PZ region +86 to -213 without amplification using 
IRD-labelled fragment. Left hand image represents the assay with the 800-IRD fragment 
while the right hand image is the assay with the 700-IRD fragment. Lane 1 is a 20 bp 
ladder. Lane 2 (control) is the 10 fmole IRD-labelled fragment without HepG2 NE. Lanes 
3, 4 and 5 are 10 fmole of IRD-labelled DNA fragment with 10, 20 and 40 pg of dialysed 
HepG2 NE, respectively. No signal was detected at either 700 nm or 800 nm.
The footprinting assay performed by the modified protocol (See Section 6.1.1.2) 
using different concentrations of the unlabelled FP1 fragment and different 
concentrations of dialysed HepG2 NE showed too high a signal intensity when 
amplified by the 700-IRD forward primer (Fig 6.8). However, lower signal 
intensity was detected at 800 nm when the 800-IRD reverse primer was used 
for the post amplification (Fig 6.9). The assay using 0.1 and 0.5 fmole of the 
+86 / -213 unlabelled fragment followed by 50X post amplification with the 800- 
IRD reverse primer showed a uniform intensity of digested bands. 
Nevertheless, no protein-DNA binding (footprinting) was detected.
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Fig 6.8. Footprinting assayof the PZ region +86 to -213 post amplified by 
the 700-IRD primer. The image shows a too high signal, detected at 700 nm, in 
all lanes with different concentrations of the DNA fragment and the dialysed 
HepG2 NE. However, the DNA fragment seems to have uniform digestion by 
the DNase I.
Unlabelled DNA 
fragm ent (fmole)
100
90
Fig 6.9. Footprinting assay ofr the PZ region +86 to -213 post amplified by the 800- 
IRD primer. The left hand image represents most of the DNA fraction with the 20 bp 
single-stranded ladder. The right hand image represents a magnified 120 bp section of 
the gel. The gel shows uniform bands as a result of DNasel digestion. The ladder 
resulting from 0.01 fmole of DNA in the binding reaction showed a weak signal while 
better signals were shown by using 0.1 and 0.5 fmole of the DNA. However, no protein 
binding was shown with the different concentrations of the DNA using different 
concentrations of the dialysed HepG2 NE.
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The same assay was repeated with the same concentrations of the +86 / -213 
unlabelled fragment using 40 pg of the dialysed HepG2 NE followed by a 1:10 
dilution of the product, using the loading buffer, after the post-treatment 
amplification with the candidate IRD primer. The results showed too high a 
signal detected at 700 nm from the undiluted samples with the different 
concentrations of the region of interest. However, samples which were diluted 
1:10 after the post-treatment amplification showed relatively uniform signal with 
the use of 0.5 fmole of the unlabelled region and relatively weak signal with the 
use of 0.1 and 0.01 fmole (Fig 6.10). The experiment again did not show any 
protein-DNA binding.
Unlabelled DNA ^  ^  _  5  5
fragment (fmole) c 5  c o  c d  c 5  < = > < = >
Nuclear extract
(ms)
1 2 3 4  5 6 78 910 1112 7 8  9 10 11 12
Fig 6.10. Footprinting assay of the PZ region +86 to -213 post amplified by the 700- 
IRD primer and with and without a 1:10 dilution. The left hand image represents most 
of the digested DNA fraction with a 20 bp single-stranded size standard. The right hand 
image represents a magnified DNA fragment, indicated by the bracket to the right of the 
left hand image. Lanes 1 to 6 contain different concentrations of the unlabelled region and 
show too high a signal after the post amplification step when loaded without dilution. The 
20 bp ladder was hidden by the very strong signal. Lanes 7 to 12 show relatively good 
signal using 0.5 fmole of the proposed region in the binding reaction followed by the post 
amplification step and a 1:10 dilution with the loading buffer. The use of 0.1 and 0.01 
fmole of the proposed region with the 1:10 dilution after the post amplification step 
showed relatively weak signal. Lanes 1, 3, 5, 7, 9 and 11 are controls which contain the 
DNA fragment without the HepG2 NE, while lanes 2, 4, 6, 8, 10 and 12 are the DNA 
fragment incubated with the HepG2 NE for 20 minutes on ice.
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The results detected at 800 nm showed a relatively good signal without the 1: 
10 dilution after the post amplification step, although some of the bands were 
quite weak. However, the dilution after post amplification resulted in loss of the 
signal (Fig 6.11). The results also showed some cross-lane contamination due 
to leakage from the sharkstooth comb.
200 bp 
180 bp
160 bp
140 bp
120 bp
100 bp 
90 bp
70 bp
Fig 6.11. Footprinting assay of the PZ region +86 to -213 post amplified by the 800- 
IRD primer with and without 1:10 dilution. The left hand image represents most of the 
digested DNA fraction and the 20 bp single-stranded size standard. The right hand image 
represents a magnified DNA fragment which indicated by the right bracket on the left 
handed image. Lanes 1 to 6 contained different concentrations of the unlabelled region and 
showed a relatively weak to good signal after the post amplification step of the digested 
DNA and loading without dilution. Lanes 7 to 12 showed a loss of the signal using different 
concentrations of the proposed region in the binding reaction followed by the post 
amplification step and 1:10 dilution with the loading buffer. Lanes 1, 3, 5, 7, 9 and 11 were 
controls which contained the DNA fragment without the HepG2 NE while lanes 2, 4, 6, 8, 10 
and 12 were the DNA fragment incubated with the HepG2 NE for 20 minutes on ice.
The same experiment was repeated with an incubation of the HepG2 NE for 30 
minutes on ice with the different amounts of the unlabelled fragment (+86/-213) 
followed by 1: 5 dilution of the DNA fragments amplified by the 700-IRD forward 
primer and 1: 2 dilution of the DNA fragments amplified by the 800-IRD reverse 
primer after the digestion and purification. The results again showed too high a 
signal detected at 700 nm (Fig 6.12) while a relatively good signal was detected
at 800 nm (Fig 6.13). No protein-DNA binding was detected.
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Unlabelled DNA 
fragment (fmole)
Nuclear extract
180 bp 
160 bp 
140 bp 
120 bp
100 bp 
90 bp
70 bp
1 2 3 4 5 6
Fig 6.12. Footprinting assay of the PZ region +86 to -213 post amplified by 700-IRD 
primer and 1:5 dilution. Lanes 2, 4 and 6 contain different concentration of the unlabelled 
region with 40 pg of the HepG2 NE while lanes 1, 3 and 5 are controls without the HepG2 
NE. All the different concentrations of the DNA fragment again showed a too high signal 
after the post amplification step of the digested DNA and 1:5 dilution with the loading buffer. 
The protein-DNA binding could not be determined due to the very high signal intensity.
(JnlabellecJ DNA 
fragment (fmole)
140 bp
120 bp
100 bp - 
90 bp •
70 bp -
clear extract (M9>
Fig 6.13. Footprinting assay of the PZ region +86 to -213 post amplified by the 800- 
IRD primer and 1:2 dilution. Lanes 2, 4 and 6 contain different concentrations of the 
unlabelled region with 40 pg of the HepG2 NE while lanes 1, 3 and 5 are controls without 
the HepG2 NE. All the different concentrations of the DNA fragment again showed 
relatively good signal after the post amplification step of the digested DNA and 1:2 dilution 
with the loading buffer. However, the binding reaction using 0.01 fmole of the DNA 
fragment showed a very weak signal. No protein-DNA binding was determined.
Unlabelled DNA 
fragment (fmole)
Nuclear extract (My)
200 bp
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Another footprinting assay using different incubation times with DNasel, 90 
seconds and 2 minutes, was carried out. The fragment amplified with the 700- 
IRD forward primer was diluted 1:10 before loading on the denaturing gel while 
the fragment amplified with the 800-IRD reverse primer was diluted 1:2. The 
digestion of the DNA fragment with the DNasel for 90 seconds and 2 minutes 
again showed a relatively uniform ladder of the fragments which was similar to 
that seen with the digestion with the DNasel for 1 minute. The ladder produced 
from the DNA fragment (+86/-213) with the DNasel digestion showed relatively 
good signal detected at both 700 nm and 800 nm (Fig 6.14 and Fig 6.15). 
However, some of the lanes showed very high signal while others showed very 
weak signal. The assay again did not show any protein-DNA binding.
Unlabelled DNA 
fragment (fmole)
Nuclear extract 
(M9)
CD — CNv - cn «  x r in  ©  h - co o>
Fig 6.14. Footprinting assay of the PZ region +86 to -213 post amplified by the 700- 
IRD primer and 1:10 dilution. The right hand image represents a magnified gel fragment 
indicated by the bracket to the right of the left hand image. Lanes 1, 2, 5, 6, 9 and 10 
show the DNA fragment incubated with DNasel for 90 seconds while lanes 3, 4, 7, 8, 11 
and 12 were incubated with the DNasel for two minutes. Lanes 1, 3, 5, 7, 9 and 11 
represent the controls without the HepG2 NE. The lanes show uniform ladders of the DNA 
fragment with both incubations with the DNasel. However, no footprints were observed.
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Fig 6.15. Footprinting assay of the PZ region +86 to -213 post amplified by 800-IRD 
primer and 1:2 dilution. The right hand image represents a magnified gel fragment 
indicated by the bracket to the right of the left hand image. Lanes 1, 2, 5, 6, 9 and 10 
show the DNA fragment incubated with DNasel for 90 s while lanes 3, 4, 7, 8, 11 and 12 
were incubated with DNasel for two minutes. Lanes 1, 3, 5, 7, 9 and 11 represent the 
controls without the Hep NE. The lanes show uniform ladders of the DNA fragment with 
both incubations with the DNasel. However, no footprints were shown.
The footprinting assay was again carried out using three different binding 
buffers (See Section 6.1.1.2). 0.5 fmole of the unlabelled fragment incubated 
for 45 minutes on ice with 30 and 40 pg were used for the binding reaction. 
After the DNasel digestion for one minute and the post amplification with the 
700-IRD forward primer and post amplification with the 800-IRD reverse primer, 
1:10 and 1:2 dilutions of the 700-IRD fragment and the 800-IRD fragment, 
respectively, were loaded on the denaturing gel. The results again showed a 
uniform ladder produced from the digested fragment although different signal 
intensities through the lanes were detected at both 700 and 800 nm with the 
best result observed with binding buffer-1. Again, no protein-DNA binding was 
detected (Fig 6.16 a and b).
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Fig 6.16. Footprinting assay using different binding buffers for the PZ region +86 to 
-213. (a) represents the digested fragment amplified by the 700-IRD forward primer, (b) 
represents the digested fragment amplified by the 800-IRD reverse primer. The right hand 
image represents a magnified gel fragment which is indicated by the bracket to the right of 
the left hand image. Lane 1 was a 20 bp ladder. Lanes 2, 5 and 8 were controls without 
Hep NE. Lanes 3 and 4 were 0.5 fmole of the fragment incubated for 45 minutes on ice 
with 30 pg and 40 pg of HepG2 NE, respectively, in binding buffer-1. Lanes 6 and 7 were 
0.5 fmole of the fragment incubated for 45 minutes on ice with 30 pg and 40 pg of HepG2 
NE, respectively, in binding buffer-2. Lanes 9 and 10 were 0.5 fmole of the fragment 
incubated for 45 minutes on ice with 30 pg and 40 pg of HepG2 NE, respectively, in 
binding buffer-3. No footprints were detected.
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The footprinting assay using different binding buffers (See Section 6.1.1.2) was 
repeated with different incubation conditions (4°C, room temperature and 37°C) 
for the proposed DNA fragment with the Hep NE (Fig 6.17). The use of 
different incubation condition and different binding buffers again did not show 
any footprints.
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Fig 6.17. Footprinting assay using different binding buffers and different 
incubation conditions, (a) represents the digested fragment (+86/-213) amplified by 
the 700-IRD forward primer, (b) represents the fragment amplified by the 800-IRD 
reverse primer. Ther right hand image represents a magnified gel fragment which is 
indicated by the bracket to the right of the left hand image. Lane 1 was a 20 bp ladder. 
Lanes 2, 6 and 10 were controls without Hep NE. Binding buffer-1 was used in lanes 2, 
3, 4 and 5. Binding buffer-2 was used in lanes 6, 7, 8 and 9. Binding buffer-3 was used 
in lanes 10, 11, 12 and 13. The DNA fragment was incubated with the Hep NE overnight 
at 4°C in lanes 3, 7 and 11 and at room temperature for 45 minutes in lanes 4, 8 and 12 
and at 37°C for 45 minutes. No footprints were detected under all conditions.
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6.2.3. Chromatin Immunoprecipitation
6.2.3.1. Optimisation of GAPDH primers for PCR
GAPDH primers were provided with the ChIP kit (Active Motif, Belgium). These 
act as a positive control in that they flank the start point of transcription of the 
GAPDH gene and should show enrichment when the chromatin is 
immunoprecipitated with the RNA pol II antibody. PCR conditions for this 
primer pair were optimised using genomic DNA prepared from HepG2 cells. 
The GAPDH primers were used to demonstrate the efficacy of the protocol and 
the reagents that were provided with the kit. The optimised PCR should show a 
specific product of 166 bp in size. The PCR of the GAPDH primers using 
different temperatures and different concentrations of MgC^ did not show its 
optimal specific product (Fig 6.18). The PCR of GAPDH primers at 58°C 
showed two bands of high molecular weight products (Fig 6.18,A). The 
temperature was then increased to 59°C and 1mM and 2mM MgCI used in the 
PCR. The results showed many non-specific amplification products (Fig 
6.18,B). Therefore, the temperature, again, was increased to 60°C and 
different concentrations of MgCI (1mM and 3mM) were used in order to 
increase specificity of primer binding. The results, again, showed two high 
molecular weight products but not the specific 166 bp product (Fig 6.18,C).
6.2.3.2. Optimisation of PZ -13/-163 region primers
The primers for the region of interest in the PZ gene promoter (PZ -13/-163), 
which spans nucleotides -13 to -163 relative to the translation start site, were 
optimised for amplification. This region has been found, in the current study, to 
be bound by HNF4a and gave some indication of PEA3 or Ets 1 binding using 
EMSA analyses. The optimisation reactions were performed using the input 
DNA cross-linked, sheared, reverse cross-linked and purified at different 
temperatures and using different concentrations of MgCb.
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Fig 6.18. Optimisation of the GAPDH PCR with HepG2 genomic DNA. Lane 1 in all 
images represented a 100 bp ladder. Image [A] lane 2 shows high molecular weight 
PCR products at 58°C without adding MgCI2. Image [B] shows PCR at 59°C using 1 mM 
and 2 mM MgCI2 in lane 2 and 3 respectively. Multiple non-specific bands were shown 
with both concentrations. Image [C] shows PCR at 60°C using 1 mM and 3 mM MgCI2 in 
lane 2 and 3, respectively. Two high molecular weight products were shown with both 
mM MgCI2.
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The first PCR reaction was carried out at an annealing temperature of 59°C 
using 1mM and 2mM MgC^. The results show the specific product along with 
additional non-specific products (Fig 6.19). The PCR was repeated with higher 
annealing temperatures (61 °C, 62°C and 63°C) and with different
concentrations of MgC^. The PCR results, again, showed non-specific 
products along with the specific product with annealing temperatures 61 °C and 
62°C (Fig 6.20 and Fig 6.21). However, with an annealing temperature of 63°C 
no products were amplified (Fig 6.22). Therefore, the annealing temperature 
was decreased to 62.5°C and another PCR was performed with 1mM MgCb, 
since it showed the best specific product with the previous temperatures. The 
specific product amplified by PCR for the PZ -13/-163 region at annealing 
temperature 62.5 °C and 1 mM MgC^ was found to be the most specific out of 
the tested variables (Fig 6.23). The size of the specific product was confirmed 
using a standard curve of the migration of the molecular weight ladder. This 
was done by measuring the migration distance of the PCR product to find out its 
size.
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Fig 6.19. PCR reaction of PZ -13/-163 
with input DNA (annealing 
temperature of 59°C). Lane 1 is a 100
bp ladder. Lane 2 and 3 are the 
reaction with 2 mM and 3 mM MgCI2 , 
respectively. Non-specific products 
were detected along with the specific 
product (A) of 151 bp.
Fig 6,20. PCR reaction of PZ -13/-163 
with input DNA (annealing temperature 
of 61°C). Lane 1 is 100 bp ladder. Lane 2, 
3 and 4 are the reactions with 1, 2 and 3 
mM MgCI2. respectively. Non-specific 
products were detected with the specific 
product (A) of 151 bp.
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Fig 6.21. PCR reaction of PZ -13/-163 
with input DNA (62°C). Lanel is 100 bp 
ladder. Lanes 2, 3, 4, 5, 6, 7 and 8 are the 
reactions with 1, 1.5, 2, 2.5, 3, 3.5, 4.0 mM 
Mgcl2, respectively. Non-specific products 
were detected along with the specific 
product (A) of 151 bp.
1 2  3  4  5
Fig 6.22. PCR reaction of PZ -13/-163 
with input DNA (63°C). Lanel is 100 bp 
ladder. Lane 2, 3, 4 and 5 are the reactions 
with 1, 2, 3 and 4 mM Mgcl2. respectively. 
No amplified product was detected.
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Fig 6.23. PCR of PZ -13/-163 with input DNA (62.5°C). Lane 1 is the 
100 bp ladder. Lane 2 is the reaction with 1 mM MgCI2. Band A 
indicates the specific product. These parameters were found to be the 
most specific in amplifying the PZ -13/-163 region with PCR.
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6.2.3.3. PCR of the PZ -13/-163 with the immunoprecipitated chromatin.
PCR was performed with the primers of the region of interest spanning 
nucleotides -13 and -163, relative to the translation start site (+1). The 
optimised PCR (62.5°C annealing temperature and 1mM MgCI2) was performed 
using the DNA (chromatin) immunoprecipitated by HNF4a antibody alongside 
the DNA immunoprecipitated by the IgG antibody (negative control), the DNA 
immunoprecipitated by the pol II antibody (positive control) and the input DNA. 
An amplified no template PCR negative control and a 100bp ladder were also 
run on the gel. A band of weaker intensity (20% lower) than the input DNA was 
observed with the HNF4a immunoprecipitated DNA suggesting no enrichment. 
This product was also of lower intensity (30% lower) than with the DNA 
immunoprecipitated by the pol II antibody (Fig 6.24). The no template negative 
controls showed contamination (Lanes 2 and 3) with the presence of the same 
product as with the other DNA templates.
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Fig 6.24. PCR of PZ -13/-163 with different immunoprecipitated chromatins. Lane 
1 is a 100 bp ladder. Lanes 2 and 3 are no template negative controls containing 
DEPC and DNase free water, respectively. Lane 4 contains DNA immunoprecipitated 
by IgG. Lane 5 contains input DNA. Lane 6 contains DNA immunoprecipitated by the 
pol II antibody. Lane 7 contains DNA immunoprecipitated by the HNF4 antibody. [A] 
indicates the desired product (151 bp).
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The same experiment was repeated using new aliquots of 10X PCR buffer and 
the primers to isolate the contamination. Stronger signals of the proposed 
product were detected with both pol II (1.8-fold) and HNF4a (2.2-fold) enriched 
DNA compared to the negative control (Fig 6.25). However, no signal was 
detected with input DNA and the no template control, again, showed 
contamination although it was of lower intensity than the previous experiment.
200 bp
100 bp —
Fig 6.25. PCR of PZ -13/-163 with different immunoprecipitated chromatins.
Lane 1 is a100 bp ladder. Lane 2 is a no template negative control containing DEPC. 
Lane 3 contains DNA immunoprecipitated by IgG. Lane 4 contains input DNA. Lane 5 
contains DNA immunoprecipitated by the pol II antibody. Lane 6 contains DNA 
immunoprecipitated by the HNF4 antibody. [A] indicates the desired product (151 bp). 
New aliquots of 10X PCR buffer and primers were used.
A further experiment for the PZ region -13/-163 was performed using new 
aliquots of all PCR reagents. The results showed the expected product with no 
contamination in the no template control. However, no increase in the signal 
strength was observed with the HNF4a enriched DNA (67%) compared to the 
input DNA (Fig 6.26).
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Fig 6.26. PCR of PZ -13/-163 with different immunoprecipitated chromatins.
Lane 1 was 100 bp ladder. Lane 2 was no template negative controls containing 
DNase free water. Lane 3 contained DNA immunoprecipitated by IgG. Lane 4 
contained input DNA. Lane 5 contained DNA immunoprecipitated by HNF4 
antibody. A indicates the desired product (151 bp). New aliquots from all PCR 
reagents were used.
Chromatin immunoprecipitated with the CREB antibody, the PEA3 antibody and 
the HNF4a antibody were used in a further PCR. None of the enriched DNA 
samples showed any observable increase in the signal of the proposed product 
compared to the same amount of the input DNA. The signal intensity with 
CREB, HNF4a and PEA3 enriched DNA was 40%, 55% and 22%, respectively, 
compared to the same amount of the input DNA. Moreover, contamination was 
observed again in the no template control (Fig 6.27).
195
2 0 0  b p
1 0 0  b p
Fig 6.27. PCR of PZ -13/-163 with different immunoprecipitated chromatins.
Lane 1 was 100 bp ladder. Lane 2 is a no template PCR. Lane 3 contains DNA 
immunoprecipitated by IgG. Lane 4 contains input DNA. Lane 5 contains DNA 
immunoprecipitated by CREB antibody. Lane 6 contains DNA immunoprecipitated by 
HNF4a antibody. Lane 7 contains DNA immunoprecipitated by PEA3 antibody. [A] 
indicates the desired product (151 bp).
The experiment was repeated with new aliquots of the PCR reagents and new 
immunoprecipitated chromatin prepared from the HepG2 cells. However, 
similar results were observed, with contamination in the no template control and 
a stronger signal with the negative control (IgG immunoprecipitated) compared 
to the input DNA and the other immunoprecipitated chromatin (Fig 6.28). The 
signal intensity with the input DNA, CREB, HNF4a and PE A3 enriched DNA 
was 1%, 90%, 70% and 57%, respectively, compared to the same amount of 
the negative control.
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Fig 6.28. PCR of PZ -13/-163 with different immunoprecipitated chromatins.
Lane 1 is a 100 bp ladder. Lane 2 is a no template PCR. Lane 3 contains DNA 
immunoprecipitated by IgG. Lane 4 contains input DNA. Lane 5 contains DNA 
immunoprecipitated by CREB antibody. Lane 6 contains DNA immunoprecipitated 
by HNF4a antibody. Lane 7 contains DNA immunoprecipitated by PEA3 antibody. 
[A] represents the desired product (151 bp).
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6.3. Discussion
The study of protein-DNA interactions is a major area of research since it 
provides valuable biological information with regard to the regulation of genes 
(Jones and Thornton 2003). The accurate identification of binding sites and the 
identity of the transcription factors bound to these sites is a very important step 
in the characterisation of gene transcriptional regulation (Morozov et al. 2005). 
The electrophoretic mobility shift assay (EMSA) is a technique which has been 
used extensively in studying such protein-DNA interactions (Fried and Crothers 
1981, Revzin 1989). This technique was used in the current project to study 
the proteins potentially binding the PZ gene promoter. The EMSA is a relatively 
fast and simple, well-established assay for studying a specific binding sequence 
for particular transcription factors in a region of DNA in vitro (Buratowski and 
Chodosh 2001). However, this assay has many limitations in studying the 
protein-DNA interactions that require in vivo conditions (Carey and Smale 
2001). The assay is limited, for instance, in studying proteins that need looping 
of the DNA to bring distal binding sites closer together; a mechanism recently 
observed in the murine osteopontin gene promoter with the looping of DNA 
facilitated the interaction of NFkB and AP1 binding to c/'s-regulatory elements 
~1700 bp apart (Zhao et al. 2011). In addition, the gel electrophoresis may 
cause dissolution of multiprotein complexes required for stabilising their 
interaction with the DNA, or inhibit the detection of transcription factors which 
require recruitment by an interaction with another factor for their cooperative 
DNA binding. The human (3-interferon enhanceosome is an example of such 
complex formation with a requirement for the binding of the structural protein 
HMGA1 to facilitate the binding of NFkB, IRF and Jun/ATF in a highly 
cooperative manner, which then go on to recruit a coactivator, CBP (CREB 
binding protein) or p300 (Panne, Maniatis and Harrison 2007).
Footprinting is another assay which can be used in studying protein-DNA 
interactions. This technique is more powerful than EMSA and gives more 
information about the protein-DNA interactions, such as the number and 
position of protein-DNA interactions in longer fragments of DNA (Gilmartin and 
Bowler 2002). The main variables used in optimisation of footprinting assay are 
summarised in table 6.3.
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DNasel
incubation
60,90 or 120 seconds at room temperature
Nuclear
extract 10 \l q , 20 p,g and 40 \ lq  total protein
DNA
fragment
0.5 til and 1.0 til from 10 pJ of total volume of the proposed 
purified biotin labelled DNA fragment and 5 \l \ of the 
IRDye-labelled DNA fragment were loaded in the gel.
0.01 fmole, 0.1 fmole and 0.5 fmole of the purified 
unlabelled DNA fragment were used in the binding 
reaction and 5 pJ were loaded in the gel after the 
amplification with one of the IRDye labelled primers.
Incubation 
of Binding 
reaction
Ice, room temperature or37°C fo r45 minutes.4 °Cfor 
overnight. 30 and 20 minutes on ice or 20 minutes at room 
temperature.
Binding
buffers
Binding buffer-1 (Andrews and Faller 1991) 
Binding buffer-2 (Cordingley and Hager 1988) 
Binding buffer-3 (Batista et al. 2007)
Detection of 
DNA 
fragment
UVP Bioimaging system for biotin-labelled.
Li-Cor4200 sequencing system for IRDye-labelled.
Table 6.3. Different variables used in optimisation of footprinting assay.
Three different binding buffers and three different amounts of HepG2 NE with different 
incubations of the binding reaction were used to optimise the footprinting protocol. 
Moreover, different incubation periods were used to optimise the DNasel digestion. The 
UVP bioimaging system and Li-Cor 4200 sequencing system were used to visualise the 
biotin-labelled and IRDye-labelled DNA digested fragment, respectively.
6.3.1. Footprinting assay using biotin-labelled primers
Although the footprinting technique traditionally uses radiolabelled probes the 
current study looked to employ alternative labelling methods. The optimisation 
of this technique was first done with biotin-labelled primers using the 
established protocol of Sambrook and Russell (2001) (Sambrook and Russell 
2001). Different amounts of HepG2 NE was added to the purified DNA 
fragment of interest (PZ +86 to -213) in a binding buffer with the presence of a 
non specific competitor, poly (dl-dC), to bind non-specific DNA binding proteins.
Binding reactions were carried out on ice, 4°C and at room temperature,
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followed by DNase I digestion, recovery of the digested fragments and 
subsequent size fractionation on a 5% denaturing polyacrylamide gel (See 
Section 6.1.1.1).
Results showed a uniform ladder of the DNA fragment indicating optimisation of 
the DNase I digestion had been achieved. However, no protein binding to the 
DNA was shown with variation in any of the parameters assessed, such as 
temperature of the binding reaction or amount of protein (Fig 6.5 and Fig 6.6). 
The results also showed a non-uniform transfer of the DNA fragments to the 
nylon membrane.
6.3.2. Footprinting assay using IRDye-labelled primers
To avoid such issues with the transfer process, which may potentially lead to 
misinterpretation of the results, in addition to the amount of time to perform the 
experiment using biotin-labelled primers, IRDye-labelled primers were 
determined to be an attractive alternative. The majority of footprinting 
experiments have been successfully performed using radioisotope molecules. 
However, the time required in producing the autoradiograph and the hazardous 
nature of radioisotopes, not to mention their limited half-life has led to their 
substitution by fluorescent methodologies (Ying, Fourmy and Yoshizawa 2007). 
The first experiment using the IRDye labelled DNA was performed using 10 
fmole of purified IRDye-labelled fragment produced by PCR (+86 to -213) with 
the same protocol as that used for the biotin-labelled primers. Moreover, the 
HepG2 NE used was dialysed (SeeSection 3.3.1) to reduce its salt 
concentration. The DNA fragment was incubated with the HepG2 NE on ice for 
20 minutes. The DNA was then digested by 0.01 units of DNase I for 1 minute, 
purified and electrophoresed on a 5% denaturing polyacrylamide gel alongside 
a 20 bp molecular weight size standard (Li-Cor, UK) to identify regions of 
protein-DNA binding. For more accurate identification of any protein-DNA 
binding regions a sequencing ladder can be used. Traditionally this has been 
G+A and C+T sequencing ladders (Maxam and Gilbert 1980), although a 
dideoxy sequencing ladder is easier to prepare and would provide the same, if 
not more information. No products were observed from this reaction at either 
700 nm or 800 nm (Fig 6.7).
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6.3.3. Modified footprinting assay using IRDye-labelled primers
Assuming that sensitivity may be an issue with fluorescently labelled products 
compared to radiolabelled products the protocol was then modified by adding 
an extra amplification step using IRDye-labelled primers, after the DNase I 
digestion (See Section 6.1.1.2). Different amounts of the unlabelled DNA 
fragment (+86 to -213) were incubated with different amounts of the Hep NE on 
ice for 20 minutes, digested, purified and amplified using the an IRDye-primer. 
The amplification of the DNA fragment was performed using a 700 IRDye 
labelled forward primer and then repeated with the 800 IR Dye-labelled reverse 
primer. An advantage of fluorescent labels is that reactions can be multiplexed 
and this method could allow the mapping of the protein binding sites on both 
strands of the double-stranded DNA simultaneously. The results showed a very 
strong signal with the 700-forward primer and a relatively good signal with the 
800-reverse primer, suggesting that the amplification step was successful, 
when comparing signal intensity to the absence of amplification (fig. 6.7). 
However, no protein-DNA binding was seen (Fig 6.8 and Fig 6.9).
The same experiment was then repeated using 40pg of the Hep NE and the 
samples diluted 1:10 with the loading buffer before loading onto the gel, in an 
attempt to optimise the signal intensity. The results with the 700-labelled primer 
showed a relatively faint signal after the dilution, particularly when 0.01 and 0.1 
fmole of the unlabelled fragment were used in the binding reaction, while too 
high a signal was detected from the undiluted samples (Fig 6.10). The signal 
detected from the 800-IRDye was relatively good with undiluted samples while it 
was lost-after-the-dilution-(Fig-6rTT)rsuggesting eitherdiffefential”arriplification 
between the two primers or a difference in their original labelling efficiencies 
during manufacture. However, again no footprints were detected with either 
IRDye-lablled primer. Moreover, although the use of the sharkstooth comb in 
order to run the samples close to each other is considered as an advantage for 
more accurate comparison, the samples showed some degree of cross-lane 
contamination due to seepage from the comb, which is a potential disadvantage 
of using such combs (Theophilus 1996).
A further experiment was conducted increasing the incubation time of the DNA 
with the HepG2 NE to 30 minutes to provide more time for the binding of the 
protein to the DNA to reach equilibrium. Moreover, based on the signal
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intensities from the previous experiment the samples amplified by the 700- 
labelled primer were diluted 1:5 and those amplified by the 800-labelled primer 
diluted 1:2 to provide appropriate and balanced signals. The results, however, 
still showed too strong a signal with the 700-labelled primer (Fig 6.12) while a 
better signal was detected with the 800-labelled primer (Fig 6.13). However, 
again, no footprints were detected.
To optimise the signal with the 700-labelled fragment and to confirm the 
consistency of the signal detected from the 800-labelled fragment with the 1:2 
dilution, the previous experiment was repeated using a 1:10 dilution with the 
DNA fragment amplified by the 700-labelled primer. Moreover, the digestion 
time with the DNase I was increased to 90 s and 2.0 minutes to determine how 
crucial the digestion time was to the uniform banding pattern of the digested 
fragments. The results showed good signal intensity at both 700 nm and 800 
nm (Fig 6.14 and Fig 6.15). In addition, the incubation of DNase I with the DNA 
fragment for 90 s and 2.0 minutes showed the same pattern of banding 
obtained by the 1 minute incubation. However, again, footprints were not 
detected. Since the signal intensities from both 700 and 800-IRDye fragments 
were now optimised, as was the DNase I treatment, further studies were carried 
out in order to optimise the protein binding to DNA.
In an attempt to enhance protein-DNA interactions two further binding buffers, 
in addition to the original buffer (See Section 6.1.1.2) were assessed in a further 
footprinting assay. Moreover, the incubation time of the DNA fragment with the 
Hep NE was increased to 45 minutes on ice. Following post-digestion 
amplification the samples were diluted 1r113-and^lT2Torthe~700=IRDye and 800- 
IRDye fragments, respectively, before they were size fractionated, since these 
dilutions had previously been shown to be optimal. The banding pattern still did 
not show any indication of protein-DNA binding with either labelled fragments.
To further optimise the protein-DNA binding other incubation conditions were 
used to perform the assay. The DNA fragment was incubated with the Hep NE 
overnight at 4°C, 45 minutes at room temperature and 45 minutes on ice. 
Nevertheless, none of these conditions showed footprints. Although most of the 
possible conditions to optimise the protein binding were tested, no protein-DNA 
interaction was achieved.
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The DNase I footprinting assay, in order to be performed successfully, requires 
large amounts of the DNA-binding proteins to saturate the DNA binding sites 
(Guille and Kneale 1997). The majority of footprinting assays in previous 
studies were successfully accomplished using purified proteins (Wu, 
Urbanowski and Stauffer 1995, Maruyama et al. 2003), primary cells such as rat 
liver (Lee et al. 1997, Lee et al. 1999, Rath et al. 2008, Kim and Ahn 1998) or 
rabbit liver (Ip, Lee and Hammond 2000) , or nuclear extract from HepG2 cells 
(El-Sankary et al. 2002, Sugawara et al. 2007) prepared by the classical 
protocol reported by Dignam and colleagues (Dignam etal. 1983). The protocol 
used to prepare the nuclear extract (Andrews and Faller 1991), although 
derived from the large scale method developed by Dignam in 1983, was based 
on a limited number of cells and missed many steps which may affect the 
quality of the nuclear extract and the quantity of the DNA-binding proteins. 
Therefore, the current study has shown that, in principle, the novel technique of 
DNase I footprinting with a post-DNase I digestion strand-specific amplification 
step provides a sensitive technique for fragment detection, with a consistent 
and uniform banding pattern. However, the failure to optimise the protein-DNA 
interactions would seem to be due to the quality of the Hep NE and further work 
should be conducted using the original Dignam protocol and rat liver which may 
provide better quality and quantity of the DNA-binding proteins.
This ‘in vitro’ footprinting assay can only show the interaction between the DNA 
sequence of interest and the binding proteins that are found in the nuclear 
extract and it does not demonstrate if these potential interactions actually occur 
within the cell (Hornstra and Yang 1993). Therefore, the use of ‘in vivo‘ 
footprinting would be useful to confirm the DNA-protein interactions within the 
cells of interest. DNase I footprinting, however, may lead to a limited 
interpretation of such interactions due to protein-DNA binding in a DNase I 
poorly cleaved region such as A or T tracts (Guille and Kneale 1997). The use 
of the footprinting assay also provides only the locations of the protein-DNA 
interactions and not the identity of the specific proteins. Therefore, the 
chromatin immunoprecipitation (ChIP) assay would be a useful way to confirm 
the location and the identity of the interacting protein, especially if the protein of 
interest was potentially known (Elnitski etal. 2006).
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6.3.4. Chromatin immunoprecipitation assay
This in situ technique has become the assay of choice for fine mapping of 
transcription factors and providing an additional physiological representation of 
the events in the nucleus which are involved in DNA processing (Spencer et al.
2003). Moreover, the technique not only gives information about the protein 
bound to the DNA but also the proteins that their binding may depend on, such 
as other proteins which are not bound directly to the DNA (Shang et al. 2000). 
Although many agents could be used in the cross-linking step of this technique, 
such as methylene blue and UV, formaldehyde was chosen since it allows the 
study of both proteins that bind directly to DNA and those associated with 
chromatin via other proteins, due to its inducing both protein-DNA and protein- 
protein cross-links (Negre et al. 2006).
The ChIP assay was used in the current study to attempt to confirm the binding 
location of the DNA-binding proteins that had been identified in the PZ promoter 
by techniques such as EMSA that are less sympathetic to the chromatin 
conformation. First, the PCR amplification reactions of the DNA template of 
interest were optimised: (-13/-163) of PZ and (-222/-55) of GAPDH. It is useful 
to have the GAPDH control (Active Motif, Belgium) to be used to amplify the 
DNA region immunoprecipitated by the RNA pol II antibody (Active Motif, 
Belgium) as an indication of the optimisation of a quite technically demanding 
protocol. In spite of variation in the key amplification parameters the GAPDH 
primers failed to be optimised to amplify the proposed product (166 bp) (Fig 
6.18). Ideally a positive control should be tested with another gene promoter 
known to be bound by the proposed protein. The chromatin 
immunoprecipitated by the RNA pol II antibody amplified by the primers used to 
amplify the -13/-163 region of PZ gene promoter was used as a positive control 
since RNA pol II binding should be found in any transcribed gene. The PZ 
gene region -13/-163 was then amplified by specific primers (See Section 6.1.2) 
and optimal amplification conditions determined (annealing temperature 62.5°C  
using 1mM MgCh (Fig 6.23)). The primers amplifying the region of interest 
were then used with the DNA immunoprecipitated by the HNF4a antibody to 
confirm the binding of this protein to the region of interest, which had been 
detected in vitro by EMSA. The product amplified from the DNA 
immunoprecipitated by the HNF4a antibody was compared to the products
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amplified by the DNA immunoprecipitated with the RNA pol II antibody and the 
IgG negative control antibody as well as the input DNA (sheared, pre-cleared 
and reverse cross-linked chromatin). Although a more intense signal was seen 
from the HNF4a enriched DNA compared to the negative control, no significant 
change was observed when compared to the input DNA (Fig 6.24). Moreover, 
contamination was found in the no template PCR control. In an attempt to 
isolate the contamination the same procedure was repeated using a new aliquot 
of the 10X PCR buffer and the same results were found with contamination in 
the no template control (Fig 6.25). Again, the experiment was repeated using 
new aliquots of all reagents for the PCR. Although the contamination 
disappeared, no significant change was observed in the intensity of the product 
amplified from the HNF4a enriched DNA and the input DNA (Fig 6.26).
As other factors had been identified to potentially bind within the PZ promoter 
region additional antibody enriched templates were prepared. CREB enriched 
DNA and PEA3 enriched DNA, in addition to the HNF4a enriched DNA were 
used in a further PZ-specific PCR. CREB and PEA3 were investigated since 
these proteins were thought, to some extent, to have potential binding sites 
within the candidate region (-13/-163). However, no enrichment was observed 
with any of the samples, with signal intensity being no greater than that with the 
input DNA (Fig 6.27). Although another PCR showed DNA enrichment with 
newly prepared immunoprecipitated chromatins compared to the input DNA, the 
intensity of the bands from these enriched DNAs was found to be similar to that 
of the negative control (Fig 6.28).
The ChIP technique has been used successfully in characterising the binding of 
many transcription factors, such as the binding of estrogen receptor to estrogen 
responsive promoters (Shang et al. 2000) and the binding of thyroid hormone 
receptor to mammalian T3-responsive promoters (Sharma and Fondell 2002). 
Although the basic principle was used in the current study, this technique failed 
to characterise any protein binding to the proposed region of PZ gene promoter. 
However, the immuno-basis of this technique may indicate that the problem 
was due to the use of an inappropriate antibody. Therefore, optimisation of the 
assay using different antibodies might have given better results. However, 
further work in optimising the key parameters would provide valuable 
information about the proteins that interact with the PZ promoter sequence.
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Moreover, the end-point PCR used in the analysis of the bound DNA sequence 
by ChIP in the current study could have been replaced by real-time PCR 
(qPCR) to give more accurate quantification of the immunoprecipitated DNAs 
and, therefore, more reliable analysis (Mukhopadhyay etal. 2008).
In recent years a number of techniques have been developed to study protein- 
DNA interactions. For instance, the CHIP method to detect sequence-specific 
interactions of the bound protein and the footprinting technique in providing 
distinct results when the sequence-specific protein binding occur only in a 
certain fraction of cells, has led to a combination of these two methods as a 
developed technique to analyse protein-DNA interactions in situ within the 
nucleus (Kang, Vieira and Bungert 2002). This combination method is 
performed by immunoprecipitation of proteins by their specific antibodies 
followed by cleavage with DMSO and piperidine and analysis by LMPCR. 
Moreover, techniques such as chromosome conformation capture (3C) can be 
used to study long-range interactions of regulatory regions at the three 
dimensional level of chromatin architecture and are based on the capture of 
spatially related chromatin fragments by proximity ligation (Cullen, Kladde and 
Seyfred 1993). This can provide useful information when it is combined with 
ChIP. This ChlP-3C technique can reduce noise from non-specific interactions 
and provide important information about DNA-protein interactions and 
chromatin looping which is important for the binding of some proteins to 
mediate gene regulation (Fullwood and Ruan 2009).
The current study, therefore, attempts to take the initial data from relatively 
artificial in vitro experiments, such as EMSA, and to contextualise them. Such 
studies include the development of a new, highly sensitive footprinting 
methodology to accurately map the binding of proteins that may require 
adjacent binding site occupancy for their own binding; and the initial studies 
using ChIP to confirm protein-DNA interactions in situ within the nucleus. At the 
end of these studies both techniques do require further development and 
optimisation, but both offer the potential for relevant detailed data with regard to 
regulation of the PZ promoter.
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Chapter 7-Hormonal 
regulation and 
inflammatory response 
of the protein Z gene
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7.1. Introduction
7.1.1. Steroid hormones
Steroid and thyroid hormones are important molecules involved in many 
complex processes in the body such as cell development, differentiation and 
stimulatory response. These hormones are hydrophobic ligands for a large 
family of proteins known as nuclear receptors (Laudet et al. 1992). They act 
through binding to their respective receptors within cells and activating the 
expression of target genes (Evans 1988). In early studies this family was 
shown to have members known as orphan nuclear receptors with unknown 
ligands (Evans 1988, Moore 1990). The orphan receptors were suggested as 
the primitives of this family while the liganded receptors were considered as 
derivatives that had acquired their ability to bind ligands through the 
evolutionary process (Escriva etal. 1997).
The structure of the nuclear receptors is organised as an N-terminal domain 
with ligand-independent activation function (AF-1) (Tora et al. 1989, Metzger et 
al. 1995), a C-terminal ligand-binding domain, and a DNA binding domain 
(DBD), between the two termini, which binds to hormone response elements 
regulating expression of target genes (Khorasanizadeh and Rastinejad 2001). 
The domain in the C-terminus, known as the ligand-binding domain, has a 
complex structure including a region with a ligand-dependent activation function 
(AF-2), an interface for dimerisation and a ligand binding pocket (Steinmetz, 
Renaud and Moras 2001). The DBD, a highly conserved region among nuclear 
receptors, is composed of approximately 71 residues containing two zinc finger 
motifs matched tetrahedrally by conserved cysteines (Evans 1988, Freedman et 
al. 1988, Hard et al. 1990). The ubiquitous eukaryotic nuclear receptor proteins 
are structurally related transcription factors that bind to specific DNA cis-acting 
sequences and different coregulators, in response to binding of their respective 
ligand, and regulate the transcription of a multitude of target genes involved in 
such processes as reproduction, development, and metabolism of lipids and 
carbohydrates (Raviscioni etal. 2006, Ishizuka etal. 2005).
Many transcription cofactors, organized in multiprotein complexes, have been 
recognized as initiating chromatin remodeling and the modification of histones 
in order to expedite the binding of the nuclear receptors and RNA polymerase
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II, with basal factors, to the target DNA (Ishizuka et al. 2005). These cofactors, 
for instance CBP/P300 (Chakravarti et al. 1996), P300/CBP associated factor 
(PCAF) and general control of amino-acid synthesis 5-like 2 (GCN5) (Blanco et 
al. 1998) act as coactivators, whereas the silencing mediator of retinoid and 
thyroid receptor (SMRT) (Chen and Evans 1995) and the nuclear receptor 
corepressor (N-CoR) (Horlein etal. 1995) act as corepressors.
Activation of transcription by steroid hormone receptors can be direct through 
protein-protein interaction or indirect by synergistic action with adjacent 
transcription factors (Schule et al. 1988, Strahle, Schmid and Schutz 1988). 
Interestingly, the target DNA is found to be bent in response to the binding of 
oestrogen nuclear receptors, suggesting the change of DNA conformation upon 
binding by steroid hormone receptors plays a part in their regulatory mechanism 
(Nardulli and Shapiro 1992). This bending may play a role in stabilising the 
receptor-DNA complex by forming a dimerisation interface and also may 
facilitate the interaction between transcription factors and between transcription 
factors and the basal transcription complex.
Hormone response elements are the DNA binding sites for the hormone 
receptors and are palindromic sequences composed of two half-sites separated 
by 3 bases (Aumais et al. 1996). The oestrogen response element has the 
sequence AGGTCANNNTGACCT in the vitellogenin A2 gene of Xenopus laevis 
(Klein-Hitpass et al. 1986). However, oestrogen was found to bind imperfect 
palindromic sequences (GGTCAACATAACC) in the chicken vitellogenin gene 
(VTGII) (Burch et al. 1988). Similarly, the palindromic sequences for 
glucocorticoid binding, with a half site of AGAACA (Aumais et al. 1996), were 
found to be imperfect (TGTACANNNTGTTCT) in the rat tyrosine 
aminotransferase gene (Jantzen et al. 1987). It has been suggested that the 
two half sites are recognized by the steroid receptors as separate elements and 
that the integrity of the half sites, as well as the spacing between them, are 
critical for the binding of those receptors (Nordeen et al. 1990). Further studies 
also suggested that a widely spaced, repeated half site (RGGTCA) of the 
palindromic motifs can function as an oestrogen response element (Kato et al. 
1992, Dana et al. 1994, Kato et al. 1995). The repeated half site of the 
glucocorticoid receptor palindromic sequences (TGTTCT) was also found to be
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important for optimal glucocorticoid inducibility, independent of the other half 
site (Payvar etal. 1983, Chalepakis etal. 1988).
7.1.2. The role of steroid hormones in the regulation of protein Z and other 
coagulation factors
Recent work has suggested that PZ expression may be influenced by steroid 
hormone levels. The increased levels of testosterone, estradiol (Yoshida et al. 
1982) and androstenedione (Soldin et al. 2005, Castracane et al. 1998) 
throughout pregnancy, where PZ levels were found to be increased from the 
first trimester and returned to normal after delivery (Quack Loetscher et al. 
2005, Ramsay et al. 2005), suggest a potential role for androgen and oestrogen 
in the regulation of PZ. The level of 17-hydroxyprogesterone was also found to 
be increased after the thirty-third week of gestation (Tulchinsky et al. 1972). 
The increase of this hormone, which is produced during the synthesis of 
glucocorticoids and sex steroids, along with the increased levels of PZ during 
pregnancy (Quack Loetscher etal. 2005, Ramsay etal. 2005), also suggest the 
potential role of steroid hormones in the regulation of PZ. Moreover, the lower 
testosterone levels in women compared to men (Reckelhoff et al. 2005) which 
is mirrored by the levels of PZ (Ravi et al. 1998), in addition to the decrease in 
the amount of androgen and/or oestrogen with obesity (Mayes and Watson
2004), along with the increased levels of PZ in obese pregnant women 
compared to lean pregnant women (Ramsay et al. 2005), also suggest a role 
for the steroid hormones in PZ regulation. Furthermore, the decrease of 
androgen concentrations and the increase of PZ levels with the use of 
contraceptives (James 1993, Al-Shanqeeti et al. 2005) again support the 
putative role of the steroid hormones in PZ regulation.
In addition to the literature above which suggests the potential role of the
steroid hormones in the regulation of PZ, the effect of steroid hormones in the
regulation of FVII (Di Bitondo et al. 2002), which is suggested to be
evolutionarily related to PZ, also predicts the possibility of similar regulatory
mechanisms, such as hormonal regulation of the PZ gene. An oestrogen
response element (ORE) detected in the gene promoter of FVII was shown to
play an important role in reducing the transcriptional activity of this factor in the
presence of oestrogenic factors. Although the ORE that is found in the FVII
promoter has two half sites separated with two spacer nucleotides, which differs
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from the classical ORE which comprises two half sites separated with three 
spacer nucleotides, the binding affinity for the oestrogenic factors was 
approximately the same (Di Bitondo et al. 2002). Furthermore, the age-related 
increase in the plasma level of FIX which is also believed to have evolved from 
the same ancestral gene as PZ is likely mediated through the activation of the 
androgen response element in the promoter (Crossley et al. 1992). The 
reported role of steroid hormones in regulating expression of these 
evolutionarily related factors raises the possibility that regulatory sequences 
may also have been conserved to some degree and that, therefore, hormonal 
regulation may account for the differences in PZ expression observed between 
the sexes and the various states affecting hormone levels.
The studies described above provide a complex picture of the relationship 
between steroid hormone levels and the levels of PZ, but all indicate to some 
degree that steroid hormones have a role to play in modulating expression of 
this haemostatic factor. This leads to two possible hypotheses; the first being 
that the balance between androgen and oestrogen in favour of androgen 
causes an increase in procoagulation by increasing procoagulant and 
decreasing anticoagulant levels. Therefore, the expression of PZ, a suggested 
anticoagulant, may decrease in response to androgen and increase in response 
to oestrogen. The second hypothesis being that in this state of higher androgen 
levels the haemostatic balance is maintained, to some degree, by an increase 
in both procoagulants and anticoagulants. Therefore, the expression of PZ may 
increase in response to androgen. The subsequent studies aimed to elucidate 
the exact role of steroid hormones in controlling the expression of PZ and, 
therefore, to determine if the level of PZ may be an additional factor that may 
contribute to levels of thrombotic risk in different hormonal states.
7.1.3. Inflammatory response
The relationship between inflammation and coagulation has been well
documented, with the body having evolved a response that attempts to limit the
invasion of infectious agents or aberrant cells through the activation of
coagulation and the formation of fibrin. This response, however, must be
localised to avoid the consequences of systemic procoagulant activation (Levi,
van der Poll and Buller 2004). A variety of defence mechanisms against
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infections have been delineated; one such mechanism that responds to 
infection by gram-negative bacteria relies on the identification of an outer 
membrane endotoxin glycoprotein known as a lipopolysaccharide (LPS) 
(Schumann et al. 1990). Lipopolysaccharides are normally composed of a 
hydrophobic endotoxin, also known as lipid A, followed by a core of non 
repeating oligosaccharide, and a distal polysaccharide, also referred to as O- 
antigen (Pugin et al. 1993, Raetz and Whitfield 2002). The defence 
mechanisms initiated against the endotoxin in many mammalian cells are 
activated through a pathway that includes the LPS binding glycoprotein (LBP) 
and Cluster of differentiation 14 (CD14) glycoprotein (Tobias etal. 1995). LPS 
initiates activation in cells such as monocytes, macrophages and neutrophils by 
its binding to glycerophosphoinositol tailed CD14 found in the membrane 
(mCD14) in the presence of LBP (Schumann et al. 1990, Wright et al. 1990). 
However, in other cells that do not express mCD14, including endothelial and 
smooth muscle cells, the LBP-LPS complex binds plasma circulating CD14 
(sCD14); this complex then binds to sCD14-LPS receptors (Pugin et al. 1993, 
Loppnow et al. 1995). The effect of the endotoxin was found to be mediated by 
cytokines, such as tumour necrosis factor (Sherry and Cerami 1988) which 
upon increased secretion might cause endotoxic shock and lead to death 
(Wright et al. 1990).
7.1.4. The effect of lipopolysaccharide on protein Z levels
The levels of a number of coagulation factors have been reported as being 
responsive to inflammatory signals through modification of transcription levels. 
For instance, the transcription of factor VIII (FVIII), an acute phase coagulation 
protein mainly produced in the liver, responds to bacterial lipopolysaccharide 
(LPS) by increasing its level in human circulation. The FVIII gene promoter 
region responsible for the stimulatory effect of bacterial lipopolysaccharide 
(LPS) contains two binding sites for C/EBP(3 and one for NF-kB. Mutation 
analysis of the disrupted down stream C/EBP binding site in HepG2 cells 
reduces the response of the promoter to LPS by approximately 50%, whilst 
mutation of the NF-kB binding site completely stops LPS responsiveness. 
However, the level of mouse factor VIII was found to be unchanged in response
to inflammation. This may be explained by the functional importance of the
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highly conserved sequence (GGG), at the 5' end of the NF-kB binding site, 
which is absent in the orthologous mouse sequence (Begbie et al. 2000). The 
expression of tissue factor, the primary initiator of coagulation, is also subjected 
to induction by LPS. Tissue factor was found to be induced in monocytes by 
LPS in certain diseases causing disseminated intravascular coagulation 
(Osterud and Flaegstad 1983). The gene promoter of tissue factor has a region 
called the LPS response element (LRS) which contains transcription factor 
binding sites, one for NFkB and two for AP1 (proximal and distal) which are 
crucial for LPS activation (Mackman, Brand and Edgington 1991). Mutation in 
any of these sites compromises LPS induction. The mechanism to control 
transcription of the tissue factor gene following LPS induction includes 
proteolysis of the cytoplasmic IkBo leading to translocation of p65 and c-Rel 
from the cytoplasm to nucleus and transient phosphorylation of JunD in the 
constitutive AP1 complexes bound to the LRE (Hall, Vos and Bertina 1999).
One explanation for the wide range of variation in PZ levels among normal 
individuals is that inflammatory response may modulate levels of expression. 
Raczkowski et al. (1987) reported the correlation between the negative acute 
phase protein (APP), transferrin, and the levels of PZ in the serum of patients 
with rheumatoid arthritis, suggesting PZ may be acting as a negative acute 
phase protein (Raczkowski et al. 1987). This prediction was supported by 
another group when it was demonstrated that levels of plasma protein Z  
decrease in response to increasing levels of the cytokine interleukin 6 (IL-6) in 
patients suffering from acute leukemia and non-hodgkin's lymphoma (Undar, 
Karadogan and Ozturk 1999).
7.2. Aims
The aim of this work was to investigate the roles of steroid hormones and 
inflammatory pathways in modulating PZ expression levels and, therefore, 
potentially account for some of the wide variation in PZ levels observed in the 
normal population.
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7.3. Methods
7.3.1. Gene expression studies of the endogenous PZ gene in HepG2 cells
Prior to investigation of the importance of steroid hormones on transcription of 
the PZ gene in the HepG2 cell model, the identity of the expression plasmids 
encoding the receptors of those hormones were verified.
7.3.1.1. Verification of the expression plasmids
Prior to plasmids verification, large scale cultures of expression plasmid 
transformed E. coli were prepared and the plasmids purified and quantified (see 
section 2.4.3). The expression vector encoding the particular hormone receptor 
was digested using appropriate restriction enzymes (Fermentas life science, 
UK) (2.4.3.3) before size-fractionation through a 1% w/v 1x Tris borate EDTA 
(1x TBE) agarose gel for 45 minutes at 10 volt/cm. The sizes of the digestion 
products were determined using a one kilo base pair molecular weight ladder 
(Fermentas life science, UK). The androgen receptor expression plasmid 
(pKC3 rAR) was digested with Bglll and Hindlll; the glucocorticoid receptor 
expression plasmid (pRShGRa) was digested with EcoRI; and the oestrogen 
receptor expression plasmid (pSG5 HEO) was digested with EcoRI and Dralll. 
The expression plasmids were obtained as a gift from Dr. Peter Winship 
(Sheffield University).
7.3.1.2. RNA analyses
Total RNA was prepared from HepG2 cells after transfection with the 
expression plasmid encoding the hormone receptor and from control 
untransfected cells, using the GenElute mammalian total RNA miniprep kit (See 
Section 2.3.1). The purity and the quantity of the prepared RNA was 
determined by the NanoDrop®ND-1000 spectrophotometer and the integrity 
was assessed using a 1% w/v (1x TBE) agarose gel (see Section 2.3.2). The 
RNA was treated with DNase 1 (Sigma-Aldrich, UK) to remove any genomic 
DNA. The RNA was then reverse transcribed to cDNA (See Section 2.3.3) to 
be used in the qPCR.
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7.3.1.3. Primer efficiency
The efficiencies of the primers used in qPCR were determined, as described 
earlier (See Sections 2.3.4.1 and 4.3.2.4), by the efficiency equation;
Efficiency = -1  + 10(-1/slope).
7.3.1.4. Comparison of the HepG2 relative expression of steroid hormone 
receptors to normal liver tissue
The relative expression of androgen, glucocorticoid and oestrogen receptors 
was measured using the cDNA reverse transcribed from the RNA prepared 
from HepG2 cells and the cDNA prepared from the commercial liver tissue total 
RNA (See Section 2.4.2). The relative expression of the particular hormone 
receptors in HepG2 cells was compared to normal liver tissue after 
normalisation to the UBC reference gene.
7.3.1.5. The effect of steroid hormones on the endogenous PZ gene
The Tfx™-20 transfection reagent (Promega corporation, UK) was used for the 
overexpression of each steroid hormone receptor in HepG2 cells using 
plasmids encoding the respective receptor, according to the manufacturer’s 
instructions (See Section 2.4.4). After the one hour pre-incubation of the 
HepG2 cells with the transfection mixture containing the expression plasmids, 
the respective ligand was added and further incubated for 48 hours at 37°C and 
5% CO2 . 1x 10'8 M 17-p Oestradiol, 2.5 x 10‘8 M Dihydrotestosterone and 1x 
10‘6 Dexamethasone final concentration were added to the HepG2 culture wells 
transfected with oestrogen, androgen and glucocorticoid receptors, 
respectively. Fresh complete D-MEM phenol free medium (Invitrogen limited, 
UK) containing charcoal stripped fetal calf serum (Invitrogen limited, UK) was 
used in the transfection. The effect of the candidate hormone receptor 
overexpressed in HepG2 cells and stimulated with the respective ligand on the 
expression of the endogenous PZ gene was measured by qPCR using SYBR 
green chemistry (See Section 2.3.4.3).
Prior to performing qPCR a housekeeping gene was selected for its stability 
(See Section 2.3.4.2), after transfection the HepG2 cells with the proposed
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receptor followed by stimulation with the respective hormone, to be used as 
reference gene.
7.3.1.6. The effect of LPS stimulation on PZ transcription
HepG2 cells were stimulated with 10 pg/ml LPS from Salmonella typhimurium 
(Sigma Aldrich, UK) over a 24 hour time-course (See Section 2.4.6). The 
relative PZ mRNA expression in the stimulated sample compared to 
unstimulated sample was measured by qPCR using the SYBR green method 
(See Section 2.3.4.3).
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7.4. Results
7.4.1. Verification of expression plasmids
Digestion of the androgen receptor (AR) expression plasmid (pKC3 rAR) with 
Bglll and Hindlll restriction enzymes produced three bands of 3.5, 1.6 and 1.2 
kb. The glucocorticoid receptor (GR) expression plasmid (pRShGRa) after the 
digestion with EcoRI enzyme produced approximately 2.9, 1.7, 1.4 and 0.75 kb 
products while the products obtained from EcoRI and Dralll digestion of the 
oestrogen receptor (OR) expression plasmid (pSG5 HEO) were 1.4kb, 1.5kb, 
2.6kb, 0.3 kb. The digestion patterns for all three plasmids are shown in Fig
7.1.
4.0 kb3.0 kb
2.0 kb 
1.5 kb
1.0 kb 
750 bp
Fig 7.1. Restriction enzyme digestion of plasmids encoding steroid hormone 
receptors. Lane 1 a 1 Kb ladder. Lane 2 contains the androgen receptor (AR) 
expression plasmid after digestion with Bglll and Hindlll. Lane 3 contains the 
glucocorticoid receptor (GR) expression plasmid after digestion with EcoRI. Lane 4 
contains the oestrogen receptor (OR) expression plasmid digested with EcoRI and 
Dralll. Digestions of the AR produced 3.5, 1.6 and 1.2 kb products, GR produced 2.9, 
1.7, 1.4 and 0.75 kb products, and OR produced 1.4kb, 1.5kb, 2.6kb, 0.3 kb products.
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7.4.2. RNA analysis
The purity of the prepared RNA, as determined by the absorbance ratio 260 
nm/280 nm was found to be >1.8 by the NanoDrop®ND-1000 
spectrophotometer. The 18S and 28S ribosomal RNA (rRNA) bands on 1% w/v 
agarose gel showed no significant degradation in all samples, indicating good 
quality RNAs. The rRNA bands from untransfected and transfected HepG2 
cells with plasmids encoding the hormone receptors are shown in Figure 7.2.
1 2  3  4
Fig 7.2. Agarose gel (1% w/v) electrophoresis of total RNA prepared from control 
and expression plasmid transfected HepG2 cells. Lane 1 shows the 28S and 18S 
rRNA bands from untransfected HepG2 cells. Lane 2, 3 and 4 show the 28S and 18S 
rRNA bands from samples transfected with expression plasmids encoding the androgen, 
glucocorticoid and oestrogen receptors, respectively. No significant degradation indicated 
good quality RNAs.
7.4.3. Reference gene validation
The tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, zeta polypeptide (YWHAZ) gene showed stability of its relative
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expression, by qPCR, in untrasfected and activated AR transfected HepG2 
cells. UBC also showed stability in relative expression with and without the 
activated hormone receptor for either the glucocorticoid receptor or the 
oestrogen receptor (Fig 7.3).
B 1.2
"§ 11V)
E o 0 9 
§  §  O S
!  -S0 7$ •§ 0.6 £ »Q.'i 0 5X  r0 re 04
s 1  0.3 ? 0.2
t§ 01
Fig 7.3. Relative expression of housekeeping genes with transfection.
The chart shows stability of YHWAZ mRNA relative gene expression in HepG2 trasfected 
with androgen receptor normalised to the untransfected cells, with only negligible change 
of 2% after trasfection. UBC mRNA relative expression of glucocorticoid receptor (GR) 
transfected HepG2 cells was found to be stable compared to untransfected cells while its 
relative expression in oestrogen receptor (OR) transfected HepG2 cells was not 
significantly affected, with a change of only 6%. The horizontal thick line represents the 
levels of mRNA relative expression in untransfected cells. The results shown were from 
three independent experiments.
7.4.4. Primer efficiency
The primers used in testing the effect of the steroid hormones and in comparing 
HepG2 relative expressions of steroid hormone receptors to liver tissue were 
determined. UBC and PZ(2) primer efficiencies were previously measured (See 
Section 5.3.3.7) and found to be 95% and 98%, respectively. The YWHAZ, AR, 
GR and OR primer efficiencies were found to be 102%, 88%, 99% and 96%, 
respectively (Fig 7.4).
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Fig 7.4. Determination of the YWHAZ, AR, GR and OR primers efficiency.
The efficiency of the reference gene (YWHAZ) primers was measured by plotting the Cq 
values versus the cDNA serial dilutions. The slope was used in the efficiency equation 
(Efficiency = -1 + io ("1/slope)). The efficiency was calculated and found to be 102%, 88%, 
99% and 96% for YWHAZ, AR, GR and OR, respectively.
7.4.5. Expression of AR, GR and OR in HepG2 compared to normal liver
The expression levels of AR and OR were undetermined in HepG2 cells, 
suggesting no or very low levels of expression. The GR mRNA relative 
expression in HepG2 cells was found to be approximately 0.65-fold that of 
normal human liver (Fig 7.5).
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Fig 7.5. The relative expression of steroid hormone receptors in HepG2 cells and 
normal liver. The relative expression of AR and OR mRNA in HepG2 cells were found to 
be undetermined whilst the GR mRNA was found approximately 0.65-fold relatively 
expressed compared to liver tissue and normalised to UBC reference gene. The thick 
horizontal line represents the relative expression in liver tissue.
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7.4.6. The effect of androgen, glucocorticoid and oestrogen hormones on 
PZ transcription
Transfection of HepG2 cells with the AR followed by stimulation with the ligand 
dihydrotestosterone did not affect the relative expression of PZ mRNA. GR 
transfected HepG2 stimulated by dexamethasone showed a 1.3-fold increase in 
PZ mRNA relative expression. A 1.2-fold increase in PZ mRNA relative 
expression was observed in HepG2 cells transfected with OR and activated by 
17-p oestradiol (Fig 7.6). The results were not found to be statistically 
significant (P>0.05) using the REST 2009 software. These results were 
obtained from four, four and seven independent experiments for 
dihydrotestosterone, dexamethasone and 17-(3 oestradiol activation, 
respectively.
Unstim ulateci AR+ligand Unstimulated GR+ligand Unstimulated OR+ligand
Fig 7.6. The effect of steroid hormones on PZ mRNA levels in HepG2 cells.
The androgen hormone shows no effect on the relative expression of PZ mRNA (blue 
columns), whilst glucocorticoid and oestrogen both produce a small increase in the relative 
expression of PZ mRNA, of 1.3-fold (red columns) and 1.2-fold (yellow columns), 
respectively. The increase with both glucocorticoid and oestrogen hormones was found not 
to be statistically significant using the REST 2009 (P>0.05). The effect of androgen 
stimulations were normalised by YWHAZ, whilst glucocoticoids and oestrogen stimulations 
were normalised by UBC. These results of adrogen, glucocorticoid and oestrogen were 
obtained from four, four and seven independent experiments, respectively.
The melt curves (Fig 2.4) of the amplfication products for the experiments 
described previously showed neither non-specific amplification nor the 
formation of primer-dimers in the transfected and control samples indicating a 
reliable quantification of the respective transcripts.
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7.4.7. The effect of LPS stimulation on PZ transcription
The PZ mRNA relative expression quantified by qPCR was found to be 
decreased gradually over the first hour. Relative expression started increasing 
by 2 hours and had returned to pre-stimulation levels at four hours and 24 hours 
(Fig 7.7). Although a trend was clearly observed showing a drop in expression 
over the first hour of LPS stimulation, the results were not found to be 
statistically significant using the Kruskal Wallis test (P>0.05, n=7) (used for 
multiple time points that do not show a normal distribution).
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Fig 7.7. The effect of LPS on PZ mRNA levels in HepG2 cells.
HepG2 cells were stimulated with 10 pg/ml LPS for the times indicated. Total RNAs were 
prepared from unstimulated and the stimulated cells and the expression of PZ was 
measured at each point by qPCR. Down regulation of PZ mRNA relative expression was 
seen at 30 minutes and after one hour whilst expression started to increase at 2 hours 
and returned to pre-stimulation levels by four hours. The variation between points is not 
significant when analysed using the Kruskal-Wallis test (P>0.05, n=7)
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7.5. Discussion
A potential effect of steroid hormones in regulating PZ expression was 
suggested, as mentioned previously, from the observations of the variation in 
protein Z levels in different hormonal states such as pregnancy (Quack 
Loetscher et al. 2005, Ramsay et al. 2005), oral contraceptive use (Al- 
Shanqeeti et al. 2005) and obese and lean pregnant women (Ramsay et al.
2005). Moreover, transcriptional regulation of FVII and FIX, evolutionarily 
related genes to PZ (Ichinose et al. 1990), were found to be regulated by 
oestrogen and androgen receptors, respectively (Di Bitondo et al. 2002, 
Crossley et al. 1992). The effect of steroid hormones on the PZ mRNA relative 
expression was investigated by studying the endogenous PZ gene locus in the 
model system, HepG2 cells. Nuclear receptors (NRs) are essential for the 
cellular action of steroid hormones. These lipophilic hormones bind the C- 
terminal binding domain of the NRs, causing their nuclear translocation and 
binding to their cognate sequences (He, Cheng and Xie 2010, Germain et al.
2006). HepG2 cells, the model used in the study, were tested for their 
expression of AR, GR and OR and compared to normal liver cells. The relative 
expression of AR and OR mRNAs was undetermined in HepG2 cells, 
suggesting no or very low levels of expression whilst relative expression of GR 
mRNA was 0.65-fold normalised to UBC and normal human liver cells (Fig 7.5). 
The HepG2 cells were reported previously for their lack of OR (Harnish et al. 
1998, Barkhem etal. 2002) and AR expression (Nakagama etal. 1991) which is 
consistent with the current study. The lack of the relative expression of OR and 
AR in HepG2 cells may suggest limitations of these cells in being used as a 
model in studying the action of those steroid hormones. However, HepG2 cells 
have been used in numerous studies in order to study the effect of these 
hormones on the regulation of genes by using the transfection of the steroid 
hormone receptors (Yuen and Leung 2008, Tang, Norlin and Wikvall 2007, 
Farsetti et al. 2001, Harnish et al. 1998, Sabbah et al. 1998). Therefore, to 
monitor the regulation of the endogenous PZ by steroid hormones HepG2 cells 
were transfected by the respective hormone receptor. HepG2 cells were 
maintained in phenol free medium containing charcoal stripped fetal calf serum 
(Invitrogen limited, UK) during the process of transfection to remove any 
endogenous bovine steroid hormones that may have skewed the results (Yuen
and Leung 2008, Sabbah et al. 1998, Wiren et al. 1997). Prior to transfection, 
the identity of androgen receptor (AR), glucocorticoid receptor (GR) and 
oestrogen receptor (OR) expression plasmids were verified by restriction 
enzyme digestion and the expected digestion patterns for all three plasmids 
were observed (Fig 5.1).
The results of transfections showed that the levels of PZ mRNA relative 
expression were not affected in response to androgen, but showed a slight 
increase with both glucocorticoid (1.3 fold average) and oestrogen (average of 
1.2 fold) (Fig 5.4). The effect of the glucocorticoid (n=4) and oestrogen (n=7) 
was, however, not found to be statistically significant using the REST 2009 
software (P>0.05). UBC reference gene was used to normalise the relative 
expression with glucocorticoid and oestrogen, whilst YWHAZ reference gene 
with androgen due to their stability (Fig 7.3). The non-significant increase of 
glucocorticoid and oestrogen does not necessary exclude the biological 
significance of these hormones in the transcriptional regulation of protein Z. 
The increased levels of oestrogen and androstenedione, an intermediate in the 
production of androgen testerone and oestradiol, throughout pregnancy (Soldin 
et al. 2005, Castracane et al. 1998, Yoshida et al. 1982) may contribute to the 
high levels of PZ which were also found in pregnancy (Quack Loetscher et al. 
2005, Ramsay et al. 2005). This is consistent with the current study where 
increased levels of PZ were found in response to oestrogen. Therefore, 
although this increase was not statistically significant, it may be worth further 
analyses to determine if oestrogen levels have a biological significance in 
controlling PZ expression. Furthermore, the role of oestrogen in reducing the 
transcriptional activity of FVII in addition to its role in increasing levels of mRNA 
in the bone marrow of ovariectomized mice (Moverare et al. 2004), may be 
mirrored in oestrogen's effects on other coagulation factors including PZ.
The increased levels of the intermediate of glucocorticoid synthesis, 17- 
hydroxyprogesterone, during pregnancy (Tulchinsky et al. 1972) may also 
suggest the role of glucocorticoids in elevating PZ levels which were found in 
pregnant women. Moreover, other coagulation factors such as FVII, which are 
suggested to have evolved from the same ancestral gene as PZ, and factors 
VIII and XI have shown increased levels in humans treated with 
dexamethasone (Brotman et al. 2006). The increase of these coagulation
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factors in response to dexamethasone may support the biological effect of 
glucocorticoids on PZ which was not found to be statistically significant in the 
current study. Furthermore, the number of independent experiments (n=4) for 
dexamethasone treatment may not be sufficient to determine relatively small 
changes in expression to statistical significance.
Characterisation of the transcriptional regulation of the endogenous PZ gene, 
stimulated by steroid hormones in the HepG2 cell model, although studied in 
the context of the normal chromatin structure, is still considered to be in vitro. 
Therefore, further studies using animal models may give more reliable results. 
Also, as described in the introduction to this chapter there is some evidence to 
suggest that PZ may be an acute phase protein. In this study the induction by 
LPS of the HepG2 endogenous PZ gene was analysed over a 24 hour period. 
The levels of PZ mRNA decreased in response to LPS by 30 minutes and 
reached a minimum level at one hour exposure. The PZ mRNA levels had 
increased by 2 hours and reached pre-stimulation levels by four hours. 
However, the results were not found to be statistically significant using the 
Kruskal Wallis test (P>0.05, n=7). The response of PZ to LPS was found to be 
similar to the time course response of other coagulation factors to LPS. For 
instance, tissue factor, which was suggested as an acute phase protein, had 
expression induced by LPS stimulation at time points of 30 minutes and 1 hour 
and started to return back to normal levels at a time point of 2 hours (Hall, Vos 
and Bertina 1999), which mirrors the response of PZ to LPS in this study, 
suggesting PZ may also be an acute phase protein. In addition, plasma PZ 
levels have been shown to be decreased in response to increasing levels of IL- 
6 (Undar, Karadogan and Ozturk 1999). Raczkowski has also suggested PZ 
behaves as a negative acute phase reactant (Raczkowski et al. 1987). These 
previous studies and the results from this study suggest that PZ may be a 
negative acute phase protein but confirmatory studies to statistical significance 
should be carried out.
7.6. Conclusion
It can be concluded that, although the expression data of the endogenous PZ 
gene in HepG2 cells demonstrated no statistically significant effect with
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glucocorticoid (P>0.05, REST 2009, n=4) or oestrogen (P>0.05, REST 2009, 
n=7) hormones and inflammatory mediators (P>0.05, Kruskal Wallis test, n=7), 
the trend of PZ expression in response to these signalling mechanisms 
correlates with previous studies of PZ levels in various hormonal and 
inflammatory states. Furthermore, the limitations of the model system may 
account for effects that did not produce significant results in culture, but that do 
have a biological significance; with the time-course of LPS induction showing a 
high degree of correlation to predicted response profiles for other acute phase 
proteins.
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Chapter 8-Discussion 
and future work
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8.1. Discussion
The levels of plasma PZ are found to be highly variable among normal 
individuals (Miletich and Broze 1987). This wide variation in PZ levels may be 
explained, in part, by inter-individual differences in the rate of transcription from 
the PZ gene.
8.1.1. The role of HNF4 in regulation of PZ transcription
The HNF4a transcription factor was found to play a major role in the expression 
of a number of blood coagulation factors, such as, FVII, FVIII, FIX, FX and FXI 
(Stauffer et al. 1998, Figueiredo and Brownlee 1995, Reijnen et al. 1992, Miao 
et al. 1992, Tarumi et al. 2002). Moreover, although the mechanisms by which 
transcription of the PZ gene is regulated have not been defined in detail, a 
recent study by Sugawara and colleagues in 2007 looked at the role of HNF4a 
in controlling PZ transcription using protein-DNA binding studies (EMSAs) and 
reporter gene assays (Sugawara et al. 2007). Therefore, the role of HNF4a in 
PZ transcriptional regulation is defined in the current study using EMSAs and 
utilising the endogenous PZ gene locus rather than a reporter gene construct. 
EMSAs using probes containing the hypothetical proximal binding site for 
HNF4a (pPZHNF4a), identified by bioinformatic analysis (-48/-38), showed 
specific protein binding as the binding was negligibly competed by a 100X fold 
excess of either HNF3B (9%), AP1 (17%) or SP1 (21%) consensus binding 
sites (non specific competitors), but was considerably diminished by a 100X 
excess of self competitor (60%) and abolished by a 100X fold excess of an 
HNF4a consensus binding site (100%) (Fig 4.2). These data suggest that the 
bound protein is HNF4a. To confirm this, an HNF4a antibody was used to 
confirm the identity of the bound protein. The addition of the antibody caused a 
loss of shifted complex and retention of fluorescent signal within the well of the 
gel, suggesting creation of a DNA-protein-antibody complex that was too large 
to efficiently migrate through the gel matrix (Fig 4.4). This was confirmed by the 
greatest fluorescence intensity shown (3.7-fold more) in the well containing the 
antibody compared with the other wells. This positive result and the mobility 
pattern of the HNF4a antibody-protein-DNA complex were confirmed by another 
EMSA using the HNF4a antibody with HNF4a binding site consensus as a 
probe (Fig 4.5). These results seem to confirm the binding of HNF4a to the PZ
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gene promoter region between -48 and -38, which is consistent with the 
reported binding region for HNF4a in the PZ gene promoter reported by 
Sugawara and colleagues which was between -70 and -30 relative to the 
translation initiation site (Sugawara et al. 2007).
A second hypothetical binding site for HNF4a (-310/-300) in the PZ promoter, 
more distal to the translation start site, and again identified by bioinformatic 
analysis, was also explored by EMSA. A probe containing this hypothetical 
distal binding site (dPZHNF4a) showed protein binding. The bound protein 
showed a specificity to the hypothetical dPZHNF4a site since it was not 
competed with up to a 200- fold excess of either HNF4a or AP1 binding site 
consensus sequences (Fig 3.3). However, these results indicated that the 
hypothetical dPZHNF4a was not bound by the HNF4a transcription factor.
The binding of a transcription factor to a binding site, however, does not always 
correlate to a regulatory interaction, since transcription factors in eukaryotes 
have been reported to bind spurious binding sites without causing a functional 
effect (Wunderlich and Mirny 2009). These spurious sites were expected, using 
information theory and simulations, to be between 104 and 106 per genome and 
arise every four kb by chance. Moreover, the widespread binding of 
transcriptional regulators found genome-wide using ChlP-chip experiments also 
suggests that many of these interactions may be nonfunctional and occur by 
chance (Harbison et al. 2004). Furthermore, the use of in vitro EMSA is not 
ideal for the detection of regulatory protein-DNA binding regions (Heilman and 
Fried 2007). The naked DNA which is used in EMSA lacks its chromatin 
context that works in vivo as a barrier for the accession of transcription factors 
to their potential binding sites (Demeret, Vassetzky and Mechali 2001). The 
role of HNF4a was, therefore, confirmed by studying the transactivation of the 
endogenous PZ gene in HepG2 cells in response to overexpression and 
knockdown of this regulatory protein. Transfection of an HNF4a expression 
plasmid into HepG2 cells has been used to study the role of this transcription 
factor in transcriptional regulation of many genes, including coagulation factors 
(Solaas et al. 2010, Pineda Torra et al. 2002, Greenberg et al. 1995, Reijnen et 
al. 1992).
The study of the endogenous PZ gene showed that the levels of PZ mRNA 
increased 2.5 fold (P<0.05, n=6) by overexpression of HNF4a in HepG2 cells
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(Fig 4.11). Increased transcription of HNF4a was not quantified, due to the 
presence of the expression plasmid, however, the significant effect of the 
presence of the HNF4a expression plasmid on PZ transcript levels suggests 
that functional protein was produced. The HNF4a transactivation of the PZ 
gene was confirmed by knockdown experiments using smart pool siRNAs. The 
knockdown of HNF4a mRNA relative expression to an average 40% (~ 2.5 fold 
decrease) (Fig 4.14), using the smart pool siRNA, decreased the relative 
expression of PZ mRNA (Fig 4.15) to approximately 36% (~ 2.8 fold decrease). 
These data for endogenous PZ gene transactivation by HNF4a, determined by 
qPCR, were found to be statistically significant (p value < 0.05, n=6).
Off-target silencing of unrelated mRNAs containing limited complementary 
sequence to the targeting siRNA has been reported (Jackson et al. 2003, 
McManus and Sharp 2002). However, Smart pool siRNAs which were used in 
the current study, contain four predesigned siRNAs with lower concentrations 
(pooling strategy) targeting one gene to minimise these off-target silencing 
effects (Dharmacon Technologies Literature) and have been used extensively 
and successfully to study transcriptional regulation of many genes (Danes et al. 
2008, Kwei et al. 2008, Hariparsad et al. 2009, Taniguchi et al. 2009, Rizzo et 
al. 2010, Lahkim Bennani-Belhaj etal. 2010).
The role of HNF4a in the transcriptional regulation of PZ was reported by 
Sugawara et al. (2007). However, the role was determined by in vitro EMSA 
analysis and reporter gene assays where synthetic naked supercoiled DNA, 
lacking its chromatin context, was used. Taken together the in vitro protein- 
DNA binding experiments and analysis of the transcriptional strength of the 
endogenous gene within its chromatin environment in response to HNF4a in 
this current study seem to confirm the crucial role of HNF4a transcription factor 
in PZ gene regulation.
Other coagulation factors such as factor VII and factor IX, which are suggested 
to have evolved from the same ancestral gene as PZ (Ichinose etal. 1990) and 
have a similar tissue-restricted expression profile, have also been found to be 
regulated by HNF4a using protein-DNA interaction and reporter gene assays 
(Stauffer et al. 1998, Reijnen et al. 1992). A role for HNF4a was also reported 
in the regulation of the coagulation factor XI (Tarumi etal. 2002). The data from 
the current study supported the importance of HNF4a in controlling the
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expression of PZ in a tissue-restricted manner, and mirror the regulatory 
mechanisms of other coagulation proteins that are also expressed 
predominantly in the liver.
8.1.2. The role of PEA3 and Ets 1 in the PZ regulation
Age-stable transcriptional regulatory elements (ASEs) have been reported in 
the promoter regions of both the human FIX and PC genes. Competition EMSA 
experiments indicated that these c/s-regulatory elements were bound by PEA3, 
a member of the Ets family of transcription factors (Kurachi et al. 1999, Zhang, 
Kurachi and Kurachi 2002). However, further study revealed that the protein 
bound to the ASE in the FIX promoter was in fact Ets1 (Kurachi et al. 2009). 
Since members of the Ets family are detected in many cell types and their DNA 
binding site core consensus sequence is common, their specific binding to 
particular target sequences has been difficult to characterise (Spyropoulos et al. 
2000). Proteins of this family show a structural similarity with a homology of 
95%, 85% and 50% in the Ets domain, acidic domain and carboxyl-terminal tail, 
respectively (de Launoit etal. 1997).
Due to the level of homology between PZ and FIX and PC, some degree of 
common evolutionary ancestry is suggested (Ichinose et al. 1990, Fujimaki et 
al. 1998) and may also be reflected in the regulatory mechanisms controlling 
their expression. Therefore, the PZ promoter was studied for the presence of 
similar PEA3 and/or Ets1 c/s-regulatory elements. Bioinformatic analysis 
(ALGGEN-PROMO) of the PZ promoter sequence identified two age-stable-like 
elements that showed close homology to the age-stable elements found in the 
human FIX (hFIX) and PC (hPC) gene promoters. These two elements in the 
PZ promoter, referred to as the proximal PZ ASE (pPZ ASE (-114/-108)) and 
the distal protein Z ASE (dPZ ASE (-816/-810)), were analysed for protein 
binding using EMSA analysis in the HepG2 cell model. EMSAs showed protein 
from the HepG2 NE binding to both ASEs. Competitive EMSA suggested 
specificity of the protein bound to both pPZ and dPZ ASEs since no competition 
of the bound protein was seen with a 200-fold excess of unlabelled non-specific 
competitors (AP1 and HNF3B binding site consensuses) (Fig 5.3 and 5.5). The 
bound protein was, however, strongly competed with a 200-fold excess of the 
unlabelled PEA3/Ets1 binding site consensus, with a 4-fold decrease in the
intensity of the pPZ ASE complex 1 and loss of complex 2, and a 6-fold
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decrease of the dPZ ASE complex 1 and loss of complex 2. These data are 
consistent with the previous studies on the ASEs of the evolutionary related 
genes, hFIX and hPC (Kurachi et al. 2009, Zhang, Kurachi and Kurachi 2002). 
Although, Kurachi etal. (2009) stated that Ets1 binds only to the DNA sequence 
G/CAGGAAG, this DNA binding sequence was found to be bound by PEA3 in 
the polyomavirus enhancer (Martin etal. 1988) and also suggested to be bound 
by PEA3 in a study of the DNA binding specificity of PEA3 using nuclear extract 
from mouse FM3A cells and bacterial extract (Xin et al. 1992). Moreover, the 
Ets 1 protein was also found to bind AGAGGATGTG in the T-cell receptor a 
gene enhancer (Ho et al. 1990) and GCA/CGGAAGT in the stromelysin 
promoter (Wasylyk et al. 1991), which are both different from the Ets1 binding 
sequence seen in the hFIX promoter (Kurachi etal. 2009).
The protein bound to dPZ ASE was also found to be strongly competed (7-fold 
decrease) with a 200-fold excess of the pPZ ASE, suggesting the same protein 
binding to both sites (Fig 5.5). However, the protein bound to the pPZ ASE 
showed a negligible competition with the dPZ ASE, with only a 1.1-fold and 1.2- 
fold decrease of the binding of complex 1 and complex 2, respectively (Fig 5.3). 
Further bioinformatic analysis of the region spanning the pPZ ASE revealed a 
hypothetical binding site for CREB located in this region. The site overlaps with 
the putative PEA3 site, sharing two base pairs. Competitive EMSA using the 
probe spanning the pPZ ASE showed relatively strong competition with a 100- 
fold excess of the CREB binding site consensus compared to negligible 
competition with a 100-fold excess of non-specific competitors (AP1 and SP1) 
(Fig 5.4), suggesting the protein bound to the region flanking the pPZ ASE may 
be CREB. However, a study found that a mutated CREB binding site 
consensus competed the protein bound to the probe flanking this region 
(Sugawara et al. 2007). The mutation in the CREB binding site consensus 
used in Sugawara’s study, AC to TG, was in two highly conserved bases 
(TFSEARCH) and, therefore, suggested that the protein bound to this region 
may not in fact be CREB.
To specifically identify whether the protein bound to the pPZ ASE was PEA3, 
Ets1 or CREB, antibodies raised against these proteins were used in supershift 
EMSA analyses. The results (Fig 5.8, Fig 5.9 and Fig 5.10) indicated that the 
protein bound to the pPZ ASE-like elements did not interact with any of these
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antibodies, although a decrease in the intensity of the protein-DNA complex 
was shown in the presence of the PEA3 antibody (Fig 5.8). However, the use 
of PEA3 and CREB in supershift analyses with their respective binding site 
consensus probes could not be optimised for protein-antibody interactions (See 
Section 3.3). The results from the supershift analyses with the PEA3 and 
CREB binding site consensus sequences suggest the lack of a supershift was 
due to the lack of antibody binding and did not necessarily indicate that the 
protein bound to the pPZ ASE was something other than PEA3, since 
competitive EMSA showed a very strong competition of the bound protein with 
the PEA3 binding site consensus.
Supershift EMSA analyses for the dPZ ASE probe were also performed using 
the PEA3 and Ets1 antibodies (Fig 5.11). The results again did not show an 
interaction of the PEA3 with the dPZ ASE probe, however, the intensity of the 
protein-DNA complex increased 4-fold in the presence of the Ets1 antibody. 
Kurachi et al. (2009) reported that the interaction of the Ets1 antibody with the 
ASE in the hFIX promoter, in supershift EMSA, was shown by a dramatic 
increase in the intensity of the protein-DNA complex without shift in the position 
of the complex (Kurachi et al. 2009), which was consistent with and supports 
the results of the Ets1 supershift EMSA in the current study.
Bioinformatic analysis identified other hypothetical binding sites for PEA3 
spanning the regions -1190 to -1184 (PZPEA3(1)) and -1219 to -1214 
(PZPEA3(2)) relative to the translation start site in the PZ gene promoter. 
These two regions showed DNA-protein interaction using EMSAs. These 
complexes, however, showed no specific binding as they were competed with 
both PEA3 and AP1 consensus sequences (Fig 5.6 and Fig 5.7).
To further confirm these findings 'in cell' PEA3 and CREB were studied for their 
role in the transactivation of the endogenous PZ gene within its chromatin 
context. The overexpression of PEA3 in HepG2 cells increased the relative 
expression of PZ mRNA 1.9 fold, suggesting a role for this protein in the control 
of transcription of PZ, either directly or indirectly. This increase of PZ mRNA 
relative expression, which was determined by qPCR, was found to be 
statistically significant (P<0.05, n=6). The introduction of foreign DNA in the 
transfection may cause an off-target effect on the expression of the gene of 
interest. Therefore, the pCATOO plasmid was transfected into the HepG2 cells
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using the Tfx-20 transfection reagent, which was used throughout the current 
study and has been used successfully in the transfection of HepG2 cell to study 
gene transcription (Dongol et al. 2007). The transfection of pCATOO was found 
to have no effect on the expression of PZ mRNA (Fig 4.12), and therefore, 
confirm that the increase in the relative expression of PZ mRNA was due to the 
overexpression of PEA3 rather than a non-specific effect of transfecting plasmid 
DNA. The increase in PZ mRNA suggests a transactivational role for PEA3 in 
PZ expression. The upregulatory effect of PEA3 has previously been reported 
on many genes, such as, vimentin in mammary epithelial and tumour cells 
(Chen et al. 1996) and human transmembrane mucin mRNA in Pancreatic 
cancer cells (Fauquette et al. 2005). The relatively moderate increase of PZ 
mRNA in response to PEA3 overexpression, although it is statistically 
significant, may, however, be due to the very high baseline levels of PEA3 
mRNA in HepG2 cells masking the true transactivatory effect of this protein on 
PZ gene transcription. The high levels of PEA3 in HepG2, which were found to 
be 1767-fold that of normal human liver cells (Fig 5.20), may already exceed 
the effect threshold on the PZ promoter. The high level of PEA3 mRNA in 
HepG2 cells compared to that in normal liver tissue may reflect the role of this 
protein in the progression of tumours, since it is expressed in many cancerous 
cells (Higashino etal. 1993, Davidson etal. 2003, Shepherd etal. 2001). 
Knockdown of PEA3 was performed in HepG2 cells, using a smart pool siRNA, 
to confirm its role in the transactivation of PZ transcription The knockdown of 
PEA3 , although the relative expression of PEA3 mRNA was reduced 80%, was 
not statistically significant (P=0.1, n=5). Moreover, the mean change in PZ 
expression upon PEA3 knockdown was also not statistically significant (P=0.5, 
n=6).
The knock down of CREB in this study, using small interfering RNA (siRNA) 
techniques, showed an increase in the PZ mRNA by 1.4 fold (Fig 5.19) in 
response to a 75% reduction of CREB mRNA (Fig 5.18). The reduction of the 
CREB mRNA by the siRNA was found to be statistically significant (P<0.05„ 
n=7). However, the effect on the PZ mRNA was not found to be statistically 
significant (P=0.2,n=7). CREB was previously reported to repress the 
transcription of both the fos (Ofir et al. 1991) and c-jun promoters (Lamph et al. 
1990). Moreover, the levels of CREB mRNA in liver tissue were found to be
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half those found in HepG2 cells (Fig 5.20). Therefore, the knockdown of CREB 
in HepG2 may not have been significant enough to show its maximum effect on 
the levels of PZ mRNA. This hypothesis may explain the relatively small 
increase in PZ mRNA levels as a result of the CREB knockdown. The siRNA 
used to knockdown CREB, although designed for high potency and specificity 
(Applied Biosystems, UK), is only a single sequence, and therefore, targeting 
one region of the mRNA. The use of multiple separate siRNAs, targeting 
discrete regions of the mRNA, can help to eliminate off-target knockdown 
effects which may occur using individual siRNAs (Saxena, Jonsson and Dutta 
2003). The fact that an individual siRNA was used in the transfection, rather 
than a pool of siRNAs increases the possibility of off-target silencing. 
Therefore, off-target silencing of another protein, in addition to CREB, which 
has an upregulatory effect on the PZ gene, may be a potential, if remote, cause 
of the non-significant down regulatory effect of CREB on PZ mRNA relative 
expression. The expression of CREB is fairly common across different tissues, 
including the liver (Yanai et al. 2005), but its regulatory role has not been 
reported with any other coagulation factors; therefore, it may not be involved in 
the regulation of PZ gene expression. However, more techniques, such as, 
transactivation by CREB overexpression could be done to confirm any role for 
CREB in the regulation of PZ gene expression.
8.1.3. Hormonal regulation and inflammatory response of the PZ gene
One possible source of variation in transcription levels of PZ might be as a 
result of transcriptional modifiers such as inflammation and/or response to 
hormones. The modulation of PZ gene expression by steroid hormones was 
predicted by a number of studies such as the reported high levels of PZ during 
pregnancy (Quack Loetscher et al. 2005, Ramsay et al. 2005), with the use of 
oral contraceptives (Al-Shanqeeti et al. 2005), and in obese pregnant women 
(Ramsay et al. 2005). Review of the literature mentioned above and in chapter 
seven suggests two possible models of steroid hormone regulation of PZ 
expression. Firstly, that upon higher levels of androgen/lower levels of 
oestrogen the expression of PZ, as a suggested anticoagulant, decreases, 
shifting haemostasis to a procoagulant state. Alternatively, with higher levels of 
androgen/lower levels of oestrogen PZ expression may increase to maintain the
haemostatic balance with an increase observed in both procoagulant and
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anticoagulant activity. The effect of steroid hormones on PZ was, therefore, 
studied in the current study by stimulation of the HepG2 cells by the candidate 
hormone after overexpression of the respective receptor. The HepG2 cells 
were tested for their expression of the proposed receptors of steroid hormones 
compared to normal human liver tissue. The relative expression of GR mRNA 
in HepG2 was found to be 65% compared to its relative expression in the 
normal liver tissue, while no expression of AR mRNA or OR mRNA was 
detected in HepG2, which is consistent with previous studies (Harnish et al. 
1998, Barkhem etal. 2002, Nakagama etal. 1991). The lack of these receptors 
might suggest that HepG2 cells are not the appropriate model to study the 
effect of oestrogen and androgen on PZ gene transcription. However, studies 
to investigate the effect of androgen and oestrogen on the transcriptional 
regulation of genes in the HepG2 cell model, after the transfection of their 
receptors, have been reported previously in many studies (Yuen and Leung 
2008, Tang, Norlin and Wikvall 2007, Farsetti et al. 2001, Harnish et al. 1998, 
Sabbah et al. 1998). In the current study, AR, GR and OR were overexpressed 
in HepG2 cells (See Section 2.4.4) using the respective expression plasmids 
and stimulated by Dihydrotestosterone, Dexamethasone and 17 [3-estradiol, 
respectively.
In the current study, steroid hormones were found to have no significant effect 
on the expression of the endogenous PZ gene in HepG2 cells at the level of 
transcription. Stimulation with steroid hormones after the overexpression of 
their receptors in HepG2 cells resulted in no effect on PZ mRNA relative 
expression in response to androgen (n=4), a 1.3 fold average (n=4) increase in 
response to glucocorticoid and a 1.2 fold average (n=7) increase in response to 
oestrogen using qPCR (Fig 7.6). The modest increase of PZ mRNA in 
response to glucocorticoid and oestrogen was not found to be statistically 
significant (P>0.05). However, these small, if non-significant increases, when 
taken together with the data on PZ levels in different hormonal states, may still 
suggest a role for oestrogen and glucocorticoid hormones in regulating PZ 
transcription. The increased levels of 17 (3-estradiol and androstenedione 
throughout pregnancy (Soldin etal. 2005, Castracane etal. 1998, Yoshida etal. 
1982) may contribute to the high levels of PZ reported in pregnancy (Quack 
Loetscher et al. 2005, Ramsay et al. 2005). This is consistent with the current
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study where increased levels of PZ were found in response to oestrogen, 
although the data was not statistically significant. Furthermore, oestrogen plays 
a role in reducing the transcriptional activity of FVII (Di Bitondo et al. 2002) and 
FV with increased levels of FV mRNA observed in the bone marrow of 
ovariectomized mice after long term treatment with 17(3-estradiol (Moverare et 
al. 2004). These studies demonstrated that oestrogen is involved in regulating 
the expression of coagulation factors with some degree of homology to PZ and 
it is therefore possible that similar regulatory mechanisms controlling 
expression may be present in the PZ promoter. The lack of statistically 
significant results may be due, to some extent, to the number of samples used 
(n=7) which could be considered as relatively small given the small increase in 
PZ mRNA relative expression (1.2-fold). Moreover, the efficiency of the 
transfection, which was not quantified, may also contribute to the small effect on 
PZ mRNA relative expression and, therefore, to the lack of statistical 
significance.
17-hydroxyprogesterone is produced during glucocorticoid synthesis with levels 
increasing during pregnancy (Tulchinsky et al. 1972). As PZ levels increase 
during pregnancy and a modest, if non-significant increase in PZ mRNA is 
observed in the current transfection data, a role could be suggested for 
glucocorticoids in elevating PZ levels in pregnant women. Moreover, other 
coagulation factors such as FVII, which are suggested to have evolved from the 
same ancestral gene as PZ, in addition to FVII I and XI, have all been shown to 
increase in humans treated with dexamethasone (Brotman et al. 2006). The 
increase of these coagulation factors in response to dexamethasone may also 
suggest a biological effect of glucocorticoids on PZ which in the current study 
were not observed to be statistically significant. Furthermore, the relatively 
small number of samples (n= 4) used to determine the effect of glucocorticoid 
on PZ may contribute to the lack of statistical significance.
Another transcriptional modifier which may have a role in the wide range of 
variation in PZ levels among normal individuals could be the effect of the 
inflammatory response on this protein. The gene transcription of acute phase 
proteins contributes to most of the increase or decrease of their biosynthesis 
(Steel and Whitehead 1994). The role of inflammation in modulating the level of 
expression of PZ was suggested by Raczowski and colleagues when they
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found a strong correlation between the levels of this protein with the negative 
acute phase protein, transferrin in the serum of patients with rheumatoid 
arthritis (Raczkowski et al. 1987). The decrease in plasma PZ levels in 
response to increasing levels of interleukin-6 (IL-6) in acute leukaemia and non- 
Hodgkin’s lymphoma (Undar, Karadogan and Ozturk 1999) also suggested that 
PZ may be a negative acute phase protein. IL-6 has been found to regulate 
genes of many acute phase proteins (Baumann and Gauldie 1994) and causes 
thrombotic diathesis, by increasing the fibrinogen levels in plasma in humans 
with inflammation (Undar, Karadogan and Ozturk 1999). Moreover, other 
coagulation factors have been reported as acute phase proteins such as TF 
and FVIII, due to their induction by LPS in monocytes and in the human blood 
circulation, respectively (Hall, Vos and Bertina 1999, Begbie et al. 2000), 
raising the possibility that PZ, as a component of the coagulation system, may 
also be an acute phase protein.
LPS is an outer membrane endotoxin glycoprotein which upon detection 
triggers a defence mechanism in both vertebrates and invertebrates (Schumann 
et al. 1990). This endotoxin stimulates mononuclear phagocytes to produce 
cytokines that are important in the inflammatory response and initiation of the 
immune system (Herrmann and Mertelsmann 1989). LPS was tested for its 
effect on the transcriptional regulation of the endogenous PZ gene in HepG2 
cells (See Section 2.4.6). Stimulation of HepG2 cells with bacterial (Salmonella 
typhlmurlum) LPS (10pg/ml) for 30 minutes was found to decrease the levels of 
PZ mRNA. The levels of PZ mRNA were further reduced at the 1 hour time 
point, suggesting that PZ may be a negative acute phase protein. The levels of 
PZ mRNA increased at 2 hours of stimulation and had returned to normal by 4 
and 24 hours (Fig 7.7). Although the time course profile of the change in 
expression mirrors that of other acute phase proteins the changes in PZ mRNA 
were not found to be significant by. the Kruskal Wallis test (P>0.05, n=7). A  
bidirectional relationship has been reported between inflammation and 
coagulation. This relationship is exemplified by the activation of the coagulation 
system by inflammation and the effect of coagulation on the inflammatory 
response (Levi, van der Poll and Buller 2004). The effect of coagulation on 
inflammation was, for instance, shown by the anti-inflammatory effect of 
activated protein C. Deletion of one allele in the protein C gene in mice was
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shown to increase the levels of circulating proinflammatory cytokines (Levi, de 
Jonge and van der Poll 2001). The induction of TF and FVII I by LPS and the 
reduction of PZ levels by increasing levels of IL-6, as mentioned above, also 
show the inflammatory effect on the coagulation system. The effect of LPS on 
PZ in the current study shows a similar pattern of regulation to that shown by 
TF (Hall, Vos and Bertina 1999). TF, which was suggested to be an acute 
phase protein, was induced by LPS stimulation at 30 minute and 1 hour and 
started to return back to normal after 2 hours. This time course effect correlates 
with the response of PZ to LPS in this study in which PZ decreased at time 
points 30 minutes and 1 hour and started to return back to normal after 2 hours. 
The increase of TF and the decrease in PZ in response to LPS correspond to 
TF's role as a procoagulant and PZ's suggested role as an anticoagulant. 
Therefore, the results from the current study, although not statistically 
significant, still maintain the possibility that PZ may be a negative acute phase 
protein.
The current state of knowledge regarding the transacting factors that bind cis- 
regulatroy elements within the PZ gene promoter and may regulate gene 
transcription is summarised in Fig 8.1.
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Fig 8.1. Transcription factors and proteins binding sites in the human protein Z 
gene promoter. The binding sites are defined in relation to the translation start site. 
Blue circles represent previously reported transcription factor binding sites, including the 
HNF4a site which has been confirmed in the present study. Red circles are binding sites 
that have been identified in the current study, to be bound by specific proteins.
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Although the current study has provided new information and corroborative 
evidence regarding the transcriptional regulation of PZ, such as the contribution 
of HNF4a to controlling the liver-restricted expression profile, all the techniques 
used are considered as in vitro and may not accurately represent the in vivo 
situation. For instance, EMSA, which was used extensively in the current study 
to define protein-DNA interactions, was performed using synthetic probes 
interacting with the nuclear proteins extracted from a liver carcinoma cell line 
(HepG2). This may affect the accuracy of the specific protein binding, since 
these probes lack the in vivo barrier for the accession of transcription factors 
represented by the chromatin context (Demeret, Vassetzky and Mechali 2001). 
Nor do isolated sites allow the synergistic interactions of adjacent bound factors 
EMSA is also not able to define the location of protein binding (Carey and 
Smale 2001) without initial information based on in silico analysis or previous 
studies reported in the literature. The footprinting assay is one of the 
techniques which may overcome some of these limitations by allowing a greater 
proportion of promoter sequence to be analysed for binding site occupancy. A 
new development of this assay with a greater degree of sensitivity was 
performed in the current study, although optimisation of the DNA-protein 
interaction remains to be completed.
The nuclear extract which was used throughout this body of work was prepared 
from a cell line (HepG2 cells) which is genetically modified, and therefore, the 
protein constitution of the nuclear extract in HepG2 is different from that of 
normal liver cells. The variation in the protein constitution, which was confirmed 
in this study (Fig 4.16, Fig 5.20, Fig 7.5), may have contributed to the difficulties 
in the optimisation of the antibody-protein interaction in some supershift EMSAs 
using binding site consensus sequences as well as protein-DNA binding in the 
footprinting assay. However, the footprinting assay is not able to identify the 
protein bound to the DNA. Therefore, the footprinting assay is mainly used to 
define the location of protein-DNA interaction sites as a first step to studying 
transcriptional regulation of a gene and the protein binding to the DNA can be 
identified by other techniques, such as the supershift assay which was used in 
the current study. The identity of the bound protein could also be identified 
using other techniques, such as the chromatin immunoprecipitation assay 
(ChIP). This assay is more relevant in a cellular context than the supershift
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assay since it is used to define the identity of the bound protein in the chromatin 
context. The assay was performed in this study to confirm and identify of 
proteins found to bind specifically regions of the PZ gene promoter by EMSA; 
however, the optimisation of the assay remains to be completed.
Finally, transient transfection of HepG2 cells which has been used extensively 
in the study of transcriptional regulation of many genes (Cereghini 1996) was 
also used in the current study. The data of gene expression studies of the 
HepG2 endogenous PZ gene, in this study, by overexpression and knockdown 
of the candidate protein using qPCR showed the role of both PEA3 and HNF4a 
in the transcriptional regulation of PZ. These data, refer, of course, to the 
relative expression of mRNA rather than protein levels, and therefore, it would 
be prudent to substantiate these findings in the future by techniques such as 
western blotting or ELISA to define protein levels. Moreover, the efficiency of 
transfection in order to investigate the effect of the overexpressed candidate 
protein was not determined in this study and, therefore, the non-significant data 
obtained from the overexpression technique, such as, with the steroid hormone 
receptors, may lack significance due to inefficient transfection and, therefore, 
overexpression in a small percentage of cells. qPCR was used to monitor the 
efficiency of transfection, however, the efficiency of the overexpression was not 
quantified due to the presence of the expression plasmid in the reverse 
transcriptase negative control. Many other techniques to monitor the 
transfection efficiency which were reported previously, such as, the use of the 
green fluorescent protein (Moore et al. 2010, Tang et al. 2009, Moede et al. 
2001, Ha et al. 1996) and the use of the beta glycosidase enzyme (Sun, Zhang 
and Zhang 2004, Bode et al. 2001) could have been used to confirm whether 
the steroid hormones investigated in this study have an effect. However, the 
efficiency of the transfections for the other investigated proteins, HNF4a, PEA3 
and CREB was suggested by the positive effect of the candidate protein on the 
endogenous PZ and/or confirmed by qPCR of the silenced protein using 
siRNAs.
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8.2. Conclusion
It can be concluded from the data shown in this thesis that HNF4a is able to 
bind to the PZ gene promoter and has an upregulatory role in the expression of 
the PZ gene when assessed in the model system HepG2. The binding of this 
transcription factor was shown between -48 and -38 of the promoter by 
competitive EMSAs and supershift assay while its role in the regulation of the 
endogenous PZ gene was confirmed by both overexpression (P<0.05, n=6) and 
knockdown (p value < 0.05, n=6) techniques. Another region (-310/-300), 
which by in silico prediction was expected to be bound by HNF4a, was found to 
be bound specifically by a protein using EMSA. However, competitive EMSA 
indicated that the protein bound to this region was not HNF4a.
Other proteins were also detected to bind specifically to regions within the PZ 
promoter. An initial hypothesis suggested that two of these regions (pPZ ASE 
and dPZ ASE) could have been PEA3 or Ets1 binding sites which are similar to 
those found in other conserved factors. Competitive EMSA initially indicated 
that both regions were bound by PEA3 or Ets1. Moreover, the protein bound to 
dPZ ASE (-816/-810) was identified as Ets1 using the supershift assay.
Further study using competitive EMSAs suggested that a region spanning the 
pPZ ASE (-120/-101) could have been a CREB binding site. The protein bound 
to this region was found to be competed by CREB, however, the identity of the 
bound protein is still not confirmed, although a study by Sugawara (Sugawara 
et al. 2007) in the same region, using a mutant CREB binding site consensus, 
suggested it is not CREB binding. Gene expression studies of the endogenous 
PZ gene, in this study, showed the role of PEA3, by its overexpression (P<0.05, 
n=6) in the HepG2 cell model. However, CREB knockdown indicated no role 
for this protein in the transcriptional regulation of the endogenous PZ gene 
(P=0.2, n=7) which supports the hypothesis that the protein bound to the pPZ 
ASE (-120/-101) is not CREB. The current study also suggested that steroid 
hormones, androgen, glucocorticoid and oestrogen have no significant role in 
the regulation of the endogenous PZ gene. However, the potential role for 
steroid hormones in controlling PZ expression suggested in previous studies in 
addition to the unconfirmed transfection efficiency of the steroid hormone 
receptors, the mild increase of PZ mRNA in response to glucocorticoid (1.3 fold, 
n=4) and oestrogen (1.2 fold, n=7) shown in this study may still suggest a
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potential role of these hormones in the regulation of PZ gene expression, and 
therefore, further study is needed to confirm the results.
It has also been suggested that PZ may be an acute phase protein (Raczkowski 
et al. 1987, Undar, Karadogan and Ozturk 1999). The results of the current 
study, although not statistically significant (P>0.05, n=7), would seem to 
correlate with this hypothesis with a transient decrease in PZ mRNA levels 
observed in response to bacterial LPS within the HepG2 model system. This 
response of PZ to LPS is similar to the time course response of other 
coagulation factors to LPS and, along with the literature, does suggest PZ may 
be a negative acute phase protein.
8.3. Future work
There are a number of areas that the present study has been able to provide 
corroborative evidence regarding the regulatory mechanisms of transcriptional 
regulation of PZ, such as the contribution of HNF4a to controlling the liver- 
restricted expression profile. However, there are a number of other areas 
where the current data has given glimpses into potential regulatory mechanisms 
that could account for observed phenotypic data without conclusive answers; 
such as the role of steroid hormones and the potential of PZ being an acute 
phase protein. Although the current data with regard to these aspects are not 
significant, the observed trends may prove to be real effects when studied 
further. Transient transfections with monitoring of the efficiency in further study, 
especially with the steroid hormone receptors, may provide more conclusive 
results for the effect of the steroid hormones on the transcriptional regulation of 
the PZ gene. In addition, specific protein binding sites have been identified that 
were characterized for the potential binding of PEA3 or Ets1, again without 
definitive answers as to the proteins' identity. Further studies, using other 
techniques, such as, ChIP should enable confirmation of the proteins occupying 
these regions. Moreover, optimisation of the footprinting technique to be used 
in such study can reveal additional proteins binding to the PZ gene promoter. 
These proteins, then, can be identified by the ChIP technique, and in turn, give 
more information about the regulation of the PZ gene.
243
Expanding the potential regulatory mechanisms investigated, the thyroid 
hormone T3 has been found to induce expression of coagulation factors such 
as thrombin and factor X and is, therefore, suggested as playing a significant 
role in the blood coagulation process (Shih etal. 2004). The identification of the 
role of this hormone in controlling coagulation components suggests the 
possibility that PZ could also be regulated by thyroid hormones, as it has 
already shown some hormonal response; further work must therefore be done 
to examine the role of both the thyroid and steroid hormones in controlling PZ 
gene regulation.
In addition, a number of SNPs have been reported in the PZ gene promoter and 
such variation in potential cis-regulatory regions has previously been 
demonstrated as being a potential transcription modifier (NCBI). Although initial 
data using reporter gene assays and a model system suggest that the -13 
polymorphism does not affect transcription levels (Winship et al. 2005), in vivo 
studies of this polymorphic variation found that it did affect the levels of plasma 
PZ in patients with acute stroke (Staton et al, 2005). Patients with acute stroke 
were found to have significantly higher PZ concentrations compared with 
normal controls and the patients with the A-13G AA genotype had the highest 
PZ concentrations while those with the GG genotype showed the lowest 
concentrations. It would therefore, be of benefit to characterise the effects of 
such allelic variation.
Insights into the transcriptional regulation of PZ have been provided, but much 
remains to be done in trying to define the exact mechanisms by which PZ 
expression is controlled.
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A p p e n d ix  A : Diagrams show the sequences of the PZ promoter region 
spanning nucleotides -716 to +217.
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7800 7900
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15-018 Pure Base QVs: H  M
Mixed Base QVs: |
2 8 8
A M & s
Signal: G:1188 A:675 T:899 C:1222 AvgSig: 996
030_mbh_pzreg2_2-r.abl 
mbh_pzreg2_2-r 
C#:30 W:C8 Plate Name:AX20000QSF
■ llll llllllillllllllllllllllB-----
1AACAGT G TAAG AAG G G AC T AAT ACACAGNNN
675 680 685 690 695 700 705
2 5 0 0 -
2 0 0 0 -
1500—
1000—
8100 8200 8300 8400 8500
Inst M odel/ Nani e : 3730/D G M3730A-17 1
Sequence Scanner v1.0
i-018
Mixed Base QVs: I
2 8 9
KB 1.2 KB.bcp
KB_3730_POP7_BDTv3.mob
TS:57 CRL:680 QV20+:677
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Appendix C: Diagrams show the sequences of PZ promoter region spanning 
nucleotides -1883 to-1284.
J M C *  Applied 031_mbh_pzreg1_1-f.ab1 KB 1.2 KB.bcp
Biosystems mbh_pzreg1_ l-f KB_3730_POP7_BDTv3 mob
Signal: G:2178A:1617T:1348 C:I040 AvgSig: 1545 C#:31 W:B8 Plate Name:AX20000QSF TS:58 CRL:534 QV20+:537. . . .  .. . . I I . .  i. I ........ II i . l i  I n llll II il I u I II I 111. Hill I Ml I II III 111
AN GG7NNC GAGGTTT GGCAAATTT GAGCT GT CT C-T GGG^NC-T CCA GGT GGAGACAGGA
5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
2000—
100 200 300 400 500 600 700 800 900
III I Illlll I la llll I II III Hill I I I  I l l l l l l l  l l l l  I l l l l l  I III l lll mil n il l l l l  IIIII II I l l l l l  I
GT GGGCAT CCGAGAAGCT GGGACTCACAGT GGAGATTCAGGT GGTAACAGAT GAAAT GACAGCATT GT CAGCATATAGATATT G 
85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165
2000-
1100 1200 1300 1400 1500 1600 1700 1800 1900
llllllllllllllllIlllllIII lllllllIIIIIIII III IIIlllllllllllllllllllllllIlllllIII. || III
TT CGAT T GAAT GACACT CAAAGGT GGCAAAACT CAAT GAAAGGATTCT AAAT ACAATTTT GTTAAAGT GGGAACAGAAGAAAAC 
170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245
2000 —
2100 2200 2300 2400 2500 2600 2700 2800 2900III.Illinium llllllll.llllllllllllllallllll II llllllllllllllllllllllllllllaiilli!!
1AAGAAGCT GACACCCTT G ATT AAGA GGGCAT GCCCGCAAATACACT GAAGTT GT GAAGTTT GCTTTAAAAAGCT GGGAAAAGA
255 260 265 270 275 280 285 200 295 300 305 310 315 320 325 330
2000 -
- f  r  r f  ' i  r  nf‘ W ^ r n -r f^ ' i  H T 1 f r  i ^ i  r  m -Tv V r  W f  a *)
3100 3200 3300 3400
Inst Model/Name:3730/DGM3730A-17115-018 Puie Base QVs- WB
_ „ 1011 
Sequence Scanner v1 .0 M<xed Base QVs: m \
4rf t f8T7jriTf i'Trr1 HTrrrr myi 'n nW rprT f -f-i^ Vr1
3600 3700 3800 3900
Printed on: Mar 04,2011 17:10:57 GMT
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2 9 0
m AppliedBiosystems
031_mbh_pzregl_1-f.abi
mbh_pzreg M - f
KB 1.2 KB bcp
KB 3730 POP7 6DTv3.mob
Signal: G:2178 A: 1617 T: 1348 C: 1040 AvgSig: 1545 C#:31 W:B8 Plate Name:AX20000QSF TS:58 CRL:534 QV20+:537
■i mu hi mu i iii i ii iii iiiiii iiiiii ii i iii mi. i iiii iiii i iiii i iiiiii iii 11 ii iii mu
/A A T  A A A G T T T A T  C T T T  AGT GAGT G A G T T A A A A T  A A T T T  G A A A G C C A G A A G T T  G ATT GTAT A G G A T  A G C T C T T G G G T  G A A T T  GC 
340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415
2000 -
1000  —
pi m mu 11 ii i ii iiiiii in iii mi in mu n m mmim....
A T T A A A A A T A C T  T C T  G C T G G A T A G T T T A A A A A C C A T C A A T A G C T G C C T A A A A A T G G A  NGN
505 510 515 520 525 530 535 540 545 550 555 560
2000 -
1500—
1000—
500-
6100 6300 6400 6500 6600 6700 6800
Inst Model/Name:3730/DGM3730A-17115-018
Sequence Scanner vl.O Mixed Base QVs
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291
AppliedBiosystems
Signal: G:854 A:678 T:967 C:886 AvgSig: 846
Q32_mbh_pzreg1_1-r.ab I 
mbh_pzreg l_1-r 
C#:32 W:A8 Plate Name:AX20000QSF
KB 1.2 KB.bcp
KB_3730_POP7_BDTv3.mob
TS:55 CRL:483 QV20+:495
NNN N NN N N N N I* 
5 10
.. ■ „ - .1*. 11 Mill 1.11II11 I ..I II I I 111.1111III dll III Hill I llll I
N NTANTT TTAAT GTAAATTT CCAT GT GGGAATACAT T T  T CACACAAAAAAAGGCACC
20 25 30 35 40 45 50 55 60 65 70 75
5000—
4003-5
3 0 0 0 -
MI Illlll II IIII II III III III IIIIII III III lllll llll llll I III II III lllllll I III Hi IIIII Illlll
TTTTCTTAAG T GAAGGCCACGTAGATTGCCAGGCT GGT GCAATTCACCCAAGAGCTAT CCTATACAATCAACTT CT GGCTTTC7A
2000 -
1000—
5000-5 
+303-5 
3000-5 
2000 -
1100 1200 1300 1400 1500 1600 1700 1800 1900
Illlll lllllI III I II IlllllII III II IllllII III I II III II I III llllllllllllllllllII III I llll III
ATTATT TTAACT CACT CACTAAAGATAAACT TTA TT T TC TTT TCCCAGCTTTTTAAAGCAAACTTCACAACTTCAGTGTATTTG  
170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245
5000"5 
+303-5 
3000-5 
2000 -
2100 2200 2300 2400 2500 2600 2700 2800 2900
I II IlllllIII IlllllIII IIIIllllIIlllll IIIlllllIII IIIIIIIII IIIlllllllIllllIII II III IIII
C GGGCAT GCCCT CTT A AT CAAGGGT GT CAGCTT CTT AG TTTTCTTCT GTTCCCACTTTAACAAAATT GT ATTTA GAAT C C TTT
255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330
5303-5
4003-5
3000-5
2000 -
—[V i i r H -r n y n T T H -r n  f r h r i i it i r f r r
3100 3200 3300
Inst Model/Name:3730/DGM3730A-I7l 15-018
n  i r I i | i i  i i “i i f i  i } i i i i  i i i  r i 
3800 3900
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2 9 2
AppliedBiosystems
032_mbh _pzregl_ I -r.ab I
mbh_pzregl_1-r
KB 1.2 KB.bcp
KB 3730 POP7 BDTv3.mob
Signal: G:854 A:678 T:967 C:886 AvgSig: 846 C#:32 W:A8 Plate Name:AX20000QSF TS:55 CRL483 QV20+:495
llll 11 lllll II I I I  II I II I I I  lllll I I I I  II I  lllllll 11 lllll I I 11111111 H I llll I I I I  I I 11.1 liilll
(ATT GAGTTTT GCCACCTTTGAGT GT CATT CAATCGAACAATAT CTAT AT GCT GACAAT GCT GT CATT T CAT CT GTTACCACC
335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410
5 0 0 0 -  
4000- j  
3000^  
2303^  
1000-=
n
T GAATCTCCACT GTGAGTCCCAGCTT CT CGNANGCCCACT CCT GTCT CCACCTGGANAT CCCNNA
420 425 430 435 440 445 450 455 460 465 470 475 480 485
: n a a t t t g i \ n  
490 495
5 0 0 0 -
4003-5
3 0 0 0 -
2000 —  
1000—
5900
■ ■ I . l l . a . i  . I  ■ I - ■ I . . i i  ■ .■!> I l l l l l .  . . . _____
>AA CNT CNCTTCNNNKNGNCCNKNN NG G ANC NNN G NNNT CNCANCANKN GCACTGNNbNNTNNNNNN NhNNN 
500 505 510 515 520 525 530 535 540 545 550 555 560 565
3000
1000
Inst Model/Name:3730/DGM3730A-17 115-018
Sequence Scanner vl.O
Pure Base QVs: 
Mixed Base QVs
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